0001016504-15-000014.txt : 20151109 0001016504-15-000014.hdr.sgml : 20151109 20151105150815 ACCESSION NUMBER: 0001016504-15-000014 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20151105 FILED AS OF DATE: 20151105 DATE AS OF CHANGE: 20151105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRATED BIOPHARMA INC CENTRAL INDEX KEY: 0001016504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222407475 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31668 FILM NUMBER: 151200220 BUSINESS ADDRESS: STREET 1: 225 LONG AVENUE STREET 2: PO BOX 278 CITY: HILLSIDE STATE: NJ ZIP: 07205 BUSINESS PHONE: 9739260816 MAIL ADDRESS: STREET 1: 225 LONG AVENUE STREET 2: PO BOX 278 CITY: HILLSIDE STATE: NJ ZIP: 07205 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRATED HEALTH TECHNOLOGIES INC DATE OF NAME CHANGE: 20020912 FORMER COMPANY: FORMER CONFORMED NAME: CHEM INTERNATIONAL INC DATE OF NAME CHANGE: 19960716 10-Q 1 inb10q_20150930.htm
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
____________

FORM 10-Q

 ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2015

OR

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from        to


Commission File Number 001-31668

INTEGRATED BIOPHARMA, INC.
(Exact name of registrant, as specified in its charter)
 
Delaware
22-2407475
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
   
225 Long Ave., Hillside, New Jersey
07205
(Address of principal executive offices)
(Zip Code)


(888) 319-6962
(Registrant's telephone number, including Area Code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)



Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
Yes ■
No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer 
 
Accelerated filer 
 
Non-accelerated filer   
 
Smaller reporting company ■

Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes □
No ■
 
Applicable only to Corporate Issuers:

The number of shares outstanding of each of the issuer's class of common stock, as of the latest practicable date:
 
Class
Outstanding at November 5, 2015
 Common Stock, $0.002 par value    21,105,174 Shares 

 
 
                                                                                                                            

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

FORM 10-Q QUARTERLY REPORT
For the Three Months Ended September 30, 2015
INDEX


   
Page
 
Part I. Financial Information
 
  
Item 1.
Condensed Consolidated Statements of Operations for the Three Months Ended September 30, 2015 and 2014 (unaudited)
2
 
Condensed Consolidated Balance Sheets as of September 30, 2015 and June 30, 2015 (unaudited)
3
 
Condensed Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2015 and 2014 (unaudited)
4
 
Notes to Condensed Consolidated Statements
5
     
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
16
     
Item 3.
Quantitative and Qualitative Disclosures about Market Risk
21
     
Item 4.
Controls and Procedures
22
     
 
Part II. Other Information
  
     
Item 1.
Legal Proceedings
22
     
Item 1A.
Risk Factors
22
     
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
22
     
Item 3.
Defaults Upon Senior Securities
22
     
Item 4.
Mine Safety Disclosure
22
     
Item 5.
Other Information
22
     
Item 6.
Exhibits
23
 
 
Other
  
Signatures
  
24
     
     
     
Cautionary Statement Regarding Forward-Looking Statements
 
Certain statements in this Quarterly Report on Form 10-Q may constitute "forward-looking" statements as defined in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Act of 1934, as amended (the "Exchange Act"), the Private Securities Litigation Reform Act of 1995 (the "PSLRA") or in releases made by the Securities and Exchange Commission ("SEC"), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Integrated BioPharma, Inc. and its subsidiaries (the "Company") or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors including, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by the Company; changes in industry capacity; pressure on prices from competition or from purchasers of the Company's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to the Company; availability of qualified personnel; the loss of any significant customers or suppliers; and other factors both referenced and not referenced in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2015 ("Form 10-K"), as filed with the SEC. Statements that are not historical fact are forward-looking statements. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as the words, "plan", "believe", "expect", "anticipate", "intend", "estimate", "project", "may", "will", "would", "could", "should", "seeks", or "scheduled to", or other similar words, or the negative of these terms or other variations of these terms or comparable language, or by discussion of strategy or intentions. These cautionary statements are being made pursuant to the Securities Act, the Exchange Act and the PSLRA with the intention of obtaining the benefits of the "safe harbor" provisions of such laws. The Company cautions investors that any forward-looking statements made by the Company are not guarantees or indicative of future performance. Important assumptions and other important factors that could cause actual results to differ materially from those forward-looking statements with respect to the Company, include, but are not limited to, the risks and uncertainties affecting its businesses described in Item 1 of the Company's Annual Report filed on Form 10-K for the year ended June 30, 2015 and in other securities filings by the Company.  Although the Company believes that its plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, actual results could differ materially from a projection or assumption in any of the forward-looking statements.  The Company's future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made only as of the date hereof and the Company does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.
 
 
1
ITEM 1. FINANCIAL STATEMENTS
           
               
               
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except for share and per share amounts)
(Unaudited)
               
       
Three months ended
  
       
September 30,
  
       
2015
  
2014
  
               
Sales, net
      
 $9,445
  
 $8,582
  
               
Cost of sales
      
 8,130
  
 7,281
  
               
Gross profit
      
 1,315
  
 1,301
  
               
Selling and administrative expenses
  
 830
  
 852
  
               
Operating income
    
 485
  
 449
  
               
Other income (expense), net:
          
  Interest expense
    
 (237)
  
 (240)
  
  Change in fair value of derivative liabilities
 (3)
  
 214
  
  Other income, net
    
 24
  
 9
  
Other expense, net
    
 (216)
  
 (17)
  
               
Income before income taxes
  
 269
  
 432
  
               
Income tax expense, net
    
 28
  
 29
  
               
Net income
      
 241
  
 403
  
               
Interest expense on Convertible debt - CD Financial, LLC
 -
  
 82
  
Accretion of Convertible debt - CD Financial, LLC
 -
  
 28
  
Change in fair value of derivative liabilities
 -
  
 (214)
  
Diluted net income
    
 $241
  
 $299
  
               
Basic net income per common share
  
 $0.01
  
 $0.02
  
               
Diluted net income per common share
  
 $0.01
  
 $0.01
  
               
Weighted average common shares outstanding - basic
 21,105,174
  
 21,105,174
  
Add: Equivalent shares outstanding
  
 50,039
  
 199,775
  
  Shares issuable upon conversion of
        
Convertible Debt - CD Financial, LLC
 -
  
 8,230,769
  
Weighted average common shares outstanding - diluted
 21,155,213
  
 29,535,718
  
               
See accompanying notes to condensed consolidated financial statements.
      
2

INTEGRATED BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except for share and per share amounts)
(Unaudited)
     
             
September 30,
  
June 30,
             
2015
  
2015
Assets
                  
Current Assets:
                
Cash
            
 $84
  
 $71
Accounts receivable, net
        
 2,803
  
 2,638
Inventories
          
 6,087
  
 5,778
Investment in iBio, Inc.
        
 501
  
 501
Other current assets
          
 358
  
 334
Total current assets
        
 9,833
  
 9,322
                   
Intangible assets, net
          
 712
  
 743
Property and equipment, net
        
 1,368
  
 1,373
Security deposits and other assets
        
 164
  
 185
Total Assets
          
 $12,077
  
 $11,623
                   
Liabilities and Stockholders' Deficiency:
            
Current Liabilities:
                
Advances under revolving credit facility
      
 $4,219
  
 $4,462
Accounts payable (includes $423 and $290 due to related party)
  
 6,034
  
 5,148
Accrued expenses and other current liabilities
      
 1,189
  
 1,536
Current portion of long term debt
        
 707
  
 719
Total current liabilities
        
 12,149
  
 11,865
                   
Long term debt
          
 3,830
  
 3,942
Subordinated convertible note, net - CD Financial, LLC
    
 5,148
  
 5,120
Derivative liabilities
          
 15
  
 12
Total liabilities
          
 21,142
  
 20,939
                   
Commitments and Contingencies
              
                   
Stockholders' Deficiency:
              
Common Stock, $0.002 par value; 50,000,000 shares authorized;
          
21,140,074 and 21,105,174 shares issued and outstanding, respectively
  
 42
  
 42
Additional paid-in capital
          
 44,684
  
 44,676
Accumulated deficit
          
 (53,692)
  
 (53,935)
Less:  Treasury stock, at cost, 34,900 shares
      
 (99)
  
 (99)
Total Stockholders' Deficiency
        
 (9,065)
  
 (9,316)
Total Liabilities and Stockholders' Deficiency
    
 $12,077
  
 $11,623
                   
                   
                   
                   
See accompanying notes to condensed consolidated financial statements.
        
3

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, except share and per share amounts)
(Unaudited)
               
       
Three months ended
  
       
September 30,
  
       
2015
  
2014
  
Cash flows provided by operating activities:
            
Net income
      
 $241
  
 $403
  
Adjustments to reconcile net income to net cash
            
from operating activities:
              
Depreciation and amortization
      
 91
  
 95
  
Accretion of financing instruments and other non cash interest
  
 60
  
 60
  
Stock based compensation
      
 9
  
 -
  
Change in fair value of derivative liabilities
    
 3
  
 (214)
  
Changes in operating assets and liabilities:
            
Decrease (increase) in:
              
Accounts receivable
      
 (165)
  
 (119)
  
Inventories
      
 (309)
  
 (1,276)
  
Other current assets
      
 (23)
  
 (83)
  
Security deposits and other assets
    
 (11)
  
 (15)
  
(Decrease) increase in:
              
Accounts payable
      
 887
  
 763
  
Accrued expenses and other liabilities
    
 (347)
  
 (109)
  
Net cash provided by (used in) operating activities
  
 436
  
 (495)
  
               
Cash flows from investing activities:
            
Purchase of property and equipment
    
 (41)
  
 (168)
  
Net cash used in investing activities
    
 (41)
  
 (168)
  
               
Cash flows from financing activities:
            
Advances under revolving credit facility
    
 8,553
  
 8,792
  
Proceeds from Line of Credit Note
    
 43
  
 205
  
Repayments of advances under revolving credit facility
  
 (8,796)
  
 (8,332)
  
Repayments under term note payables
    
 (147)
  
 (135)
  
Repayments under capitalized lease obligations
    
 (35)
  
 (24)
  
Net cash (used in) provided by financing activities
  
 (382)
  
 506
  
               
Net increase (decrease) in cash
    
 13
  
 (157)
  
Cash at beginning of period
      
 71
  
 451
  
Cash at end of period
      
 $84
  
 $294
  
               
Supplemental disclosures of cash flow information:
          
Cash paid during the periods for:
            
Interest
      
 $173
  
 $174
  
Income taxes
      
 $-
  
 $-
  
Supplemental disclosures of non-cash transactions:
          
Accretion on embedded derivative feature of convertible note payable
  
 $28
  
 $28
  
Amortization of prepaid financing costs
    
 $32
  
 $32
  
Financing on capitalized lease obligations
    
 $14
  
 $185
  
               
See accompanying notes to condensed consolidated financial statements.
          
4
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)
 
Note 1. Principles of Consolidation and Basis of Presentation
 
Basis of Presentation of Interim Financial Statements

The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the "Company"). The interim condensed consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission ("SEC") and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto, together with Management's Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2015 ("Form 10-K"), as filed with the SEC. The June 30, 2015 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results of operations for the three months ended September 30, 2015 are not necessarily indicative of the results for the full fiscal year ending June 30, 2016 or for any other period.

Nature of Operations

The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products.  The Company's customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.

The Company's business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. ("MDC"), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. ("AgroLabs"), which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers,  under the following brands: Naturally Noni, Coconut Water, Aloe Pure, Peaceful Sleep, Green Envy, ACAI Extra, ACAI Cleanse, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the "Vitamin Factory"), which sells private label MDC products, as well as our AgroLabs products, through the Internet,  (ii) IHT Health Products, Inc. ("IHT") a distributor of fine natural botanicals, including multi minerals produced under a license agreement and (iii) Chem International, Inc. ("Chem"), a distributor of certain raw materials for DSM Nutritional Products LLC.

Significant Accounting Policies

There have been no material changes during fiscal year 2016 in the Company's significant accounting policies to those previously disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2015.

Investment in iBio, Inc. The Company accounts for its investment in iBio, Inc. ("iBio") common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the "iBio Stock") at the time of the spin-off of this subsidiary in August 2008.  The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be a permanent impairment of the investment.  To date, there were cumulative impairment charges of approximately $2.2 million.  The market value of the iBio Stock as of September 30, 2015 was approximately $0.8 million based on the trade price at the close of trading on September 30, 2015.
 
 
5
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)

Pursuant to the Company's Loan Agreement with PNC Bank, National Association ("PNC"), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time.  During certain periods in the three months ended September 30, 2015 and the fiscal years ended June 30, 2015, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days.  (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).

As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future.  Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock providing net trading proceeds of approximately $79 which were used to prepay principal outstanding under the Term Loan.  (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).

Earnings Per Share. Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible debt, subject to anti-dilution limitations using the treasury stock method and if converted method.

The following options and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three months ended September 30, 2015 and 2014:
 
 
Three Months Ended
 
September 30,
 
2015
2014
     
Anti-dilutive stock options
 1,080,950
 401,200
Anti-dilutive shares for
    
convertible notes payable
 8,230,769
 -
Total anti-dilutive shares
 9,311,719
 401,200

 
6
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)



Note 2. Inventories

Inventories are stated at the lower of cost or market using the first-in, first-out method and consist of the following:

   
September 30,
  
June 30,
   
2015
  
2015
         
Raw materials
 $3,702
  
 $2,371
Work-in-process
 1,036
  
 2,061
Finished goods
 1,349
  
 1,346
Total
  
 $6,087
  
 $5,778


Note 3. Intangible Assets, net

Intangible assets consist of trade names, license fees from the Branded Proprietary Products Segment, and unpatented technology from the Other Nutraceutical Businesses Segment.  The carrying amount of intangible assets, net is as follows as of:

               
 
September 30, 2015
  
June 30, 2015
 
Gross Carrying
Accumulated
    
Gross Carrying
Accumulated
  
 
Amount
Amortization
Net
  
Amount
Amortization
Net
               
Trade names
 $1,525
 $909
 $616
  
 $1,525
 $891
 $634
Unpatented technology
 547
 547
 -
  
 547
 540
 7
License agreement
 347
 251
 96
  
 347
 245
 102
Total
 $2,419
 $1,707
 $712
  
 $2,419
 $1,676
 $743


Amortization expense recorded on intangible assets for the three months ended September 30, 2015 and 2014 was $31 and $34, respectively.  Amortization expense is recorded on the straight-line method over periods ranging from 13 years to 20 years based on contractual or estimated lives and is included in selling and administrative expenses. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test.  Future unanticipated events affecting cash flows and changes in market conditions could affect such estimates and result in the need for an impairment charge.  The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives.  No impairment losses were identified or recorded in the three months ended September 30, 2015 and 2014 on the Company's intangible assets.


7
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)
 
The estimated annual amortization expense for intangible assets for the five succeeding fiscal years is as follows:

 Year ending      Amortization  
June 30,
    
Expense
 
         
2016, remaining
    
 $73
  
2017
    
 97
  
2018
    
 97
  
2019
    
 97
  
2020
    
 93
  
2021
    
 76
  
Thereafter
    
 179
  
Total
    
 $712
  

Note 4. Property and Equipment, net

Property and equipment, net consists of the following:

   
September 30,
  
June 30,
   
2015
  
2015
         
Land and building
  
 $1,250
  
 $1,250
Leasehold improvements
  
 1,159
  
 1,159
Machinery and equipment
  
 5,416
  
 5,362
Transportation equipment
  
 16
  
 16
   
 7,841
  
 7,787
Less: Accumulated depreciation
        
         and amortization
  
 (6,473)
  
 (6,414)
Total
  
 $1,368
  
 $1,373

Depreciation and amortization expense recorded on property and equipment for the three months ended September 30, 2015 and 2014 was $59 and $61, respectively.



8
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)
 

Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt

As of September 30, 2015 and June 30, 2015, the Company had the following debt outstanding:

 
Principal Amount
  
Interest Rate
  
Maturity Date
 
As of September 30, 2015
  
As of        June 30, 2015
        
Revolving advances under Senior Credit
              
  Facility with PNC Bank, National Association
 $4,219
  
 $4,462
  
3.25%
  
6/27/2017
Installment Note with PNC Bank
 1,669
  
 1,802
  
3.75%
  
6/27/2017
Line of Credit Note with
              
 PNC Equipment Finance
 337
  
 307
  
4.57%
  
7/29/2019
Promissory Note with CD Financial, LLC
 1,714
  
 1,714
  
6.00%
  
7/7/2017
Promissory Note with Vitamin Realty, LLC
 686
  
 686
  
4.00%
  
7/7/2017
Capitalized lease obligations
 104
  
 125
  
0.00% -
2/26/2016 -
   
7.10%
  
9/21/2017
               
Promissory Note with E. Gerald Kay
 27
  
 27
  
4.00%
  
7/7/2017
Total outstanding debt
 8,756
  
 9,123
        
Less: Revolving Advances
 (4,219)
  
 (4,462)
        
          Current portion of long term debt
 (707)
  
 (719)
        
Long term debt
 $3,830
  
 $3,942
        
               
Convertible Note payable - CD Financial, LLC
 $5,350
  
 $5,350
  
6.00%
  
7/7/2017
Discount for embedded derivative
 (202)
  
 (230)
        
Convertible Note payable, net - CD Financial, LLC
 $5,148
  
 $5,120
        
               
 
SENIOR CREDIT FACILITY

On June 27, 2012, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. ("IHT Properties") and Vitamin Factory (collectively, the "Borrowers") entered into a Revolving Credit, Term Loan and Security Agreement (the "Loan Agreement") with PNC Bank, National Association as agent and lender ("PNC") and the other lenders party thereto.

The Loan Agreement provides for a total of $11,727 in senior secured financing (the "Senior Credit Facility") as follows: (i) discretionary advances ("Revolving Advances") based on eligible accounts receivable and eligible inventory in the maximum amount of $8,000 (the "Revolving Credit Facility") and (ii) a term loan in the amount of $3,727 (the "Term Loan"). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and common stock of iBio owned by the Company. Revolving Advances bear interest at PNC's Base Rate or the Eurodollar Rate, at Borrowers' option, plus 2.75% (3.25% as of September 30, 2015 and June 30, 2015). The Term Loan bears interest at PNC's Base Rate or the Eurodollar Rate, at Borrowers' option, plus 3.25% (3.75% as of September 30, 2015 and June 30, 2015).  Upon and after the occurrence of any event of default under the Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%.  The Senior Credit Facility matures on June 27, 2017 (the "Senior Maturity Date").
 
 
 
9
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)

 
The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof.  The Term Loan shall be repaid in sixty (60) consecutive monthly installments of principal, the first fifty nine (59) of which shall be in the amount of $44, commencing on the first business day of August, 2012, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the first business day of July, 2017. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof.

The Revolving Advances are subject to the terms and conditions set forth in the Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) $8.0 million or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Loan Agreement, of eligible accounts receivables ("Receivables Advance Rate"), plus (ii) up to the lesser of (A) 65%, subject to the provisions in the Loan Agreement, of the value of the eligible inventory ("Inventory Advance Rate" and together with the Receivables Advance Rate, collectively, the "Advance Rates"), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time ("Inventory Advance Rate" and together with the Receivables Advance Rate, collectively, the "Advance Rates"), minus (iii) the aggregate Maximum Undrawn Amount of all outstanding Letters of Credit, minus (iv) such reserves as Agent may reasonably deem proper and necessary from time to time.

The Loan Agreement contains customary mandatory prepayment provisions, including, without limitation, (i) the requirement that if the trading price per share of the iBio Stock falls below a certain amount, the Company must sell the iBio Stock and use the proceeds to repay the Term Loan and (ii) the requirement to prepay the outstanding amount of all loans in an amount equal to fifty percent (50%) of Excess Cash Flow for each fiscal year commencing with the fiscal year ending June 30, 2013, payable upon delivery of the financial statements to PNC referred to in and required by the Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which prepayment amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof until the aggregate amount of payments made with regard to the Term Loan pursuant to the Loan Agreement equals $1.0 million.  The Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Loan Agreement.  As of September 30, 2015, the Company is in compliance with the fixed charge coverage ratio maintenance requirement.

During certain periods in the fiscal year ended June 30, 2013 and continuing through the quarter ended September 30, 2015, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days.  However, PNC temporarily waived the requirement to sell the iBio Stock due to certain trading rules and restrictions under Rule 144 under the Securities Act of 1933, as amended.  As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future.  Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock, providing net trading proceeds of approximately $79 which proceeds were used to prepay principal outstanding under the Term Loan.

In connection with the Senior Credit Facility, PNC and CD Financial entered into the Intercreditor and Subordination Agreement (the "Intercreditor Agreement"), which was acknowledged by the Borrowers, pursuant to which, among other things, (a) the lien of CD Financial on assets of the Borrowers is subordinated to the lien of PNC on such assets during the effectiveness of the Senior Credit Facility, and (b) priorities for payment of the debt for the Company and its subsidiaries (as described in this Note 5) are established.
 
 

 
10
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)
In addition, in connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC.

CD FINANCIAL, LLC TROUBLED DEBT RESTRUCTURING

On June 27, 2012, the Company also entered into an Amended and Restated Securities Purchase Agreement (the "CD SPA") with CD Financial, which amended and restated the Securities Purchase Agreement, dated as of February 21, 2008, between the Company and CD Financial, pursuant to which the Company issued to CD Financial a 9.5% Convertible Senior Secured Note in the original principal amount of $4,500 (the "Original CD Note").  Pursuant to the CD SPA,  the Company issued to CD Financial (i) the Amended and Restated Convertible Promissory Note in the principal amount of $5,350 (the "CD Convertible Note") and (ii) the Promissory Note in the principal amount of $1,714 (the "Liquidity Note", and collectively with the CD Convertible Note, the "CD Notes"). The CD Notes mature on July 7, 2017.

The proceeds of the CD Notes were used to refinance (a) the Original CD Note, (b) a $300,000 note issued by MDC to CD Financial which was assigned by MDC to the Company, (c) past due interest in the aggregate amount of $333 and (d) other expenses owed to CD Financial by the Company in the aggregate amount of approximately $217.

The CD Notes are secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and iBio Stock owned by the Company. The CD Notes bear interest at an annual rate of 6% and have a default rate of 10%.

The CD Convertible Note is convertible at the option of CD Financial into common stock of the Company at a conversion price of $0.65 per share, subject to customary adjustments including conversion price protection provisions.

Pursuant to the terms of the Loan Agreement and the Intercreditor Agreement, during the effectiveness of the Senior Credit Facility, (i) the principal of the CD Convertible Note may not be repaid, (ii) the principal of the Liquidity Note may only be repaid if certain conditions under the Loan Agreement are satisfied, and (iii) interest in respect of the CD Notes may only be paid if certain conditions under the Intercreditor Agreement are satisfied.

The CD SPA contains customary representations and warranties, covenants and events of default, including, without limitation, an event of default tied to any change of control as defined in the CD SPA.

In connection with the CD SPA, the Borrowers entered into an Amended and Restated Security Agreement and Amended and Restated Subsidiary Guaranty.
 
As of September 30, 2015 and June 30, 2015, the related embedded derivative liability with respect to conversion price protection provisions on the CD Convertible Note has an estimated fair value of $15 and $12, respectively.
 

 
11
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)

The Company used the following assumptions to calculate the fair value of the derivative liability using the Black-Scholes option pricing model:

   
September 30,
  
June 30,
  
June 27,
   
2015
  
2015
  
2012
             
Risk Free Interest Rate
  
0.64%
  
0.64%
  
0.72%
Volatility
  
70.80%
  
71.60%
  
144.10%
Term
  
1.75 years
  
2 years
  
5 years
Dividend Rate
  
0.00%
  
0.00%
  
0.00%
Closing Price of
            
  Common Stock
  
 $0.10
  
 $0.09
  
 $0.09

OTHER LONG TERM DEBT

Related Party Debt.  On June 27, 2012, MDC and the Company entered into separate promissory notes with (i) Vitamin Realty Associates, LLC ("Vitamin Realty"), which is 100% owned by E. Gerald Kay, the Company's Chairman of the Board, Chief Executive Officer and major shareholder and certain of his family members, who are also executive officers and directors of the Company, and (ii) E. Gerald Kay, in the principal amounts of approximately $686 (the "Vitamin Note") and $27 (the "Kay Note"), respectively (collectively the "Related Party Notes"). The principal amount of the Vitamin Note represents the aggregate amount of unpaid, past due rent owing by MDC under the Lease Agreement, dated as of January 10, 1997, between MDC, as lessor, and Vitamin Realty, as landlord, pertaining to the real property located at 225 Long Avenue, Hillside, New Jersey.  (See Note 7. Commitments and Contingencies (a) Leases – Related Party Leases).  The Kay Note represents amounts owed to Mr. Kay for unreimbursed business expenses incurred by Mr. Kay in the fiscal year ended June 30, 2008.  The Related Party Notes mature on July 7, 2017 and accrue interest at an annual rate of 4% per annum. Interest in respect of the Related Party Notes is payable on the first business day of each calendar month.  Pursuant to the terms of the Loan Agreement, during the effectiveness of the Senior Credit Facility, the Related Party Notes may only be repaid or prepaid if certain conditions set forth in the Loan Agreement are satisfied.

Capitalized Lease Obligations.  On September 17, 2015, the Company entered into a capitalized lease obligation with Regents Capital Corporation ("Regents") in the amount of $90, which lease is secured by certain machinery and equipment to be financed with funds available from Regents and which lease matures on September 21, 2019.  As of September 30, 2015 and November 5, 2015, the Company has borrowed $14 of the $90 available from Regents. The lease payment amount (based on the current amount outstanding under the lease) of approximately $2 is payable quarterly and has an imputed interest rate of 5.7%.

Equipment Financing Note.  On September 22, 2014, MDC entered into a Convertible Line of Credit Note (the "LC Note") in the amount of $350 with PNC Equipment Finance, LLC ("PNCEF").  The LC Note is convertible into a term note upon completion of the advances under the LC Note.  During the period from September 22, 2014 to and including the Conversion Date (defined below), the Company was able to borrow up to the full value of the LC Note ($350).  The "Conversion Date" is the earliest to occur of (i) July 31, 2015 or (ii) the date when the Company notifies PNCEF that no more advances will be requested or (iii) the date when PNCEF has made advances in an aggregate amount of $350.  As of September 30, 2015, the Company has requested and received advances under the LC Note in the amount of $350.  Prior to the Conversion Date, amounts outstanding under the LC Note bore interest at a rate per annum ("Floating Rate") which is at all times equal to the sum of LIBOR Rate plus 325 basis points (3.25%).  The Company completed the advances on July 29, 2015 and converted the LC Note to a four year term note.  On the Conversion Date, the Company elected a fixed rate interest of 4.57% as offered by PNCEF.
 
 
12
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)

 
In addition, in connection with the LC Note, the following loan documents were executed: (i) a Security Agreement with PNCEF and MDC; (ii) a Guaranty and Security Agreement with PNCEF and the Company; and (iii) a Cross Collateralization Agreement with PNC, PNCEF and MDC.

Note 6. Significant Risks and Uncertainties

(a) Major Customers. For the three months ended September 30, 2015 and 2014, approximately 87% and 81%, respectively of consolidated net sales, were derived from two customers. These two customers are in the Company's Contract Manufacturing Segment and represent approximately 47% each and 63% and 26% of this Segment's net sales in the three months ended September 30, 2015 and 2014, respectively.  A third customer in the Branded Nutraceutical Segment, while not a significant customer of the Company's consolidated net sales, represented approximately 77% and 78% of net sales in the three months ended September 30, 2015 and 2014, respectively, of the Branded Nutraceutical Segment. Accounts receivable from these two major customers represented approximately 86% and 83% of total net accounts receivable as of September 30 and June 30, 2015, respectively. The loss of any of these customers could have an adverse affect on the Company's operations. Major customers are those customers who account for more than 10% of net sales.

(b) Other Business Risks. Approximately 62% of the Company's employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed on September 1, 2015 and will expire on August 31, 2018.

Note 7. Commitments and Contingencies

(a) Leases

Related Party Leases. Warehouse and office facilities are leased from Vitamin Realty, which is 100% owned by the Company's chairman, Chief Executive Officer and major stockholder and certain of his family members, who are also executive officers and directors of the Company.  On January 5, 2012, MDC, a wholly-owned subsidiary of the Company, entered into a second amendment of lease (the "Second Lease Amendment") with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026.  This Second Lease Amendment provides for minimum annual rental payments of $533, plus increases in real estate taxes and building operating expenses.  On May 19, 2014, AgroLabs entered into an Amendment to the lease agreement entered into on January 5, 2012, with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which was to expire on January 31, 2019 to extend the expiration date to January 1, 2024.  This additional lease provides for minimum lease payments of $27 with annual increases plus the proportionate share of operating expenses.

Rent expense for the three months ended September 30, 2015 and 2014 on these leases were $184 and $210 respectively, and are included in both cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. As of September 30, 2015 and June 30, 2015, the Company had an outstanding obligation to Vitamin Realty of $1.2 million and $1.0 million, respectively, included in accounts payable, accrued expenses and other liabilities and long term debt in the accompanying Condensed Consolidated Balance Sheet.

Other Lease Commitments. The Company has entered into certain non-cancelable operating lease agreements expiring up through January 31, 2026, related to office and warehouse space, equipment and vehicles (inclusive of the related party lease with Vitamin Realty).


13
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)

The minimum rental commitments for long-term non-cancelable leases are as follows:


             
   
Operating
  
Related Party
    
Year ending
  
Lease
  
Lease
    
June 30,
  
Commitment
  
Commitment
  
Total
             
2016, remaining
 $40
  
 $422
  
 $462
2017
  
 24
  
 563
  
 587
2018
  
 14
  
 563
  
 577
2019
  
 2
  
 563
  
 565
2020
  
 1
  
 563
  
 564
2021
  
 -
  
 563
  
 563
Thereafter
  
 -
  
 2,517
  
 2,517
Total
  
 $81
  
 $5,754
  
 $5,835

Total rent expense, including real estate taxes and maintenance charges, was approximately $225 and $252 for the three months ended September 30, 2015 and 2014, respectively. Rent expense is included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.

(b) Legal Proceedings.

The Company is subject, from time to time, to claims by third parties under various legal theories.  The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company's liquidity, financial condition and cash flows.

(c) Other Claims.

On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent the Company a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company.  In the Demand Letter, Cedarburg demanded payment by the Company of $0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA.  In addition, in the Demand Letter, Cedarburg informed the Company that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of $0.3 million.

On May 30, 2012, the Company sent a letter responding to the Demand Letter and setting forth the Company's position that it has no obligation to indemnify Cedarburg as demanded.  On June 18, 2012, Cedarburg responded to the Company's letter and, on July 27, 2012, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded.  On December 18, 2012, Cedarburg responded to the Company's letter and, on January 15, 2013, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded.   As of November 5, 2015, the Company has not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter.  The Company intends to vigorously contest Cedarburg's demand as set forth in the Demand Letter.

Note 8. Related Party Transactions

See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt for related party securities transactions.

See Note 7(a). Leases for related party lease transactions.
 
 
 
14
INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (in thousands, except share and per share amounts)
(Unaudited)

 
Note 9. Segment Information

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company's operating segments.

The Company has divided its operations into three reportable segments as follows: Contract Manufacturing, Branded Proprietary Products and Other Nutraceutical Businesses.  The international sales, concentrated primarily in Europe and Canada, for the three months ended September 30, 2015 and 2014 were $1,992 and $2,283, respectively.
 
Financial information relating to the three months ended September 30, 2015 and 2014 operations by business segment are as follows:
 
 
                           
   
Sales, Net
  
Segment
              
   
U.S.
International
    
Gross
      
Capital
      
   
Customers
Customers
Total
  
Profit
  
Depreciation
  
Expenditures
      
Contract Manufacturing
2015
 $6,930
 $1,815
 $8,745
  
 $1,041
  
 $59
  
 $54
      
2014
 5,743
 2,065
 7,808
  
 1,151
  
 60
  
 351
      
                           
Branded Proprietary Products
2015
 147
 172
 319
  
 128
  
 -
  
 -
      
2014
 129
 210
 339
  
 6
  
 -
  
 1
      
                         
                           
Other Nutraceutical Businesses
2015
 376
 5
 381
  
 146
  
 -
  
 1
      
2014
 427
 8
 435
  
 144
  
 1
  
 -
      
                           
Total Company
2015
 7,453
 1,992
 9,445
  
 1,315
  
 59
  
 55
      
 
2014
 6,299
 2,283
 8,582
  
 1,301
  
 61
  
 352
      
                           
                           
                           
     Total Assets as of                     
   
September 30,
June 30,
                    
   
2015
2015
                    
Contract Manufacturing
  
 $9,113
 $8,482
                    
                         
Branded Proprietary Products
                          
 
 1,296
 1,324
                    
                         
Other Nutraceutical Businesses
                          
 
 1,668
 1,817
                    
Total Company
  
 $12,077
 $11,623
                    
                           
                           

 

15
 
 
Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANICAL CONDITION AND RESULTS OF OPERATION

Certain statements set forth under this caption constitute "forward-looking statements." See "Disclosure Regarding Forward-Looking Statements" on page 1 of this Quarterly Report on Form 10-Q for additional factors relating to such statements. The following discussion should also be read in conjunction with the condensed consolidated financial statements of the Company and Notes thereto included herein and the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2015.

The Company is engaged primarily in the manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company's customers are located primarily in the United States, Luxembourg and Canada.

Business Outlook

Our future results of operations and the other forward-looking statements contained in this Quarterly Report on Form 10-Q, including this MD&A, involve a number of risks and uncertainties—in particular, the statements regarding our goals and strategies, new product introductions, plans to cultivate new businesses, pending divestitures, future economic conditions, revenue, pricing, gross margin and costs, the tax rate, and potential legal proceedings. We are focusing our efforts to improve operational efficiency and reduce spending that may have an impact on expense levels and gross margin. In addition to the various important factors discussed above, a number of other important factors could cause actual results to differ significantly from our expectations. See the risks described in "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q.

For the three months ended September 30, 2015, our net sales from operations increased by $0.8 million to approximately $9.4 million from approximately $8.6 million in our three months ended September 30, 2014.  For each of the three months ended September 30, 2015 and 2014 we had operating income of approximately $0.5 million.  In the three months ended September 30, 2015, our gross profit remained substantially the same as it was for the three months ended September 30, 2014, approximately $1.3 million in each period, as a result of our cost of goods sold increasing by approximately $0.8 million. Our profit margins decreased primarily as a result of decreased margins in our Contract Manufacturing Segment, as our net sales increased by $0.9 million and our cost of sales increased by $1.0 million, resulting in a net decrease in our gross profit of $0.1 million in this segment.  The increase in the cost of sales was primarily due to the higher cost of the raw materials used in the products manufactured for Life Extensions.  We maintained our consolidated selling and administrative expenses at approximately $0.8 million in each of the three months ended September 30, 2015 and 2014.

We continue to focus on our core businesses and push forward in maintaining our cost structure in line with our sales.  In our branded product segment, we are developing new customer relationships focused on the international markets in Canada, Mexico and Asia.  We are also developing new products to include branded products for solid dosage which will be manufactured by MDC and sold using our AgroLabs brand or to our customer contacts developed through selling our branded product for private label. We believe that this will increase sales and further leverage our fixed manufacturing and selling costs in each of these segments as we diversify our branded product offerings to our existing and developing customers.  While this sale cycle has taken longer than management had anticipated, we expect these relationships to produce sales in the fiscal year ending June 30, 2016.

Critical Accounting Policies and Estimates
There have been no changes to our critical accounting policies in the three months ended September 30, 2015. Critical accounting policies and the significant estimates made in accordance with them are regularly discussed by management with our Audit Committee. Those policies are discussed under "Critical Accounting Policies" in our "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in Item 7 of our Annual Report on Form 10-K for the year ended June 30, 2015.
 
16
Results of Operations
Our results from operations in the following table, sets forth the income statement data of our results as a percentage of net sales for the periods indicated:

 
For the three months
 
ended September 30,
 
2015
  
2014
       
Sales, net
 100.0%
  
 100.0%
       
Costs and expenses:
      
Cost of sales
 86.1%
  
 84.9%
Selling and administrative
 8.8%
  
 9.9%
 
 94.9%
  
 94.8%
Income from operations
 5.1%
  
 5.2%
       
Other expense, net
      
Interest expense
 (2.5%)
  
 (2.8%)
Other income, net
 0.2%
  
 0.1%
Change in fair value of derivative liabilities
 (0.0%)
  
 2.5%
Other expense, net
 (2.3%)
  
 (0.2%)
       
       
Income before income taxes
 2.8%
  
 5.0%
       
Federal and state income taxes, net
 0.3%
  
 0.3%
       
Net income
 2.5%
  
 4.7%

 
For the Three Months Ended September 30, 2015 compared to the Three Months Ended September 30, 2014
 
Sales, net. Sales, net, for the three months ended September 30, 2015 and 2014 were $9.4 million and $8.6 million, respectively, an increase of 10.1%, and are comprised of the following:


 
Three months ended
  
Dollar
  
Percentage
 
September 30,
  
Change
  
Change
 
2015
  
2014
  
2015 vs 2014
  
2015 vs 2014
       (amounts in thousands)        
Contract Manufacturing:
              
US Customers
 $6,930
  
 $5,743
  
 $1,187
  
 20.7%
International Customers
 1,815
  
 2,065
  
 (250)
  
 (12.1%)
Net sales, Contract Manufacturing
 8,745
  
 7,808
  
 937
  
 12.0%
               
Branded Nutraceutical Products:
              
US Customers
 147
  
 129
  
 18
  
 14.0%
International Customers
 172
  
 210
  
 (38)
  
 (18.1%)
Net sales, Branded Nutraceutical Products
 319
  
 339
  
 (20)
  
 (5.9%)
               
Other Nutraceuticals:
              
US Customers
 376
  
 427
  
 (51)
  
 (11.9%)
International Customers
 5
  
 8
  
 (3)
  
 (37.5%)
Net sales, Other Nutraceuticals
 381
  
 435
  
 (54)
  
 (12.4%)
               
Total net sales
 $9,445
  
 $8,582
  
 $863
  
 10.1%


For the three months ended September 30, 2015 and 2014, a significant portion of our consolidated net sales, approximately 87% and 81%, respectively, were concentrated among two customers in our Contract Manufacturing Segment, Herbalife and Life Extensions.  Herbalife and Life Extensions represented approximately 47% each and 63% and 26%, respectively of our Contract Manufacturing Segment's net sales in the three months ended September 30, 2015 and 2014, respectively.  The loss of any of these customers could have a significant adverse impact on our financial condition and results of operations.  Costco Wholesale Corporation ("Costco") (a customer of our Branded Proprietary Products Segment), while not a significant customer of our consolidated net sales represented approximately 77% and 78% of net sales in the three months ended September 30, 2015 and 2014, respectively of the Branded Propriety Products Segment.
 

 
17
The increase in net sales of approximately $0.8 million was primarily the result of:

·
Net sales increased in our Contract Manufacturing Segment by $0.9 million primarily due to increased sales volumes to Life Extensions in the three months ended September 30, 2015 of approximately $2.1 million offset, in part, by a decrease in net sales to Herbalife of approximately $0.8 million (primarily in the international markets for Herbalife) in the three months ended September 30, 2015.
·
Net sales in our Branded Nutraceutical Segment decreased by approximately $20,000 in the three months ended September 30, 2015, primarily as the result of the decreased sales volume of $0.1 million, including a decrease of approximately $83,000 with Costco.  The decreased sales volume was offset, in part, from the release of an estimated sales allowance of approximately $0.1 million for a customer the Company has not done business with in the past five years.
·
Net sales in our Other Nutraceutical segments decreased by $54 primarily as a result of decreased sales to customers of Chem.

Cost of sales.  Cost of sales increased by $0.8 million to $8.1 million for the three months ended September 30, 2015, as compared to $7.3 million for the three months ended September 30, 2014.  Cost of sales increased as a percentage of sales to 86.1% for the three months ended September 30, 2015 as compared to 84.9% for the three months ended September 30, 2014. The increase in the cost of goods sold amount, as well as the increase in the cost of goods sold as a percentage of net sales, was primarily the result of the increased sales to Life Extension.  The cost of the raw materials for the Life Extension finished goods, on average, cost more per bottle than goods produced for our other customers in the Contract Manufacturing Segment as they tend to use raw materials with trademarked characteristics which limits the ability to negotiate pricing.  A secondary cause is the production of more capsules than tablets.  There is a higher loss factor in the production of capsules than in tablets.  Our Contract Manufacturing Segment had a $1.0 million increase in the cost of goods sold, while the cost of goods sold in our Branded Nutraceutical Segment decreased by $0.1 million (primarily as the result of decreased sales and secondarily as the result of decreased markdowns on inventory) and a decrease of $0.1 million in the Other Nutraceutical Segment as a result of decreased sales.

Selling and Administrative Expenses.  There was a slight decrease in selling and administrative expenses of $22,000 in the three months ended September 30, 2015 as compared to the three months ended September 30, 2014.  As a percentage of sales, net, selling and administrative expenses was approximately 8.8% and 9.9% for the three months ended September 30, 2015 and 2014, respectively.  The decrease was primarily from decreased legal and other professional fees of approximately $24,000.



18

 
Other income (expense), net. Other income (expense), net was approximately $216,000 for the three months ended September 30, 2015 compared to $17,000 for the three months ended September 30, 2014, and is composed of:

       
 
Three months ended
 
September 30,
 
2015
  
2014
 
(dollars in thousands)
Interest expense
 $(237)
  
 $(240)
Change in fair value of
      
derivative instruments
 (3)
  
 214
Other, net
 24
  
 9
Other income (expense), net
 $(216)
  
 $(17)

The variance in the change in fair value of derivative liabilities from the three months ended September 30, 2014 to the September 30, 2015 was mainly the result of the decreased volatility in the closing trading price of our common stock from 88.5% as of June 30, 2014 to 79.4% as of September 30, 2014.  As noted above, there was not a significant change in the estimated fair value of derivative instruments from June 30, 2015 to September 30, 2015.  The volatility of the closing trading price of our stock is one of the variables used to calculate the estimated fair value of our derivative liabilities associated with the underlying derivative instruments.  The other components of other income (expense) were not significant.  Our interest expense for each of the three months ended September 30, 2015 and 2014 was substantially the same and other income increased by approximately fifteen thousand dollars of additional earned income from providing back office support, logistics and operational support for a start-up company which sells over the counter pharmaceutical and nutraceutical products through retail and internet based outlets.

Federal and state income tax, net. For the three months ended September 30, 2015 and 2014, we had a state tax expense of approximately $28 and $29, respectively.  We continue to maintain a full reserve on our deferred tax assets as it has been determined that based upon past losses, the Company's past liquidity concerns and the current economic environment, that it is "more likely than not" the Company's deferred tax assets may not be realized.  The state tax expense is the result of MDC using all of its state net operating losses in the fiscal year ended 2013 tax period.  All of our other subsidiaries still have adequate net operating losses for state income tax purposes to absorb any taxable income for state tax purposes.

Net income. Our net income for the three months ended September 30, 2015 and 2014 was approximately $0.2 million and $0.4 million, respectively.  The decrease of approximately $0.2 million was primarily the result of the change in fair value of derivative instruments of approximately $0.2 million.

Seasonality

The nutraceutical business tends to be seasonal. We have found that in our first fiscal quarter ending on September 30th of each year, orders for our branded proprietary nutraceutical products usually slow (absent the addition of new customers or a new product launch with a significant first time order), as buyers in various markets may have purchased sufficient inventory to carry them through the summer months. Conversely, in our second fiscal quarter, ending on December 31st of each year, orders for our products increase as the demand for our branded nutraceutical products, as well as sales orders from our customers in our contract manufacturing segment,  seem to increase in late December to early January as consumers become health conscious as they enter the new year.

The Company believes that there are other non-seasonal factors that also may influence the variability of quarterly results including, but not limited to, general economic and industry conditions that affect consumer spending, changing consumer demands and current news on nutritional supplements. Accordingly, a comparison of the Company's results of operations from consecutive periods is not necessarily meaningful, and the Company's results of operations for any period are not necessarily indicative of future periods.
 
 

 
19
Liquidity and Capital Resources

The following table sets forth, for the periods indicated, the Company's net cash flows used in operating, investing and financing activities, its period end cash and cash equivalents and other operating measures:


 
For the three months ended
 
September 30,
 
2015
  
2014
 
(dollars in thousands)
       
Net cash  provided by (used in) operating acitivites
 $436
  
 $(495)
Net cash used in investing acitivites
 $(41)
  
 $(168)
Net cash (used in) provided by financing acitivites
 $(382)
  
 $506
       
Cash at end of period
 $84
  
 $294

At September 30, 2015 and June 30, 2015, our working capital deficit was approximately $2.3 and $2.5 million, respectively. Our current assets increased by $0.5 million and current liabilities increased by approximately $0.3 million, resulting in a net decrease in our working capital deficit of $0.2 million.

Net cash used in operating activities of $0.4 million in the three months ended September 30, 2015, includes net income of approximately $0.2 million.  After excluding the effects of non-cash expenses, including depreciation and amortization, and changes in the fair value of derivative liabilities, the adjusted cash provided from operations before the effect of the changes in working capital components was $0.4 million. Net cash provided by our operations from our working capital assets and liabilities in the amount of approximately $32,000 was primarily the result of increases in inventories of $0.3 million and $0.2 million in accounts receivable and offset, in part, by a net increase in accounts payable and accrued expenses and other liabilities of approximately $0.5 million.

Net cash used in operating activities of $0.5 million in the three months ended September 30, 2014, includes net income of approximately $0.4 million.  After excluding the effects of non-cash expenses, including depreciation and amortization, and changes in the fair value of derivative liabilities, the adjusted cash provided from operations before the effect of the changes in working capital components was $0.3 million. Cash used in operations from our working capital assets and liabilities in the amount of approximately $0.8 million was primarily the result of increases in inventories of $1.3 million and $0.1 million in each of accounts receivable and other current assets and offset, in part, by a net increase in accounts payable and accrued expenses and other liabilities of approximately $0.7 million.

Cash used in investing activities was used for the purchase of machinery and equipment for approximately $41,000 in the three months ended September 30, 2015, compared to using approximately $0.2 million for the purchase of machinery and equipment in the three months ended September 30, 2014.

Cash used in financing activities was approximately $0.4 million for the three months ended September 30, 2015, $8.8 million for repayments of advances under our revolving credit facility and $0.1 million from repayments of principal under our term notes payable offset, in part, by advances of $8.5 million of proceeds received under our revolving credit facility.  Cash provided from financing activities was approximately $0.5 million for the three months ended September 30, 2014, $8.8 million from advances under our revolving credit facility and $0.2 million from proceeds under our convertible line of credit for equipment financing offset, in part, by repayments of advances under our revolving credit facility of $8.3 million and principal under our term note in the amount of $0.1 million.

As of September 30, 2015, we had cash of $84,000, funds available under our revolving credit facility of approximately $1.0 million and a working capital deficit of approximately $2.3 million. Our working capital deficit includes $4.2 million outstanding under our revolving line of credit which is not due until July 2017 but classified as current due to a subjective acceleration clause that could cause the advances to become currently due. (See Note 5 to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q).  Furthermore, we had income from operations of approximately $0.2 million in the three months ended September 30, 2015.  After taking into consideration our interim results and current projections, management believes that operations, together with the revolving credit facility will support our working capital requirements through the period ending September 30, 2016.
 

 
20
Our total annual commitments at September 30, 2015 for long term non-cancelable leases of approximately $587,000 consists of obligations under operating leases for facilities and operating lease agreements for the rental of warehouse equipment, office equipment and automobiles.

On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent us a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company.  In the Demand Letter, Cedarburg demanded payment by us of $0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA.  In addition, in the Demand Letter, Cedarburg informed us that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of $0.3 million.

On May 30, 2012, we sent a letter responding to the Demand Letter and setting forth our position that we have no obligation to indemnify Cedarburg as demanded.  On June 18, 2012, Cedarburg responded to our letter and, on July 27, 2012, we sent another letter to Cedarburg reiterating our position that we have no obligation to indemnify Cedarburg as demanded.  On December 18, 2012, Cedarburg responded to our letter and, on January 15, 2013, we sent another letter to Cedarburg reiterating our position that we have no obligation to indemnify Cedarburg as demanded. As of November 5, 2015, we have not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter.  We intend to vigorously contest Cedarburg's demand as set forth in the Demand Letter.

Capital Expenditures

The Company's capital expenditures for the three months ended September 30, 2015 and 2014 were approximately $55,000 ($14,000 funded with capitalized lease financing) and $0.4 million ($0.2 million funded with capitalized lease financing), respectively.  The Company has budgeted approximately $0.3 million for capital expenditures for fiscal year 2016.  The total amount is expected to be funded from lease financing and cash provided from the Company's operations.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Recent Accounting Pronouncements

None.

Impact of Inflation

The Company does not believe that inflation has significantly affected its results of operations.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.


21

Item 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended (the "Exchange Act") is recorded, processed, summarized, and reported within the time periods specified by the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the Company has evaluated the effectiveness of its disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2015, and, based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these controls and procedures are effective in providing reasonable assurance of compliance.

Changes in Internal Control over Financial Reporting
No change in our internal control over financial reporting occurred during the three months ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

None.

Item 1A. Risk Factors

The risks described in Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended June 30, 2015, could materially and adversely affect our business, financial condition and results of operations. The risk factors discussed in that Form 10-K do not identify all risks that we face because our business operations could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. There have been no material changes to our risk factors from those disclosed in our Form 10-K for the year ended June 30, 2015.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURE

Not Applicable.

Item 5. OTHER INFORMATION

None.
 

 
22
Item 6. EXHIBITS

(a)            Exhibits

Exhibit
Number
10.1
Convertible Line of Credit Note, dated September 22, 2015, by and among INB: Manhattan Drug Company and PNC Equipment Finance LLC in the original principal amount of $350,000
10.2
Cross Collateralization Agreement, dated September 22, 2015, by and among INB: Manhattan Drug Company, PNC Bank National Association and PNC Equipment Finance LLC
10.3
Security Agreement, dated September 22, 2015 by and among INB: Manhattan Drug Company and PNC Equipment Finance LLC
10.4
Guaranty and Suretyship Agreement, dated September 30, 2015, by and among Integrated BioPharma, Inc. and PNC Equipment Finance LLC
31.2
Certification of pursuant to Section 302 of Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
32.1
Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer.
32.2
Certification of periodic financial report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer.
101
The following financial information from Integrated BioPharma, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Operations for the three months ended September 30, 2015 and 2014, (ii) Condensed Consolidated Balance Sheets as of September 30, 2015 and June 30, 2015, (iii) Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2015 and 2014, and (iv) the Notes to Condensed Consolidated Statements.
23
SIGNATURES


Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


INTEGRATED BIOPHARMA, INC.
 

Date:  November 5, 2015 
By: /s/ E Gerald Kay
 
 E. Gerald Kay,
 
 President and Chief Executive Officer
 
 
Date: November 5, 2015 
By: /s/ Dina L. Masi
 
 Dina L. Masi,
 
 Chief Financial Officer & Senior Vice President
 
24
 EX-31.1 2 exhibit31_1.htm
Exhibit 31.1
Certification of Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, E. Gerald Kay certify that:
1.  I have reviewed this quarterly report on Form 10-Q of Integrated BioPharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
Date: November 5, 2015 
By: /s/ E Gerald Kay
 
 Name:  E. Gerald Kay,
 
 Title:  President and Chief Executive Officer

 
 
 EX-31.2 3 exhibit31_2.htm
Exhibit 31.2
Certification of Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Dina L. Masi, certify that:
1.  I have reviewed this quarterly report on Form 10-Q of Integrated BioPharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
Date: November 5, 2015 
By: /s/ Dina L. Masi
 
 Name:  Dina L. Masi,
 
 Title:  Chief Financial Officer & Senior Vice President

 
 EX-32.1 4 exhibit32_1.htm
Exhibit 32.1

CERTIFICATION OF PERIODIC REPORT
As adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q for the third quarter ended September 30, 2015 of Integrated BioPharma, Inc. (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), E. Gerald Kay, the President and Chief Executive Officer of Integrated BioPharma, Inc. certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to his knowledge:

(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification accompanies the Report pursuant to Section 906 of Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 
 
Date: November 5, 2015 
By: /s/ E Gerald Kay
 
 E. Gerald Kay,
 
 President and Chief Executive Officer





EX-32.2 5 exhibit32_2.htm
Exhibit 32.2

CERTIFICATION OF PERIODIC REPORT
As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q for the third quarter ended September 30, 2015 of Integrated BioPharma, Inc. (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Dina L. Masi, the Senior Vice President and Chief Financial Officer of Integrated BioPharma, Inc. certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to her knowledge:

(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification accompanies the Report pursuant to Section 906 of Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 
 
Date: November 5, 2015 
By: /s/ Dina L. Masi
 
 Dina L. Masi,
 
 Chief Financial Officer & Senior Vice President

EX-101.INS 6 inbp-20150930.xml XBRL INSTANCE DOCUMENT false --06-30 Q1 2016 2015-09-30 10-Q 0001016504 21105174 Yes Smaller Reporting Company INTEGRATED BIOPHARMA INC No No inbp 28000 28000 28000 14000 14000 2000 0 0.071 2016-02-26 2017-09-21 P15D 350000 2017-06-27 2017-06-27 2019-07-29 2017-07-07 2017-07-07 2017-07-07 2017-07-07 202000 230000 179000 76000 73191 0.65 0.85 0.85 8000000 0.5 1000000 60 59 2517000 2517000 563000 563000 6034000 5148000 423000 290000 2803000 2638000 60000 60000 1189000 1536000 1200000 1000000 6473000 6414000 44684000 44676000 32000 32000 31000 34000 1080950 401200 8230769 9311719 401200 74898 76161 2700 2200000 12077000 11623000 9113000 8482000 1668000 1817000 9833000 9322000 90000 104000 125000 14000 185000 84000 71000 451000 294000 13000 -157000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note 7. Commitments and Contingencies</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(a) Leases</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Related Party Leases.</div></div> Warehouse and office facilities are leased from Vitamin Realty, which is 100% owned by the Company&#x2019;s chairman, Chief Executive Officer and major stockholder and certain of his family members, who are also executive officers and directors of the Company. On January 5, 2012, MDC, a wholly-owned subsidiary of the Company, entered into a second amendment of lease (the &#x201c;Second Lease Amendment&#x201d;) with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026. This Second Lease Amendment provides for minimum annual rental payments of $533, plus increases in real estate taxes and building operating expenses. On May 19, 2014, AgroLabs entered into an Amendment to the lease agreement entered into on January 5, 2012, with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which was to expire on January 31, 2019 to extend the expiration date to January 1, 2024. This additional lease provides for minimum lease payments of $27 with annual increases plus the proportionate share of operating expenses.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent expense for the three months ended September 30, 2015 and 2014 on these leases were $184 and $210 respectively, and are included in both cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. As of September 30, 2015 and June 30, 2015, the Company had an outstanding obligation to Vitamin Realty of $1.2 million and $1.0 million, respectively, included in accounts payable, accrued expenses and other liabilities and long term debt in the accompanying Condensed Consolidated Balance Sheet.</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Other Lease Commitments.</div></div> The Company has entered into certain non-cancelable operating lease agreements expiring up through January 31, 2026, related to office and warehouse space, equipment and vehicles (inclusive of the related party lease with Vitamin Realty). </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The minimum rental commitments for long-term non-cancelable leases are as follows:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Operating</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Related Party</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Year ending</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Lease</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Lease</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Commitment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Commitment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016, remaining</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">40 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">422 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">462 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">24 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">587 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">14 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">577 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2019</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">565 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2020</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Thereafter</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,517 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,517 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Total</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">81 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,754 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,835 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total rent expense, including real estate taxes and maintenance charges, was approximately $225 and $252 for the three months ended September 30, 2015 and 2014, respectively. Rent expense is included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(b) Legal Proceedings. </div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 27pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#x2019;s liquidity, financial condition and cash flows. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 27pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 27pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(c) Other Claims. </div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On May 15, 2012, Cedarburg Pharmaceuticals, Inc. (&quot;Cedarburg&quot;) sent the Company a letter (the &quot;Demand Letter&quot;) setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the &quot;Cedarburg SPA&quot;), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company. In the Demand Letter, Cedarburg demanded payment by the Company of $0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA. In addition, in the Demand Letter, Cedarburg informed the Company that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of $0.3 million. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On May 30, 2012, the Company sent a letter responding to the Demand Letter and setting forth the Company&#x2019;s position that it has no obligation to indemnify Cedarburg as demanded. On June 18, 2012, Cedarburg responded to the Company&#x2019;s letter and, on July 27, 2012, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. On December 18, 2012, Cedarburg responded to the Company&#x2019;s letter and, on January 15, 2013, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. As of November 5, 2015, the Company has not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter. The Company intends to vigorously contest Cedarburg's demand as set forth in the Demand Letter.</div></div></div> 0.002 0.002 50000000 50000000 21140074 21140074 21105174 21105174 42000 42000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note 6. Significant Risks and Uncertainties</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(a) Major Customers. </div></div>For the three months ended September 30, 2015 and 2014, approximately 87% and 81%, respectively of consolidated net sales, were derived from two customers. These two customers are in the Company&#x2019;s Contract Manufacturing Segment and represent approximately 47% each and 63% and 26% of this Segment&#x2019;s net sales in the three months ended September 30, 2015 and 2014, respectively. A third customer in the Branded Nutraceutical Segment, while not a significant customer of the Company&#x2019;s consolidated net sales, represented approximately 77% and 78% of net sales in the three months ended September 30, 2015 and 2014, respectively, of the Branded Nutraceutical Segment. Accounts receivable from these two major customers represented approximately 86% and 83% of total net accounts receivable as of September 30 and June 30, 2015, respectively. The loss of any of these customers could have an adverse affect on the Company&#x2019;s operations. Major customers are those customers who account for more than 10% of net sales. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(b) Other Business Risks. </div></div>Approximately 62% of the Company&#x2019;s employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed on September 1, 2015 and will expire on August 31, 2018.</div></div></div> 0.47 0.87 0.81 0.47 0.63 0.26 0.77 0.78 0.86 0.83 0.62 5350000 8130000 7281000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note </div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">5</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">. </div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt</div></div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2015 and June 30, 2015, the Company had the following debt outstanding:</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6">Principal Amount</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="3">Interest Rate</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="3">Maturity Date</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of June 30, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Revolving advances under Senior Credit </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Facility with PNC Bank, National Association</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,219 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,462 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">3.25%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">6/27/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Installment Note with PNC Bank</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,669 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,802 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">3.75%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">6/27/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Line of Credit Note with</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PNC Equipment Finance</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">337 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">307 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">4.57%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">7/29/2019</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Promissory Note with CD Financial, LLC</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,714 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,714 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">6.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">7/7/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Promissory Note with Vitamin Realty, LLC</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">686 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">686 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">4.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">7/7/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Capitalized lease obligations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">104 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">125 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">7.10%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2/26/2016 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">9/21/2017</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 43%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 4%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Promissory Note with E. Gerald Kay</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">27 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">27 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">4.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">7/7/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total outstanding debt</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,756 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">9,123 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Less: Revolving Advances</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(4,219</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(4,462</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 27pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current portion of long term debt</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(707</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(719</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Long term debt</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,830 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,942 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 43%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 4%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Convertible Note payable - CD Financial, LLC</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,350 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,350 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">6.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">7/7/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Discount for embedded derivative</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(202</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(230</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Convertible Note payable, net - CD Financial, LLC</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,148 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,120 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div>&nbsp;</div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">SENIOR CREDIT FACILITY</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On June 27, 2012, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (&#x201c;IHT Properties&#x201d;) and Vitamin Factory (collectively, the &#x201c;Borrowers&#x201d;) entered into a Revolving Credit, Term Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with PNC Bank, National Association as agent and lender (&#x201c;PNC&#x201d;) and the other lenders party thereto.</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Loan Agreement provides for a total of $11,727 in senior secured financing (the &#x201c;Senior Credit Facility&#x201d;) as follows: (i) discretionary advances (&#x201c;Revolving Advances&#x201d;) based on eligible accounts receivable and eligible inventory in the maximum amount of $8,000 (the &#x201c;Revolving Credit Facility&#x201d;) and (ii) a term loan in the amount of $3,727 (the &#x201c;Term Loan&#x201d;). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and common stock of iBio owned by the Company. Revolving Advances bear interest at PNC&#x2019;s Base Rate or the Eurodollar Rate, at Borrowers&#x2019; option, plus 2.75% (3.25% as of September 30, 2015 and June 30, 2015). The Term Loan bears interest at PNC&#x2019;s Base Rate or the Eurodollar Rate, at Borrowers&#x2019; option, plus 3.25% (3.75% as of September 30, 2015 and June 30, 2015). Upon and after the occurrence of any event of default under the Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on June 27, 2017 (the &#x201c;Senior Maturity Date&#x201d;). </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in sixty (60) consecutive monthly installments of principal, the first fifty nine (59) of which shall be in the amount of $44, commencing on the first business day of August, 2012, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the first business day of July, 2017. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof.</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Revolving Advances are subject to the terms and conditions set forth in the Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) $8.0 million or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Loan Agreement, of eligible accounts receivables (&#x201c;Receivables Advance Rate&#x201d;), plus (ii) up to the lesser of (A) 65%, subject to the provisions in the Loan Agreement, of the value of the eligible inventory (&#x201c;Inventory Advance Rate&#x201d; and together with the Receivables Advance Rate, collectively, the &#x201c;Advance Rates&#x201d;), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (&#x201c;Inventory Advance Rate&#x201d; and together with the Receivables Advance Rate, collectively, the &#x201c;Advance Rates&#x201d;), minus (iii) the aggregate Maximum Undrawn Amount of all outstanding Letters of Credit, minus (iv) such reserves as Agent may reasonably deem proper and necessary from time to time.</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Loan Agreement contains customary mandatory prepayment provisions, including, without limitation, (i) the requirement that if the trading price per share of the iBio Stock falls below a certain amount, the Company must sell the iBio Stock and use the proceeds to repay the Term Loan and (ii) the requirement to prepay the outstanding amount of all loans in an amount equal to fifty percent (50%) of Excess Cash Flow for each fiscal year commencing with the fiscal year ending June 30, 2013, payable upon delivery of the financial statements to PNC referred to in and required by the Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which prepayment amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof until the aggregate amount of payments made with regard to the Term Loan pursuant to the Loan Agreement equals $1.0 million. The Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Loan Agreement. As of September 30, 2015, the Company is in compliance with the fixed charge coverage ratio maintenance requirement.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During certain periods in the fiscal year ended June 30, 2013 and continuing through the quarter ended September 30, 2015, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. However, PNC temporarily waived the requirement to sell the iBio Stock due to certain trading rules and restrictions under Rule 144 under the Securities Act of 1933, as amended. As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock, providing net trading proceeds of approximately $79 which proceeds were used to prepay principal outstanding under the Term Loan.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the Senior Credit Facility, PNC and CD Financial entered into the Intercreditor and Subordination Agreement (the &#x201c;Intercreditor Agreement&#x201d;), which was acknowledged by the Borrowers, pursuant to which, among other things, (a) the lien of CD Financial on assets of the Borrowers is subordinated to the lien of PNC on such assets during the effectiveness of the Senior Credit Facility, and (b) priorities for payment of the debt for the Company and its subsidiaries (as described in this Note 5) are established.</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition, in connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC.</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">CD FINANCIAL, LLC TROUBLED DEBT RESTRUCTURING</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On June 27, 2012, the Company also entered into an Amended and Restated Securities Purchase Agreement (the &#x201c;CD SPA&#x201d;) with CD Financial, which amended and restated the Securities Purchase Agreement, dated as of February 21, 2008, between the Company and CD Financial, pursuant to which the Company issued to CD Financial a 9.5% Convertible Senior Secured Note in the original principal amount of $4,500 (the &#x201c;Original CD Note&#x201d;). Pursuant to the CD SPA, the Company issued to CD Financial (i) the Amended and Restated Convertible Promissory Note in the principal amount of $5,350 (the &#x201c;CD Convertible Note&#x201d;) and (ii) the Promissory Note in the principal amount of $1,714 (the &#x201c;Liquidity Note&#x201d;, and collectively with the CD Convertible Note, the &#x201c;CD Notes&#x201d;). The CD Notes mature on July 7, 2017. </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The proceeds of the CD Notes were used to refinance (a) the Original CD Note, (b) a $300,000 note issued by MDC to CD Financial which was assigned by MDC to the Company, (c) past due interest in the aggregate amount of $333 and (d) other expenses owed to CD Financial by the Company in the aggregate amount of approximately $217.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The CD Notes are secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and iBio Stock owned by the Company. The CD Notes bear interest at an annual rate of 6% and have a default rate of 10%. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The CD Convertible Note is convertible at the option of CD Financial into common stock of the Company at a conversion price of $0.65 per share, subject to customary adjustments including conversion price protection provisions.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the terms of the Loan Agreement and the Intercreditor Agreement, during the effectiveness of the Senior Credit Facility, (i) the principal of the CD Convertible Note may not be repaid, (ii) the principal of the Liquidity Note may only be repaid if certain conditions under the Loan Agreement are satisfied, and (iii) interest in respect of the CD Notes may only be paid if certain conditions under the Intercreditor Agreement are satisfied. </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The CD SPA contains customary representations and warranties, covenants and events of default, including, without limitation, an event of default tied to any change of control as defined in the CD SPA.</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the CD SPA, the Borrowers entered into an Amended and Restated Security Agreement and Amended and Restated Subsidiary Guaranty.</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2015 and June 30, 2015, the related embedded derivative liability with respect to conversion price protection provisions on the CD Convertible Note has an estimated fair value of $15 and $12, respectively. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company used the following assumptions to calculate the fair value of the derivative liability using the Black-Scholes option pricing model: </div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 27,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2012</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk Free Interest Rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">0.64</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">0.64</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">0.72</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">70.80</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">71.60</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">144.10</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Term (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">1.75 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">5 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend Rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Closing Price of</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common Stock</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.10 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.09 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.09 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">OTHER LONG TERM DEBT</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Related Party Debt</div><div style="display: inline; font-weight: bold;">. </div>On June 27, 2012, MDC and the Company entered into separate promissory notes with (i) Vitamin Realty Associates, LLC (&#x201c;Vitamin Realty&#x201d;), which is 100% owned by E. Gerald Kay, the Company&#x2019;s Chairman of the Board, Chief Executive Officer and major shareholder and certain of his family members, who are also executive officers and directors of the Company, and (ii) E. Gerald Kay, in the principal amounts of approximately $686 (the &#x201c;Vitamin Note&#x201d;) and $27 (the &#x201c;Kay Note&#x201d;), respectively (collectively the &#x201c;Related Party Notes&#x201d;). The principal amount of the Vitamin Note represents the aggregate amount of unpaid, past due rent owing by MDC under the Lease Agreement, dated as of January 10, 1997, between MDC, as lessor, and Vitamin Realty, as landlord, pertaining to the real property located at 225 Long Avenue, Hillside, New Jersey. (See Note 7. Commitments and Contingencies (a) Leases &#x2013; Related Party Leases). The Kay Note represents amounts owed to Mr. Kay for unreimbursed business expenses incurred by Mr. Kay in the fiscal year ended June 30, 2008. The Related Party Notes mature on July 7, 2017 and accrue interest at an annual rate of 4% per annum. Interest in respect of the Related Party Notes is payable on the first business day of each calendar month. Pursuant to the terms of the Loan Agreement, during the effectiveness of the Senior Credit Facility, the Related Party Notes may only be repaid or prepaid if certain conditions set forth in the Loan Agreement are satisfied.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Capitalized Lease Obligations.</div> On September 17, 2015, the Company entered into a capitalized lease obligation with Regents Capital Corporation (&#x201c;Regents&#x201d;) in the amount of $90, which lease is secured by certain machinery and equipment to be financed with funds available from Regents and which lease matures on September 21, 2019. As of September 30, 2015 and November 5, 2015, the Company has borrowed $14 of the $90 available from Regents. The lease payment amount (based on the current amount outstanding under the lease) of approximately $2 is payable quarterly and has an imputed interest rate of 5.7%.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Equipment Financing Note.</div> On September 22, 2014, MDC entered into a Convertible Line of Credit Note (the &#x201c;LC Note&#x201d;) in the amount of $350 with PNC Equipment Finance, LLC (&#x201c;PNCEF&#x201d;). The LC Note is convertible into a term note upon completion of the advances under the LC Note. During the period from September 22, 2014 to and including the Conversion Date (defined below), the Company was able to borrow up to the full value of the LC Note ($350). The &#x201c;Conversion Date&#x201d; is the earliest to occur of (i) July 31, 2015 or (ii) the date when the Company notifies PNCEF that no more advances will be requested or (iii) the date when PNCEF has made advances in an aggregate amount of $350. As of September 30, 2015, the Company has requested and received advances under the LC Note in the amount of $350. Prior to the Conversion Date, amounts outstanding under the LC Note bore interest at a rate per annum (&#x201c;Floating Rate&#x201d;) which is at all times equal to the sum of LIBOR Rate plus 325 basis points (3.25%). The Company completed the advances on July 29, 2015 and converted the LC Note to a four year term note. On the Conversion Date, the Company elected a fixed rate interest of 4.57% as offered by PNCEF.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition, in connection with the LC Note, the following loan documents were executed: (i) a Security Agreement with PNCEF and MDC; (ii) a Guaranty and Security Agreement with PNCEF and the Company; and (iii) a Cross Collateralization Agreement with PNC, PNCEF and MDC.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div></div> 0.0275 0.0325 0.0325 0.65 4500000 1714000 686000 27000 0.0375 0.06 0.04 0.04 0.06 0.02 0.095 0.06 0.1 0.04 0.057 44000 P4Y 164000 185000 59000 61000 59000 60000 1000 91000 95000 -3000 214000 15000 12000 -214000 0.01 0.02 0.01 0.01 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Earnings Per Share. </div></div>Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible debt, subject to anti-dilution limitations using the treasury stock method and if converted method.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following options and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three months ended September 30, 2015 and 2014:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div><div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2014</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Anti-dilutive stock options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,080,950 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">401,200 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Anti-dilutive shares for convertible notes payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">8,230,769 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total anti-dilutive shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">9,311,719 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">401,200 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div></div></div></div></div></div></div> 15000 12000 0.06 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Investment in iBio, Inc</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">.</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div>The Company accounts for its investment in iBio, Inc. (&#x201c;iBio&#x201d;) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the &#x201c;iBio Stock&#x201d;) at the time of the spin-off of this subsidiary in August 2008.&nbsp;&nbsp;The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be a permanent impairment of the investment. To date, there were cumulative impairment charges of approximately $2.2 million. The market value of the iBio Stock as of September 30, 2015 was approximately $0.8 million based on the trade price at the close of trading on September 30, 2015. </div></div><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the Company&#x2019;s Loan Agreement with PNC Bank, National Association (&#x201c;PNC&#x201d;), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. During certain periods in the three months ended September 30, 2015 and the fiscal years ended June 30, 2015, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock providing net trading proceeds of approximately $79 which were used to prepay principal outstanding under the Term Loan. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).</div></div></div></div></div></div></div></div></div> 0 0 0 P1Y273D P2Y P5Y 0.708 0.716 1.441 0.0064 0.0064 0.0072 P13Y P20Y 909000 891000 547000 540000 251000 245000 1707000 1676000 73000 93000 97000 97000 97000 1525000 1525000 547000 547000 347000 347000 2419000 2419000 712000 743000 616000 634000 7000 96000 102000 1041000 1151000 128000 6000 146000 144000 1315000 1301000 0 0 269000 432000 28000 29000 887000 763000 165000 119000 3000 -214000 309000 1276000 -347000 -109000 23000 83000 -11000 -15000 8230769 50039 199775 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note 3. Intangible Assets, net</div></div>&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Intangible assets consist of trade names, license fees from the Branded Proprietary Products Segment, and unpatented technology from the Other Nutraceutical Businesses Segment. The carrying amount of intangible assets, net is as follows as of: </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gross Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gross Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 28%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Trade names</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,525 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">909 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">616 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,525 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">891 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">634 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unpatented technology</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">547 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">547 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">547 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">540 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">7 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">License agreement</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">347 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">251 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">96 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">347 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">245 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">102 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,419 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,707 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">712 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,419 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,676 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">743 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization expense recorded on intangible assets for the three months ended September 30, 2015 and 2014 was $31 and $34, respectively. Amortization expense is recorded on the straight-line&nbsp;method over periods ranging from 13 years to 20 years based on contractual or estimated lives and is included in selling and administrative expenses. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test. Future unanticipated events affecting cash flows and changes in market conditions could affect such estimates and result in the need for an impairment charge. The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives. No impairment losses were identified or recorded in the three months ended September 30, 2015 and 2014 on the Company&#x2019;s intangible assets.</div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The estimated annual amortization expense for intangible assets for the five succeeding fiscal years is as follows:</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 18pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; MARGIN-LEFT: 35%; MARGIN-RIGHT: 35%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Year ending</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" width="133" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom" width="4">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width="133" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expense</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px" width="4">&nbsp;</td> </tr> <tr> <td width="188">&nbsp;</td> <td width="16">&nbsp;</td> <td width="39">&nbsp;</td> <td width="94">&nbsp;</td> <td width="4">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016, remaining</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="39">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="94">73 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="94">97 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="94">97 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2019</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="94">97 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2020</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="94">93 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="94">76 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Thereafter</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="94">179 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Total</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff" width="39">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="94">712 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="4" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> 237000 240000 82000 333000 173000 174000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> 2</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">. Inventories</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Inventories are stated at the lower of cost or market using the first-in, first-out method and consist of the following:</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-LEFT: 121.5pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="WIDTH: 62%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 16%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 16%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Raw materials</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,702 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,371 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Work-in-process</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,061 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Finished goods</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,349 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,346 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">6,087 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,778 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> 1349000 1346000 6087000 5778000 3702000 2371000 1036000 2061000 800000 1266706 184000 210000 225 252 21142000 20939000 12077000 11623000 12149000 11865000 350000 0.0375 0.0325 0.0375 0.0325 0.0325 0.0457 8000000 350000 4219000 4462000 8756000 9123000 707000 719000 3830000 3942000 0.0457 4219 4462 337 307 4219000 4462000 3727000 600000 0.30 -382000 506000 -41000 -168000 436000 -495000 241000 403000 241000 299000 -216000 -17000 1669000 1802000 1714000 1714000 686000 686000 27000 27000 5350000 5350000 5148000 5120000 3 485000 449000 81000 5754000 5835000 1000 563000 564000 2000 563000 565000 14000 563000 577000 24000 563000 587000 40000 422000 462000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note 1. Principles of Consolidation and Basis of Presentation</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Basis of Presentation of Interim Financial Statements</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the &#x201c;Company&#x201d;). The interim condensed consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto, together with Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (&#x201c;Form 10-K&#x201d;), as filed with the SEC. The June 30, 2015 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results of operations for the three months ended September 30, 2015 are not necessarily indicative of the results for the full fiscal year ending June 30, 2016 or for any other period.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Nature of Operations</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company&#x2019;s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. (&#x201c;MDC&#x201d;), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (&#x201c;AgroLabs&#x201d;), which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers, under the following brands: Naturally Noni, Coconut Water, Aloe Pure, Peaceful Sleep, Green Envy, ACAI Extra, ACAI Cleanse, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the &#x201c;Vitamin Factory&#x201d;), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (&#x201c;IHT&#x201d;) a distributor of fine natural botanicals, including multi minerals produced under a license agreement and (iii) Chem International, Inc. (&#x201c;Chem&#x201d;), a distributor of certain raw materials for DSM Nutritional Products LLC.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Significant Accounting Policies</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There have been no material changes during fiscal year 2016 in the Company&#x2019;s significant accounting policies to those previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended June 30, 2015.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Investment in iBio, Inc</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">.</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div>The Company accounts for its investment in iBio, Inc. (&#x201c;iBio&#x201d;) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the &#x201c;iBio Stock&#x201d;) at the time of the spin-off of this subsidiary in August 2008.&nbsp;&nbsp;The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be a permanent impairment of the investment. To date, there were cumulative impairment charges of approximately $2.2 million. The market value of the iBio Stock as of September 30, 2015 was approximately $0.8 million based on the trade price at the close of trading on September 30, 2015. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the Company&#x2019;s Loan Agreement with PNC Bank, National Association (&#x201c;PNC&#x201d;), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. During certain periods in the three months ended September 30, 2015 and the fiscal years ended June 30, 2015, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock providing net trading proceeds of approximately $79 which were used to prepay principal outstanding under the Term Loan. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Earnings Per Share. </div></div>Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible debt, subject to anti-dilution limitations using the treasury stock method and if converted method.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following options and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three months ended September 30, 2015 and 2014:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2014</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Anti-dilutive stock options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,080,950 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">401,200 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Anti-dilutive shares for convertible notes payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">8,230,769 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total anti-dilutive shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">9,311,719 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">401,200 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> 358000 334000 217000 24000 9000 533000 27000 54000 351000 1000 1000 55000 352000 41000 168000 8553000 8792000 79000 43000 205000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note </div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">4</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">. Property and Equipment, net</div></div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Property and equipment, net consists of the following:</div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Land and building</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,250 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,250 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Leasehold improvements</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,159 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,159 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Machinery and equipment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,416 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,362 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Transportation equipment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,841 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,787 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Less: Accumulated depreciation and amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(6,473</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(6,414</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,368 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,373 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Depreciation and amortization expense recorded on property and equipment for the three months ended September 30, 2015 and 2014 was $59 and $61, respectively.</div></div></div> 1250000 1250000 1159000 1159000 5416000 5362000 16000 16000 7841000 7787000 1368000 1373000 1373000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Land and building</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,250 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,250 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Leasehold improvements</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,159 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,159 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Machinery and equipment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,416 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">5,362 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Transportation equipment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">16 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,841 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">7,787 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Less: Accumulated depreciation and amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(6,473</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(6,414</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,368 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,373 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total Assets as of</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Contract Manufacturing</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">9,113 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,482 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Branded Proprietary Products</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1,296 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,324 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Other Nutraceutical Businesses</div> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1,668 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,817 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Total Company</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">12,077 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">11,623 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note 8. Related Party Transactions</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt for related party securities transactions.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">See Note 7(a). Leases for related party lease transactions.</div></div></div> 8796000 8332000 35000 24000 300000 147000 135000 501000 501000 -53692000 -53935000 1992000 2283000 9445000 8582000 6930000 1815000 8745000 5743000 2065000 7808000 147000 172000 319000 129000 210000 339000 376000 5000 381000 427000 8000 435000 7453000 1992000 9445000 6299000 2283000 8582000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Three Months Ended</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2014</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Anti-dilutive stock options</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,080,950 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">401,200 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Anti-dilutive shares for convertible notes payable</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">8,230,769 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total anti-dilutive shares</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">9,311,719 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">401,200 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="6">Principal Amount</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="3">Interest Rate</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: #000000 1px solid">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="3">Maturity Date</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of September 30, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of June 30, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Revolving advances under Senior Credit </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Facility with PNC Bank, National Association</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,219 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">4,462 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">3.25%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">6/27/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Installment Note with PNC Bank</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,669 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,802 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">3.75%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">6/27/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Line of Credit Note with</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PNC Equipment Finance</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">337 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">307 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">4.57%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">7/29/2019</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Promissory Note with CD Financial, LLC</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,714 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,714 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">6.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">7/7/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Promissory Note with Vitamin Realty, LLC</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">686 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">686 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">4.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">7/7/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Capitalized lease obligations</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">104 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">125 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">7.10%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2/26/2016 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">9/21/2017</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 43%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 4%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Promissory Note with E. Gerald Kay</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">27 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">27 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">4.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">7/7/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total outstanding debt</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,756 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">9,123 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Less: Revolving Advances</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(4,219</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">(4,462</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 27pt; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Current portion of long term debt</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(707</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(719</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Long term debt</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,830 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">3,942 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 43%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 12%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 4%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Convertible Note payable - CD Financial, LLC</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,350 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,350 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">6.00%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">7/7/2017</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Discount for embedded derivative</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(202</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">(230</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Convertible Note payable, net - CD Financial, LLC</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 11%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,148 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,120 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 27,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2012</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk Free Interest Rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">0.64</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">0.64</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">0.72</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">70.80</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">71.60</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">144.10</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Term (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">1.75 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">5 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend Rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Closing Price of</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common Stock</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.10 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.09 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">0.09 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gross Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gross Carrying</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amount</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 28%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Trade names</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,525 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">909 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">616 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,525 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">891 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">634 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unpatented technology</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">547 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">547 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">547 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">540 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">7 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">License agreement</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">347 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">251 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">96 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">347 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">245 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">102 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,419 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,707 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">712 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,419 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,676 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">743 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Operating</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Related Party</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 43%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Year ending</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Lease</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Lease</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Commitment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Commitment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016, remaining</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">40 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">422 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">462 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">24 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">587 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">14 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">577 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2019</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">565 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2020</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">564 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">563 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Thereafter</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,517 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,517 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Total</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">81 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,754 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,835 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="WIDTH: 62%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 16%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 16%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Raw materials</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">3,702 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,371 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Work-in-process</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,036 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,061 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Finished goods</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,349 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,346 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">6,087 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,778 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 25%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Sales, Net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Segment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S.</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">International</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gross</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Capital</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Customers</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Customers</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Profit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Depreciation</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expenditures</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Contract Manufacturing</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">2015</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">6,930 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1,815 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">8,745</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1,041 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">59 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">54 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2014</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,743 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,065 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">7,808 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,151 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">60 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">351 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 22%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 6%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Branded Proprietary Products</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">2015</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">147 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">172 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">319 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">128 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2014</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">129 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">210 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">339 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="WIDTH: 22%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 6%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Other Nutraceutical Businesses</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">2015</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">376 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">5 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">381 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">146 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2014</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">427 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">8 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">435 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">144 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 22%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 6%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Total Company</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">2015</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">7,453 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">1,992 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">9,445 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">1,315 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">59 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">55 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2014</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,299 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,283 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,582 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,301 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">61 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">352 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; MARGIN-LEFT: 35%; MARGIN-RIGHT: 35%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Year ending</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" width="133" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amortization</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom" width="4">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width="133" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expense</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px" width="4">&nbsp;</td> </tr> <tr> <td width="188">&nbsp;</td> <td width="16">&nbsp;</td> <td width="39">&nbsp;</td> <td width="94">&nbsp;</td> <td width="4">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2016, remaining</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="39">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="94">73 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="94">97 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2018</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="94">97 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2019</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="94">97 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2020</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="94">93 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="94">76 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Thereafter</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width="39">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="94">179 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="4" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" width="188"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Total</div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="16">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff" width="39">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="94">712 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="4" nowrap="nowrap">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Note 9. Segment Information</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company&#x2019;s operating segments. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company has divided its operations into three reportable segments as follows: Contract Manufacturing, Branded Proprietary Products and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe and Canada, for the three months ended September 30, 2015 and 2014 were $1,992 and $2,283, respectively.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0.2pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial information relating to the three months ended September 30, 2015 and 2014 operations by business segment are as follows:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"><div style="display: inline; FONT-SIZE: 10pt; FONT-STYLE: normal; BACKGROUND-COLOR: yellow"></div></div></div></div>&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 25%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="10"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Sales, Net</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Segment</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S.</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">International</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gross</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Capital</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Customers</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Customers</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Profit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Depreciation</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expenditures</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Contract Manufacturing</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">2015</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">6,930 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1,815 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">8,745</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1,041 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">59 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">54 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2014</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">5,743 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2,065 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">7,808 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1,151 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">60 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">351 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 22%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 6%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Branded Proprietary Products</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">2015</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">147 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">172 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">319 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">128 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2014</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">129 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">210 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">339 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="WIDTH: 22%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 6%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Other Nutraceutical Businesses</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">2015</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">376 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">5 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">381 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">146 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">- </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">2014</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">427 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">8 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">435 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">144 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">1 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="WIDTH: 22%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 6%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Total Company</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">2015</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">7,453 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">1,992 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">9,445 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">1,315 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">59 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">55 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 22%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: right; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 6%; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2014</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">6,299 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">2,283 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,582 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,301 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">61 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">352 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div> <div style=" MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="6"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total Assets as of</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">September 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 30,</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 62%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Contract Manufacturing</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">9,113 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">8,482 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Branded Proprietary Products</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1,296 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,324 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Other Nutraceutical Businesses</div> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;">1,668 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">1,817 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Total Company</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">$</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;">12,077 </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 16%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">11,623 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div> 830000 852000 11727000 9000 0.88 0.88 0.88 0.88 0.88 0.10 0.09 0.09 -9065000 -9316000 34900 34900 99000 99000 21155213 29535718 21105174 21105174 utr:sqft iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares 0001016504 inbp:IBioIncMember 2008-08-01 2015-09-30 0001016504 us-gaap:DerivativeMember 2011-07-01 2012-06-27 0001016504 2012-06-01 2012-06-27 0001016504 inbp:CdMdcNoteMember 2012-06-27 2012-06-27 0001016504 2014-07-01 2014-09-30 0001016504 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0001016504 us-gaap:WarrantMember 2014-07-01 2014-09-30 0001016504 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember inbp:MajorCustomer1Member 2014-07-01 2014-09-30 0001016504 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember inbp:MajorCustomer2Member 2014-07-01 2014-09-30 0001016504 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember inbp:MajorCustomer3Member inbp:BrandedProprietaryProductsMember 2014-07-01 2014-09-30 0001016504 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember inbp:TwoCustomersMember 2014-07-01 2014-09-30 0001016504 inbp:VitaminRealtyLlcMember 2014-07-01 2014-09-30 0001016504 inbp:BrandedProprietaryProductsMember 2014-07-01 2014-09-30 0001016504 inbp:BrandedProprietaryProductsMember inbp:InternationalCustomersMember 2014-07-01 2014-09-30 0001016504 inbp:BrandedProprietaryProductsMember country:US 2014-07-01 2014-09-30 0001016504 inbp:ContractManufacturingMember 2014-07-01 2014-09-30 0001016504 inbp:ContractManufacturingMember inbp:InternationalCustomersMember 2014-07-01 2014-09-30 0001016504 inbp:ContractManufacturingMember country:US 2014-07-01 2014-09-30 0001016504 inbp:OtherNutraceuticalBusinessMember 2014-07-01 2014-09-30 0001016504 inbp:OtherNutraceuticalBusinessMember inbp:InternationalCustomersMember 2014-07-01 2014-09-30 0001016504 inbp:OtherNutraceuticalBusinessMember country:US 2014-07-01 2014-09-30 0001016504 inbp:EuropeAndCanadaMember 2014-07-01 2014-09-30 0001016504 inbp:InternationalCustomersMember 2014-07-01 2014-09-30 0001016504 country:US 2014-07-01 2014-09-30 0001016504 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember inbp:ThreeCustomersMember 2014-07-01 2015-06-30 0001016504 us-gaap:DerivativeMember 2014-07-01 2015-06-30 0001016504 inbp:ConvertibleLineOfCreditNoteMember 2014-09-01 2014-09-22 0001016504 2015-07-01 2015-09-30 0001016504 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001016504 us-gaap:WarrantMember 2015-07-01 2015-09-30 0001016504 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember inbp:ThreeCustomersMember 2015-07-01 2015-09-30 0001016504 us-gaap:NumberOfEmployeesGeographicAreaMember us-gaap:UnionizedEmployeesConcentrationRiskMember 2015-07-01 2015-09-30 0001016504 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember inbp:MajorCustomer1Member 2015-07-01 2015-09-30 0001016504 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember inbp:MajorCustomer2Member 2015-07-01 2015-09-30 0001016504 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember inbp:MajorCustomer3Member inbp:BrandedProprietaryProductsMember 2015-07-01 2015-09-30 0001016504 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember inbp:TwoCustomersMember 2015-07-01 2015-09-30 0001016504 us-gaap:RevolvingCreditFacilityMember inbp:PncBankMember 2015-07-01 2015-09-30 0001016504 us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2015-07-01 2015-09-30 0001016504 inbp:TermLoanMember inbp:ScenarioEventOfDefaultMember 2015-07-01 2015-09-30 0001016504 inbp:TermLoanMember us-gaap:EurodollarMember 2015-07-01 2015-09-30 0001016504 us-gaap:DerivativeMember 2015-07-01 2015-09-30 0001016504 inbp:IBioIncMember 2015-07-01 2015-09-30 0001016504 inbp:AgrolabsMember 2015-07-01 2015-09-30 0001016504 inbp:ManhattanDrugCompanyMember 2015-07-01 2015-09-30 0001016504 inbp:CdfinancialLlcMember 2015-07-01 2015-09-30 0001016504 inbp:EgeraldKayMember 2015-07-01 2015-09-30 0001016504 inbp:PncBankMember 2015-07-01 2015-09-30 0001016504 inbp:PncEquipmentFinanceLlcMember 2015-07-01 2015-09-30 0001016504 inbp:VitaminRealtyLlcMember 2015-07-01 2015-09-30 0001016504 us-gaap:ConvertibleDebtMember 2015-07-01 2015-09-30 0001016504 us-gaap:MaximumMember 2015-07-01 2015-09-30 0001016504 us-gaap:MinimumMember 2015-07-01 2015-09-30 0001016504 inbp:VitaminRealtyLlcMember 2015-07-01 2015-09-30 0001016504 inbp:BrandedProprietaryProductsMember 2015-07-01 2015-09-30 0001016504 inbp:BrandedProprietaryProductsMember inbp:InternationalCustomersMember 2015-07-01 2015-09-30 0001016504 inbp:BrandedProprietaryProductsMember country:US 2015-07-01 2015-09-30 0001016504 inbp:ContractManufacturingMember 2015-07-01 2015-09-30 0001016504 inbp:ContractManufacturingMember inbp:InternationalCustomersMember 2015-07-01 2015-09-30 0001016504 inbp:ContractManufacturingMember country:US 2015-07-01 2015-09-30 0001016504 inbp:OtherNutraceuticalBusinessMember 2015-07-01 2015-09-30 0001016504 inbp:OtherNutraceuticalBusinessMember inbp:InternationalCustomersMember 2015-07-01 2015-09-30 0001016504 inbp:OtherNutraceuticalBusinessMember country:US 2015-07-01 2015-09-30 0001016504 inbp:EuropeAndCanadaMember 2015-07-01 2015-09-30 0001016504 inbp:InternationalCustomersMember 2015-07-01 2015-09-30 0001016504 country:US 2015-07-01 2015-09-30 0001016504 inbp:ConvertibleLineOfCreditNoteMember inbp:TermNoteMember us-gaap:SubsequentEventMember 2015-07-29 2015-07-29 0001016504 inbp:RegentsMember 2015-09-17 2015-09-17 0001016504 inbp:CdfinancialLlcMember 2008-02-21 0001016504 inbp:ManhattanDrugCompanyMember 2012-01-04 0001016504 inbp:ManhattanDrugCompanyMember 2012-01-05 0001016504 inbp:EnvironmentalIssuesMember 2012-05-15 0001016504 inbp:StockPurchaseAgreementMember 2012-05-15 0001016504 2012-06-27 0001016504 us-gaap:RevolvingCreditFacilityMember 2012-06-27 0001016504 inbp:DefaultRateMember inbp:CdfinancialLlcMember 2012-06-27 0001016504 inbp:PromissoryNoteMember inbp:CdfinancialLlcMember 2012-06-27 0001016504 inbp:CdfinancialLlcMember 2012-06-27 0001016504 inbp:LoanAgreementMember 2013-06-30 0001016504 inbp:IBioIncMember us-gaap:MinimumMember 2013-06-30 0001016504 inbp:AgrolabsMember 2014-05-19 0001016504 2014-06-30 0001016504 inbp:IBioIncMember us-gaap:MinimumMember 2014-06-30 0001016504 us-gaap:LandAndBuildingMember 2014-06-30 0001016504 us-gaap:LeaseholdImprovementsMember 2014-06-30 0001016504 us-gaap:MachineryAndEquipmentMember 2014-06-30 0001016504 us-gaap:TransportationEquipmentMember 2014-06-30 0001016504 inbp:ConvertibleLineOfCreditNoteMember 2014-09-22 0001016504 2014-09-30 0001016504 2015-06-30 0001016504 us-gaap:RevolvingCreditFacilityMember inbp:PncBankMember 2015-06-30 0001016504 us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2015-06-30 0001016504 inbp:TermLoanMember us-gaap:EurodollarMember 2015-06-30 0001016504 us-gaap:LicensingAgreementsMember 2015-06-30 0001016504 us-gaap:TradeNamesMember 2015-06-30 0001016504 us-gaap:UnpatentedTechnologyMember 2015-06-30 0001016504 inbp:IBioIncMember us-gaap:MinimumMember 2015-06-30 0001016504 inbp:CdfinancialLlcMember 2015-06-30 0001016504 inbp:EgeraldKayMember 2015-06-30 0001016504 inbp:PncBankMember 2015-06-30 0001016504 inbp:PncEquipmentFinanceLlcMember 2015-06-30 0001016504 inbp:VitaminRealtyLlcMember 2015-06-30 0001016504 us-gaap:ConvertibleDebtMember 2015-06-30 0001016504 inbp:VitaminRealtyLlcMember 2015-06-30 0001016504 inbp:BrandedProprietaryProductsMember 2015-06-30 0001016504 inbp:ContractManufacturingMember 2015-06-30 0001016504 inbp:ConvertibleLineOfCreditNoteMember inbp:TermNoteMember us-gaap:SubsequentEventMember 2015-07-29 0001016504 inbp:RegentsMember 2015-09-17 0001016504 2015-09-30 0001016504 inbp:RegentsMember 2015-09-30 0001016504 inbp:ConvertibleLineOfCreditNoteMember 2015-09-30 0001016504 us-gaap:RevolvingCreditFacilityMember inbp:PncBankMember 2015-09-30 0001016504 us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2015-09-30 0001016504 inbp:EgeraldKayMember inbp:VitaminRealtyLlcMember 2015-09-30 0001016504 inbp:RevolvingAdvancesMember 2015-09-30 0001016504 inbp:TermLoanMember inbp:ScenarioEventOfDefaultMember 2015-09-30 0001016504 inbp:TermLoanMember us-gaap:EurodollarMember 2015-09-30 0001016504 us-gaap:LicensingAgreementsMember 2015-09-30 0001016504 us-gaap:TradeNamesMember 2015-09-30 0001016504 us-gaap:UnpatentedTechnologyMember 2015-09-30 0001016504 inbp:IBioIncMember 2015-09-30 0001016504 inbp:IBioIncMember us-gaap:MinimumMember 2015-09-30 0001016504 inbp:IBioIncMember inbp:MinimumSharePriceAcceptableBeforeRequiredToSellMember 2015-09-30 0001016504 inbp:OperatingLeaseCommitmentMember 2015-09-30 0001016504 inbp:RelatedPartyLeaseCommitmentMember 2015-09-30 0001016504 inbp:CdfinancialLlcMember 2015-09-30 0001016504 inbp:EgeraldKayMember 2015-09-30 0001016504 inbp:PncBankMember 2015-09-30 0001016504 inbp:PncEquipmentFinanceLlcMember 2015-09-30 0001016504 inbp:VitaminRealtyLlcMember 2015-09-30 0001016504 us-gaap:ConvertibleDebtMember 2015-09-30 0001016504 us-gaap:LandAndBuildingMember 2015-09-30 0001016504 us-gaap:LeaseholdImprovementsMember 2015-09-30 0001016504 us-gaap:MachineryAndEquipmentMember 2015-09-30 0001016504 us-gaap:TransportationEquipmentMember 2015-09-30 0001016504 us-gaap:MaximumMember 2015-09-30 0001016504 us-gaap:MinimumMember 2015-09-30 0001016504 inbp:VitaminRealtyLlcMember 2015-09-30 0001016504 inbp:BrandedProprietaryProductsMember 2015-09-30 0001016504 inbp:ContractManufacturingMember 2015-09-30 0001016504 2015-11-05 0001016504 inbp:RegentsMember us-gaap:SubsequentEventMember 2015-11-05 EX-101.SCH 7 inbp-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Principles of Consolidation and Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Inventories link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 3 - Intangible Assets, Net link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 4 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 6 - Significant Risks and Uncertainties link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 7 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 012 - Document - Note 8 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 9 - Segment Information link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 1 - Principles of Consolidation and Basis of Presentation (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 2 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 3 - Intangible Assets, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 4 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 7 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 9 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 1 - Principles of Consolidation and Basis of Presentation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Statement - Note 1 - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Statement - Note 2 - Inventories - Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 3 - Intangible Assets, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Statement - Note 3 - Intangible Assets, Net - Finite-lived Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Statement - Note 3 - Intangible Assets, Net - Estimated Annual Amortization Expense for Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 4 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Statement - Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Statement - Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Debt Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Statement - Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Calculation of Fair Value of Derivative Liability (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 6 - Significant Risks and Uncertainties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Statement - Note 7 - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 9 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Statement - Note 9 - Segment Information - Operations by Business Segment (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Statement - Note 9 - Segment Information - Operations by Business Segment - Total Assets (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 inbp-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 inbp-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 inbp-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Employee Stock Option [Member] Document And Entity Information IBio Inc [Member] The name of an equity-method investment of the company. Customer Concentration Risk [Member] Related Party Lease Commitment [Member] Information about related party lease commitment. PNC Equipment Finance Llc [Member] Represents the PNC equipment finance. Note To Financial Statement Details Textual Operating Lease Commitment [Member] Information about operating lease commitment. statementsignificantaccountingpoliciespolicies Warrant [Member] inbp_CapitalLeaseObligationQuarterlyLeasePayment Capital Lease Obligation Quarterly Lease Payment Amount due quarterly for the Capital Lease obligation. statementnote1principlesofconsolidationandbasisofpresentationtables Antidilutive Securities [Axis] inbp_BorrowingsToFinanceMachineryAndEquipmentToSecureCapitalLease Borrowings to Finance Machinery and Equipment to Secure Capital Lease Information about the borrowings under the specified debt. statementnote2inventoriestables Accretion on embedded derivative feature of convertible note payable The amount of accretion on an embedded derivative. Sales Revenue, Net [Member] statementnote3intangibleassetsnettables us-gaap_AccruedRentCurrentAndNoncurrent Accrued Rent statementnote4propertyandequipmenttables Antidilutive Securities, Name [Domain] Accretion of Convertible debt - CD Financial, LLC The after-tax amount of accretion recognized in the period associated with any convertible debt. statementnote5seniorcreditfacilitysubordinatedconvertiblenotepayablenetcdfinancialllcandotherlongtermdebttables Amendment Flag Concentration Risk Benchmark [Axis] statementnote7commitmentsandcontingenciestables statementnote9segmentinformationtables statementnote1antidilutivesecuritiesexcludedfromcomputationofearningspersharedetails Concentration Risk Type [Axis] statementnote2inventoriesinventorydetails us-gaap_IncreaseDecreaseInDerivativeLiabilities Change in fair value of derivative liabilities Concentration Risk Benchmark [Domain] statementnote3intangibleassetsnetfinitelivedintangibleassetsdetails Lease Arrangement, Type [Domain] statementnote3intangibleassetsnetestimatedannualamortizationexpenseforintangibleassetsdetails Concentration Risk Type [Domain] Lease Arrangement, Type [Axis] statementnote4propertyandequipmentnetpropertyandequipmentnetdetails Minimum [Member] statementnote5seniorcreditfacilitysubordinatedconvertiblenotenetcdfinancialllcandotherlongtermdebtdebtoutstandingdetails Minimum Share Price Acceptable Before Required to Sell [Member] The minimum share price of the common stock of an investment by the reporting entity before the reporting entity is required to sell its investment. Maximum [Member] Accounts Receivable [Member] Unionized Employees Concentration Risk [Member] statementnote7minimumrentalcommitmentforlongtermnoncancelableleasesdetails Range [Axis] statementnote5seniorcreditfacilitysubordinatedconvertiblenotenetcdfinancialllcandotherlongtermdebtcalculationoffairvalueofderivativeliabilitydetails Range [Domain] statementnote9segmentinformationoperationsbybusinesssegmenttotalassetsdetails Document Fiscal Year Focus Customer [Axis] statementnote9segmentinformationoperationsbybusinesssegmentdetails Net income Net income Document Fiscal Period Focus Customer [Domain] Notes To Financial Statements [Abstract] Debt Conversion, Name [Domain] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Notes To Financial Statements Document Period End Date us-gaap_IncreaseDecreaseInOtherAccruedLiabilities Accrued expenses and other liabilities Current Fiscal Year End Date Debt Conversion Description [Axis] Transportation Equipment [Member] Interest expense on Convertible debt - CD Financial, LLC Entity Current Reporting Status Major Customer 3 [Member] The third major customer. us-gaap_DepreciationAndAmortization Depreciation and amortization Entity Voluntary Filers us-gaap_CapitalLeaseObligations Capital Lease Obligations us-gaap_LongTermDebt Total outstanding debt Amortization of prepaid financing costs Entity Filer Category All Countries [Domain] Machinery and Equipment [Member] Document Type us-gaap_DilutiveSecurities Change in fair value of derivative liabilities us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets us-gaap_SeniorNotes Senior Notes us-gaap_ConvertibleNotesPayable Convertible Notes Payable Cost of sales us-gaap_ImpairmentOfIntangibleAssetsFinitelived Impairment of Intangible Assets, Finite-lived Cash flows from investing activities: Entity Well-known Seasoned Issuer us-gaap_NotesPayable Notes Payable us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by (used in) operating activities Due to related party, current Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in shares) Add: Equivalent shares outstanding (in shares) Segments [Domain] Accounts receivable, net Segments [Axis] Statement [Table] us-gaap_LineOfCredit Long-term Line of Credit Cash Cash at beginning of period Cash at end of period Investment in iBio, Inc. Subordinated convertible note, net - CD Financial, LLC Convertible Note payable, net - CD Financial, LLC Convertible Debt [Member] Supplemental disclosures of non-cash transactions: Current Assets: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net increase (decrease) in cash us-gaap_AccruedLiabilitiesAndOtherLiabilities Accrued expenses and other current liabilities us-gaap_InterestExpense Interest expense Income Statement [Abstract] Regents [Member] Information about Regents Capital Corporation. inbp_OperatingLeasesFutureMinimumPaymentsDueAfterSixthYear Thereafter Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the sixth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used in) provided by financing activities Geographical [Axis] Credit Facility [Domain] Credit Facility [Axis] Revolving Credit Facility [Member] inbp_NumberOfConsecutiveMonthlyInstallmentsFixedAmount Number of Consecutive Monthly Installments, Fixed Amount Represents the number of consecutive monthly installments that have a fixed amount. inbp_ConsecutiveTradingDaysForStockPriceThreshold Consecutive Trading Days for Stock Price Threshold Represents the number of trading days that the stock price has to be below a certain threshold. inbp_NumberOfConsecutiveMonthlyInstallments Number of Consecutive Monthly Installments Represents the number of consecutive monthly payments for a term loan. us-gaap_StockholdersEquity Total Stockholders' Deficiency us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage Selling and administrative expenses us-gaap_TableTextBlock Notes Tables Earnings Per Share, Policy [Policy Text Block] Inventories Total us-gaap_Revenues Revenues us-gaap_OtherAssetsCurrent Other current assets Common stock, shares outstanding (in shares) Additional paid-in capital us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Total Assets Total Assets Stockholders' Deficiency: Capital expenditures Current Liabilities: Legal Entity [Axis] Entity Registrant Name Property and equipment, net Total Entity Central Index Key Entity [Domain] Commitments and Contingencies Disclosure [Text Block] us-gaap_NumberOfReportableSegments Number of Reportable Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Property and equipment, gross us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: Accumulated depreciation and amortization Sales, net Entity Common Stock, Shares Outstanding (in shares) Commitments and Contingencies Litigation Status [Domain] us-gaap_Liabilities Total liabilities Litigation Status [Axis] Loan Agreement [Member] Information about the loan agreement. Long-term Debt, Type [Domain] Segment Reporting Disclosure [Text Block] Long-term Debt, Type [Axis] Trading Symbol Scenario [Axis] Scenario, Unspecified [Domain] Intangible assets, net Total Net us-gaap_FiniteLivedIntangibleAssetsGross Gross Carrying Amount us-gaap_AssetsCurrent Total current assets us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated Amortization Investment [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] us-gaap_LossContingencyEstimateOfPossibleLoss Loss Contingency, Estimate of Possible Loss us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Investment [Axis] us-gaap_NetIncomeLossAttributableToParentDiluted Diluted net income Debt Instrument, Name [Domain] Debt Instrument [Axis] Line of Credit Facility Less: Revolving Advances UNITED STATES us-gaap_LiabilitiesCurrent Total current liabilities us-gaap_DebtInstrumentTerm Debt Instrument, Term Financial Instrument [Axis] Property, Plant and Equipment [Table Text Block] Adjustments to reconcile net income to net cash from operating activities: Changes in operating assets and liabilities: Supplemental disclosures of cash flow information: Counterparty Name [Domain] Counterparty Name [Axis] us-gaap_FairValueAssumptionsExpectedTerm Term (years) us-gaap_FairValueAssumptionsRiskFreeInterestRate Risk Free Interest Rate us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Stockholders' Deficiency us-gaap_FairValueAssumptionsExpectedDividendRate Dividend Rate Depreciation Depreciation Change in fair value of derivative liabilities Property, Plant and Equipment, Type [Axis] Accumulated deficit us-gaap_LongTermLoansPayable Loans Payable, Noncurrent us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears 2019 Property, Plant and Equipment, Type [Domain] us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears 2020 Land and Building [Member] us-gaap_OperatingLeasesFutureMinimumPaymentsDue Total Leasehold Improvements [Member] us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear 2016, remaining us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears 2017 us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears 2018 Subsequent Event Type [Domain] Subsequent Event Type [Axis] Statement of Financial Position [Abstract] Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] us-gaap_ShareBasedCompensation Stock based compensation us-gaap_LongTermDebtPercentageBearingFixedInterestRate Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Embedded Derivative, Fair Value of Embedded Derivative Liability Subsequent Event [Member] Statement of Cash Flows [Abstract] us-gaap_TreasuryStockValue Less: Treasury stock, at cost, 34,900 shares us-gaap_LinesOfCreditCurrent Advances under revolving credit facility us-gaap_DebtInstrumentInterestRateEffectivePercentage Interest rate Cash flows provided by operating activities: us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_DebtInstrumentInterestRateIncreaseDecrease Debt Instrument, Interest Rate, Increase (Decrease) us-gaap_ProceedsFromSaleOfLongtermInvestments Proceeds from Sale of Long-term Investments Security deposits and other assets Current portion of long term debt Current portion of long term debt us-gaap_SalesRevenueGoodsNet Sales, net us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Concentration Risk Disclosure [Text Block] Financing on capitalized lease obligations us-gaap_IncreaseDecreaseInOtherCurrentAssets Other current assets us-gaap_PaymentsForRent Payments for Rent Income taxes Diluted net income per common share (in dollars per share) Interest Interest Paid Anti-dilutive stock options (in shares) us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Weighted average common shares outstanding - diluted (in shares) us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price us-gaap_SharePrice Common Stock (in dollars per share) Share Price us-gaap_IncreaseDecreaseInInventories Inventories us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income before income taxes Income tax expense, net Accounts payable (includes $423 and $290 due to related party) Cash flows from financing activities: us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Weighted average common shares outstanding - basic (in shares) us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate Basic net income per common share (in dollars per share) us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment Common Stock, $0.002 par value; 50,000,000 shares authorized; 21,140,074 and 21,105,174 shares issued and outstanding, respectively us-gaap_FairValueAssumptionsExpectedVolatilityRate Volatility Class of Stock [Axis] Advances under revolving credit facility Branded Proprietary Products [Member] A specified segment of the reporting entity. Three Customers [Member] Three major customers Major Customer 2 [Member] Represents one of the major customers of the company. Contract Manufacturing [Member] A specified segment of the reporting entity. Common stock, shares issued (in shares) Accounting Policies [Abstract] Common stock, shares authorized (in shares) inbp_CapitalizedLeaseObligationMaturitydate Capitalized lease obligations Capital lease obligation maturity date Schedule of Derivative Liabilities at Fair Value [Table Text Block] 2016, remaining Two Customers [Member] Indicates that the reporting entity has two major customers. us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive 2020 us-gaap_RepaymentsOfLinesOfCredit Repayments of advances under revolving credit facility us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Major Customer 1 [Member] Represents one of the major customers of the company. Common stock, par value (in dollars per share) inbp_CapitalizedLeaseObligationInterestrate Capitalized lease obligations Capital lease obligation interest rate. inbp_DiscountForEmbeddedderivative Discount for embedded derivative Represents the discount amount for embedded derivative. us-gaap_RepaymentsOfNotesPayable Repayments under term note payables Repayments of Notes Payable inbp_DebtInstrumentMaturityDate1 Maturity date Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. inbp_DebtInstrumentConvertibleAggregateAmountAdvancedtrigger Debt Instrument Convertible Aggregate Amount Advanced Trigger The aggregate amount advanced that will trigger the conversion of the line of credit. Convertible Line of Credit Note [Member] The convertible line of credit note that can be converted at the earliest of a future date or a date when no more advances will be requested, or the date when the company has made advances in an aggregate amount of the line of credit provided. Vitamin Realty LLC [Member] Represents the Vitamin Realty LLC. Schedule of Inventory, Current [Table Text Block] Default Rate [Member] Represents the default rate. Inventory Disclosure [Text Block] E. Gerald Kay [Member] Represents the Company's Chairman of the Board, President and major shareholder and certain of his family members, who are also executive officers and directors of the Company. Schedule of Debt [Table Text Block] Eurodollar [Member] us-gaap_InventoryWorkInProcessNetOfReserves Work-in-process us-gaap_InventoryFinishedGoodsNetOfReserves Finished goods Other Nutraceutical Business [Member] Information by business segments. International Customers [Member] Information by geographical components Variable Rate [Domain] Europe and Canada [Member] Information by geographical components. Variable Rate [Axis] inbp_InvestmentSharesSold Investment, Shares Sold Represents the number of shares sold for an investment. inbp_OperatingLeasesFutureMinimumPaymentsDueInSixyears 2021 Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the sixth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Environmental Issues [Member] Represents information about the environmental issues. us-gaap_OtherExpenses Other Expenses Stock Purchase Agreement [Member] represents the information about the agreement. Other income (expense), net: Related Party Transactions Disclosure [Text Block] Derivative [Member] AgroLabs [Member] Information of Agro Labs. Statement [Line Items] us-gaap_InvestmentOwnedBalanceShares Investment Owned, Balance, Shares Related Party [Axis] Financial Instruments [Domain] Related Party [Domain] Manhattan Drug Company [Member] Manhattan Drug Company Treasury stock, shares outstanding (in shares) us-gaap_InventoryRawMaterialsNetOfReserves Raw materials us-gaap_ProceedsFromSecuredLinesOfCredit Proceeds from Line of Credit Note Revolving Advances [Member] Represents the revolving advances. Scenario Event of Default [Member] Represents the scenario event of the reporting Company's default. inbp_LineOfCreditFacilityCovenantAggregateRevolvingAdvanceReceivablesAdvancerate Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate The maximum percentage of eligible accounts receivable used to calculate the aggregate amount of revolving advances that can be made to the company. inbp_LineOfCreditFacilityCovenantAggregateRevolvingAdvanceInventoryAdvancerate Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate The inventory advance rate used to calculate the aggregate amount of revolving advances that can be made to the company. us-gaap_LeaseAndRentalExpense Operating Leases, Rent Expense Gross profit Gross profit us-gaap_InvestmentOwnedAtFairValue Investment Owned, at Fair Value Licensing Agreements [Member] Derivative liabilities Trade Names [Member] Term Loan [Member] Represents the term loan. inbp_LineOfCreditFacilityCovenantMaximumAggregateRevolvingadvance Line of Credit Facility Covenant Maximum Aggregate Revolving Advance The maximum amount of aggregate revolving advances that can be made under the credit facility. Unpatented Technology [Member] Debt Disclosure [Text Block] 2021 Amount of amortization expense expected to be recognized during the sixth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life. inbp_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearsix Thereafter Amount of amortization expense expected to be recognized after the sixth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life. us-gaap_IncreaseDecreaseInSecurityDeposits Security deposits and other assets us-gaap_RepaymentsOfLongTermCapitalLeaseObligations Repayments under capitalized lease obligations Intangible Assets Disclosure [Text Block] us-gaap_AccretionExpense Accretion of financing instruments and other non cash interest Number of Employees, Geographic Area [Member] PNC Bank [Member] Represents the name of the Bank. us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd Line of Credit Facility, Interest Rate at Period End Equity Method Investments, Policy [Policy Text Block] Promissory Note [Member] Represents the type of the note. CD MDC Note [Member] Represents the CD MDC note payable by the reporting entity. us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life CD Financial LLC [Member] Represents the CD financial LLC. us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Term Note [Member] Information about the term note. Equity Component [Domain] us-gaap_NonoperatingIncomeExpense Other expense, net Equity Components [Axis] Other income, net Schedule of Finite-Lived Intangible Assets [Table Text Block] Long term debt Long term debt us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_OperatingIncomeLoss Operating income us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2017 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2018 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2019 us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_AssetImpairmentCharges Asset Impairment Charges Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] inbp_LineOfCreditFacilityCovenantAggregateRevolvingAdvancePercentageOfAppraisedNetOrderlyLiquidationValueOfEligibleinventory Line of Credit Facility Covenant Aggregate Revolving Advance Percentage of Appraised Net Orderly Liquidation Value of Eligible Inventory The percentage of appraised net orderly liquidation value of eligible inventory used to calculate the amount of aggregate revolving advances that can be made to the company. inbp_LineOfCreditFacilityCovenantPrepaymentProvisionsPercentageOfExcessCashflow Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow The prepayment requirement as a percentage of excess cashflow for each fiscal year. Property, Plant and Equipment Disclosure [Text Block] us-gaap_AreaOfRealEstateProperty Area of Real Estate Property Line of Credit Facility, Lender [Domain] Lender Name [Axis] inbp_LoanAgreementMandatoryRepaymentAmount Loan Agreement Mandatory Repayment Amount Represents the amount of loan agreement. EX-101.PRE 11 inbp-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 9 - Segment Information - Operations by Business Segment - Total Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Jun. 30, 2015
Contract Manufacturing [Member]    
Total Assets $ 9,113 $ 8,482
Branded Proprietary Products [Member]    
Total Assets 1,668 1,817
Total Assets $ 12,077 $ 11,623
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`"EY94?#F.=LP@$``#@9```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@`0O8))M8S6.+=N4\O;8*2"H"FJ! M2G/)3V>],\DZWZ47#R^.PF!IVBZ,BR9&=\Y8J!HR*I3649>4J?5&Q73K9\RI M:JYFQ,1H=,PJVT7JXC#F'L7DXG9!WNN:!I%\JY5EO=1W: MZ5175-OJR:0E94S6=)#T8G"G?+Q1)K5@RY;UPNK(RZRS_S$,SI.J0T,435N& M^-)2V.2_4MZ=KVBJGMJXD_';NRL]M7U-:+1[L[I>IBXA_38NDAJV]89>DXKND!I9:_\G[?:=4UM-6AKEPCQ]%HSS5]]&G^6[^-CX7 M["]'GFM__=W0>S&P_K1'2.R40X#DD"`Y#D%R'('D.`;)<0*2XQ0DQQE(#CY" M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_ M83)Y!5!+`P04````"``I>65'2'4%[L4````K`@``"P```%]R96QS+RYR96QS MK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][ MCZZ\#JFL#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH` MA3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`*7EE1Q8J%YF?`0``8A@``!H` M``!X;"]?6K#Z+VZU&'9WU]G98SMTKFP*WU5A(>F]76_>FBZJHC]97=T;;$[%T?O-,^G MKAO.R3:KG[-'V_TZZ[9[R48O17?T<9V]-=TYE-['X&XG>>@WZ)>OK?_/]LWA M<-KYQV;W6ODZ_E'AOC;(7#I(TT%*";)TD%&"QNF@,25HD@Z:4(*FZ:`I)6B6 M#II1@N;IH#DE:)$.6E"")`BM';P5Z*^E=&[UL<_16H+=R]%:@MW+T M5J"W1OI6@CR4< MO0WH;1R]#>AM'+T-Z&TAM'+T-Z&TO'W3[E-A0T#K6._DW>WX]T?';>IGR'NU^^$S0=02P,$%``` M``@`*7EE1[4"80'*`@``.@L``!````!D;V-0&ULO59=;]HP M%/TK%D^;M#:0]`M$(S'::976#A76/;O.!:[JV)EM4.FOWXU3TM`V6,&^ M.>?:]YYC)T-ENX.)T1D8AV#98RJ5'5#PO+-T+AL$@15+2+D])(BBIW-M4NYH M:A:!GL]1P(46JQ24"\)N]R2`1P0@*Y-VXF&^RBC+)`KN4*OX&H715L\= MNWP4((?!:X!G4.8IB)5!MXF[!:8:\IBIX!+&M%8\Y])"@7H)>LQ8IQE7FZ"8 M_4#U8']E,WW!'519NP^*[$MN(*%%=[*708_YOJ$Z995J[?55*M,A%MW=];<(%>NPRP^T33L%,L643^6F74F_JW-@UT".#L,RJ`?5K'5,1[% M4=\C:+2+#,K*XN>V[=2=1V;H)-B?\PDW[C^UPM>T;434[U2JWZ9@(Y6P2^7( MCNQ*%4N1>-66E*.QIG.A+"2,1E9+3,AF"9LZ^J-<;3A?N>1*`-N#<[3'WH[? MY=QH!ZS'#MC$H!*8D3Q,S\L$]9R0.%=J3>W3AJZ'>F#D@8[.#=Y+8"-KR6Y? MV`VX>LZ1WY"_>C:,Y^K\66&6:U7/.2;.%!22F\9TLM&Q;UR@)%'K.2LYI\2ANRA%E^^G0%.['+XOON><$><6I)OJ^GH4WZ+]<6:UA)(1>Y=M9L`E)*!K%J5.^=_)AY=FG&2=A[>?V%NB=M;=` MK]_>`F&WO9QAK[4TU(GVG0ZC9LZ(I$Q0KARN@3V_-1$^KL[+K+T^88,+:CFG M>W#V\$'8X(,Z3M3@@SKO1`T^J.6$>W`:?%!W347OOP<:?1TUO`=RSC4J3%0>%M8\Z'$4]=_3Y9U+0,NNW&K:[^/7\=))1P3 MUL.3MPX\*@A7>]V8P(2;9QM$QP@)8@.:ATFL,#&YLEYSC*%?$\?%EJ^!3(OB MFFA`+CER<@#F;B!F=24%$QXX6M_CI1CP;N>;!)."0`,:#`9")Y1D]8O9&MN: MBHSZNHJ.&QYP8:5:*9"WW5CV.Q4[(W@=CG*00_OT]T\/*4.ROG(?U%#5MNVD MG:6Z.#`E;XO'YW0VN3(!N1$054$Q[!S,LU/GU]G=_?(AJZ<%+7-*\Z)7$U>VMKX[IGY$9Z^J_@)02P,$%``` M``@`*7EE1YE&UL[5I; M<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/`0LZ?O.14?GZ#AY\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$8 M1V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I M.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R M#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2BW`A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O= M05SP6.XYB1'^QL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU M4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[ M!Z5&T?95O-RCEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^ M34@3_BNEVOZKR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2 MM!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-) MP>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(* M!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MSAD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q; MY.FOH70^+,_Y/%_GM,T+,T.WF)&Y"M-2D&_#^>G%>!KB.=D$N7V8 M5VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q& MMV"XU_$L%.!D8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9E MM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+ M$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE M,6>F\M\M#`DL6XA9$N)-7>W5YYNTB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)D MU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;S MHYG@'K.'YA,L0Z1^P7V*BH`1JV*^NJ]/ M^26<.[1[\8$@F_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::Q MK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV M-J/D3@H\W/[O#;#"Q([A[8N_`5!+`P04````"``I>65'BB==1T@"``#@"0`` M#0```'AL+W-T>6QE@BX^#N1X0@^7;S_40MU^PZX=O9A-O.?+F^G^(4=N(3`<7S)(A@L MKZ'W(P%WQ8IP5T0!Q6SV"+J/8/C'LJ MJ)!`Z8W0*BS"$2XX-B)M'Y'O`N)VF!Q M/0JPCXFQPX'[/'/@1&Q<[4"]&9PS&PB^J-V1SWF-8_BQ9]`1Z.R MI.UG2@K.L!/KH)7H>L?H@P/T<8AVK&`C)'G6_N8@I!K`$H(MEHJD8^2G1.4: M-ZH[P5Z3'U)X[I3?NJ8AOSYTIR2WT'W-$BQ7MAZ=+NGJYO@ZV2L!)S+_[5:= M(>$5%L>\)G]-VJM>M?]YA,S#^&8W\$^/M]>5WU&-WZOP/0J2FE!%^$X#,F_R MO=%-]XKO4-TU9]8,A=V.*I3HWZV]+)HLPSFJJ?I.MD+9P0@.]E M(H*#_0UGI&8?K8+AGR[^!5!+`P04````"``I>65'K&UE5K<#``###0``#P`` M`'AL+W=O'>^\?Q/?.NK@( MRVJ34K\8C6*S,9V.[WQO'+Y;^=#IA,6P'OG5"AISX9NA,RZ-Y'@\&P5C=0+O MX@;Z6#W3XFMHL0]&MW%C3.KL%M9I<-6']W&Q`FN^F1`1+'3?7^G.+*OOMA)6 MQ_2IA63:937!HG\R>P_"T'\;[K"SNW:752TG4LZVC/S9-S!/D0+S`Z&;!(_F3M\OJW$E])#\9[#)A`N= MS!_!#SVX-;(JL8(0TVT>;OFR`P<=_,S]QE+<^*<_?8"?WB5M;YO@K2VU\HM2 M"5N(OYY@'Q,T>Q\F?7^39V)9S<8(?(0(]V`A_5A6Y=Z:/)+1?X92PO]R)UP) MSFZ*Q9EKQ2>7D"(NW7;R,#2Y#_CQ95L:#@O`FW#9UMM04="Y=ZUQT;0"[Z*W MT&)46G&;\((-$)`D(/EJT$=MM6N,("!%0.I8T(2`)@0T.79H4P*:$M#T_Z`K MGXRHQ5MQ'<`UT%L3A5_]HA+0C(!F#$@BZ-(]XN2A32:2VB>D]@E36Y7:2;MU M%D:@.0.:(NC6./!! MG`>#"UU\UDWQFEHXIAJ.&=0LHV#M`'5*I:X/6$WC<]8T?LAC6HMK-+'9UZFF6M?'>EW/*(J*7;_2;/$&=T1D M_D9!U/'Z6,GK4XJBEM?':E[/*8IZ7A\KNAS379**+CG1.3ME35%4=,F)SBB% MP:>HO<#U@U:]E"B* MNBXYUSFO)'5=4MTE*YSMW']+T6Q%4=L59SNW,RB: MKRAJN^)LSZBO.8<=.OQ_Y:QU1Z8H:KOB;&.6)K!I+W)!Q&\;'.$R33_'W+Y*QY.EE4^ M0>!A8;#V')_]Y;YX7?+L+7EW]/CP+U!+`P04````"``I>65'6[$%/&H"``#C M"```&````'AL+W=OY7GMA14ZOHJY:\L(\?FT:S/[M2$WO&Q_\?N&UNI1"+01%'@R^4]60EE>T M]1@Y;_PM/.\A51*M^%V1.Q^-/;7Y`Z5O:O+SM/%#M0=2DZ-0(;"\W,B>U+6* M),E_;=`/IC*.QWWT[SI=N?T#YF1/ZS_5291RMZ'OG<@97VOQ2N\_B,TA40&/ MM.;ZUSM>N:!-;_&]!K^;:]7JZ]W\DR!K)9RIH+(R![7T61*7"]NU>JM"//@IL)8!1HI=D8!@R*0 ML9T`Y+OL2-O1UX"]443S@*@'1.,,(FV/'P%CQ4SBQ"0Z2#:1AU&LY@&I$Y!J^WH"D-H\Y@F9DY`9/TP@K`3-(U9. MQ,KXHPF$E2PXB+43L3;^9`)A)>D\`D(G0R_+"%/'W6N64,!-L;6[^OK9W5L- M`@@3R!;<-$!NEBECF'J^K`8M>,#`7>P0V=U.4:QFP3,&[HH'4]`HFJCY7A,N M.A]WR8.I:/3IY94\9&,U"UY?X*Y[,&6-TJE[9C79)THPZBD-81?=:[EWI-=6 MF)8RK`[]?*N[7O`A+_(.7\@OS"Y5R[T#%;*SZ39TIE00B0^?9,JE_.(8)C4Y M"S7,Y)B9'FPF@G;])\7P75/\!U!+`P04````"``I>65'NUYFPGX#``#&#P`` M&````'AL+W=O:.`DJX"PX3??MUW@,(9'C^!+`^6?F,S8_S.(DNH]^S[D, MOIJZ[9_#O92'IRCJUWO>E/VC./!6_;,575-*==GMHO[0\7*C@YHZPG&<1DU9 MM>%RH<=>N^5"'&5=M?RU"_ICTY3=OQ6OQ>DY1.$X\%;M]G(8B):+:(K;5`UO M^TJT0<>WS^$+>BHP'21:\;OBIWYV'@SP[T)\#!<_-\]A/##PFJ_ED*)4AT]> M\+H>,JG*?TW2<\TA<'X^9O^NIZOPW\N>%Z+^4VWD7M'&8;#AV_)8RS=Q^L'- M'#3A6M2]_@W6QUZ*9@P)@Z;\@F/5ZN,)_F&Q";,'8!.`IX"ICCT@,0').8#H MF0*9GM>W4I;+12=.07\HA]5&3TK>#4E4YJ#7V=24>CWX,HQ^+C%;1)]#'B/! M,\D*)&A21"JYM0(.;>$8*MPN4!A%?K]",E9(YG-(='P27Y9(M:0%")#DA-#; MH@)$C#)\GX1820B0H,LB9$X"$H:N<>>B`D099AYWG5I)*)!@!PE(4(*H@V04 MQ1XDJ94D!9+$00(2YKPE1D,]UB:SB,#4B,L;Z=72)0KQ?%\CNC0A,C5R9X\4+PVBP"[<8 M$\6)!XO='5%J;NQEF;EF-6J<^];XH\_ZV/T1&6>C+I+,@R2[7L/;),Q.PJRV MR6W[Y6+CXM1E'OL6VRW6PPV2:[N"YNS&$W\ M&*/;JN*L\M@OV.ZX&)FWI8L&>=%85+=I[+:+P2R)RW:-!B,44Y2Y=LXMY6TJ MN_]BL$WJ\M])$[O>&861H3S/,H]O!VPW80SF29'CT3(:YZ-E-`PG<9;Z[&B[ M$V,P4.KZ3#4:M1:48N3ZC!B5.4UHAJ[])YJU1PWO=KIM[(.U.+82>I=I=&I- M7_#07EV-KU3+"@WF.65'?V^@>[8#``#M M$0``&````'AL+W=O[H.@>3J:,FL^V).INE\.MBZSMMNMGX/F5)ML/Q2512`8 M4T&9Y96_W0S'OM?;C7UIB[PRWVNO>2G+K/ZW,X4]/_C<'P_\R)^/;7\@V&Z" MJ6Z?EZ9J>AN%_\Q:TQJBU_YOCUV:9GO[RG:'_;\Q6`?HK[!)ULTPZ?W]-*TMAQ+?*_,_L)W7@W?9_A%,RQS%P@L$%,! M#\D"B07RJB"`9$._/F5MMMW4]NPUIZR_VOR^P^N^D:YEKQE:Z[K4#`<_]D=? MMY'AQ`M>:^=*N3H_0H=R(CM21&,!VI)%PQBX7;GP*L%U/^ M1.9B?KY/,U&"K4CC]J?@^$"@TJ`:":^E([-F7-SV%*"\^.HL%ZM"9`3GH5C& MTA%CB5PQBX5[D2IP?7FU2ITS.V3"<)E)WS/+228+7RZWP9VS!\9R"VYS"O!= MK*FQC=#CU,"^8Y:3N*TIP'4Q94UDNF?%]?K_Z48#PMB7F,C&.%=?GVR!976,'LQ?R4/9MO6?V<5XWW:-ON'7]X(3]8 MVYJN&?8A\KVCR?;33F$.;;\9=]LU_!L!.ZT]C7^N3/_P;/\#4$L#!!0````( M`"EY94=MX^&U_0$``#H&```8````>&PO=V]R:W-H965T&UL MA97+CILP%(9?Q>(!8F-N2420)E15NZ@TFD6[=H(3T!A,;2=,W[Z^0(94F&81 M;/.=_WP6PN0#%^^RIE2!CY9U\A#42O5[".6YIBV1&][33M^Y<-$2I:?B"F4O M**EL4O@[FS16+9<@,<"_"@(X]6":"R( M_BF`SLSNZPM1I,@%'X#LB7G8X5[CPH3H9"!MFMZ2M(LO9O5>;.,5WB19?8N63/7>*YBT,2Y'Y^L/2`7J-DT2AQ1ML5 M(X?@,(P1RN(5(P_H-4H7C5)GM%LQ2J=&*`E7C3R@URA;-,ILRF[E81P=$L6[ MU4>V1#D7.'O->W*E/XBX-IT$)Z[TB6%?[POGBNH4M$D"4.N#_#%A]*+,,--C MXB^`M02P,$%`````@`*7EE1TE7M=<7!```DQ0``!@```!X M;"]W;W)KW$/;GEX]K]D<=)$U+]5)E]TONZHNLK:[K?=>9<%%G]7Z+SZO+F"G=L^''<']J^P5NOO"EN>RQT MV1RKTJGU[LU]%Z^IC'ID(/XYZDLSNW9Z\1]5];._^6O[YOJ]!IWK3=NGR+JO M3YWJ/.\S=4_^A4F_GMD'SJ_'['\,Y7;R/[)&IU7^[W';'CJUONML]2X[Y^V/ MZO*GQAJ"/N&FRIOAT]FWK,W6J[JZ.,TIZT=;O'9XW2?I,CO-D*TKJ1D:W_O6S_52 MK+S//@\B,$,2@WP17I>,RFF\>5S'0%91V#JL(@/R3I"$Z^N-:IY'2$YW',D M121XKB(B542W\?(0]5Q*2*V*@(&16(7!/S)*DAE'HN8DF*6`[Q M,F)$(,+TA"$6("QD")^<6$-S5VIDD4&0E0CTB9@I!9F%")FQ3R=*6+SO`F@U MQC$"5HUA%M)?2\_E:CL1AE)P:A&(+"Q"TEPGC0B%G`LAT M0\!I&2$+(Q`!K04-C1F`!)DX9EZ2%*$HM.D7VAN%L37ALX,4XIQ1K!JDA&\S M@VF3%!'*888@04A)QL52A!;*QK%%3/M#C&HLEE!!6YU88@IF?B<(+6Z7T>N" MEJ.-Q,_5@$^J`1_5<*\!0KR:$;)3(\CN!=Q!^18C!+3C@?&ID%M*D(F#@/.8 MD8IL]DM`&QY(+(A;7A%2K!C#@%7/T(8'"K6P78-FUE7-O4L3)J5-Y]"N!P$* MXE8GA!:"=9J)DC;]0QL?C,;'N3",QL>MW",$%AL1H&T/T/8$Y\((+60,G!I# M!;[%N@WT'A'0]KAU,!DA=AK'XUIIL<,"VD`!#50P12<(1:QC&48%%O_8)&V? M$NV3*SI!*&8L-D4&EA931M+F*=$\;;:_DC9/"9CB9G9?_<,;H8C;BT^0C1C: M.R5ZI[@QHCF4(*348R:]9QY+4737HG4*BUDK:;.3:'8BYKK60,`PZ3WS6`IM M=!*-3G!&AY#DG.6>>2R%MCF)-@?,/]QDA!37*\C$M_[OSR)>4W-:]I5FO3IE>_UW5N^/9>-\5&U;%<.QT:ZJ M6MWI\E\"USGH;#O=Y'K7]I=1=UV;,S-STU:G\0AP.H=<_P]02P,$%`````@` M*7EE1X5>E_6B`0``L0,``!@```!X;"]W;W)KM3+N2#OO^P-CKNI`"W>'/9CPIT&KA0^I;9GK+8@Z MD;1B/,L^,2VDH661:D^V+'#P2AIXLL0-6@O[YPP*QR/-Z5)XEFWG8X&5!5MY MM=1@G$1#+#1'>LH/YWU$),!/":/;Q"1ZOR"^Q.1[?:19M``**A\51%BN\`A* M1:'0^/>L^=8R$K?QHOXU[3:XOP@'CZA^R=IWP6Q&20V-&)1_QO$;S%NXCX(5 M*I>^I!J<1[U0*-'B=5JE2>LX_?F#0I>(I5J]ESO."7:/0C.$;S'G&K`@6U&^VX/06G2&PO M=V]R:W-H965T&ULC5/;CML@$/T5Q`182K:JVH=* MJWUHGXD]MM$"XP*.MW]?P)?U5I':%S,S/N?,@8%\0/OJ6@!/WK0R[D1;[[LC M8ZYL00OW@!V8\*=&JX4/J6V8ZRR(*I&T8CS+'ID6TM`B3[5G6^38>R4-/%OB M>JV%_7T!A<.);NA<>)%-ZV.!%3E;>)748)Q$0RS4)WK>'"^[B$B`'Q(&MXI) M]'Y%?(W)M^I$LV@!%)0^*HBPW.`)E(I"H?&O2?.]922NXUG]2]IM<'\5#IY0 M_925;X/9C)(*:M$K_X+#5YBVL(^")2J7OJ3LG4<]4RC1XFU%'D%@?B.A%GMSD&N(TB09FXI!88R818$"^IW6W!ZC\X3G?^;OIWIA[7#[>3P/P1VL\!V+;";!!X_ M;G&-N&PO=V]R:W-H965T&UL MC5/;;MP@$/T5Q`<$+[NY=.6UM)LJ2AXJ17EHGUE[;*,`XP)>IW]?P)>XU4KM MBYD9GW/FP$`^H'UW+8`G'UH9=Z"M]]V>,5>VH(6[P0Y,^%.CU<*'U#;,=19$ ME4A:,9YE=TP+:6B1I]JK+7+LO9(&7BUQO=;"_CJ!PN%`-W0NO,FF];'`BIPM MO$IJ,$ZB(1;J`SUN]J==1"3`=PF#6\4D>C\COL?DI3K0+%H`!:6/"B(L%W@$ MI:)0:/QSTOQL&8GK>%9_2KL-[L_"P2.J'[+R;3";45)!+7KEWW!XAFD+MU&P M1.72EY2]\ZAG"B5:?(RK-&D=QC\[/M&N$_A$X`OA(4O&QT;)YE?A19%;'(CK M1)S=9A_@-HH$9>*26G#H4O$8JY=BPQ]R=HE"$X:O,*<)LR!84+_:@M-K=)[H M_-_T[4R_7SO<3@[_0V`W"VS7`KM)X,N?6UQC3A-FF_W5A*W.5(-MTM5QI,3> M^/%(E^IR.X]IB.P37N2=:.";L(TTCIS1A\FF,=2('D+[[.:6DC:\GR514/L8 MWH?8CE=J3#QV\P-97FGQ&U!+`P04````"``I>65'-OBT(*4!``"Q`P``&``` M`'AL+W=O*D5Y:)^],(`5FZ&V6=*_KVTNH=5*[0N>&F8;8W(*I(THKQ)+EG6LB.%GFLO9HBQ\$I MV<&K(7;06IA?9U`X'FE*E\*;;%H7"JS(V81]@'P1*5C5]2#M:A7BB4:/$QK;*+ZSC] MV>]FVFT"GPE\)7Q)HO&I4;3Y53A1Y`9'8GL1SBX]>+@)(EZ9V*CF'=I8/(7J MM4BS-&?7(#1C^`9SGC$K@GGUFRTXO47GD<[_3<\6^L/6839UY_\AL%L$LJW` M;AZ1_SGB%G->,-E?3=AF3S68)EX=2TH<.C=MZ5I=;^>)QS/YA!=Y+QKX)DPC M.TLNZ/S)QF.H$1WX]LG=GI+6OY\U45"[$#[XV$Q7:DH<]LL#65]I\1M02P,$ M%`````@`*7EE1U;`S9BC`0``L0,``!D```!X;"]W;W)K&ULC5/;;MP@$/T5Q`<$+[N;5"NOI=U44?M0*O&MEW)&VWG<'QES9@A;N#CLPX:1&JX4/ MKFV8ZRR(*I&T8CS+[ID6TM`B3[%G6^38>R4-/%OB>JV%_7T&A<.1;N@<>)%- MZV.`%3E;>)748)Q$0RS41WK:',Z[B$B`GQ(&M[))K/V"^!J=[]619K$$4%#Z MJ"#"=H5'4"H*A<1OD^9'RDA*91H\3[NTJ1]&$^^9!/M-H%/!/Z)P,9$JB\UVE[-K%)HP?(4Y3Y@%P8+ZS12< MWJ+S1.?_IF]G^L.ZPNV8G?^'P&X6V*X%=E.+^[];7&/.,^;^4Q*VNE,-MDE/ MQY$2>^/'*UVBR^L\\323#WB1=Z*!'\(VTCAR01\FF\90(WH(Z;.[/25M^#^+ MHZ#VT7P(MAV?U.AX[.8/LOS2X@]02P,$%`````@`*7EE1VX<6XFE`0``L0,` M`!D```!X;"]W;W)K&ULC5/+;MLP$/P5@A\0RK13 MIX8LP$Y0M(<"00[MF996$A&2JY"4E?Y]2>H1M3#07L3=U MO&MEW)&VWG<'QES9@A;N#CLPX4^-5@L?4MLPUUD052)IQ7B6?6):2$.+/-6> M;9%C[Y4T\&R)Z[46]M<9%`Y'NJ%SX44VK8\%5N1LX552@W$2#;%0'^EIW.02XC2)!F;BD%ARZ M5#S%ZK78;/DM.D]T_F_Z=J;OUPZW8W?^'P*[ M66"[%MA-(S[\.>(:HX4F)O_+BE2W6YG2>>SN0#7N2= M:."[L(TTCES0AY--QU`C>@CML[M[2MKP?I9$0>UCN`^Q':_4F'CLY@>RO-+B M-U!+`P04````"``I>65'6T3[TZ0!``"Q`P``&0```'AL+W=ODH/YSP@(N"[@-%N8A*\7Q#?0_)2'VD2 M+("$R@4%[IUY.+OTX.$FB'AE8J.:=VAC\12JUS+-DX)=@]",R3:8\XQ9 M$,?USQ"WFO&#^;L(V M>ZK`M/'J6%+AH-VTI6MUO9VG+)[))[PL>M["-VY:H2VYH/,G&X^A073@VR=W M>THZ_W[61$+C0OC@8S-=J2EQV"\/9'VEY6]02P,$%`````@`*7EE1W8BG7NE M`0``L0,``!D```!X;"]W;W)K&ULC5/;;IPP$/T5 MRQ\0`\LFU8I%VDT5)0^5HCRTSUX8P(KMH;99TK^O;2ZAU4KM"YX9SCESQI=B M1/-N.P!'/I34]D@[Y_H#8[;J0'%[ASUH_Z=!H[CSJ6F9[0WP.I*49%F2W#/% MA:9E$6NOIBQP<%)H>#7$#DIQ\^L,$LE2>!-MYT*!E05;>;50H*U`30PT M1WI*#^<\("+@NX#1;F(2O%\0WT/R4A]I$BR`A,H%!>Z7*SR"E$'(-_XY:WZV M#,1MO*@_Q6F]^PNW\(CRAZA=Y\TFE-30\$&Z-QR?81YA'P0KE#9^2358AVJA M4*+XQ[0*'==Q^K-/9]IM0C83LI7P)8G&IT;1YE?N>%D8'(GM>3B[].#A)HAX M96*CFG=H8_$4JM_8=`O@CLM@+Y/&+^YXA;S'G![/]JPC9[JL"T\>I84N&@W;2E:W6]G:65'=P\"5:4!``"Q`P``&0```'AL+W=O:R^FR+%W4FAX,<3V2G'S MYP02AP/=T+GP*IK6A0(K^E>.7E+UUJ&8*)8I_C*O0<1W&/UDZT:X3THF0 M+H3[)!H?&T6;C]SQ(C;(.*5B8UJWJ&-Q6.H7HI-=I>S2Q": M,.D*2$GOMQBU=JLOM/,9#9)_P(N]X`\_<-$); M0XWHP+=/;FXI:?W[61()M0OASL=FO%)CXK";'\CR2HN_4$L#!!0````(`"EY M94>RVS`,L0$``!8$```9````>&PO=V]R:W-H965T,F;(%RA/!" MSOC/K/EJZ8G;^:+^/9S6I3]S`_5;5W8B)(*:CX(^X3C`\Q'"`E+%"9\ M23D8BW*A4"+YRS1V*HSCM).E,^TZ(9D)R4KX$H7@DU&(^8U;7N0:1V)Z[GL7 M[QU<>Q&G3$Q0<7;S0C$DVF-.,61',J5^U2.@U>A+HR>?T MW4*_VR;<3>Y9]+E`N@CLM@+I+!"_/>(6-_"3ZZ93AIS1NNL3>ETC6G#VT4U& M2>L>Z;H04%L_O7-S/=W;:6&Q7U[A^BLH_@%02P,$%`````@`*7EE1RQ<:=FB M`0``L0,``!D```!X;"]W;W)K&ULA5/;;N,@$/T5 MQ`<4QTF:*G(L):VJ]J%2U8?=9V*/;51@7,!Q]^\7\*5N%:DO9F9\SID#`UF/ MYMTV`(Y\*JGM@3;.M7O&;-&`XO8&6]#^3X5&<>=34S/;&N!E)"G)TB2Y98H+ M3?,LUEY-GF'GI-#P:HCME.+FWPDD]@>ZHE/A3=2-"P669VSFE4*!M@(U,5`= MZ'&U/VT"(@+^".CM(B;!^QGQ/23/Y8$FP0)(*%Q0X'ZYP#U(&81\XX]1\ZME M("[C2?TQ[M:[/W,+]RC_BM(UWFQ"20D5[Z1[P_X)QBUL@V"!TL8O*3KK4$T4 M2A3_'%:AX]H/?^Z2D7:=D(Z$]`>!#8VBS0?N>)X9[(EM>9C=:N_A)HAX96*C MFG=H8_$8JI=\M=UF[!*$1DRZP)Q&S(Q@7OUJBY1>HZ>1GOY.7T_TW=+A>G1X M^[O`9A)8+P4VH\#N^Q:7F-.$N?O1A"W.5(&IX]6QI,!.N^%(Y^I\.X]IG,D7 M/,]:7L,+-[70EIS1^/?SYQ(J%P(=SXVPY4:$H?M]$#F M5YK_!U!+`P04````"``I>65'/CJT1*0!``"Q`P``&0```'AL+W=OF9QSYHPO68_FS38`CGPHJ>V!-LZU>\9LT8#B]@9; MT/Y/A49QYU-3,]L:X&4D*19KSR;/L'-2:'@VQ'9*-"@>49FWFE4*"M0$T,5`=Z7.U/FX"(@+\">KN(2?!^1GP+R>_R M0)-@`204+BAPOUS@'J0,0K[Q^ZCYW3(0E_&D_ABG]>[/W,(]RE=1NL:;32@I MH>*=="_8/\$XPC8(%BAM_)*BLP[51*%$\8]A%3JN_?!GFXRTZX1T)*0SX5ZK`U/'J6%)@I]VPI7-UOIW'-)[)-SS/6E[#'VYJH2TYH_,G&X^A0G3@ MVR&ULA53-CML@ M$'X5Q`,LCA-GJ\BQE&Q5M8=*JSVT9V*/;;3`N(#C[=L7\,]Z5U%S,)"TR*/N6=3Y-@[*30\&V)[I;CY>P:)PY%NZ)QX$4WK0H(5.5MXE5"@K4!- M#-1'>MH0,@AYXS^3 MYKME(*[WL_JWV*VO_L(M/*'\+2K7^F(32BJH>2_="P[?86HA5EBBM/%+RMXZ M5#.%$L7?QE7HN`[CR9=DHMTFI!,A_41@HU$L\RMWO,@-#L1V/,QN<_!P$T2\ M,K%1S5=H8_(4LM=BLT]S=@U"$R9=8\09^CH'#;GZ%RZ^@^`=02P,$%`````@`*7EE1\Y\#">F`0``L0,` M`!D```!X;"]W;W)K&ULA5/+;MLP$/P5@A\0RO(K M,60!=HJB/10(=34S/;&N!E)"G)TB39,<6%IGD6:T\F MS[!S4FAX,L1V2G'S<0:)_9&NZ%1X%G7C0H'E&9MYI5"@K4!-#%1'>EH=SIN` MB(`7`;U=Q"1XOR"^A>1W>:1)L``2"A<4N%^N\`A2!B'?^.^H^=4R$)?QI/XS M3NO=7[B%1Y2OHG2--YM04D+%.^F>L?\%XPC;(%B@M/%+BLXZ5!.%$L7?AU7H MN/;#G\W#2+M-2$=".A/NDVA\:!1M_N".YYG!GMB6A[-;'3SBFP&4>\_W?$)>8\81[^:\(6>ZK`U/'J6%)@I]VPI7-UOIVG-)[)%SS/ M6E[#'VYJH2VYH/,G&X^A0G3@VR=W6TH:_W[F1$+E0KCWL1FNU)`X;*<',K_2 M_!-02P,$%`````@`*7EE1Q^\K(&O`0``%@0``!D```!X;"]W;W)K&ULC53=;J0@%'X5P@,4=<9.,W%,9KII=B\V:7K17C-Z5%+P M6,"Q^_8%_*G;3+9[(W#X_L@!LP'UJVD`+'E7LC4'VEC;[1DS10.*FQOLH'4[ M%6K%K5OJFIE.`R\#24F61-$M4URT-,]"[5'G&?96BA8>-3&]4ES_.8'$X4!C M.A>>1-U87V!YQA9>*12T1F!+-%0'>HSWI]0C`N!9P&!6<^*SGQ%?_>)7>:"1 MCP`2"NL5N!LN<`]2>B%G_#9I?EIZXGH^JS^$T[KT9V[@'N6+*&WCPD:4E%#Q M7MHG''["=(20L$!IPI<4O;&H9@HEBK^/HVC#.(P[=]%$NTY()D+RA.[CV(DZ9F*#F$II0//KJ)8]W4<8N7FC")"O,:<(L".;4 MKUHD]!H]"?3D>_IFIN_6"3>C>WK[O._C[C&G&;,?Z1,KYJD MD\#F'R8S9OO%A*T:IT#7X7X:4F#?VK%O2W5Y`LS:B`0``L0,``!D```!X;"]W;W)K&ULA5/;;N,@$/T5Q`<4Q[E5D6,IZ:IJ'U:J^K#[3.RQC0J,"SCN_GT!7^JM M(O4%9H9SSLPPD/5HWFP#X,B'DMH>:>-<>V#,%@TH;N^P!>U/*C2*.^^:FMG6 M`"\C24F6)LF.*2XTS;,8>S%YAIV30L.+(;93BIM_9Y#8'^F*3H%743 ML9E7"@7:"M3$0'6DI]7AO`F("/@CH+<+FX3:+XAOP7DNCS0))8"$P@4%[KU!]CM[[Z"[?P@/*O*%WCBTTH*:'BG72OV#_!V,(V M"!8H;5Q)T5F':J)0HOC'L`L=]WXXN4]&VFU".A+2;P0V)(IE_N*.YYG!GMB6 MA]FM#AYN@HA7)C:J^0IM#)Y"])JO]MN,78/0B$D7F/.(F1',J]],D=);]#32 MTY_IZXF^7U:X'K)O=S\+;":!]5)@,[:X^[_%)>8\8?;?DK#%G2HP=7PZEA38 M:3=65'QI#S=;(!```6!```&0`` M`'AL+W=O3*IZT5T[<`"K_F&V"=W;US:&LBE:;K!]^/[,L2E&I=]-!V#1A^#2''!G M;;\GQ%0="&KN5`_2O6F4%M2ZI6Z)Z370.I`$)UF2/!!!F<1E$6HONBS48#F3 M\**1&82@^L\)N!H/.,5SX96UG?4%4A9DX=5,@#1,2:2A.>!CNC_E'A$`;PQ& MLYHCG_VLU+M?/-<'G/@(P*&R7H&ZX0*/P+D7NY[/ZC[!;E_Y, M#3PJ_HO5MG-A$XQJ:.C`[:L:GR!N(22L%#?AB:K!6"5F"D:"?DPCDV$X*(61#$J5^UR/`U>A;HV6WZ9J9OUPDWDWO^<%O@?A;8K`7N MXQ:__;W%->84,;ODMDE^U22/`NE_3&;,OY^"K!HG0+?A?!I4J4':J6]+=;D" MQRPT_@M>%CUMX2?5+9,&G95UQR?TNE'*@K-/[G*,.G=)EP6'QOKIULWU=&ZG MA57]?`N77T'Y"5!+`P04````"``I>65'W5#$/[H"``!`"P``&0```'AL+W=O M[%[31.2.%7)`FFZ;[^`:-P4#3=1R7?.?T#%O[A0]LZ/A`COLZE;OO2/0IP> M@H!OCZ3!?$%/I)7_["EKL)"7[!#P$R-XIT5-'<`P1$&#J]8O"SWVRLJ"GD5= MM>25>?S<-)C]79&:7I8^\/N!G]7A*-1`4!;!H-M5#6EY15N/D?W2?P0/+R!1 MB"9^5>3"1^>>"O]&Z;NZ^+Y;^J'*0&JR%JVIA./S MWOU93U?&?\.JU<=+]T\6&IE=`(T`#H*ACET0&4%T%:!906P$\540SPH2(TA2YBLT'0;:PYBM*4]GGH@!Z-"MARZ/]A3*H@,$"YD,W.4[>QP49.]4*>I/&==@]=="'KJ^]6A:2[_`5!+ M`P04````"``I>65'!W<2-_X!``"E!0``&0```'AL+W=OD:;T\L[57D6?\HFC3PJM`\L(8$7\.0'F_\P)O M++PUYUJ9@I]G_L0[-0Q:V?`6":AVWC[8%HE!6,#/!GHYVR/C_6ACC?C^I?;5KM_D@D%)S^:DZJUF:QATY0 MD0M5;[S_!D.$E1$L.97V%Y47J3@;*1YBY,.M36O7WCW9X(&V3`@'0C@1IC[+ MA&@@1#=";),Z9S;7%Z)(G@G>(]D1\V<'6PT71D0K(VG5="1IBWM3O>8A#C+_ M:H0&3#C#'!SFAO"U^F*+T%NBAZ[%_0;%@$@?=XC&#M$\1#2$"!\+Q(L"\2`0 M?3896TSK8CA,@#'[N,+A8ASH6_/8SVK1SVKP$S\66"\*K)\(Y#";,,+) M.OV,FVL5#A<_X259])(\X<5ATB@(DB#]S\M-[K][3 MG*K3Y-F'YOK\4S_HB>0&R$TFSSIRAA]$G)M6HB-7^G+:FU1QKD`[PR\K#]5Z M9DX'"I4RVT3OA1LC[J!X-P[%:3+G?P%02P,$%`````@`*7EE1YPO9DW6`0`` M$04``!D```!X;"]W;W)K&ULC93-;IPP%(5?Q>(! M8OZ9C!BDA"IJ%Y6B+-JU9[@,*`83VS.D;U__04G$D&ZP?7W.\6?9.!\9?Q4- M@$3O'>W%P6ND'/88BU,#'1%W;(!>S=2,=T2J(3]C,7`@E3%U%(>^G^*.M+U7 MY*;VS(N<721M>WCF2%RZCO`_CT#9>/`";RJ\M.=&Z@(N)9@!;!*$4X4 MT9(B=!3IQS52H^DMA=5$F1_>%I4N*,J"KU&B593(H60?5XF7*%83^%%Z6U1. M0>E_H,2K*+%+V&V@6$T0Q?<;*+,H_1HE645)',K]Q@%93>KOLHT#LJ(DRW:? M4/#B]@[D##\)/[>]0$&ULC51;;YLP%/XKEG]`N24DBPA2DJG:'B95?=B> M'7*XJ#:FMA.Z?S_?("PB35^P??AN1^"3]5R\R1I`H0]&6[G%M5+=)@AD40,C M\HEWT.HW)1>,*'T452`[`>1D28P&<1BF`2--B_/,UEY$GO&SHDT++P+),V-$ M_-T#Y?T61W@HO#95K4PAR+-@Y)T:!JUL>(L$E%N\BS:'M4%8P.\&>CG9(Y/] MR/F;.?P\;7%H(@"%0AD%HI<+'(!2(Z2-W[WFU=(0I_M!_=EVJ],?B80#IW^: MDZIUV!"C$Y3D3-4K[W^`;V%I!`M.I7VBXBP59P,%(T8^W-JT=NW=FS3TM'E" M[`GQ2!A]Y@F))R17PL)VZI+9OKX31?),\![)CIB/'6TT7!@1K8RD5=,M25O< MF>HECZ,P"RY&R&/B"6;O,-&("+3ZK$6,Y^BQL[AOFRQG399>8/%8()T52+^0:ZW=3W>H*Y@7.5R;..5/"+B*II)3IRI2^SO7DEYPITL/!I MB5&M9^QXH%`JLUWIO7!CQQT4[X8A.D[R_!]02P,$%`````@`*7EE1\LZ^U]Z M`@``,0H``!D```!X;"]W;W)K&ULC9;+CILP%$!_ M!?$!`S:O,")($ZJJ750:S:)=.XD3T`"FMA.F?U^_2,G4$&\"=LZ]'&/[XF(D M])W5&'/OHVM[MO5KSH?G(&"'&G>(/9$!]^*?$Z$=XJ))SP$;*$9'%=2U`0S# M-.A0T_MEH?I>:5F0"V^;'K]2CUVZ#M$_.]R2<>L#?^IX:\XUEQU!602WN&/3 MX9XUI/T=\0I>6OY'Q&S9C M2&3"`VF9^O4.%\9)-X7X7H<^]+7IU774_VQ"$V8/@"8`W@)`O!H0F8#H4T"@ MS=2XOB".RH*2T6,#DK,-G@5.91*1V6,JFQ@24YTOLO=:0K`I@JM,9!@X8W:& M628J323Q#0F$@-4"3A;1W`(:B_QQ@LB:(-()8'@OF2JFU\/0#$A@L@Q5%FA1 M);:JQ$8%W#\EGJMH)@_S9:;2S"8'CT42JTAB1."*B&92D*Z(&"9RF-W4*I(: MD>AQ@LR:(+//[MU(,K,$LY61_,\LBFRL(AO[W-XMLXV#R,2$CT5RJTANG]LY ML]-,'*]X:,3A=8#0JJ&ZI8?#V@#`G@(X;%T#1:LOU0(MR]CK$(`.FW>"DA6H MFJ#8H8X`>TT#D<,&-E"^MH$-`T+HX&(O:B!VV((3%(.UNF:CEG7LI0TD+O.D M(9"%JZO&4&F6.NC8"QQ([3-UOX8UE($5J)J@^'.M#&8?]P&=\0]$STW/O#WA MXIR@/NHG0C@62<*GQ/=J<7Z[-5I\XO(V$_=4GVAT@Y-A.J#=3HGE7U!+`P04 M````"``I>65'>Y="+^0!``"Z!0``&0```'AL+W=O]%>.V$(:`UF;2=LW[[^ MP2E=(9(;;`]GSC>6[P%T-(FM0R3,$QP2YLN*'(;>Q5%SB^*-1V\"B0O;4O%GP,P/NR"*/"! MM^9<*Q/`18YO>6730B<;WB$!U2[81]M#9A16\*N!04[FR-1^Y/S=+'Z4NR`T M)0"#DS(.5`]7>`;&C)$&?XR>_Y`F<3KW[B]VM[KZ(Y7PS-GOIE2U+C8,4`D5 MO3#UQH?O,&XA-H8GSJ3]HM-%*M[ZE`"U]-.-36?'P?W9A&/:?`(9$\@M@;C" M'"D#C'5V,T:LA$<_": MY*;!VG\60CQD-860T2#]'Y)83><@3I.N[C-6GK&>Y.]7CA%&7R!3T<&)LO0^ M9#T+67O(9@&R?A@2ST)B#\D6(/'#D&06DHP0$BY`G"A[X$S264CJ(=$"Q(G2 M!R[79O9R;<;+M70D3A.EV7U(-@O)QIUD"S?8:=*(?('@R;OLZ1E^4G%N.HF. M7.DG;M]CQ;D"[1$^Q0&J=2.]+1A4RDQ3/1>NM[B%XKWOE+=V7?P%4$L#!!0` M```(`"EY94?+X`6&M@$``/X#```9````>&PO=V]R:W-H965T9SSVK/).#89V`9X7TP#E5?T[`Y'C`,9X3+UW3&I<@ M>4867M5Q$+J3`BFH#_@8[XO4(3S@M8-1K_;(U7Z6\MT%3]4!1ZX$8%`:IT#M MV31Y>]Y$FRR\C%"4V89(4Y!4R\ M((A5OVF1X%OT)%A\;U!,B-W_'=+9(5TWD09^&GWVV'J,"%4$S&;W/:0(D.W7 M1LGJOW)0C9\WC4HY"!-Z7K++2!\3=R]?\B<[ZF$RKS)YUM,&?E'5=$*CLS3V MUOT5U5(:L%5%=QN,6OL8EX!!;=S63A=283Y#8&0_O[;ER>=_`5!+`P04```` M"``I>65'^:"I/RH"``#"!P``&0```'AL+W=O<\P.NFBEOAA$*1^BYK.*PN]]\+*@EX%:3K\P@"_MBUBOY\QH@]ZX\=I< M:J$V_++PI[I3T^*.-[0##)_WWA-\K&"H$$W\:/#`9_=`R1\H?5.+;Z>]%R@' M3/!1J`@D+S=<84)4DGSR+QOZ\4Q5.+\?T[_H=J7^`7%<4?*S.8E:V@8>..$S MNA+Q2H>OV/:0J,`C)5Q_@N.5"]J.)1YHT;NY-IV^#N:;/+!E[H+0%H13`8Q7 M"R);$/U3X!LSW==G)%!9,#H`WB/UMN&CQ)D*D;3VKW5H81+/R; M"K),.&.>+;-,5(:`>3(QOC1P:H2C1C37"*U&>#\@<@9$-B#ZVS+53&?Z,`P, MDV`9JAS0HDKL5(FM2GP_('$&).Y>XGDOAH$PV2U#E0-:5$F=*JE5V?!B,V=` MMJ$7PR0Q3%=ZL5"4;OB)Y$Z5W*JD]P-VSH#=AEX,L]K)?\BB!@R<'GK[GHB% MLCR&*RXCE>79!AWHUAEG2+:F8Z!/:9RM6%F2/&+`3MQQ-S.K;+/U!+`P04````"``I>65'A\Y`A*$%``"((@``&0`` M`'AL+W=O[\FJXJJK]Y6A4/J^R;5I>Y/ML=_C+2UYLT^KPL7@=E?LB2Y=-T'8S MDE%D1]MTO1M.QLVU'\5DG+]5F_4N^U$,RK?M-BW^N\XV^9KMRG>\&1?9R-?PF+A^MJY&&^+7./LJC]X.Z^*<\_UU_N%]> M#:.ZAFR3/5=UBO3P\I[=9)M-G>G0\K^0]&^;=>#Q>Y]]UG3W4/Y36F8W^>:? M];):':J-AH-E]I*^;:J?^<==!GTP=<+G?%,V_P^>W\HJW_J0X6";_FE?U[OF M]:/]BXL@#`^0$""[`*')``4!BAN@(4!S`PP$&&Z`A0#+#8@A(.8&.`APW(`$ M`A)N0#WG[W`'4; MCJ8$+F\!NC34&ND@SE(4N'H%2-/TMAU[,OHMY*+F'Z,S*@2M7@BAC00BJ@U@'(URY$D09<]:XQ$4I090QL<9O M.HBUQG%!2A!D3+CT30=Q_$SBJI4@R)BSY!0N2`6"C!-"3`#UG?Y<3`&0J`J7 MN`*).U8.7)!*?MZS6X"4X=8;.'?[`S,QY;<=Q)ERA:M6@6J=H#JEO]@I7-T* MA.NH70P@?ENXP!4(W+'N?7"!*]A076_"W4F]+11=.!>F%BSJ.XMZP"BB;[BG MJ-8N1,(YE2C<+E0".8C[F'D'<8K5N*?H"'(0V]@*>1W3@!MP[!>>DI7$'T`8O]W0B MS=?*Q0U`^QV>.$I<>\AQ'%3C+J%AA^]K]G@*K@%*F*:F<=%JV./[AG3:E/,K MF-42+FT-)X&$D\/@JC71YS,P]5!"0#,$(JK!A6W\XS_.J='@BC62TR,)9D4\ M`)AQH$??7,+9PPQN$,;?`1#W-H\`:<,]91G<(@Q81*+#C4T!,KT=_OSL%P") MJ@+/],!TDI[IN).J#&RJEJ!F&$74@SN3`=-)+&&"``E#CM'"8TRU&]S"#%A8 MPGIPBGN3T^+N9"-&O1Z*>>5:W'JLMQ[JE@@@ M(>+3ULYU$2*)NG`[L]+?^%-U`?1Y63A(5(4[EO6/(X@[DCE`FGE&L+A?6?WY M`7\*4'01$=2,1A9,K__DYW04_4F+GMH[SRG#'.[`5R,6 M9I:X_YMY2*FSFDZE"3"&PO=V]R:W-H965T+SY]P'48CP[#?1>QL`\=3]U M\YZ0UG=3?V_.6K?>C[*HFF?_W+;7IR!H]F==YLT7<]55]Y^CJ?:TW:W-KBTNEO]9>]$X711^IR_PO!GW/V0]\O';1?Q^FV]%_S1N],\4_ MET-[[MB&OG?0Q_Q6M-_,_0^-::]]T63QV\[H-T MD;UFB-9-J1D>OO1/WS8R5.O@K0^$&'C`;"U&C(B@BTZF`)\:#L-PF$ZPLXA( M+6>0+H-\G(3$243+`1090&&`^"/)>,!4=AH6HT!DTZ`=@E0,RU0BDDIDJZ5^ M:L@C9NLPR7*2F$P2XWR3F20.DRXG2<@D"0:8J=?68E:?JZH>J^I0K+*F))G4 MDA'AP7FS:?,0 M&4?6%B02H19D30.GEV7::R!DR!I!(F-H$FC[`'2&C-%JH)T!@-$G!^+T"6C[ M`,GH$X+B-)YO$XV;ID2;""A.EYR),*0`M(D`?E1DC,4+:'\`SF>%`[&Z1`L? M$DZ7T!V2A291L&E"M(U`RNE1^@L]HFT$K/!!,+[%)2UZZ40?SU`=00S%2EKT M4G#R.!#CG9.T,TC<77"6-3FQ>Y`MBJ!^ M@[0P^6S<>K(FKVA_4%;ZD*;3N;8($N'"AXK#0<2C1%N)0I<`F*-D06D2+:S* M",P$2!XIVG>4^R*9V;=N$;1:[MZ(9+>/]C)E;2J9R;5%S"H)%];&$?B1_32G MB<,5:VG);/O0]E*YH'$'S!2S3K1'*N>1WJK5'A>/3\9SV!8:SQG?X M9GW-3_JOO#Y=JL9[-6UKRN%X\6A,JSL.X9?(]\XZ/XPWA3ZV_6727=?V;-7> MM.;JCHK'\^K-_U!+`P04````"``I>65'.BYP03<"``"4!P``&0```'AL+W=O M-C$_EF/:'OK$*(@P_ODF:J]TCPC5][4+7JE M@%TQAO3O'C6DWSJ^8PMO]:7BLN#FF3OH3C5&+:M)"R@Z;YV=ORE322C@5XUZ M-AH#F?U`R+N<_#AM'4]&0`TZ.&"M0TTD@L_,=XWI>4PO'8NG]3NQ7I M#Y"A@C2_ZQ.O1%C/`2=TAM>&OY'^.S);B*7AD31,_8+CE7&"K<0!&'[H9]VJ M9Z_?I)Z130L"(P@&@9\L"D(C")\51$80W061.AJ]%740)>0PSRCI`>N@_'?X M&X%3:2*<`5-NX@R8*NYD]9:'09RY-VEDF&#$[#7CSQ.%=4D&QA4))F,$SM02 M@3((%I;01!S-(Z5&_'3].$5H4X3CPPC--IXPB"8-(F.0?DXY9O:6>9EGBB>8 MTC"A]SAL/!DV-@;^0EC+!`MA+1,NA+5,]#AL,ADV,0;Q0EC+)`MA+;->"&N9 M]''8]638M3%8^'Q[P_@+08HGF/)_9C9L.ADVU0:1]WF15#&M#JL9;^7/,X5E MO)=YJ)R`=%QW='EA1"^J"S!P)->6ZTMCJ`Z-9A?(R^]+O1`-2/>+NTV>=?"" M?D)ZJ5L&#H2+JU7=@V=".!*YO%7L@$JTR&'2H#.7P[484]TU](23SO;`H1'G M_P!02P,$%`````@`*7EE1QB%C1=1`@``EP@``!D```!X;"]W;W)K&ULC5;=CJ,@&'T5X@.,@F)_8DWZD\WNQ2:3N=B]IBVM9E1< MH'7V[1<0K3-+U1N!SW,.YR/`1](P_BXR2B7X*(M*;+Q,RGKM^^*4T9*(%U;3 M2OVY,%X2J8;\ZHN:4W(VI++P41#$?DGRRDL3$WOE:<)NLL@K^LJ!N)4EX7]W MM&#-QH->%WC+KYG4`3]-_)YWSDM:B9Q5@-/+QMO"]0%&&F(0OW+:B$$?:/-' MQM[UX,=YXP7:`RWH26H)HIH[W=.BT$IJYC]6]#&G)@[[G?HWDZZR?R2"[EGQ M.S_+3+D-/'"F%W(KY!MKOE.;`]:")U8(\P6GFY"L["@>*,E'V^:5:9OVSS*P M-#&#$(T2(DN('H38+$V;BEF(`Y$D33AK@*B)WAYPK>!< MBRAE((R:6@-A@EL=O:=A!!/_KH4L!@TPNQ8S@CA8%13W&%\Y<-I`GFL*9`30 M\RGV%K$:<=%"<#1M(NQ,A,.U".U:H&F!R"D068'PL\DA9M=AHN>8_?^8IT:P MTPBV`GA:('8*Q#,RZ3#Q2"8=9C%M9.$TLK`"RVF!I5-@.2.3#K,:R<1B<#!M M9.4TLK("<%H`!DX%$Y[*I0-A-)),#PIGF(%N,_;,SSEN$+DET)Q\+`CCYZ!# M#YIQ`4'WX8?V].,96Q6ZCS^<<_X[$/ZZH_W!]5U2?C5U4(`3NU6RO3;[:%]K MMTA?_U_B.[C>MQ7S(9,F-;G2GX1?\TJ`(Y.JN)A*<&%,4N4K>,$>R-0KH1\4 M]")U=Z'ZO*V;[4"RNGL&]&^1]!]02P,$%`````@`*7EE1Z4H*C*[`@``MPH` M`!D```!X;"]W;W)K&ULC5;;4_>]941,AJWGF6Y[ M;?*,G459U/2U\?BYJDCS=TE+=EGXT&\;WHK#4:B&(,^"CK0_<+ M_Q'.US!1$(WX7=`+[Y4]%7[#V(>J_-PM?*`RT))NA9(@\O-)5[0LE9)T_F-% MOST5L5]NU5]T=V7\#>%TQ.,BWPO1W=DW,IWMAE36T?8B6X9277O][V MS`6K6HKO5>3+?(M:?R_FGQA;FIN`+`%U!`3O$D)+"*<2(DN(IA)B2X@[`KS? MA\02DJD.V!+P5(?4$M(;0F"F0T_F$Q$DSQIV\?B)J"4.YQ+>*!&I['&M)N>1 MZ\9'U?J9A_$L"SZ5D,6@'F9I,+!#!%+=:8%\%QUI.D+)L,7*8,($#&.>6@P< MQCRW,>6DQX3#F1XN)AC'K%A./#TS8#DS8'_O0"B3C`I%3(+("^#IEI#&U MZ8G!X`3>CEL?M;:H*)VEXV%B9YC8ADFO;9*>S=)@XC`$`(S[)$Z?Q/K,Q@6P M4P"/C]JSP2`\)6;J=$G=P]%W6::=RP2;F=-F9B1F>%P``J>";I9),;B3U()@ M&O6S_C?!*XM#$$SJ$X3N2/94PG>6[-*"(`+@;J:G%@C`Q%#('&PO=V]R M:W-H965T-#Z M>!]%:G,03:GNY%&TYLI.=DVIS;#;1^K8B7+;!S5U!'&<14U9M>%RWL\]=\NY M/.FZ:L5S%ZA3TY3=WY6HY7D1LG"8>*GV!VTGHN4\NL1MJT:TJI)MT(G=(GQ@ M]RO(K:17_*K$68W.`UO\6LI7._BQ782QK4'48J-MBM(OPM_#]PFW,A:];_! MYJ2T;(:0,&C*=W>LVOYX=E>*V(?A`>`#X!(`KG`'ZLM\*G6YG'?R'*AC:1>/ MW1MY9Y.8S('JLYD*53_Y8&??EDG.Y]&;3>0U,-*LG`8@NV@BDQ^%P`!)QA#P M$$*"!$V0^`KR:959KVE=E4Z3QK<9Z$%+A5&>!6F_2.%Z5` M:!^6H&O+$HK=O(IG"0&$VYJE%,MY%0V$6YMQBNV\B@;"[ M9_DG!IR"\B^`"KSI"MR$4XX7<4;I;MSL;(;[<`IR(IYS@N$!-SS$!!MY49H1 M;`0,72)@%!MY%2\(3PX`!P'%1E[%*1L0X!L#)!0;P;`Q<`((WQ@@I=@(AHV! MT@OXQ@"<8B/XPL8`&=YT&<%&@XAD(\AQ4([;:/)WYD6\2#ZN431Z43V6>_&S M[/95JX*UU.:=MW]!W4FIA65'N"=]O]'8DS3.(XPYPV;53D+OLZI_+<' M)H9ME$1CXK4YU]HF<)'CB7=L.+2J$2V2<-I&NV13+BW"`7XW,*C9'EGO!R'> M;/#SN(UB:P$85-HJ4+-M[*\:649K"2?JRSF5@+FJ@2> MC0`'>7970Z%*]*WVQS-EI]NWG=_#`P``9!,``!D```!X;"]W;W)K&UL MC9C?CILZ$,9?!?$`!8_YYU4VTBY'5<_%D:I>M-=LXB2H@'.`;-JW+^"!3;:S M9FX2<'XS_L:Q/XPW5]/^[$Y:]]ZONFJZ1__4]^>'(.AV)UT7W2=SULWPR\&T M==$/M^TQZ,ZM+O934%T%$(9)4!=EXV\W4]O7=KLQE[XJ&_VU];I+71?M[V== MF>NC+_RYX5MY//5C0[#=!$O/2?Q$,NTQ&9B.^EOG8WU]XH M_L68G^/-O_M'/QPUZ$KO^C%%,7R]ZEQ7U9AIZ/E_3/K6YQAX>SUG_SR5.\A_ M*3J=F^I'N>]/@]K0]_;Z4%RJ_INY?M%80SPFW)FJFSZ]W:7K33V'^%Y=_++? M93-]7^TO68AA=`!@`"P!2S]T@,0`^180395:95-=_Q1]L=VTYNIUYV+\M\7# M@+=CDB&SUTW9AI*ZJ?%I;'W=R@PVP>N8"!FX89XM(Q8B&+*378!/A<,4[N@@ M1T*M]R#G'N1M$1*+D.L)(C)!9!.$]QJ3"6EL%19)E`O*+12G$4-)3"J)L91H M/4%")DC(4J+;4BPB,A%_#.46@C")UY6DI)(42V$DR,@$V7HI%LG2R%6*A=(L MS-:5*%*)LDK`H<0B(HR$0PE"(F8L)A&24J;FX8]Q#@M"L7)H028)&5($+64V MC\0EQ4)QY)*"B5C#`K060"TI(P7M(D*NSS=D1)2ZRD&(8VB"-B2!CI0QIJR@ MG43$C'(L(U+'S,X1`L&9*;0I"72EC#,BM)N(E%$.,L(Y[Q&2'"VT,8F,](.[ MYP4R`C+'\P*AA*&$-B:A:#>XA9X1BJ*/F?QOYN.G/&U,$-)N<"<%H?=2[@8% M&#%!&&)P'M28">I("1@K828&QP9B9S/8L1BB1C?P*T)T&Z[@/(B,@Y2V:( ML_QH3X*,X00(N9=?QEY^M">!HHW@?EC4NU[^MB3@6Y*D+4FB)2G&=ES27B+% M^G1#9MB$2L>X(I6`XKSGT+8DT7(49TP^>%=B['*0$4JY]@5(`7#>NR1M3))A M3,BHR+G)1RJ+,X:W2-J>9+R^ST=&2.?;TT*%C'4D::>3"6.GCY!SIX],PI%" M&YU,&4L:H3AV+0),%+__DX*;PXM:M\?I4*?S=N;2]/9@86E=#HZ>8#S\>-?^ M+!YR>_SSEF:[.1='_5_1'LNF\UY,WYMZ.@].<]G6LO!VO8/4$L#!!0````(`"EY94?/]BSHTP$```<%```9 M````>&PO=V]R:W-H965TUG':J%1V0M#X&S^A0 MII9PP*^6#FHQ!S;[28@/N_A1'8/01J",GK5U(&:XT9(R9HW,@_^,GO\?:87+ M^>3^S75KTI^(HJ5@O]M*-R9L&("*UN3*]+L8OM.QA<0:G@53[@K.5Z4%GR0! MX.33CVWGQL'?R<)1MB[`HP#/`A1_*8A&070G@#Z9Z^N5:%+D4@Q`]<1^;'0P MN+0FQADHYV9:4J[X;*NW(MHG.;Q9HY'!"^;%,_@Q47HBB6<$F@"K*?"4(EJF MP#Y%EFP;1*L&D3-([[I('=+Y+CRR1RAZ#)4>RN(,;R>)5Y/$8RO[;8-DU2!9 M;25>MN(1E*;98Z@Z+MSI2*,7171:XV+,]N="? M1%[:3H&3T&;[N[U:"Z&I<0F?D@`TYE2:%XS6VDYW9B[]C^H76O33L3.??<4_ M4$L#!!0````(`"EY94>Y]3ND+RT``&;$```4````>&POMRX\:9Z._L4W1-R16I"N+P3FFO7^>SI5R%>2==RP2N M/*39*BS@SVSQ.E]G,ISG2RF+5?RZW^V.7Z_"*'GUS>_RZ)O?%=^(4H3<2CR99C)_'>OBV]^]QJ?X><&XBI-BF4.S\SEO'GU M3JX[8M`-1+_;&S4O7J>/'=$=^2\J$&[E(LJ++`3`KL.5;-YU<7U__NWMR?WY MF7A[\?[FNY/;JQ-Q<7W:,MHI+#`+8UC87'X2?Y1/S?ONLW`>)0MQ][2:IG'S M:I1,U\W?3LLLPVU[%^4S&/G/,LQP*\196#C0'AYVQX>#;@MP[Z)89N(4GEND MF0/9W2J,\?JM7*=9@3">IJMUF#@WZJ4JN*K[[XJP*!W\_=E%J1KA^S0&.@LS M!9ESVW7:\N`/,HX/?TK2CXFXDV&>)G(N+O*\E%D;K.EJ!21V5Z2SGP)Q1W0F MWI=%7H0)H6,_2A3Y'32','1[_[1V-KS7/?Q3ZP,W,HO2>2NR-.G^RV]^XZ-/ M,XR-^'?PH[-/S3O5O-Y[_]1K_G("C\[Y\3A<-*\^A''N0'Z:`GDG.>PZ?,O3 M.)K#\N:$?XDCY2)]$._7,B/.SL7^AR0LYQ'<XYW-"]^FZ5Y+M99^A`Y#]X!32$E`"PB MG*^BA*1"$3U*(3^M<;7.<&J%\%"4S%)7=KPOEL!/?$WLJU$.".PWCIQ)"@G4 M5^C)G'4MPV0A<<<>PB@3CV%<2ESG''#]R&#&43B-XJB(/)!:D'BWC6]0AGDTLZX+(!PQ8YE$4H?DSSR-XS#+Z2+]ZHHB9Z:7CO2#C!9+ M'"J$Y89`6/88P+Z6:#P44P)_@X@\F<_?B/._ED"),0H2SR@;GE;B.`(!'N*^ MEVL`9$:(R#UH.6M!RZ8I=EKN7.WRAO%:!.#;,`:`)"@8,()>)O;^4";M]HQ6 MN2=Y#N,[,N0TS)<>ZD9C+A>9G$G`#^Q@"WL_PLAIYA$>>"DO2$,`Y-';*`W` MOIEU_#)DIF`,"4;'_$D+4%";[P'V!UE'N.8;O`#?9&"#9J#;46!+H+TU0NB] M]4["A&@&S,%4R2/8#'PF)7`W@7GBO::1<%F)6P<3)_-')(0<[&D0T+#WCVG\ MB-0%H@8(`F3X#!]U3"N#K77X1+P`-#B+RSF,M#?L#PCNO?YQ5\Q!^A=,F@)R("K9I`W5'A2YC8O9G,RV4: M`\KSWX*<>HC@KF3VY#)JS1S=ZW:ZW3[BD-7ZUV+4#;I=^E]+J+`LEL"<_R[G M7XM^+^@-X>ID2"#AG^#C].#/O)*D*.L0VY5D"X!:\K6\SRJR&G7Q[;4_DTJV>WIK3P1U(O@W*0?7Z:2Z?$'>AQ< MA\=H#A-,GT1JK/\0>:I-$?Q8YDI^$/I!H('HE[8)![_C7S.:)DM7VXU\)L&F M!?%'LIF)?:U38N-XO<:U1]7BU68TU?Y<\K<#$3%/>=$!BG$J%U&2X-"(?HK?M-TJD8K;;KHK MU^N8)!^HQ7F4S^(4A*LD-,PTZ@$8$W9M#42T>_4>PV?#K"!-#FEFC+'FN'&P M\3YVUP(J$7(UE?,YF1?&B'N080%#TCH:-F$K_UL"D;E*HFECH1'-$6;X M7MDB3-1:`\^,]D0XL6],<68P)_YR+S\5XFT,@O[?M@JK\-H[+UMZRZ_P-U%C MM/+#>[\$#W$VXR@UXU-;`S/;&G@P#^?5P\`!`G0!*SF8@?D)E`2LOM1&`H&L M7#"Z.]0Z1\&VR-ABC-(;,%!6(7O&8.N"U1F''W&P69J!"\4KVB_2A20-]#$J M0,'"0'DYS:-Y%*+G'=`=&B9&LI=5K@,'S%>)Q.F_(R5 M!#R'S(_N,,%P6P(;];J'W1ZNZ58NT+1'6.\._Q5_08B4`ZW-Z_-/,XY&DG>4 M4Y!F'Z"^.S]%B.D>7"2'"N)[5*WPB\:PKR@7_#L:(XR>\+M<% M[QSNQ(8&-1@LN:(FAU@8GF@,Y\1B!_PSC<%X6?K/TXW.SX>U<>945"O9&L+U-6TS('9\WPC(,27,[!#PXC$+$]K MMA@UC[KX"+259AZ,F'ERN6!$*A9\(_;#`XHU9D`K*-+++T,ISFUK+T3_;:#'2P-)X6&+VV+LT?UJ*665HN<%]^A)]6(>"#UQ*( M!?J]&>SE''<6UZ7V"\@.4(LU"X%V35&HI#'8&8BC*:XK?\-R@@3C=9I$:)@# MK8',_0'6!:;"29Q*`8X_*/H;"08U`GL72[D.Q+<9JMKSY!%F/SD]N0"C"XA! M?3\%5X32JC_`(@O@L=P.;I@E&CL"]"V'>PJZ1'Q"W";54L$P)56.]X+9)C,4 M]W!'B(&XC)=#PJ)"$VXJ@%Q2(-1BF63^.JU@./B:`-N?'0A.#UW7'GNK'I,: M6)/N8*O'R%9@L/WH@#CH>X6"=T##*0"RKVSFQN\V6>0RCE%&H3,)HB^<`KT" M5Q@H2>1\E&BX\8(U;5EW:#+!V5@>((7L1P#5Q7?W6L+=F/L-G<)5MHIMWE%V M+*@NIA`Q38&#*:88`F8 MH*S,A!LP"#%9@K@#ZJK,R"0UPXN9BA3.6<39BID4L;2 M5DW*JOGOLN,ZHB55*CK(Y7F)L"J^LV>^3$%XGQ@4DF:YN3X%KSCY*4`9PMM] MDN>I#O@B#N$61F%1-SR,O093(>6SFPNP<%X$>$+RZ@M5BP:,,3.6DG4CC!4C M3X-63C!+=71491V4Q\$&$5/S0X%HW>^-#L@1`-^&+#`]RSQ\RG%;R8T&Y0*H MPPB.U,XD4BX\@3J#3-!U+>B8E\C'2@F1/_O$,L+*$RB+%+9*K87BA3'NKGU; M);`;&Q\6/$T1K61'G#$M:G;0'I&BG"V-4_:$;<+)?93#54ZE-BUE),E/>]1YQ@ M#<=!!R@:8;Q.'WG;1GHSD/B7(7LE%35;5*XIFRQS9V/0JU&!*58D&59_*.,N M3Q'/-`B@6:/SH41[""`"(4YBOCZU>M+XXW\MPZR07B%09T=PA^=B,@AZQSV3 MV7JP866#"#&!^U>A7-$^1L_7\->G"&4EB+"]R;%2:A]1G%*4Q3BQ?VB@:#&:554SF8[,>2=<T#WJ!L>CKAAV>T&_ MVVW>O0T6CX(^S#@9'P,>.-4?^@8Y#@:]7C#I'9NYO*'Y/HSR3)U30B;E9P?" M^Z)CSU3[CLJ38C!S%$2((2!\R:87%:]FVBA'XWBA]$>6%X=1$JAO0!AB)4%4 M<81:11A-M$_STIL&YNJ1(_KGMF;E[8E!,.GVX;,?#"8]\4.:_033'I(\R@FI M@S%5!PA6:PZ1IO+5T:-EA@)'HA+ZF M#TU:(>JH$PR73Y_J6>Q"H`V73AB86C8.LZ1MO]]7NPNDTPM&_1%\'G>/D:#` M%ZA^.P*E"K\-AN*#=Q-'PPG]?ZB^=<5$7#H>TP"N]4<]<3SFK\,1&/U]0\/] M8-@[IDDG7:3E2:]?^W4\09`FPT%]);IT&2L^,J2$-'&1\4(939;?WJ#'Y8"# M8;VRJ^,'A!R#"A:<%0O<40\=QNB)*GD"QEAFC-T,X46'#,FQ-U`&+-@;_:[Z MSE4@7+!+T2KTH6!56(BP(OS'T:/*&T5Y32_FSU?<`UW#0+Q/$5A4448H2S-: M"^I.*N-X(J$*0&.\C^4J)FO1S$.?+N9""F7.U3S'*ILB?BSG"^-"X_:47(RA M5Z)#%+9Y-Y5Q)!^54,_H*`KI+5K2FL,E&')0@IXL3FVO5LN!L8&#WY$)BKE' M4'%HQ.'FR4<.\)+6)W>D2F>1Y*]*;)32F.F$!HHL-`SX6?9LJK7PAF!07)LH MB<0T`86[;>!@AFPAZP%34!58RW0HL2PM5!D90S1HL]H4B-8S1@8QC('.)Q>@ M1AF("+1NL##D(P@.1`>ZZDA/%9RH%54P%_"!`3*BIPZ8:#:4H`8HB(3V5S1' MF_$A0KK,*J+?V7$C5DO=0('#QKPY%<4SU=4W0;,A47*K''@@HZ:.-T#Y7X.>1^CSF3^#M8[S> M[PF0;12V"1_0V^F![Z'%(HI!KT(?4OV#5;]TWE:_I.\"?R\.%=^9F[=4[GK. M3LNUHMT-U0*BOUQ,`1R.*`O0/`'!L5@RXV/^!-NV%AOZ%5W_BJVS])YL%VD M\\:]AL[SDL4(2/%%KI^X8?^#[-!6%_"]<0$/C0OH5FE.=R/ED?@?(5AKU1<>/!R'9`^$*=\VY- M^6"CKM"_;5N%4_?$,.B303<,AL!O@TY_])48O^Y/7I.(0"A#O"#II8WPTIO^']>=/-Y7"@RCQ0]/3.C!^JD5$!J@C\;J$*!04R#LM)7#;D/VADAZP,`!ZU3MXL$ MG+WYV<6]>'=R>G%YIEF&01)^3I(H44G, MT,(V\UA0A3GY-(@^_E5%^G7.L)X`H,&W$1>@BL!K4"9++$GZ6!D9XT&H8G.Z M(>"<`/ZRU;4O^#K'P MC-U/SL"A]4,N.1^]?PC1?V[+)S(254J;DP!49Z2\8I0#Z4-0[4"^1'*;5II# M10W,#5@-@[\D=OZ4A5SMD];E^:0I-&I66<4J559)%QLJ9O!0750% M[Y7K[!L[P++G'S$L@1(F4B(4J4C9V9-R4>*Q3[8@5+X" M&>'9)V6(]6JX%MX28LM`56Z3[L/3JD\KA1K$$X;386LL0JVHEXOY%3,UJ-0/ MP!]*-$*05726,I,+RKM%N4W"7/B'6G0%DX2D[C@E6^GUW&0U;?K\==*"AC^;OC"4*W9M M,++$S5\-\-ANK974LY3W+P@E@,=6MV]1Q9G[;P]PQS5<&!D/*:5O51/120L5FW\2>%8U?U#N M!NPOVOJJ;#A/L>V+L8J%_"2S6:3JQ3#-B2#P*AE4HMSBS-1X>8\%*1:V MRY:CQ$[X&2'1(".J`"\;4&/M&#VNU2]6\V`,R.V3A)>AAFNDCW``"J=<' M\XO*&RN_09W2I5UI3J++DBU253MO+"XR\&$*,!*(990>\%<[-JV\.H4H810E M;$&3N-5WK=@HCZ31_P+K:..F^#(48TY7D_HFO.(]V5Q#6,W;-#,:NT]$EHN] M7J7%OEA3*7R%95'K6RIK20"VIB?Y%SE0`5G MG.$+F6X"TVF%Y+"MS7E5A")Q3;@B4I7U>.Z$"U_Y2'.1I;'MCGCU?*#."WJN%'9S5?2@:?';A?3U.LJV5?T/%L*:4YPH4@`8/%=$ MIZ,^AG2FSB-E?1)?%1;3FGL^LIKV@`IA$-LZQMF7R$#ETG,Z*S-?#VO@T MI<`*R+)*((55NM0!UUWII"ZOE5"G+/59M71:S@G,RP M9OB-4E7,MS>$5<]I$@]::PM>*W)0YE1=''RM0^Y7X-GCL=:VQ(K)GM"7>E#[ M:^MP4DAGVZ(L3537$&R8O$K\@W6(M"ZN3ZY/+TXN.8-U?_O^P]O+\S-Q=O[V M7MR>W]W??CB]_W![NYU:5*1ZI](C1/:Z/P%H!X[&5<$V*U@8C*STSGM] M+\R'8W"P'-O+,"W@LSYV4M'#>3K/5D%-ZWR_"< MH3=I2`I](/&KD768M/+K*XGA@:7J&\);FE>Q>_V+R@%P"@"&F]AA35M3%O9# M-:V8R0=5I*`E?Q.5`4G;4.P-5/=":L^CT`9Z!L]<-K%G::4<*S-K=UK8#^@0 MZ1JK.M&Z,G%<-]9B)0$';'WNSP^4[C*]P$`5N914SZIM&KIA3_3U3IJ=HW#I MKR61:-EU_O1A#70G<4AA!BIII`P4+&#\%?<]RLSI%.;$.6U M\QXJQ\4)/,>*(/'<3(/6I%U!G6),KV#C(H`7,!Y5@9K`'ZVW^[14IVZ=\0#7 MA5+<54S)E5D<#_<'W75)0(N%%KS8QM'2SSG\Z-M\#,2A56YR2$$EOIP!ZE*) MGJ7^-58"JCHM;&4`VL]7(D]0]#7"C%UE#=C,K,KZ'%%D3[_5Y"T[78?"T"DH MFU\BRO!SA`@8^E8?Q-:DE1&^BP'TU*!C_[W:4'X2WX*9`GORU!ZM:*LPU.U1 M?35/NF?CDPX[,9V0@-B&7TTIMX6,&)% M63/<0>:7*W4B#B$-XQE5Y?)MM4G8%?$LMSH&]C8&S^WP;K9,J37,NM!+IEX! MZ5S&K47+MD$\,O_TQ6V4_R3>825NO4`3Q.=0?%5]3/KP\7V*O<$(J$FW<]2% MGR:]SA@_>\-AIX=?R"G>IXKU`]'K3&`>,1)G$65LYGKP;I=&M3].XY06>J-% MN-TE6>S!;;TN?=!)(/IX?__=^:VX?`\V__WY[97R!10-W5"Y%16Z=FK%BU23 M+=Y7Q8L=IPX3X4#"V,Z'`W>DLL)V=-K:7:CS=T1S8`D9[TLSUG/>EWK44I0U MWPN4")W6PHJ:`FLN=16WSVNL0>*OL\;J3KO[`](4"\0/B1+1_M[:">855!Z< M"/&S3_2-.]M`0@;L%?5[.=4M>SIDNW)-MSY@Q\]W_`<=\%S93NW!-]Z\4Y$X M&)N;!\/U$9GG#7;@'[%>+"EJ9U+(?GG)T9A<Q0V&AT'^,L6K8VY/+5>MKS#IM7:H'?T<0<2GA;UL0I$ M#&$".>-HSLRB3J0N!.)0=>_%=K`P;$QI/D4Z2!5V=6KU9ITZ^=IGGA@2_M<@ MJ@+,_LJ%X^XQJ"$JE&$?#W1B33B5Q/6'8C0>B-&1.AK54W]/U!&I/O\Y'O%) MJ9[Z<\@'I@[5GP/[W-2AZ`M)L!V>X> MM>$E_-I)&T[K@%E*[G3#1>TK&Z8_ZK^0XYNV3TV(-`YW_H(LC7+\$AQV:E"D M3M+5NZ]9U5N!6W,0D*46AQ$X<^0H1QDW[(_,49/',,.60D"^.`V`3$?[>0ZP MSOFE10\I*1I`$.X1Q5B[ M;H&5,Y_56EU6!TD[5GNN4YJX@R'4*W"X5&<:L'I/Y3S,IM@&D!O=ZL/HIM/5 M*W/'JP.L4B_J?CIL%1:.<,CKU9G$@@U53$+W%[0'7#B&$06ZSHN5H'.$6O#@(*SO!I-J0U?36@UGKB.ZPS MS1I+!A;)'L%&S76S7[KU)OP$5.7?G(8Q1E8E_EW;!GN/>?W8<4VE*AJ1*17@ M,-K$XS?SG;_-G0VT3^U4FUG;%]?LW0@MM_1MIA>7'-K)N*NZ^Z$3Z@4V`&NWDE"G;HI7F=F58'#"&M8HI\D1P8B+-J:J;`);-&@JBU0 M)*VD6B,I0`1KB!3W,F6H5&BGMG8ESFR2;3*@:;/+142%2L4V;`2-FB=K6>3? M,_8[)I/1.W+Y4`%9)=!J`L``&IB0KS\=PBM/]%$5>JRVSYF,"O.>NZ*YM+I- M],(UGLD9JYS/7F>84(I$R:W!KVRI;;EZ=^1"E952E.5)/)09`8UV59EH3B;- M93%$(RR"*]@@2$-/K6Z-S!LJ$ZT,KD-[C!9IQAWU,"J%,0,#Q6_-G,^/[_5M MCL!&-8+>MVWJO$MU?M?/]M[/^[X)B8RG-(;`BA[ MSP%9:GZE;M;=G:L^U)%IV&.B&53K%,>&H#,-=YW.^>>\UJ<^G&+<-C(]::VY M<^V@9?.JT.K;DY,;I9^J@H!^%ISD0%WG`Y>W#:`@Q+!\7%?N3]!_VC0]&3LC%.%"]LT?TE\I$(#F&_- M9L^.SZO>:8L=!S03?.C<=>HM7$VC)0IG5M$KZQL[D3?TDMMZUP;J!P)BB\Z" MM727IB5@YZ[C`7>Q.**_CX+)<$1_=X?DMV(,=C3DA8(3.QQ05[`1MJ+H'E%G MBYX8=\4`/C82$,W7&T[`3N^+`?C7O3YJ@$,>N=<'A[L'PPR.*ZX?%@TW MF(P%_`L.=F_(3]%@P_X$M,MP,*(JNYYI*:?9B)Z=!,/10#"]'`=#;`85#.!W M6/!(=;T;!_UC``OI"/9E=-3'6[JPW!XL5S>.4BW*?,P/: M_R',LW$G>P#6&$'I#Y_;)>Q7<$2XG33V`#`,>)Q@HZL>W-4?.+'/Y]K\[NMO MOM=1.G?_Y62:T\H=O8PA>5!:5]R5JFJL"RQ"3S^)OZC/#+_UXO_3C M_=*/]TL_WA:4.U+7:<^[@[CU6_9?.OY^Z?C[2W7\??'+^,3^/9VT=(P8+D:Z M][Y\\FZVE',\Q8&'W@%J`[15Y7O^29$)!V_J1.*R"CC2M"V[,MT_,4X;79Q; M,65CPYRU#4S;IY=N[#]P1^6MM@J!*.3A)<4>W9[+/\^V?6DNO&MSX9>C+-"= M96N;H7N#OA2?_W#=1UN)?W,;TO\V,?&_J7?HKZ4[YU8"D&Y\*=J_M+W\TO;R M2]O+?Y2VEYO%@)GVTBZI0Q:+,O$]E6W_S-KAG[)(^V7%L]O9JFS87*GB0ZX% MO-$M*I"*=*)$)45?BJ__I?6(NZ2'MT*8FS.V1J!:+'W'BSGK2Q;MGR*+YA9Z M8+88Q)H)EBB'E.(H&M58S6,7B;XX>O+/G@KK,72N@)"( M*M]*;"<)LK#*:MQA$J5M]F?!:TN9!N+]1W`2\V6TQL@BUER$"V<%9(QM2*#B M&/-`GPH(>%4.,HEGQ$7U9I93KDE_?N":9>4Y*V129?D;CS/'U32WZBDD&NN#3'&JS\="NS_5PA8#PJVD?DS8^Z%I#>('XP*\^NHP>',[0;^5R M9E0M'=MFU&_PLW6@S>:R*!B9SZ'36J10-_CNV[Q86TZ3SQZ=R+B$/`U MA8#;-J<9<:98CJ>>Q8Y#FX4[:W3?96B%E.^KD'(;-!Q6)D!T8+D=].=W]-R< MC,.R3M-0!Q1$_%=EQ+-09+]=A_D9[L]_T&\#LY[9B.4(X=4+TWP3)+JQ:= M[0*G%KRM]K$>?L)7-G!E$QCNS3$H(.Q]'19&E;.2J9,=C#O`=4CO%?D^!-V. MB,$)W"'[[I#^-;:^0Z1='_K@=;<*QKX#:8SG_\2Y[MQQICIWM,KDDAQ'Y6)I M._9*->FWHNRN?MSZ253,GTQ&]-F-KV&2BB(SBEP!1?,W5US[_`-/R'E'HH*% M<0L54&ZZSY(SJN6VD.MO&H@CQ[Y7#<0OK0;BW^NN&N>Z@;BQ.QWW<^1;V+/0 M:OMJ`]0_ZPZTM?_^62?Q]R1W/$7_CM6+-Z]"W9'[UG0Y]M-FX\$7T\]-U4[Y MINKZ4J<:87,]5L8L&-4F2.B*SEF"S@&ST*=@*_(4#NN`M0>WAAZ-M8DJ_.EEKZV9=& MM$5Q.&GRV$>ZXSSE7J-["3O:@^W%M,=MCAK1VDJU]"NXX`>3>T!3XE MFEN>3)JHUV8_NT=LPD>S-I(P@OXFC!PKG[TB%3/P1W=>[)=M]L>\IV8/^>.] M52OA\;D=]:X+6C[+@6B1QJXOK4J`YA[%H#,6__*;WV#RU^\FNS;WLPOR(::5 MBR[L]\WYAG;+=R[C]JR$]FUY3RZTKWEA]T[S9*WK801ZK"<;-RU2PX_>X M>ZU`683*U6)M<1!OY8[#D<^4O3PG#I^M>_D5L.6I:GRHXL)UJ>H3IC6^K9** MCKKI;\P=6B.WVM'^VAJ7ML9#ATZPXL;YL:J_<6@-RW&<^ZDXQ_F52W7\!K,J MW'$>X5=P]"<#;Z:K[[=N1_Z?:[5`+@5:13^8(N(`3%X=1_2>F]BV4:`;5G,8 ME+I*W6+KU%(1I&T3UCK[B5[-N="_>KH/MI&(>VNPR=&9^,309HCO/Z96["HMSM8C8WL?RYDXX$/AKXW\[P39(-=(8/;-A9BM*U@XMW;R9'OUQ/= MMJ\*W=1P3B=T?CZL>W?QR+OC55119XKS``S0=)&%ZR58@B>9#&UX/H":2$@' MF_MW0KLW=+AM'>"SLL!*-0U;+#R[3*0M'745/G5$CV/PPX?B__\__PVJ(UK; M1'B4LZON\0W"-PS;;[@*DV58@+T@SK)R88IZ6I/WB"I`)#H9F-E#W\RD@OY# M^&:H%4C>>BQ^_4KWUDFKV5`6GV^9+ M&SMJ3],>`'0:NV[SV.8:3B>?M1ELIT_+!FA)D&](<-Q6_6D4:'Y_L@WV0ZL) M)%:2FB:^^N;=LZ\M)7VV9+R^N#\_$W?W)_?G=[L_7J]*=77!CB.V18.D5;+J M!+FV48//K73;079=[XMT]*;"R:U7M.T@NZYHJW&;#VV$=%<(/H^)#NNUL;OP MU.L\+[[Y+U!+`0(4`Q0````(`"EY94?#F.=LP@$``#@9```3```````````` M``"``0````!;0V]N=&5N=%]4>7!E&UL4$L!`A0#%`````@`*7EE1TAU M!>[%````*P(```L``````````````(`!\P$``%]R96QS+RYR96QS4$L!`A0# M%`````@`*7EE1Q8J%YF?`0``8A@``!H``````````````(`!X0(``'AL+U]R M96QS+W=O65'?FO&+#X!``!I`P``$0``````````````@`&P!P``9&]C4')O M<',O8V]R92YX;6Q02P$"%`,4````"``I>65'F5R<(Q`&``"<)P``$P`````` M````````@`$="0``>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`"EY M94>*)UU'2`(``.`)```-``````````````"``5X/``!X;"]S='EL97,N>&UL M4$L!`A0#%`````@`*7EE1ZQM95:W`P``PPT```\``````````````(`!T1$` M`'AL+W=O65'NUYFPGX#``#&#P``&```````````````@`%5&```>&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`*7EE1W]OH'NV`P`` M[1$``!@``````````````(`!"1P``'AL+W=O65'25>U MUQ<$``"3%```&```````````````@`$H(@``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`*7EE1X5>E_6B`0``L0,``!@````````````` M`(`!=28``'AL+W=O65'P`>1U*4!``"Q`P``&``````` M````````@`$G*@``>&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`*7EE1S;XM""E`0``L0,``!@``````````````(`!`BP``'AL+W=O65'6T3[TZ0! M``"Q`P``&0``````````````@`&3,0``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`*7EE M1W65'LMLP#+$!```6!```&0`````` M````````@`$F-P``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`*7EE1SXZM$2D`0``L0,` M`!D``````````````(`!YSH``'AL+W=O65'KBQ=W:\!```6!```&0``````````````@`'"/``` M>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`*7EE1Q^\K(&O`0``%@0``!D````````````` M`(`!A4```'AL+W=O65'T(-[-J(!``"Q`P``&0``````````````@`%K0@``>&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`*7EE1]U0Q#^Z`@``0`L``!D``````````````(`!+48``'AL+W=O M65'!W<2-_X!``"E M!0``&0``````````````@`$>20``>&PO=V]R:W-H965T<+V9-U@$``!$%```9``````````````"``5-+ M``!X;"]W;W)K&UL4$L!`A0#%`````@`*7EE1QZ[ M%##W`0``U04``!D``````````````(`!8$T``'AL+W=O65'RSK[7WH"```Q"@``&0`````````` M````@`&.3P``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`*7EE1\O@!8:V`0``_@,``!D` M`````````````(`!6E0``'AL+W=O65'^:"I/RH"``#"!P``&0``````````````@`%'5@``>&PO M=V]R:W-H965T'SD"$H04` M`(@B```9``````````````"``:A8``!X;"]W;W)K&UL4$L!`A0#%`````@`*7EE1\JH#`T=!```NQ8``!D``````````````(`! M@%X``'AL+W=O65' M.BYP03<"``"4!P``&0``````````````@`'48@``>&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`*7EE1Z4H*C*[`@``MPH``!D``````````````(`!RF<``'AL+W=OL$"``#,#``` M&0``````````````@`&\:@``>&PO=V]R:W-H965TX)WV_UP$``*D$```9``````````````"``;1M``!X M;"]W;W)K&UL4$L!`A0#%`````@`*7EE1VY>G=_# M`P``9!,``!D``````````````(`!PF\``'AL+W=O65'S_8LZ-,!```'!0``&0`````````````` M@`&\&PO=V]R:W-H965TY]3ND+RT``&;$```4``````````````"``<9U``!X;"]S:&%R9613=')I =;F=S+GAM;%!+!08`````,``P``(-```GHP`````` ` end XML 14 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Calculation of Fair Value of Derivative Liability (Details) - $ / shares
 3 Months Ended 12 Months Ended
Sep. 30, 2015
Jun. 30, 2015
Jun. 27, 2012
Derivative [Member]      
Risk Free Interest Rate 0.64% 0.64% 0.72%
Volatility 70.80% 71.60% 144.10%
Term (years) 1 year 273 days 2 years 5 years
Dividend Rate 0.00% 0.00% 0.00%
Common Stock (in dollars per share) $ 0.10 $ 0.09 $ 0.09
XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 2 - Inventories - Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Jun. 30, 2015
Raw materials $ 3,702 $ 2,371
Work-in-process 1,036 2,061
Finished goods 1,349 1,346
Total $ 6,087 $ 5,778
XML 17 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 9 - Segment Information (Details Textual)
$ in Thousands
 3 Months Ended
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Europe and Canada [Member]    
Revenues $ 1,992 $ 2,283
Number of Reportable Segments 3  
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 4 - Property and Equipment
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]
Note
4
. Property and Equipment, net
 
Property and equipment, net consists of the following:
 
   
September 30,
    
June 30,
  
   
2015
    
2015
  
                 
Land and building
   $ 1,250     $ 1,250  
Leasehold improvements
     1,159       1,159  
Machinery and equipment
     5,416       5,362  
Transportation equipment
     16       16  
      7,841       7,787  
Less: Accumulated depreciation and amortization
     (6,473 )     (6,414 )
Total
   $ 1,368     $ 1,373  
 
Depreciation and amortization expense recorded on property and equipment for the three months ended September 30, 2015 and 2014 was $59 and $61, respectively.
ZIP 19 0001016504-15-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001016504-15-000014-xbrl.zip M4$L#!!0````(``MY94=^/HK[)Z8```PE#``1`!P`:6YB<"TR,#$U,#DS,"YX M;6Q55`D``S:W.U8VMSM6=7@+``$$)0X```0Y`0``[%WI<^,VLO_^JM[_@%62 MK9DJR2:IVY[QEGQ-E/B*K!S[ODQ!)"0AH4@-#]O*7_^Z05(B)4*W;4GAUNZ. M10+H7S?Z0@,D/_WG96"2)^:XW+8^Y]0C)4>8I=L&MWJ?<[\^%AJ/%\UF[C]G MG_Y5*'QA%G.HQPS2&9%VW[<,YES:`T;^.&_=D`)1BB=*Z>&6_-J^()JBE@NJ M6E#*A<+9IY>.8_(3_'\"]"SW<.3X^/GY^T/-%MW_*]'YZ>[R3TH%;G>&X0Y]1T^L/'=OP=<_5;6=XY+O8J:S4B\JD MRQ-SO70JP;T4`7#7+FEJ=9ZD@Q91!Y-;?\UIC;<[U!W/BT6Y[J9C$K<0DIJ$ M9-F6Y0_2:1B><^R-ANP8&A6@%7.X'O5SN9Y."&ZDD'&]H2-I#W=2.GB!*AN@ MR@EPK9P-: MF!G?Y:OT.OO?_R'D$U(]<<6M%NL2@>*D[[#NYQS:22&RA*,7U\B%MU%+/N=< M/AB:+'<=(8,,N`_WG7)NT1W;8\]N*U<"CC:S`E59B5\,]Z`D$MY#&SKT;/UOQ[[U&'NO>^AP6$X3]#G M7RIW9IH_6_:S]D22"=:35P2)^.ET21#OEJT&&&P8Q+\,A/U.-/ M[)J!E3I+FD(ZZ*)2*Z\(6HIC8]C+RQI@5UX!]KGM./8SIJQM^YI;F&K=4KW/ M8>$V:EC&U3>?#T6\LA\9+(+8!1URCYHW8%),&B"^7N`RBSE#ZG@C]"R-%^X6 MP-G`0.XM`UC.UT>_X[)O/ERY>@KCH6@U=3UHG1YQM*):*=:E&JB6)E+9A,U7 ME):8\26D)>$?M**LO"7_\D&MQO_< MC/.2U!XFC*^`>)9/_CIJ&\82>S_`N%PPSN M75.=FR`LP4)LU!MPF_?=H,V=[;&%G@J6@!)/!5YLXJO69$,JB&BR<1VK+C5M M*7RWV)-M/L%,).^%43PNBD2W!TL_I]9?LPJK*)'"5@I:-97S!.XMZBMP#-0T?J:CE)A1?S^\MM6#2#_`<<8I_]2:E$$V,FTF^%113'[>3J,DRFF)]=L$2%7NK M1;4>):)IL&*HT[S7A0W+?@IPHIQGG("$:0^.:7DVK%N#W_/7,4DOD]"U,1PZE+O,P#J;8X@5+X?DP1#:]!LU M?6AT!8L#5#<>@7E=:5:4BE2:M8VDN3GGF\J^Q70&/A2&=-]0.VNO),]T;I:4 M4;ABG1VZ!Z(H2"I*G#[:!,'OX01?+[[B7K4M]8G*Y'Z*[!!T5)3CWVL>=E[#V&%:!4)S&%#NLNV#3;"(Y"X:XWNTX6FF&^&AW-6AJO5Z]*] M_8I2##9$Y]-<&]=T768*E]1+E=52;5-<,37ES%U/>B6E5JY(BULEK3@/9"J` M+4&6"U9`EM>[ZLJ6($\60K":7%\WJU*/H-64=/&F4=X0XWP]KH'3K$E1EXN5+:%NX5YKH+70Y M%+0A9W"ICA/JGH_B=^9N'DFWBN79GZHILYHT!__FS%9>G5GY_"H;,NL/?('N MD@T=("^J?O"W*4P/NL:KZ@^.#=F+-WHPJ1AVO+VZ1KD_42I.^H%2=<;';P7E M6_%>FF^N1;4L/>90*:DSN==K\&X8')M3\X%RHVF%YV!6GT9H(4V$2I7:%"_I M5->'-E?*BBK-)`%:M;(&M)B@1?&$@4D9%WWJ]-B2A[ZE1U:EWJRH)8'.P[`1 MW)5.V$K]T;;@3F_NK2I>)5[35*2^IJC.@3N-83.\\^6;P#OG&%1I?;R6QPUN MBMJ<.+LJ(OW5BV[Z!C.N'7N`3UWX7CC8%74L/`;[P!RQ)9E2DI1ME6Y(Z7R4 M/D!P7&,P-.T18^*CDNT6U(Z4T$/ZM/NR=X M32KXDH)IVC[*_8T5_G>*U;:%-7JE/KMG%T@\YC-YW<;%WY>*N7)2CSZ:T M&C[-!;/YH6'VJT^]2"X7SI^+WPV3INQ@ MK]7J+)#E"2\HI4ES;U6M3-?V5R,LIF6\,7_NN]QBKOO(>F+3)SKAZSE4QP,5 M?A?^!?]C]>;-65&M%>6EL+JJ;H2X\EJ(I>O'6JFFO;*,SR'$@R]'@W,XPT>M M'\+7Q"R"79'K1J52>V5!;P!;N@^@UM1E36G]W9R:E'R]5DQ3S_2MD84HYMMU M3;KO4"]J:2J7BB+]*4F9*F[\X*94WZ9V["2P-L$^]^Q\45KU4Y72ZR);<*I? M?HI?'ZJ^D'<$;D\`&'#2+2Q;\NYD7D>O+5.ZW"J1M,K.*?Y&? M_"BHY>JVV!D?3<.];TQ@80Z9I<\_,1#F4TJINMH1O'6I5J:IRD2S+E5\LLVT M7=]A;:!];MKZ7\N_:,>ME:KU:N[LWZ9W:O`GXGHCDT$?[@Y-.CHAW#(AA3TE M71BPT*4#;L)%CP^`68L]$\<>4"N\Z_*_V0E1E:&7^W?/.YT:D=PV6E^:=X7S M^W;[_O:$0+-3TK[ZHUUHW#2_W)V0/WW7X]W1:=3PYNJZ'38+K[3O'\(+-\V[ MJ\*/5\TO/T(3]4@KIU&'Z_JY=>&S^WU6`,KQPW;AMWOSWA+0%4W?`5`N9 MR@<7\L0%3>PN-7X@!;P)U_!U!/KI\OV>&>_UO1/2L4TCZ(9/VI/J$8E-/8&E M`TE,/HY]#(-'=!;]35-AT,3ZV..SP$7MY6)R*B/-4H;X>2:7X.W58W_8A,4$?:'>[7&>D&SRQA:$7;A,3 MQS!(%Z(2"<]FD>!P5IX\][G>)]P%T2@_$/O9"E[2[/59])9",<7?O>`K)$XA ME/>Q'HIRNNASUB57+^'S,.1>T'8$C@']TW:`<8BY^(J6\"K<]2C0MKND#Q2# ML$D&HDS@(A1;P(6\R29L/&[`DQ,X>8,[3/=L^`6#Q$`>D7N+_$0MGSHC4L[C M6Z2U/+F]O,@3B@.;YJ@0,.?Z'9<;'-LEA\@3)EX^9,`$>8`$-`#2!8/0Z+6N MV%Z(DGS`;A.YZ*>/0=/@_5[C]\!.6ABG'\DS]_I3X@<5<$!EW&C>D,/G\82Z M0PK7H#$JYT\@`3:"7R+CPY=(8C^LX."!6^)^\U%T7=O&9_""J:86H=$CBXB] M6LK7ZK5Q4\8\`GQ6*WFUHB:N(@S(DECP]D_DE;T,N2-6N$2\M`CZ1<(NJBAM MK7)$VCBIZ9(@0WQ2T`!]1(X'P>,`0`>&,`,F3!(^62=F]OMRL9@G0]-W(XX9 M_@5-H2$3&PK$HR\L4(J.STT!U8X>/D#`>*C6%7IQ2T=$K0NE*.4)[G/P,'W98BF MPF2?J8LXQ.`\K26T/[P>#QJ@5#'/M@%&>!CD&A+ M!AC&(QMZPIN3HB*4L"SL$^T.-11ZN:%5N>093(E\K]9*HLGWFJJ`=;M#\.[@ M]$U0>;R,"@)Z)#:GT20Z-NB7;KO"9%Q8$@<.P&4FOFT]Z&*@BHHWR&'TB#0* M>R-JJNN!NP_>PPNP+8R-^&"G;>);`9"-:*-"Z'7X1!,T."(-<47"YD^^Q<97 M\O'00OK40"=@QUZJ;(^+AFB*4TX#S0EF%ZP-&(,60D3JD1)=R$_)*BXC&CZ. M@<:)L2&/5_#,]$06(E7`,_'$C)W+QZNFC1X?'8W!.MXJ0CNGIGB<_[$/'FT% M^_V'K'\W39WWQUF\<;HLGNT(\XU824"N@>V$74ZE`5&*BA^3T%&?39%>32+4 M5$[@!G$5[_A#=(FVW^O/Y$9HKD%2CXF#-->##'1\ZAYO/S&(].CC/@C[=H-L M6%AD-)[8>`M!I60?'X_(/\H2UXBY^\\U*G24EH6YM!ZKC6&\1K=>$&Y]2K'# M8"R67=C4-.UG]V1:>KLV9_'Y,5G7VQF_-X:?RM28D>"'^!4NWP),&T`X);\W M+]L_GI":\L.4KJJQ*ZU0*'A)2+%Y=WEU)Q3ZY10\B.'U3P@L3^!7#IRA::)C M$I]T4H+?0UP>A+\[-KY0"?\,&0K^(]AR)I?$;V,+/*;IBV?L,Z%3\MM5J]V\ M:-Q$Z@P9KFI^,-*=GP(MBO>CA24F@_8!V:F8,`,[HO**'#VT+B\;-Y]&=^$>=D5EY5I9Z:=F7;^ MX[6S;7O4W'_%7"X!6TKGLD9[V"A]_B-%/6]<_/RE=?_KW67AXO[FO@7&KNN, M=;NY5U'M99;5P4;C`F"K^I;X[N6[>Q;\YB4>51A0;KU+.6Y<"%7GU$'GS\#; M!*B-87[_%N@J2U:3'3Q3LPAQ22'O+-'9`QARQ!"6GATZ_)P+_MTGU=@3F'NH MP9J6J7"FPGNMPI4#5N&5,\*N^,\.9H1Q8/N>$5;W)PV,B7V7/="[P=S<%<6@ M:Z6]\$0AXGT+IIDJOZ$JERO%3)J^N:(8='4_,L2LW'*0,+>JRON2(6:Z?)`PMZO+U?W($+,:XL'4$.O[DR%F MB]6WK"'NA2/*RBX'"3,K(6:Z?"@PMZS+YZJYXOLWLH)/9CX[9#Y:OJR^^\&SS(1V0?,R$\I,*"O5'F2I=M'X6_[X MT^)WH>W%6F`GBQ/I_JL(_LNP_8[)%G'R[F_76(*#E2L;M7<_D3#M8XM+^]BL M!1?CJ1F9 MR7YW^2NG2W[M;^=Y$5FT^'1D](G@Z(O"^%W3]&^NXSM"/6:)3_[J?>KT<$C\ M)CD=#AW[A0^@N3DBWVM:.?S`XRRYI#XCE#YV/Y(;UP.\\.+;.&/HA M5_XIX_5,+\T#$ZVZBR:XAR$E]I%M<-&NW_D3''B>=!U[0#QHC5_"QG_S^(=N M4CYP26<$;I@[P5>M\8OT/KA@ASQ1A]N^"PX`-0(W`S2/Q(6^#=4480)?O MZ_UPI#R!0(.DJ?'$'+SM>^#:P\]FHW<'HG@_T4>W?=,@?0J1@1*,7PX'>M$0 MK-L%#H@=A(J0-S%EW[W@(\ZG`)!_\[G!O1'PR3$TRFU%7_\@]SB0FO)Y+N1#]8_DGM0=8=<"/MX"_>;>=[->;FWR"T= M$;4LLF@M3RZ809V.[_3(`^3I`ZHSW^,Z-:%7T]*/R`?!_3??]D['32>7/L+0 MD&['?!XX1Y-YX!W)![PZ:7K)!NCB;L3-Y`B><+J0_GM]Z&X$#7$UP,'##RS> M!4#"1P8>'\=]]&S]+_+@.["Z`/?;Z,&2`?/N/`D2\5L*=XA:13:5^C26"=./ M#XT8ECP&&;$4@-5';R(;E,7Y"?F1_C][U];;.(ZLWP]P_@.1T\$F@)*VY6NF M=P;(K6&<41AI[O M"1>I7.&,Y>#>/M6.VV3D`)@!-@%@B3`1_I2Z\F_^'$MYSW4&"J2DV)MAD"00 M7^R.5QDQ'%I(K>/!UHU89HWP-Y5B(L![XK^NSP':31S!/5P1L-'Q_1"$=ZQ> M]DJF0PX2M\2,6 M-6(6K=.]:K.T-K,4@7LP2VG9D28F,2LHV5S)"`:)>4F,4'W:I"R,R,;<5[&7 ME$XG@.C.)QY/Z01.$6O,4TK:X+I8*8\)$"_?65COSAO5B%IFQ\06AX8)Z0:& MD'^$(+YF9S$O/"Y=;W1;1@\$FA7KW8"V:I7,SZ%DR]D(K$ M+35*MN93:3]N^$0M6Q'9,@I&#H`6BSD36#Y^V0^%)!K0Q2CT8I,K44[*[DG??TM%=^%3*_9?U(W9+=,W`_1E2H4=N#!5G."#S-KWM7-U_WB&/_NF>9C5JSTVKN@:]SHGM\WC3KG:/0MX_& M3!P]]H3K'/DXMK_W6^VX5C.SBUE!T'I6T%ZQ@M8V5B!_]4_#8`@8^S\@XZ_A M?3M%>9;2EJJBU`J)S<_]-B)7L;>S$2*O,.1Y'1>["PDTZ_5FK=9I+B%0S?MZ MXE9Q[^3=B?L>!GY`513P"O:U:\LHK+7J2RE,3?Y&,E- MF#+SI`$NNMC^[/W6-!!C)(]B)(%1LEQR@;LB`JJBP+Q MT@;T&TY'W?"`D?8QN7<&*E2"B!%W417Y?L#>B@!+DA!TZ#S5BW*;M6/SXR4W MZ2'`T7]!\'T.+.$C)I;D-[^^LFJ=K81W._ORMVY]/UO01N1AI4O,'@3GLGYM MD"FF4VS@$N(-53N9U]E85R_'B0[(3)@F*RWE;_/XVJ M1/&*XU'/A,JAW82XO%GR;J#2AM.AXS*)X"CQ4U8D&2:;2M/#!B6I;PNB=%'7%X$D]9KV?W4B<:2K67SK0JJ3'86^G`A MB*\,2Q:+Q6E&J]KF_E+#PT9CES\QIL34XB#QH)E8Q,"@F'LR9)767*9VX)KH M#MD.A9DF9-8?J"=/!(R]XSI!4CU/[L7&+<$@,H7;8,R9WM93=DBFWMGCV(%) MX*+3<`#;3AKJDNZ+DT:KP_$5`?PM$_@%';#Z?.#>G`7N316X_S4WP-G3&?.L MX8B*GZ>/CG]TC_I\QR;,"]D-"[Y)%A3=]O`T9O*..'J8NR:Z5YJ:),20MV2^ MJJOKTN#'3/!AO=TX:P<#Y+D;"P_H&E\-FJ+)G8U*J\DHGF*B:V%C*QW?C` MROPR)LXGZ&,FFFTMB>JK1G1=TN\=AW<1N%*W1/CK5O"Q<%A`Q1/\:8=6L,JD M-A9[IQ(#^+D':[Q0<8'+BN>%!8[%GZV[`GC0S?&Q7 MF(^+G5MW`\[M-?)X$^**OOO:S!*W_OG`,R=X*N" MV$]*8NRD#_S:M>;7D:H&PDJ:G9-%E2Z0C7Q)NI#&_$+\X'O_=\YM_YZ[]O.J M6\5E./BGO8BX;KV1)RXS[PN)FO=-2XCJ+"*J8W;KSR?J@O6"M]<#&[H>N-EZ MX&L?AUHS+:V2T+&\17^#A-PSL.J"*(M(8I-HD/NPQX4-)C%0CU7&)HS@;AHR MIWY$SB_(U]AJ&N3Z^EPF'U5OX#4V;3\P,2*HL6\O]*XZ6R>G8-$#TO7N^,.> MN+/.QVY>Q_U:B9A_.E?F2N7+<\6N;"^I:I[O<]?E4ZR^VB#/^)A:W-#SR_K8 MF#D@JH(27#S^_<,_K^$;CPL(#(K.*WABR-OEC]`N?W!??5#G,\@(<)U'--1J M^]$V7=U<7-Y(P7[\0J:.'0Q_(9T:?MHC%BS"'X,!]0:_[M74YS$^)Q%]1GO* M!/X9$9LZ4B)UZ(+\O-8C)IJ-_6T<.5*)8TX6G/&':`/C?XOCEGJ_[K7E:FZ% M`[YN3%UR.D)0NJ$UK::]X#2_[;!_%:GEI&K%YC/A[OL9G%B_J M5_HHZN_8A+L3>7"?/<%3!N/#*[*YY6W[G1*]C*!DY-3W7RZR'YIAFIQEY)A: MG*I,3J/LVY_YDIW7QJO.=C^.PR6D??B%Q0T M#;-^LNT7%.AW=92)S(T(L;E>(6ZV32W$NR?$SW7ZSY*2C8.+YU`>UWF6D]Z` M0&)_R_S>&?DNM^"TUDGYBZ/::-22A+69\'1Q%VHY-N1YFMS^;'8^F[5ZIT24 MOU$)=%FEU-CPRO,#ZKKRH*<;?(0B@Q&K@P9+^>[J$I'Y=I>7(KUNM-O5@(7Z M3>P[2>;;\6%&FKNU:N!#+CHE/,."DE%R%QK`:51T[*\@T*BRR=1_^AQ MJZ/+)[I\HLLG52^?=#Z;)U@^.2D1Y;I\LLOEDUO!1X[O<_&4ZJZ;.]"V.ABQ M>L^K5`TCIDBO&YUZLQ*1=14:^\LD)A4A2[W(*C'\/:/9R8VI'.YPIUV7V48N).5PZ+8.*?3D!'CD?N&'7Q92F5`HJZ M`+/!8F*[VZY$8%V%!'69A*0B9*ZUF*AE>2>%1!<3XV)B14!B%>2[W(*CBXF[ M!Q(SQ<0*@41=2ZP^2#RG8_F^QO\P&PBC/B.\YSH#BLU#<&K]58.CZH`")>(=>>XOA&N/]=J7L3F2O?MURFA:SOS='/0K_FUI_#?>$K=G5&1>O/:_.' M6G^T_KP/F?J!AO+TJNRVT)=;FO13#KO7P)+:D4HUL#Q+!]:=T2P'-MZ9IQP> M>$!=PL/`#ZAG.]Z`V*P75`T[PR9:TV!'30-3,X.5`>R+U0Q.\MS.-6'!N>A$/@NE3$7^)0K MOHC0Y0`1`B9&NGBPG6:@4I87UM4,E%K<0:>VB=+HYKN!EF1X2PA+M-Y4H8DN MHS=;1^<[JS*H MIP%1C\W#GLM6K>132?%.>@4O3@(VC&ZCMNT>E9>$;HV=Z@77NK-=S/-&W3EI MFEIW/E">7E>"W@?_-!;@'UT>VK5Z3,G(67=Y2!^'4WXBJS"B/@Y''X>S*X?7 MZ.-P/EC6ZIQ[$R8"!U"5.@]G3)\H?CC2;\'=))E;3UB]&(BTC$9KZ]FHR@%D M+<2E:O/50KRC0JR/B%&DZW?>ZM-@]&DP^C08?1K,IJ#ASO1V7SB^Q4,O('TN M"!OUF&TSF]CP^X0&SH15!P[J%M6JM7:;M6T_>[>S+:I:;W:XM=MLU,JU/[NC M-R42*]W:K5N[RU.\U^3H(MG'+)(9Q&.!KI1]S`[637=_MXQZL[OM4L7N=[!J MW2DG+'JK[IA;+_/MONZ42$=T][?N_BX/"-#DK+W[._X&XW#U93K0)F\#',KD MUKOC\F"05>/WN1<<31D:$70YKOUEOA"ZLBBJV1:Q[?[RYNK['3F_N[RX>B!? M3\^OKJ\>_KD4UKV:A?\*_<#I/Y6:BXM+Z`N7O62)C(\`3QX;[ ML,&`DD"]?:9//M7K1L?LP-1PO^?`CSX*+\AZ7V790,CG9/=>7:F$'U7+<4': M<]*&4[DNG_J_D`/GD,`B+1`Q%&100QH=:YT5V8)CKS-C]J@/A('P,]<9R`PA MM63;A$\$LY@SD=WT*.?)!8XW@>6CYL,*<1TC^NB,``O2D>RW0!9T#02]:DQZC M`FTJV!X?#%E`,C;KY(L/!M!GY$Z2(>1PEZ'@-L@5W(A?&WA7@=$^^4+X6"UR M[(8^,8\[K7URT``-W$?1!%+OV3C`3AM!&C7ID%IR1=)%Q=]$&S&S[DBQOQF2 M%:U`E)/\8<^6':!_H5#;?LN3ID1;#<6`_"$.]P`\VZ]/0#4@H74@P9SK4 M1MO@T/#,%?C9@C#.\4+EAJ3CX'UCQA-_B"+9FSW=`LO%VY(+!/(&O@$:QV/7 ML>1%:I?VEPK^B`8@]3X:@'0@4:!5T0#?\`:\\P*FS"G88I,?XYVEWNXQ[\4> MUV_95SBIC?5T:C?\>C<\!K6QG#&8TQYU::1_**X%YM#Q$YU1FD6*Y!AF"'O_ M@A"68"QJ6<1Z!I0?MVB&:-'2ID@/@SX*AB_$" M^#_7Q:FD\4UV4J&&OB/`EO6=/HSA`1/(0>OD$*^;#AUK.)MO/A)H-@WI-YF* MKB*VJ?%ZH0]C^`Y*2TFX(\0`1;:9[47($MLP)%N#&!F(FS! M`D&!!-IWSZ8R5AOC+CW-`E=?2J-T:2GY+)W,:?2T*V:[P#I3P=)B.]O]2"LA M5)%2"J$XRCJH6:3Z.1&24BP0B-C2.M`!_#3`F$C9"!\#)A3A``C#H!RT+YK/ M!?4",071/'@\!-QR7",CQW6EN`+Z?T(P$EN:S(T^`![>5T`L'..WW=:^D5]. M2M4*23>D75D"O>;@W.R'B(TR`LY$8E&T*Q&4(BVWTM-#TGXML?CUA+IAXG4+ M<&$VG91\O8A@E4;A`R:S*-*<*G=>O%8T]S"/#U/X_2B+!GN`Z2E@O`,"X'.8:8;O"7MDPI*$P@4#SFW2I\"G""J? M'T9P()X.-E:"TL15SA1"*0('[RJ5H;Q;!6Y#";%SF%O#MRC?\,.S!9V"@":! M``8(Z??_7K,@P(P<_!2G%>-A)X?`)?#GIS/Z-P-FF=LD&X4?5`)`N M5^_!6GT?G6M?\)'B(BH0_%][JYWQ5CD/@R$BA?#U^:'5RDS10237`I-$0DT3 M#$$_'66;`D&E#$/`"!J"T@('8DWR(D14BVM3IJJ7ABHV^,0V^,@*53EF>!VM-5#B+7E3%.X`#Q/W02( M!:C`3R6D8'4)2LE/8D08*B6J$><35"4S1S`%``%I]Z*@(+V-,^R21W)9"8F\ M#OHC1,G2K\97C13PQMI3%.,#C@@<-^^G$HF)Z/55="?W%:\1=DSA;-X\E,AQ M7PJ93S[59T&>PE'Y<-+U>9'&`^_06WA!!.5QPZ=4")A19F\M#MM'9;B)N=]) MS)P(+SW+(B".?(1=L$#7!TP.*2C\(>$9L``!HR=]9EKS9@ES;QZF!8X2410P M&-8;2!N"ZQ/<3:<<"H.^8W*Z(%&:-2V.U&C00)`B25]*`U^\H!9;-X3?RB9Y@*'@X4`(*9D&@$56W+1+TK#^> M]\)3T"3$6,IH?ZH==[M195!1BK>@=V/,`_O=RF;(XL'1I!^3?_`I:#$8;?0R M0,R8"RHD=+?:I)2U+_:31D,E*.I(\BVW$#2BWY%PK9APN8`@7HDM+?&/:;,2D M2U`RQU-TC4F`+E>-G2YXDPWW\0RLC^4@Q(H&4.2B@84=SDX=W6G$EV?W/E/V MR=HW0&0VZ32,^DE=!6)^4IR3M!I1/1@YC&!R)BY1-(7!#Z!`#M@%'!QLYJ?. M2>*5HVNFX!`Q#K-3L=3,Z:9=\6Q[$O>GC69%9EUAG(N*9978L"OT_Y['I$&9 M^?_BTJ.R#6B%TH\?9=N"\.XK_,*2]W(%P._#'D24<5)Y23]0]M;BQJ`X,$;K M3:V?'I^ZS![,`OA4Y3\=75*EW@W?@:$/E]V@K*FD4@*?7!UH%7P@REC"%]2SB].(J$Q<@GS<#-(6;% MOH>>Z_A#\!4Z1[(+QAETG=HJ/V^HP/_YBB_=M&QD0O&5S3TVMT*%\J0+9(\8 M&#'[EP@3J6C@5JIF2N/CIKX"WA-'<`]O`Z6_`E\]\HH'T^KP$9;]NBYN]!Q7-ZG MU_*Y7/)P]_W'V?7E!;FX/'L@=Y?W#W<_SA]^W%W=_*Z;NW?-Q"YM[E9)JFP3 M-59"%(Y!8W2GF@WM-'Z[#84UQ):3)5$32-W][6E!]W3V,7%E96EJ0A%/F`.- M\Y,:@'/Q0M6"]Y7U1(CY-;.."ZUU#=)CP11Q; MRU(JAN>S:87$QS6#PGU.+PD\TPC&P.I$>CF%JU"'R!;)0?[@@`5=NGCG2R:L M&YUZLZ!]7Y9=T4WFYXK;=&:EQ%F044#F?)TQV@@_MQ,/ZG[Y4]0*J3HA88). MW&BCC>F;C>FQ60)S^I`N;448)]G\3.)%,%7U80F6RVNT(?$3)9\:M9KL=/\O M>]_:VS:2K/W]`.<_$-X)D`"2AZ3NR4X`WS+KW<0V;,^<=SX-VF3+[@U%:GCQ M97[]6]5-2B3%IDB)DBB%"\Q&ELCNJNJJZNI+U6-SG1=&"RO';^=G"[8;6V=Z M'GNT$T_&;!_:-F!M1CR?;^#-;H@M'N7';L)WQ`;G>_-#N!JEKU-J>[A)]9+A M1Y(7R?.:3FU9Z6`1!S;-'FS\D/!N_*I575(<8CN\V8D-"=(74AKX&;2-!\;\ MWCLPT'_'VWTB>-UV=O`5_:JI[]9RXS6XF'X`NX/WV9,U[GL9L>_"U`:1M[&P M?\8#W72&3")*]/$*!&\/KV',3VM^4H_[O?DUBE;V?5EBHOS$3L3,#!;;`Y_H MA[L=\QL?:R[E#SH"J('^I<-N<=,T^TYRE-&*3MV/W\\.PJ,W:V57N+F,P:_H<@PH6&^OQ6/ M2.#?*37\A7@JWGVASB623E+1!..'88KWLU7O+J[95'%'1E#?;-X>A#I*SBWC M^S+S8[HR6VYOJ2DE^]GH*.U-^34@J.5OC5X=A%[)+LXM9ABWPBL]%M>(#+`" M<&#D0:3LAC<@Q;S+H^$BP6F46)859^`%'72*(,8))V!,F#O/?/@II/@GW((. M.^:;<&6FX[T8L(/5Q/O8"DGLO[IDX.HWN-;K7 MZ%ZC>]O2/7T_=*_8W%](K9J']O"A[/&/E+&!/-ZQ([EEWG?EBTO#XW0\H^<% M?';@6PX(L;5&9/;71C:/D:X>][L[ENVZX*GO&MW8-S(;%6Y4>,_)K%B%![O& MBJ]4@ M1M9P+FUT>)LZK!WW&QT^'.78$S(KU6&MVSW6#DZ):[5QV&P68ON\;MQ[K)?H M?=A%3%B'%5TEJ[BUCZ/"'FJB%]KQH">]GWOH"E$'&AJES#@B;32RT1^ M^"6@C^P;NP)F8T*-RJ\YV0V*MQL MR.U;0'AF.3R'^B8L6;5/ZXM#HZ&LYOTXDFEH:#2DH>''TY`]W4&*B2CK9F[O8;4W"=;3\M*#ZPEN'^J`KB:YZ_M_7=PJ7Z^O M?@6&;[]Q:*P?5X8U!YH^!!&OIJ:W87'7&^+Z;\HY??#+C)"DT60%UD7`,$27 MB6K91_4_$P6,/3HE'"9CZL[PFVR!B(-E9K%<_>_,)Q-F*[>46%C1&!XR&+SB M"4BZ]W&2SF4"KS`.QJ^_FP!\7Q\JOU"66J?R'O"50L.;OCSYYRMD382X, MR1RPA+AF"[YF=*Q5A8L='_8 M7P3'BB1[E0G#]9,^6'P%^EU\/%G!5WF?`-5*MY#4V2L)@E86QA>V%"=Y7M3= MDT(-!;;`.)A!'[F\2#NO4!LB)<7`"F@.HMR_B1U@/6U-;2G::#28`\I!(QRX M'(':'5<,5U)IQ<_PO>6@>DV%LO#:MDY8I9G#P7%$FS?%<@S1L:_H>D_YBGC` M)\_4#FA+^1>S+(^9\`G]R;]!>>C;L?+^CH9UEP?'J#<3%N*-<(`[CE#_2$&@ MU./P4YQ1+S8LG4]*%_A,U4(HJ&_N,7\.P7T#VZ5L\A"X6!7X M`8OX(HK%##T*1C9P0\R@Z+4(:)UY!D@"+Y`OHJ>K0T%.A@9)@-8X^\0PW#CF M52;83_<=AW'!;R?'\TH7BV@469V#P4_)&Z]VZT1\N/#VC'63<"!Z2L!7`7_` M&?`W@6%Y6D3NRX$061TB1$9Y!J('@C;G@GMXE$,X@R2(W" M%M$?8K3/0=0B@Y,`HJ&7>$#_PK$$34'A&*8P\,C/A%G<"8TA[IJ1S9%.8MT) M3\EK]\]%)5!2M=&QDHLO<.4\BV][69+%DO\/`M,""_MW(Z<$'$N($_Y2>O]`!A?H6,..B=F91Y)+0+5GF6$X8O.`U%U9YCQ::)IQNH)GKOXDA%@ MA_VED?)"\C$($?BCP=3!V7\RM6@$GL=),I^QPP34EVCQ6#F?!RD04S''%#:_ M*#D!CF3&0/&$.YEACYRC%;Z/8)(>J.6\?$CZ'`Y]BH2C7^2^!RB.0JEQ8%E) ME(F(Z_-Q%7(NABX!.'`,<$[:-:UH>>':TT%U"# M5<-E!/C@%/8TB)>-.98U#A'\!(&I[4!8Z,;$^P+AO@C._@J@4VJ^T+!I! M=S8A9JP!9O-H-Q/@M:?*_?VB:Y^3(("Y#0K!IYFC"=GJ>XQWT8")&4!M0N*M M^<(BT\='33^@E!(AO7#9LR`^:05?+(?@&DCD121AR*,=!&P$A.US%P.\PE0? MTNA!@C*U`D_IP-H,9BF<6QR&)+_O@)=[%V%`AZ(+;2?$1YE) M*UJIZ*/8_!I:8OALQ"NWR+$#FL;713/;/$9_E"G#1+R#2W$<)P@:7N%?+J:9 MY'#I<]P;O!.+W#$-HQ"N32O.>_&["S_BON7ASJV7X$A,L0SDFT]9`&>ATK92 M:$`6KA%-QPC$M@2'QA;[8-3\R-TGR0(XBZ8Z<&UH'S#1?A)NER&QS__\^?`:S\2,OV( M.\'GS#,LQX-8_YZ^^J>68WS__+__HRC_C#]T:7N^R\?D%!W9':S\B7EM_TY< MAK,J^CJ-(Q9"$[=T#(S]BF=>^I<^.]0R# MG_SM&Y]G_HQWP1^_"%S'Q%%PQ1-'BDD-".$M[Y>CRZLO1PHS?SDR='W4Z>J# M(Y@2F*#H]0'FX_84^#SZK!ZK^J"7E$,1%C&8;@IVVX)P?1WC(>U_* M>0X/>:P#Y?1$1'!I3M5A6]7;NE89IX-A-J='G[L]7L1=QMN MS(ZQYHI9W>"J,I:U@=;=*,N1BY*R$AYBB#.,(LR,=!DS_6%_M[Q MCKN4SYE+R-TNI\M,*\&PKLL9[N\%N\O-+\%P1Y4SW-T+AO-L-,%JM[\OK#KV M(Z[7L;G[MRE-1SWX_1)>ASF\;EJ/+VW#Q4WU9H0?7A4[IIJOWE6L8UY)'WZ]IO-_@I`C3S#91R@F/,=ZC$V777H*-=\;;<2RG$% M:1]?9?298QZ%9H4-"T0;_'F&X2%UIW@%XXI,:+A1P@]#EZYX\T*XWJ!J!F_X MT0TS;L)SV0*N/V=LNM*8NINWR$D1D4D>?;[I_R$2`W:3YGCH>\[T3SZ.^=^78T>FXS`[C MX]+NS/O61[*M!5A]]M/CDMWI&J3U\TF3[@5HP]YJI+D4+YDR?J!92IGCE'6Z MNG3)WANE"9MU68:8[IR8[E)B-.F26ZN$F(P(;Q:_G887W.[H(]_7CXS)=XGA M?R-V,(9_^6GPHG-+L*'W^UN7Z2;8&$C=7#^]?;6ET3AU"=ZCO'&=J&RU8YT_A@M3&Q%2779,\$U_J^$V5\=S[NVY]]=T=+16W(J M[DBC!'@M2?`2.M8FN[B<@6QI!*$O[*RO2/=71AXPC&1TG3@,A"B/P](JD=OU M^G3F!65`ISPHT]>@DUD\'R8\Q<<[487T=3[4/=F\F^]7"_1;1N%Z7:F=+&C< M0M=)TBZ(B_DA'BR`[O!L#X\MC;768$!>F7-$-;:%D$G,2O3F2S--KT39LNG5 MUZ*7CP&0G!5I+B7EOF0VV@S--X[%C+?9C90R=MY5>_V.?O2Y MT`U?D8#W,;S-9],7Q<6;->&O'ON;BHLXQ>\,-RT>8HM+K][5^AX[_Q&^PP06 MX]-:]]]#.U7`4!5NJN35$B2CN*&8W>/'S+(M#=(GW4)^I MBWND=L#O&SOCQ,N)>[_'2N3B$IWE](*W_%;IJ25N].+K#(^#<+%$K.A!?C7[ MQ0DLS!=YANXPZS-Q/WD:]DT\+Y@@O:_4-9C'[YWCI>*IXT.+##Z^*68X]<,0 MH0=T^%$!Y@@3%R\T>O&;P/Q.ODD??%"-X.&_F(?([\S[K"V:@7XM-@$%$+EY M@1?=HO?Q+"MPW\)>)M1_B[*#>\?2%-&[X,%Q09MYCF@\?45$,B>9]YZ88*Q)-4-8Z>/ M];HWOA^7[E=J_^[^CZ_PC>VX$*-F50YZHV@2^5>A\Z[[SZHP\JI!5=9$&JKO MTI5%8M_MJ M,O?J^`]^+5I5M.DK3'\6 M,W\(!4_,V5O5[84!@&B?!9B/AWQ%A8&C'V%4&F.HKS&LB!E7,V/`D'7+-E!> MSQME.QAEZ]9>V:1.=9G^_-B_)\56$+:GPH$.%U1]O6!IW,-'[SE);&(D]@NW M;(2K%55>"@+Q0U*X?NGG&-5:2QVJK5$O68=_NW(M5/HY0NPM7/KYA]2-^E-8 MJ?9V5:VEJX>INX6GTS103!T`\`X&O"8UA18X+MF+F74IJL*6*5RZ-JH)#WG> MJ]P"KQ`PP["E=]36H#_:H8?+6#]M"JVA,8O&+(J81?O',8==+ZJ;A30_$7/P M.@_)B`7V8K:OVTHDVR-TP".83@`A5&V86,&OQ;DHO9X9M3J:UAIHNYSORQQ0 M=0H[OV;YWAC-AHQF]YL`-3*9>+P0@SC+G:8J^"R_UI^ZL9^ZWC]YH*9)S7FZ MSQ?"W-^QY/+U>/''*!?H;0/%G]+%,>2IBLF,JE59V*`@^E4*8B0O,*=O0A!_ M!;S()UXKOK2?J<>!:*Y?;.IZ3VQ:I&K(_#7.[^4I_+=%ZHHF66R:#FDL M$:]:3PQ#I-?@5CGS$4<@4[;'R3K[^'VRO'YTB5^<74<)``B.Q2OG$VC95UR* MF#>8`I``;NF_P[O]HO-A$S, M>SM6[AT.$=$*&^(I&48P"2P^A<=?-D!\CS0+.E`_UA7P319S;(%L,"'N=^HG M@37F0@[A\C+2*CA61[)M]7@8M9U,XO)=1+&88G7B:*"PFKGH#W[CR3%V1B_R MM+6E&UBOZ>VJU^J=9(T`5>N;S%*G*2P-SY<)(YI"P)L!]&!=WI9RQ5.=B#6# M.5U`#H-G4X":<00/)K!7F"L<@$<1I21I';.QCZF.[[4>.G+;BW!+HUY,\N9%%@N6#3,3SZZAK^!-[$?* MW1J\@>AJ(@W2=6!-##Z.`P)Y@?&D>$2`]W#,08$6&L_TFN.`AKQP]!..)B$! MB$F!$?JB&_3R,V2B"&--<.I%>6G%D\-24)7>(E:EU@LACL)Z(060YW!*(2#XH%2X`GR0M<4 M!O<+\[9&DKLHL_VD$TR3%_=8+UZG')_JG,%0P9!S>*TB M1=EF8DF5Y9SO4.44UL;B<;JTPO"G-N?W2RRJV)V(ZJ<@_RQ M4V8WH<=:3O%^=:"OS2R#MNE71*R%AXC]B)$V+QC^FT?'@?65C8NI\"UN;'#6 MOD&3DV"R,(-T-3YK=^)32('>-T\O>970RV=J=4/T>B=&N.-,Y35T6]PG1B2%W-K%P*6F2BN,C]1DB?'RO&Q$%OT-RD)Z.6*8 MJI9<$UF4UHO?["G!IE-:0E:32DTM% MK:-42NO*5V90&POGS;:-EQJ0)B\MW:NE`956E16$(H>BT+N].@HEMR:WIDNK M.6L#M;;^((>?'*R707]K_,1>PO6'[=%;.B$,MU&OQU_XHA?.GN4B/YW-K0K<2QUNSO@>"M1NS0"ZNS!$*\2D4OO_N^` MX271MAQTO:L5WI^I-O)9BI;8S12O._ MU(T5GAMV,E:KS/QR=,!ZV]XJD[YT@::IJ_M\/EO=N,Z8%0(3W`A&K'SUI7:3 MNZXQ:DNPL26,6/GX:+TJV-@`1JR4%WF6K3[IY-**:]*KE)B.O*I6^NH!7W(Y2SYZWJ< M=O]B9K!P9B@KM1@N9ZDI=OBOJG=*QXU+QW#UYA=B;V8[+_+?HCLN);29;D5S$7@_ZMRM? MEO>3*]TMLE0C69:!A^U*5[G=CEXG64*#X:[\*;7IFIX3^)9ZSE2,(.E]11)+ M#8U\1R=+RXN22+T;P@IZT#G(\E`6(.:N,I=VFB6/6*/2ESR"5F;[C(([UWIQ#'H=S9#]RTU*'M>7^0= M>43?[Q4D?4Y+%=27$KR\V(VV8,AK4Y\)9!)3$0=EAJ`C=:4+ M(.@5,8&SF>W#[+>N\+O2E5-'7:8],2+6HK>4MLMW$O34C9ZU".8+.#`/F`#, MRC2])S75=OIPJC!%E3%29A3DZ^VVME1MUF'D+'!=O&?/EQIK:KX\S%_F=Q9) MJ8+X4F8@C:N'U1-_1XT`X^QS.G4\MK;Z^K6E+:$]3LC[EI80N=_/:LCBA M`.4"@/N,E_;A90B]$]]WV4/`2R+>.R)?VH.ET/48LY_#)@M[I7GHWU],*1+) MY`4BWRJIS!=^HJ@?$+V8&A02_7D(%COHCU+R7YW2%=CFWYUB.1\(8GDJ$"*; M/]*5]B/2G'>DG(/:=L1Z]IH-!CT-LE[6*;[P21>=8F8^B(H:15YF0EGM86@I%*5T4 M/C4($6#V<%J?4O%;'IMB!6>*2;^NZA[3.S*+]SSF^5$U-ZK8A+]C\>-NJHPI M#8M$8665\%!/B9WJ*=&QGA(>-;5$L:G9-0C%G]V#F#?$PSTE<12E1&=1=-:4 MJ')G$-=]PPHO9(+;`KRT3)H/4:5%E#$<.XA0[XGR=Q^E5>CV9]16:__N_H^O M\(WMN#"'997%?J,HI\R*=/6I3C<;)?&'*$?.MZ>JK$BNJN]"]WAY=7YQ=1\6 M(7QAIO_T48$U,/QUI!@@,&]*#-!%?CZ%?T^):49_8Q4AZN+'D%CQ/P$X,O^J MLHKJ.07,][2CC6'^:NI!@/XN5L$K@II2]1A5![S>J.E!JFFB5-S^:V@<#:)Q MZ!N`O3I0B':1U7`6AJ_;MX-&G0Y*G6()WXTN[5%'FO<"#>BN__[_]^0J.9!ZB9LS(ZC7XV^EDW_;S*N5S0 MJ&6CELV$WFAFHYG-A-[HYY[HYT%,Z,5V"@II7/-0\U#ST!8?RK;=R,DL7C;\ MAV%0.AX?I7NI\AJ?/GQ7;#??HF,_ZT9D@LBR,X1HM";SP_W\+N\NYHGH7F7. M>.1+?SLAQMID_K0%ZD8%E9K#?RXC6&OU])ZR8YDF4@YX!W*B(;AX<#2.TQC_K_-[#"MM:L4)VRO=Y5^RTKJWI_]I=@XU-DC[8K,]5U3 MC/)>=[`7KBDD>=\FUT:5&U5N5/E'(+-256XWBGQX&K(G9#8^N5'E`R&S8E56 M&U4^/!W9$S(K5>4#]LFUNN_4W''"]K^&)0I)!,BW/SM1M=P;7WJOND:,Y+FM M++J,DUW?ZBW`0.F#%KW5U7:>!%>F&$2GL.MKCAD;T]FD MZ6BM@;KS%69C.HWI[)_I#+2=A]2-X32&LW^&TX1KC>DTIK-BN-8?[/S0K#&= MQG3VSW0&W4YC.-+=T>@;Q)(57\;WYI2%?5U[B57<5^CKEUSM= M:B"NKJG`=PNXS\K8<3F@M/_D4JI,'-M_\A3*0:H7P5(Y,C5\Z"HOQ%-^ZFC\ MBY\ZW1;TXDVIX;-G:KT=*YF$,"]!"_;J^2Y!4VPC__.1F%#_R8&'GJ'O*7#G MF/`J$FX_"@ALK:.\4>)ZBN\`/>'G!^*)E@W@PB6&'Q!+`?8H#-`$(7H4"\CS M.,U`"[,-*T!:F`TBM"R.D`T_$7/";(:4(3<1]=ZQ<@\-"8&QR90P%Z_,8OO( M%%!*'IC%_#>%N!2)AN?`7!7B*Q8EG@]-VT"/]<;[<.E?`8/G//9HLS$S"+0$ M0TH>^3UJ,4H9\_%,2>> M8W.89\[2=,H!Q^%5)(B/-^@.!RV'SS%VH&W_6/D2^`&T$MA`%S/8E`L/&K>! M?S(>XSB#L`SB/2EC`14.G1A/,$(4Y0JLN-^IC^-@,E0!A$D/+#-\5_$"H'W. MBQ"(%U@^OHL$V13Z0T$3.TX<].`^4@%J'K%-+,^!M]OTF5@!;PX;B)0&&"1Q M501U,:E/71AA"C*D'$7=8*X13#RP#`,E2UP7A\.ESPSU:4XG-&8$KHN4P'B, M`TOHT[%RY<2IM!P.P?Y"08+,A&]@@%$OW;GVAVR6M+G09D+.N;7\XQ5^&7WR M%@W[N+@W6S@1>DV?_[Q6[[T*^]YHIBGC?Q7U6,?_%__M[/`*!FON>X3])]4Q M\HS=BN_LS#NJ1\^9^>5(&PX/HA[]'V#,.`7L!)12)OFY ME/M;7*X6O?DPIZ[3.3A\@EWC9RQ1B.Y*5VFVJBZKP5P:UN0L(ZOX^[;!/"[%H%B86&H!:^?BF9H0EN]"RCDMJE*1\PV.PY M126E2V=>Z,#O9"\]65K;+84]U,+E72UYEZIB95V$RLU^TI-K+0[KZ35W"LUL=).8J4-I[,TL5(3*^5= MZ70I&?O4K;EOJF7$M$:UI5IYKXJK+:7\FS;8;*KKYJHM_2BQV+*Z2X=U\V!9 M^V/']MO\1_C.)Q8S/A5_[X6B=:"8+?-3P9)/]?6ZM8P(UTGMK,/-B*I3.]/A MY(:+D=*8#/Q-O.O!:3W)RN[DA" ME_+J?;29]UR2@CK)XJ$]90SY25E(YLLF\(,QVJ`::HJ/'E"CR:GI%J8<D=]RW# M>%;Q(H[,?*3*[ MV:AU?PH+'%*1A-B`\5QYSQ?YN2(OWG)>J,M3 MO1V/9_>'N>R!AZFW(AW7]?PV@Z;%)R?PE;!@`4^#=VR/X:LBMUYDYL*[%>;F M)I:'86:NKAWWFN14%DSYDH?7V_RTLYSVU'4,ZNW1_%K+*OPU(G-]'Q4C76NIG9V# M4#28$C\NF95JL]Y2^_LQXZZDS3;BU7`OL$_YW MKA/;!`!XJ]/=*]"U#<.#-R;4F-`*)K3SN+=&)M0LYFL=6BQ/O:J5.ZSEHFGU6^JPP0QO;*>QG?*VTVL-!L/&=J0QQ&KIB_+L(TF>4K3L_A57 MW3S[[):"_!!P+YZNQ(KDR)NCF(4IO[RZDN"_$Z,_-<'UV)M MC_<$>J/W^P.U+V4@05B2A:^4>/3$-F_A66*52+;_\Y9:F`9W0US_[=XEMD<, MCMQZ^A;_A;/X._/)A-FWE%C^VU=K*:^]7E=J(L-DPG`F_2NQN)C0O%D6Y24) M-'5#+.9GD*<)E+HI7>]M9P!RJ.O+75)/+T<=$SC,;"5GKLJEI&G=Y'09ZZD< M"?D3H);CG4>=46D20%QW/L2U3XYE4M>[^"M`D.KRHM$[4B/6U<%`1E=F]Q40 MFR]$7>YQM+[>J8;8LQ`,>@4UD\?_NM:5CG'8X4H$Y28)L>CT^ M427C8@A(S!O:7/CO7,[,?D;U7( M9#&2FLM$KX-,1EM0C%[=%4-F]1M3C*X^W`O%*"V3K%[Y:S>V<4KL[XN"Z49B MZ:H]+;$C4%^QY'&)$_,4S>@+LW$IE!FAQYF&657.=+0V0,X(E';(BFK`@56EER%-_Z9)$+)`E<^(RVJODFB\,=+WJ8$"5;@WD!0/E M&?>B5U>-!/712!I5PZ=T(+C8XXHTY6]FCJ3!<[?;3Z^!EM+DV(\XS^'T5T@^ ML;%$P^U)`[OAH)?<7HMW59*(M$#21$C#XY&67DT4(F(-A9&N4`?J0$K)TJ%9 M8^D@7:\.T@I_2N`7R]P%_G^;2I" MN-3WR]=V_:)S=REY9,MRY=5KU3%;T@5I.4X9)HI%&>0L1L270RE+:J`:N<#7DE5'4S;"R+"*0SX&+(5*UL3`K^&#WU#;>+CR?85K] M]?@&?N#S!/R;266OK?5`+7WV2/"\YV,_,=>P)/[:X]+R`>LN9E![=]5B\HOX9\9YN7.>9 MF=0\??O-PZE1.`5HY\3PV?/B^47ILL4#J5&T.ZE"S\5)JHZ5,C6/!U)G#JO- M37(BSGXK')2>5*_:7:T()QD45<=)F3'I2:^*M+7^<).L7$^I2RH=%.DDV^T4 M4J\,BJKCI-2@2)=>[>ZH5Q4KE[;A3!8]<6FYRV=(?=$8YIV6HJ>,]'2I<7;5 MSDKTG/B^RQX"?CWRWKDAN(H\9U:`)8_7`F'(N?&0)[H<>JKBHA02@5P!1J,J MN'!L)])G\7HE"!A=Z734UK64PY!1L#*A9>3;E3JVMC98C4Z?RF/B(FNY(HM0 M/>=`O-]/*4:,HI*T+EVP%:-5?C-CF+KBN0:M^7(],\JX/(Z[HX^X05-Z19':MQG$I[;X:44G1JZT\R21U\F`:-WU#I`G7V<. MDXNSC*Y7H*T4@IK\*#QU);(X;?S"L/S^2L98`3M.X&Y=N^7[/2L*(6)B!T)80[N[TH7AZMJ]<4GDL".= M7GO]E1SV^NSR3D#+"V+3&9V)Y,U%+XCG>*[>OG8;2=RR6%.?J>MOQGF MW$=BL[_Y1:4SQ^8%#OD?)[9YXU(/;RKAG]A">$B"]YFH,+"U,;N[V\;LKA,` M<2'.JX7M!N:4&Y?!.$XMH,X9*XE!Y\#%I\1C_*?X^.=6`]PI#+2$VW6$NP*< M<*-L2?%G*A'^S6_>LXDR6; M>$%#8)X+9P)_S$[5!;*Z.%,9.RZ'0V>A&DQY$J4`8`]L$IB,8["#&P(G904F MY4]C=P&^'BK0H\M[.&7.S1-Q)Z0%WQK'+84HYQ!8O&!CAN-.'5>HW7O?>:30 MCJN\,/\)U-M3O.#!8R8CB/[>XGWP(?K'*TQ3QJ%^$/L MA0_*RQ,SGE!96U&WSA1B+L$]F`L1<6YK061CPMP%<>'[BR+CLIE=@9K)+[*< MR&+"QH#EN7Z%(VER7157M@IKJ??D!)8)[4"/)-+0_P8VKXTDAB1);^Q=I%BH M"E>2N9WKT_5, MGUH\[H1@=ZX/"S:,_9W8=@`MBO-6&'/E"PPW6MU_9O(=\TA9><,`GH+X3"7" MI%8PA$T:V.SUA)F!IL%X,0O>GDMY"'RP8330F!6CDINSP-R#T?PK8.AS'MXJM"GD)-NR(SGZN*>D M3&!8GKQ0D`DL><$_NFJD/K(7B/*A#87-5%*9SO/]3\):#N>712R/2LHLQ@NOUI!,[8.$>6/@;SBT*0\_V"#.; MB?YT$KDOC`2",3%@B,$KM=`=BVOB_"]X[#OE/ABG,X^$"_%G<3\2^K(#W^7S M';K[8`H^>C[+@AM[P%C!=1!]D8HF.C+20"';D#!!"?3Y9G3W0BEH8V$9R'SZ<[=BE,6V%H+^8IC.:C MNV480.)WLU4`?-9&HUZR'8-GR048K3@8`S\$'I:O\'()X1.Y05T,,G"X1+HIU*1$`/GM_"P5.HHEQMR#`">1 M:Q!QML0[8*B#SH0K=>1P0`_!X4#L!,'H,[5"WQ-IK#>E&%.ROW$1P4VV;:#5 M3$4FENM]4MX_?%!.7<+#MQO7`A\5/COSB/C*L5D+!A!\!@3;_X?5I5O*B>50 MY2;`5>`-)09%8N\L2J8B#)[GKL\V?W;F-'SXQ`E[;WQ0KCEQ5XG73L/7:$1L M:"1>N"2>+0;`4;YG'[CW#>__*U]`JQT@Y'UZTR7U0*:B>-2RX(QO8H M;6?F:!2Q?>TII@BCXCLZ?`+[RP,_+(6AEOEBDX$D&F4)4^,K+^(#SZK^+ M]AU86+TNZEMYK[7T?K\U4/NS'C@HR(?%*)L_S^LMI4)87^S:@])&N^[>E-EM M9SP6?[/8H2G?/3H)'L&XP-^IP^.8^.;9-U.E, MR'P=,LXZ^<#=K%3;ZO$P:AL5`C@,50367B9.9+`DB`:*SV.\/_A-'&!F]%)F M$VH!HO0U#4CZ6KV;+!SN1`!O^^#H;P+7"S`N"1?KF5$&5EA39K7.Q/[BS=79 M_V?O6YL;58Z_WZ.Y_^F4'(1K)`@$#T0)_D)+(N0_?,KWNZ9_HBL%(/(CN!6+A=QT'@F782 MQY`69/K=->D70`E_O(4S'+_+PU_C6F9A1+%W+IUC&2[#$-<4_U=]Q2C99QC(P MX:>_8*=2\5WFG!WF$*H)X@O1(&*G`,DQ5QQ.\;(XP@O+ MZ*9JA%*?_MK;`=#:4E`)BQ_#=.&A<+:P39>.\O+Z/3$@"]YR+L(NTF9CL,EN MC/]7B[].7ZABH>5ABF1]?2JM"MV];BDS<9P@U1RWQ&7']$DMQ&6I`5&XC>ZI M9K;=^-0OE1L?_Y!%/H3"0#@]>[O`%]F10>J@BR79"ZS(H,#2Z7_M@K'<(7_M M.-ZP+KVG!8:'2V0RW?1H+&(-WE1+2N4LU4Q\W_X.I2Q6P5_VJHOO])DEEMS` M!!X3NG@09G\DLC6-8YH/A6.'.G+LQ&[UT_9]SPW0H3I"I/$H6Y$P6) MIV#Z9%&:=?E%=C\M_(SCXMX.L%:D>+ZT9((@8BX)>2:^:2\L\]AZH3+IAG9\ MEV0QGMBFF[A_\R1T[:?!,F22"WXS)=`6%4^1>5W_(6:L*NFW[,%B&/I1"4#BM=N, MHP5*F;&7ALTB$G.>U#KZ)6AA3UELA*FPQ-<35Q8['+V%P+Z36>NUFF.&Q#*/ MF@U$IE,F%70,RV-O4QOBYS*"-24G3Z1L1.+"^-8^[?5J:$<0P[E9JS3^[=V_ MO]-W%K'7FUK$OQ`F%+LDZ"2G".RON-#2DL(=&/XL_.OB[.[_?1+&TL>U3O=R MZIV;9`G86_&:75R>G5_>)2-Z$SM'A^T&?AG^GQ]^7PG/OA:$W M^[PB4*QG",M"-3VV'.Z7@]';:7'NH5FX:9SU@[06-QBF`G\L5.`Y4X&Y5RQM MK/3B;W_E;X3VCM`^N;HY.[]YA>G?%HW?!'G^+,1I(;T`_\IFOW_HRYZ^.SLXO+;Z\?RLO3=A04C@1%Z82@,#NX#?DH+P.(O0YB3^,#>\7T M;R%8X9>V?&GS7"\7_KV_^#?3)&0Z/6@$*HG7-U(^%O,E%L[Y%B++BFW:XV]= M:(]7SEM6CC?;D.5D@>2<]+_T>H<$YFK8C6)%E4I`[CN?0>/(W_:68/WFG?31/6 MI7VWP'40/]MQ:I'@**^M'AHD1O+46SE?,UL!II@;BXHJB?IHTK8*W.#*%=2+ M"3>\[?,H*IR)RJ!G(@+*?4>7/;X)]%BTD1495G4Y=:-A#)W<6IA[8@'!2A(^Q$D(,<-@,1HW70UXJMLU#)XR`@87!:L8.C,M$S2\2KP]4&CN\?5XFT$%08)8LZ\O%+UM(VJ_FBEMTR5%EK-[WRU`T$-=2X M.[O0_WKWDEPB=B.X5`/OS'6>5*9WV:?@J^??K*,O8T;_^$X>#.>X#[;2G-VX;:UG;R&2[[QC M,TZD2LKZ4/-_(9J%F'C5>HRR&Y%I&]G+Y&!G MAM^+11,,ZYE]J=2AO&>.2R]Q4A(N51%N61YJR?8;H^,LX`K/P2?7=KX'%B M>]0NW[++J9-,Z=4GF?QD$IK#&VNV0:PZ09/=WSX;,IO(V)7H4@#*=EJEX6Y4 M;Y;?G?NW3>1]]&_;=J^REL&;/EL"!9_&*V0@LP_URN@("N@$)+N4,%KJZ9E9OZ[U/"Z M9TA7`$W1G@6UD"QBKG<#%SY]RK7J0295R^FNB*9.H6E93PTH?%).?&=U5B!.21U6RW9ZPR^R+8FI^M%61V)B`R M=U=/*=)E41ZVGEN$N<;])1/1C&G!'&^V/PSSD;4D7KL0YV>WY<\'X$T_I4@? MBIH\XD(_H4?;23)K1K,Z4KJ+9G1MP>VV=[[A!JS+=)Q4S.-V"](=P-)#.2Y% MZ_LUEN>"0";*",H(3$<D2[ELEM/02UB>JXLJB.QFV[4UA&&@*9*!^; MY4-7>R8?Z_M_?GWH]Z4\\*J?0HK=1$$EF@9_Y95Z!)^&H'P83B)W_@PDD7Z MJ&!.XBJ$SLMAKJ7RKI9XF;);!0MV??.](,BL&?Y'YN].7NY>YB0N_<9RU.A' M)TF&VI82<')VG6I9837)I`+\QE3OQJ&V*$/>!(?9A:WWRF&I-5QF1%RD$B*V M\IE9GE"6A^_*^<%8R4I\9I;^VRN?9=;S->@V_?E6/C.K!0XU>01R/:OQF5DG M>ZB.WI75!+&>JV%=Q3G-K#4+=#VK\IE3BG;?ZYE#96;%97V\7ONW^?7(H3.[ M2*L^UNNG\Y)4Z5HRSL:VNEY_..?).]*XI95)-BZIM[07&K>N]C![=VN`Q@IE M8K9_2ZT%KILGU<+2W"IV'XE*G3MZ]5 M/4HK.M1Y6`^M_.P7K8=6XWJ4*X6&8$.P[15LF4IU&W[Z_?GJM!6,_JC_7@RK MYNU6-0_^73+-TEAPS7"`&J?TEG)O<0%?`H1N?7NFPTYF>A8LO%WJ&77NG!S M9:USI'YRB]AP0M@X=RE+U[IT0S/<&\E,WK.&:K[& MUGX798_EM5`>4!Y0'F"YQT!L0OA6*WP*&RXIUQ6[NG>X@$]AP^7CNH)AP$)`R^^M[LECS$O_-./3-,]6[BU>5U5`=ADGC]_ MX@*3K*HRVHW,[O:*JW`'%*!D]1N_K51WJ1\CN%%P0%9CYEXW1+&%(B&EPK>@ MP@HH68CV7J*]V9T(B[VLXZC0@==/PHX[V10YUN?X9Z?T;=\P0^&'X493^B+R MMQ6*@7Z;5&TB-C=XZ!B3'_;(6ZUA>!7YG8BRG!SVU%)B>5 M?]#4@C@`.WN8!$;5;)6I'T=#X@6-\M/TY&C]7X2/QAJJ-,6T:6GWFQNN"^Y)T`0 MU5WZ+K8C.KU2]LGN\P#E;JRV!);=IT161$G7@=I!Q9-@FXP61 M3RIDEP5C39],FLHO2]M>:43])PI">_JR7!_X9E;\(7V/FE:VN=.1U:47$F%\ M*"2K*<3+*:37L[#-MCS:>F?F@IWJS&VFZ07F>]YN"1%BW`P/A5OBVIXOG/K$ MLD/AJ\'42O@B"K<1RY"TW1A45)L\$3^T678G^Z%(A344!L+IF?"5?H7J(L,1 MA>_?3^-22UY\BOK=8S0@9N3;H4V)#5-P/>1_ M?G/,'^YX><6*_HOQZZ$0MP0*-JRFPSXHMI!9FUKA[6A]'YL;+W%GHJOI=W94 M?S5-T%QHU\IH>"^-M*R&]V-],EII>)])065"M3="M:V$#C,)555E9T*I&#,I M/C7F;+>*U__JWK$?8MLCV'&.QUFDJ\-LPO,IJI&54JLPR6)%T>IGA4ED<&V\ MQ/GV[^A6!M)HH.CIETP'7[A!Z$=LA.-G.QB<6C\LDPWT(TY,S&1-&\N9JQ0; M^IMY2Y-8E9%26!IE42EK>J-4EH*)GDEE#N3SJ*1K:IM4<9X:P>.Q:UW0G3H( MX]^=1KY/_W^%8+O`7"H3/9/*H22O4;GU^?40/,HG.%.1U$!P:%!5:9T;OFN[ M#T&JRN09F=JF77Z"54G.G.#!4!U-UK7V-@IJH3AOABG%F3-,*9Z\PVY9BI^( M&Y%"N\D?MR$=AZW7-^(]4,?ZD5W3QQKM/&+55NB:GAJN81E;]-IPK&3*XN3= M$BP(+$KV>Y50(]EJYDZCC-4"9-\:#@F2C[YYGA5Z]#_9%A(%P0[D%9RXM[5?!I,DYS3!8B-. M4CD/RY2'G5"L%W9)^.&W(I*SW1X]>P,&,!,Y+&6?7T?,81V2L!V9HJLI=1H9^^2W&I2'F>96G<9E M[?.0PU"FU:2I^Y+.4C;")//<@7JH=;IMI2BNMLM/LNV=]=/!NGG)(:K:05N] M*"\#"57.G,:1,MF7W5@/)%0YV_!;/WFMFY<`^&<.8%[S+!AQ9<:*KXLUVY_32FQ3/&Z MM#'?>[!TONE3F!OMS;?G\4!)JX167@(&A377[9+&DC@92IVLW=4[;,"GL%;T M:I(L*E(WL5MX.UVO*8)U3IK;0MF1]")AS4QE,;HLHT*8+U(JN-A9^2A8T/M. M]V-14251'TT`E2ZHI:,]"-#!@!2*16FQ&/1''-IVJM&1CF_$XK)EQ@9;@(O= M'IHGLFO+>\AZK7R=HA1C$U&595&7V]SORUQ0%2]CA.X["DU#0M/^(0`@D2E3 M^:O^(*VL(#!6,.*.$5,IG$N1N0GGDB5N0K5>:=;4CWO6(/ M@R7YAB_"V89)W$LS6U1Z_0Y$.0X$;RJL!`(*+41"94OZCH&!B-[NH_?OD4L0 MN+"`N]?':1\WHGV?)*@(@%4+J=>/:_NVXLVXPYN+!?4WY,ESGFSW03"L)\,U MZ=4^)@M#ABA(5\'JMVY:0:%/! MK"`<+`V1DEHI:3O\MIHINW2W%C>+D_Q()/ZMVV6'$>&G'3X*UY>GPHGA_BD* ME\:B&(=P'`2>N>ALQ$6D#K0`Q%:[A.515CIF4!.55L-J,&*V?0J;!FS1S,." M@-5&"@*V`X`MNH47ZRZZ1_N_>`V<;52KU"+XV-XL=P'+8)$RK)/HTO9H,BH0 M@W3%L&RA;VW1M2@FM:,C13]2)%F'0?2.J,?+"6CN&^LA9C@.*ZJX:`NXXL9Q MX;!!BQ*'0>'N^]A*B8)1JPF0F-_0(PIW=^%6D#N6P+MPB-R]N'`M7>'L:`RF MJ%8/=?`N''`L@T7*[A;X+C8ING`UNW"IQ>#&A>OPI5R7;^!8XV\6BYS$D;UZ M<:`"REJZI`!"2>&`LGY/$U*R0T!9OZ<)#"6%`\I:NE""2EM&0%FOL901/(64 M].KZH5A`66=N)-C=P_E_(WL>WTE\M5V6,H$7$=Q26.MIC*KJ>)C;!53`I[#6 M:PA50MQV`15X"?%9.QSJ>`F!EQ!X"0%C+8I)K7ZD3-@EQ`0&T7@)T;%+B&O? MF]E!X/DOJ3"RT[/$?[,-1Q2^?S_EPHWC*I^"(S70H2=!=.>!8!HL43`GJE"N76@S]B(]PL@Y?R77Z_FV3 M)_=/.S1FMBO<$,,)7_CQY?!JH_$KN=%X!-T>!GX<#`05\"FL]4H.<=L-5."5 MW&>-`S\..);!(@6OY#KEQZUJZ+;G20LMB*6MN-F)^PG#7E2!DQ_R8Y9=N[L5GOI5O#HII';#YA MDR-%WNA&UG"SEG:J=C\-J;5>?R.#`28-[F`*7-+J'*Q6&=#`4E;KG-73A@+: M8'C4!>VH:V/(POFA\(WXAF,)_V>\X'E7!0JWMGD%PD-]O6H+N9E*FZF<)1M] MXED%RDKA4SB4%905B.=Z'`5EI*AN.2BCLP`'"Q^,N.]4I$9J,7B)U"@$>HRX MA^:^WGFAX0A>%`:AX5JL4;A%[D,N7%:,4VX\OGXLZD.,5.X$+N!36&N$_424 M%1616[7@*(!NZ*`BH=>KUX(B#ONA%R[5BI3@Q5-'+IZ^DR#X)-R0)\]Y8G;[ ML?7$JM5B>#6_%-9Z]/1+W/(3R/?9STFYI[/DB)9#S7'HU9\ M2/P9'L'O,Q(&VB%]79$P*;Y^T:6&[P_W'PJ3JQ$F`OMJ5^&64DS;DP0+G'3Z[.?4Z?#D>B)@`82<(F"[`E@L^H$=-7?',EBD M8'T/K.\!!C]=BSWNS%'(K.5U8_BWHR@8/!C&_-.M^4BLR"%7TS-R']ZQ+]^1Y_#$\->]NQ0YL$Q^%7P_;_:3@161U%,#TWI'_113.MQ@:LQLA[X9QI/ITLGTV60FGP;V M_\AB[E]]E'@:ZER@L?1Q;3N14^_<)&Z2M%10%Y=GYY?QGO/\^;/PT[;"QT^" M+K$_#P23.$XP-TS;??AR("W^GAN6M?S[WO,MXK.7*>^T7N#M`]S[$:#B][!T MHCTV[^Z7`Z6:J[R\SP7B+-^2><@N]'Q!E<2].L((GP[`Y^^12Q`YB)R*R%%T M4,A9/C.X: M3]AP?A,'8(!/(<(5XP:8,7-L.D<2P2#;^/SW'"-G-ZPL71ART M."X8%.ZN9M))H]+AN,4TDET#JV!MBXC7YO$J'XX0KQRC`3Z%M>)5UK1#N4N` M;?N8#H_FV/AWK(+^+R_$\(-?]VS*M>QLU>)@[7PO`ZN.B7RH#X5^P0!1"`Z% M"D(0(=@N!+G1@G@ ML\R76-@XDWP;IP-;OS>;>:YP&WKFGWB"4S>%31>>JMFUD+$#"^*5([Q*$\0K MXA7QVC)>JQ:^*E/.*JLHUE?;M4,ZPA.Q+MS0ECSFIAZ6 M+&&MJST_H[$<=UFJYE``2W)?*8'[+W2#WRO6$3\=P,^Q:4:SR#%"8B%X@#YC(Q`[PAL*.&X0T)_1 M:_S@!@'_&4`W"'1>L(SBKMIGQAHI<^W"(Q0[`T4_M/]GA+;G(B`1D*T#\I*@ M8D0#<29W5HF5QJ`RA!^?FU(N&CP;X%/*$UPG\4')$ M*Z(UH74DCQ"MB%9.T(JV`.*5)[R.)S*B%='*"5I'JM9)M/)3X:++Y2S^X(&1#`>?$)F M9.^1Z-TX==X:K`N#ASRM5"[@N-`1MMJJE;@A7!=O85`>6I0'9=CF!23*`\H# M+'F8M!GMA.*`X@!+'-!<0GE`>4B92UJ;T84H#R@/L.1!EI3^R`.&B4$X';SS M0L/AXD00VBW$9O%7J?A;7G3OD)8[=E1076G:2U]A**(FMYF)52:O7RVLV?"R M#L6D5C&115UJTPE$,4$QX4!,=+E-2QB%!(6$`R%!DPO%!,6D@,DUTMN\AT(Q M03'A0$QT344A63^8+-[$LW#[S0''686S;X3(R#7Q@N+UPN^>OZI M,;=#PXG?WJ&=IZ)RT\YSS+IYKBRRG'KG)CDFQ9:?>WY&KWN]7,V);X38)@BA M4WIN;TC<(DBX-OQPOVGX78'/?B#:NT9!KQNNIA;,:$E-"^]2^6]B^`)QK2ZJ M]%ZKV]A0[MR2(FP0-CU^1B]WYUK;1W1!1I?-ZSLGIM@J)'?V3[W9S`Y;2&#% MSC4(1X0CPA$T'-N(X\562O@Y%OD`(?Z*)(]$P2T*FW&^B)0+[B.N@E7S,<$8LCI7%AOT*(Y85"XNZ9) MQ_>#[P^"0&'>*V&Q36BUL=O&&')W8\&W83+@P[="&;/[&#KF?P MX*,;%.*!'>*61PIKQFV;Y:/QP*[K!W:*Q(5=AQYD\P=VT/4,GGMT@T(\KT/< M\DAAS;CMYOT(GMMD+NPZ]"`;]R`'T/4,GGMT@T(\KT/<\D@AXA;/ZSBQ MZ^X>B4^,:4A\+JP[:'XD)QWYC$(PH+>-OVC]P#ZD[X6&8YN?B__N)V$RP:;6L3X7K%@%W82' M=F0`O*%-%06[4T>;<9O7]MC9"04!BB`,17W8YI4JR@+*`AQ9&*MMAHWRT]@)NO8P:R=#F:O?(V4CWM6;V"T:0\*"=^2 M>4AF]\3?>XW]]A8<\=7Q]@W%UWHOK;9ZK$&Q6/M#G#(\;.^$"V`#`40J(K5Q MI&Y5[16T/`\BX^]$YK5CN'9FTO^B*HVP?!L%!<4EZ+BTJ:Y"DA+^S8C46JU2U`9-8=1UB@G+685PJX5C9NP:UGB+Z1:V7-`8(D(#`ZCNI1A2WFU\]6]'[O;C>JTO MOOE>>Z&LW<85ZHEN/:[7>B*I)0-44Z#[UREYPHQN)G%10">#^"T&R^)I*\(5 MX8IP[2!<6XXT1*@B5(M"]=KWIC;>N2)6.<#J&9G[Q+3C\V=$+"(6/F+/G^?$ MM6Q61K.*5O^X89"C\,-YK2%Y%ONP]Y,`7(1*Y4 M[47":BTY4W$6-A;H@Y*EL3M[:\JHFTQ^V!]O$P"0'8D351)@K.?.6:`(ZWXS MV3/9E<6Q/$39[3RL>\%DSV1W+.H:$%L111=%%T6WS+8K:3)NNYV'=2^8[)GL M#B%Z$%=3/Z6%3TTK6` M)5D#I06A%8X"0>'NVG:U]).FMECZ"2N>]8?"6H'+ZI:WV1D:@=L?"FL%KBZ. MI3:+[2%P^T-AK<"517G8S4X1?8,%?`IK!>Y(0M1V`!/P*:P5M6I'E6T-<_-?9N$AO_"7EN1&>8FU`%D)8]<7C*5TKY/M5D`G:FT.WL<1(#PR62M M+G!%OF5-YRD6),^+YF?A>X'N7C`)0H1U!448T8U,\BO"JLQ5*#6*,#()B4D( M(BPK8Q1A1#=': M#PIK32*5E0GTX+F\%%`$!3<4U@I;108?JHRP[02%M<)655';=@$4\"FL%;8C M!&T'(`&?PEI!.T#0=@`2\"FLUQWK)&AKB%XN7@]G]TRF:H-EA'<#&"PCBAT` M97`'PSG#.<,Y@SD8SAG'UPX7@5/A)?N(Q8RR42A;9I.,))%-"? M!$%^D"+.!36&^/)E$9JPC<#L`"/H6U`GT^7+A3SY\9H>VY)R_)AW?D M.3QQ////W__Z%T'X;7T0;_K5=NV0?+>?B'7AAH;[8-.G'P&](_;LCTRX'U!XL,'4CZ0)*3EY.!*AT(MO7E MP!S(DX/?"QWF38V9[=`WPWC57+IJ/ENUY-/`_A]9+/+KP5(\:W4B094^KBVY M.GQ[YV9Q=A:_%OR_LW*?Y'D.?/0N`YMM4+U?'WR"5T+Q!A`:9MO;$;-#JH M6Q++"`1*WBW/C%AV-*,F*>/T^OCL[.+RV^N'=,UJT$-K4I\+S!(83KZJ3@I_ M=;*-A[>OEN-V_Q?#=31+VUD=@THWI`[%2!1\,C.HUP+$EBLT^VVKZZT4)A+V MH47[<^L)P)J(ZXU===5R`/"J9/;>N;G%E5K&\.RJ=6`%KE"UH\/5->MS#D_7 MK%%89#<'!^5$Z4P:*WE;2^Q#5P@"N=S98.4*6# MEDX7E:/;.UD@#^!91N6B)LC:3K#>6K)C%T(88 M`K2DME[)UV5(@;J2WS;^(EZ7?4C?"PW'-C\7_UU&Y>!M3PKYT@N),#D4DE444DDH M9=6T\&XGW#;'@G2HL/^E_\KC%J<\NYA)':RUZ[`(]T9@!W3Y?6'NDX"N,951 M^I7%!?I=**_U)R#[_:8>/@O<4?[8L^$]_E(CZH<`> ML/IV0(E_A9!@W'M12'$:"-Z<#I)^-ONB8)BFYUN&:Y+%H[X='U\+/Q]M\U$@ M`5-I=O!(>:0O7\ M;K\]U[^-X/X-/=#0W]`TS%'X8;C2E+R*?+KHHG/@40'3D:]^;^S8)#?^%O;8BDPW@ M6L)52'U[X3)BOR91:)N&(YQ$`663[HS!`N@V"UEW8Z+HIX'A,&ZHL+!8=DHK M'9Z./3-\FXF1*YQ']&$D'OW4<`W+$&/TT@ M_?L[?<=ET'(V.1XOA*'@8'T9"KW>N)BO"YCL2+'757=&KRQ)F[)U=TS67?ZS M.)):W5%KKQ"8X]`U]-!1"\^46WBF,LPKI5`IW>TUQ4U.Y75SG.-VNS!8+DE8 MY*"M,6R43V_K!8"+]LAZA\YN)&`FYP^(3(C(W/\S)Q\WHKX5J<2%QX4ON/#I M4WDT*KD'8\_WY'\*G5VQ1%E>T;91?I4%>'6R6?"V=7[\LQ>JY1OOA<$ MJ$HZ^4Q4):A*]JA*3HVYO2UDL>5%1Z>S-P*WXT5&1T0R"NAD$+_='1X/BQ&] MB%Y$;[_0NSU_`Y&+R(6(W&O?F]IXOXS0Y0^Z9V3N$],VBA:^1P`C@$$!.,XB MLVR67-8MLW?ST4O!8@W-'<[44WN\$O+X2VY^'W6].8DD#[@`F%TP][9K#6#G@5>1Z)$U5ZG[#8WLKNW$L/ M48Z<]E>>97$L#U&>>X3R_G#:1WD>B[H&R<1$<49Q1G'>87N6-!FWYQZAO#^< M]E&>AQ,4YAY!O#^<]E*8-13F@A`O?3V5+KO;Y/54@8J_92Z=8%4)7UF1ME31 MZ&-1B4Q-/"LD!4]-I@B$Q#AA,Q:D:QV62F7/@S;$JN]Y3PK?=!9%!"ILYMZ1Y0Y&''"`8T\C(CS MB/,(:42<1YQ'2"/"FD>P5W1UM,JL=)G7A0RRO'9#[RX",8]L+WED:0^MVE3` MSR/;G4=>8F8O@!W%&CD%S"D$L9:5,8HU@ATY[998#U"H$>K(*0IU/X6Z](W6OFHBUESI M$)/.=D@Z2TT\S*2S*M?!/2*SUD1@69EP$7:8E\:+&.&5S%JAK,A\!(,CE+M( M9JU05E74RAW$""=DU@KE$0*Y>PCAA,Q:@3Q`('(8T(:Q[!WLIAI[(= M;F2OPD?B"Y<1:U=&HM`V#4`.84@UMB]#*&.G'9,J-4Q=CU"L".G'1-K64,3',&.G'9, MK/E+24&A1DX!G:QBA[X.8H03,NMM:J9I".7N8803,NN% M,@*Y>PCAA,Q:@80T(LXCSB.D$6'- M(]A;.>QGML.-[)T7&HYPZLWFAOOR[K(/T\JP@5D5WVA?;/,2.L,QIQ!*-.NB M-E2Y"Y_)\_TY`T%_X-X?3B$(MBQ.)MC7#.&.G'9,L">BIO&72(J"C9P"YA2" M8,NB*J-@(]R1TXX)]A`;D2+6D=.N237NU8UEG6%WL_YEG6%W,[[)K+?YB*A, ML)-.!U'""9GU]C<3E;&*8.X>2C@ALU8PC\7A6$$P=P\EG)!9;T<=497X2-M! M,'>1S'IM9D1R!R'""9GU=E$==MC"6#\,6[YCW#MD\6;ZB$;(.(3*/UG:>-KS M.E3RZ'A"V5/KG-.Q]/%U\FX69"G2\@SHXO+L_#*>S^?/PD_;"A\_";K$_CH0 M3.(XP=PP;??ARX&T^'MN6-;R[WO/MXC/7J9F;GF4V`A*(*=]G?I/@?09X_"X'GV-:JHC")&Q(_]QC;]!ABW"\'HVK'M0+'``E$G9W3C_LFT$(#7&_L-=69(8!&E7(*=@M MH2+WLJA,L`4EGWCGP[K:+YFURI0LJ@H?C0/0S`+^)32S5GYV%3X27[B,V#$6 MB4+;-!SA)`KH3X*`K!A:D/:FCMD?>9QNO1+HV%SD[1OE[D>:M=9&HS$DB=AX M%8$F'$S;J$EY!V/D-2"LLCB66V]/V8RD0;97L/QWG>6_X>I#CBO$5%"I*E5$ MEA?=.Z2AR0!U25A@$O96^$X1)5V';#RIA54Z%L[BP'@J+NFM7T`V(:8R=5:4 MU@M2-"-C-:7=I5__=A0%@P?#F'^Z)0\SXH8W9.[YH>T^G-F!Z7A!Y),[\AR> M.)[YY^]__8L@_/;V`X?*]L,WXA+?<(Y=Z]B:V:X=A+X1VD_D_'E.W(`()I5\ M.L`-F5*U\`<+:AM(^D"2DY>3@2H="!8Q[9GA!%\.!NJ!8%M?#DQ%F2@3]EGD MVHM?VX&G*;(^B`+KX/>QRK"2)K\(-?5PH+UQH&WE0,[D8*C4P(%K>_ZE%U*\ MILFT&6W*0!H-%#U-V\7EUS?B5$W1LHB395W1U\A[?=0:#8^&3TZ,@%C,'J0T M4G(]=Y=U5R55S2)LLDK4QF=7HV_3JJ8HRIHJX3GXY-K.EX/0C\C!T89G7_NV M2=XOSY`MCRK]<>$^D2!DLG?\;`>#BQ/;NW#-'W&VS1\WAOM`XO=_4"S,HMGB M_8PU5>7A4,L0F<&<^(/G>]^Q!P&C*CCX73HN[S>.LX(5//)S?DOY'M$^O. M8QHJEV\J*.I8A\9WN;5C/$PRU$^3/&23HRCC$N3(Z^JQ/#FC+>1,2I`C378C M9^LFIF39"-7)":FM\TA]%.('YQ3[X4NA15O=P93,?7\PD4;#U5WLW0,K$;2^ M;&L$9>@C1I`JCTH1=.<3@UJ&+_'WXFG<8'YLQ?5PDB9I=:54;9(F:,,#JU&4 M#^WABN#72-$_#2.KZ9GM1/3=Q6Q>16$0&BZKD5'6EEQ95&4RTC,759'I3JW(ZAOI M)4FKF:]\SV*=KW$V7Y.A.M3E<;-\O?L5M;)M<]?5DO-62QK*NK:5J\V$U.^QX#,/YIZ.CGS]_'K)G'WK^ MPQ%U/=4C]O$1^^)!\OWP94Z_3_DD+!IUZL)C].?U^Q@,6 M?[$O[##^6QF)XHKB*_3\UP_+SG7\BZ.\ M$5./.R.N-[/=_`=NFYGU)[X?=/EIBN^LZ4Q$.IY1)M+2>,#^*Q?U*]9FFGYG M:2>EWJ5$T/>G-O&%P'RDWM>*.`;$/'SPGHY.+_Z/&J>2)$LR-0VU)<5O/UX? M-E@)X[MFF'"QH%RZ;?"VS/I:B)>?FTRM+![[9[/_^TPMCB\>_& M>K<"JT0LWUV9AX1<"E+;L]XQ$1I^>$9]TM_?)O]U[-?/UGY$-5/RD^4BO3W8 M2OU@^6[JTT#9PL%Z8,3I(%;`0G\=@K.&EA^7>?6D-;G/OI_2/ M8\J8Q;Q"JN=OB1GY=FB3X/S9="+J$WSUO1F[1HG"^!;E:GIN^"YU1H)KXB\N M6EXV#Q`+[?EL[G@OA,3G`E=S-@+?XMO@9+WMNYFSUHI2Z#>"_V7XON&&B-JM MJ%V9*43J1J2>>BXK.N3'$WUC!W^>O)P0UWR<&?Z?,=QN#8<$-^2)N/^_O3-K M;A,)XO@G4I6MQ)M5WF3'V4JM$[M\Y#4U$6.)+03*`-YH/_W.()!`&M#%P!S_ M%Y>M`]/=OQ[FZ".EWVBN-=G7GI>+U1'731HG$5^'[WPF_^Y7\D_$B@^MF*Z\ M=&DVVOLTNN%3JMI]G)YY*X65-G>QQUQMWL^NY?.IILS^<%A3''8(AW7:88=P M6+,<]MUV.$Z1@9I'8*Z^DE<$*14$*>J!P-^=]O=W[?_C1A+S>]C'(\8?C<>? MYW^C]0L8/EP;/G:M#V>5.NLC#?CEO0=^8\MG/M[%9"+,%5\OR^]D'O7=3\C< M#Q\I"9+E76#HD7"!SN&"YTC)Q0=64JS[IPZ:4(_YPZ%X[_!YF[)H0<>A=T-"XA%+ M!NJ:@5$J+)`Y$AFK'_%XI*H'R()G(IY!!_-0E,';&RDUGF0ZC!_IA/IOHCZ9 MHF"I&:/4DG'K\'"I.NVZ&3$E0<`4M\W]J2NW154$':HBZ,?)J/RX'PY_W##J M^K/$?<$S.F5N,!PJ M@4=2+:Q[#LY4Z=5)_JALNK6K4J3Y'^/0#J;YNTTPTOS-2?/7GU0L;;&TQ=+6 M/K[FKE8^K*UQ["R34)3=^=DAS4;VKB-.BE3:KK5)RS75$T ML&X'Z^^$^>(@X)'?U3K.W8N"@#`0?3;1V]HMG7%OJ1D\2WF6]#MYIFQ^%Y%P M>VE5Z>5;_''+YP3)_>LG^DK2P/!3[-H.*56-*%DME)6;_]<$O2'!0L'"'9V2X#:3;A70-6510'X:NA7E4?_CED0Y M"U6Y`,-!,'PEX8PD"0D_L70J0BY)N+0-C'H9`8DL_6 MEDQ4X'(<+K=3RDC@_4T,'5(.1&5;3&!R'"96;-=CIUPI(+>_4G\AE+%:(5+; M'S]-(@.?X_"QJQ_&'G`TZGYA`#)1.$THFXNMT$V$QR816KQN."T2"4OQ$3)1 MP8J4E4<23FF^9O[MS].YV6"LQ=G04)$+%.RCP`_MI*`L%RB04X!F7.8UX](? M*S=CTA'_K"E0KM;1U+\MD9YU/1WV!PO*@NI/?<]E2DW'NZ%7BLWPGM$B!ABA M&5=_]&&N8)T7V#U-Z)]US!#.@AK-N#1KQF4[4)@PZ-J6"+,&S?S![JF#)M1C M_G`HWFC&I4J>H`L>";B&70`#\-1^==3NK74Y7F7/O&4_HSI MKY2_FZ7/K\,!MUXW>WA2U_WEF+MHS#Q7\R]KK%LJ6"4S.!P=Z8'EK[3M M@:/!Y8?RKS=BB*)L(6)]OI$YS8O:3,6DWG#_D$B6LUF1KR\PA/J/'IHW7VD+ M#)_3ID[KIKRS2$GUC@'*2+=\8+QT;+[O@2:34 M4I8L'P)^Z7'HK6N^E3J.W9'0XV]=ISZ7W_2,S0,$WA`@E=QE$BB)Z2P*O"_S M!8O>LNFIH8_6TWBHE]]A*KZ2R8RO6-FR_+Y#5#3([S`5676F1<22[!C,12X: M-6`?&:/!<'A2;*RI,*B+955C?&$@=<8W&;0$<(7]H,JM,""!&+?X^*_"47P=@6 M'CP,7L(%'UCYA;QG.IF%41!-#0]L/8F,>C58R@B.*]TYKNR")X3_:1/^UZNY MT=C1"3-;L<&'O34T5JS:N_?&BKJ8WZ[>1%HW1NS:Y&ALV%]CPXYMC69D9C0C MZQB+YDJT:";6?S,QK8!`=YB^NL-TAP'*)YY)%,HG:ED^L>I!Y4J(;7L0RA_V M:-AR)D>(]&1\QP(@!-@Y+:T,PM2!2 M]Z!,Y3Q*5KW;1\*N'*[4KCF//2-O<4C4:3NW#Q;7`\'8>Q/GF(9/R&L1JY'3 M'4-O)1ZL]S6?)C3D8W2TVFC+_\CV7^Y?\P*-EB*A+A-!JMRB=G"#BIVET=HY M&-)@NL<-:3"&I\%H10C28'I/@]&*!Z3!:)D&HYR1IC08TRS?6KJ+A;9$2I-U M*4W]\B1?:>=J>9H11A\8GW^-)Q.Z2,3$_9J^1HP^TE^IS_CP&CW1(`"#K2R^ M3]*ZI=!FA1#'C`F7G9?B<0;W_,(DX:N![!,WT7SN9\8SD\%*W4>)N#D9S4*[ MAD`Y]MDE"O;*;2L(R,G5*">W/W,C)]<),UL1<(-8%^3D:IV3VY_Y[0H;001' MR>3(R=4E)U>YK='7PX2^'MJ0@+X>&O7UT(4*]/70J:^'+E2@KX=N?3VZ(*-T ML$E^FWNPV7366);+?BN:?#SM^(DQZNV86&]'.1:HMV-6O9V>@4"]'3WJ[2C$ MX/)R<'%E7E&)[+95JN2`HA*.E!-JJ03%44YJ3B6?65'\2?FHWD*```*D@``%0`<`&EN8G`M,C`Q-3`Y,S!?8V%L+GAM M;%54"0`#-K<[5C:W.U9U>`L``00E#@``!#D!``#M7=USXC@2?[^J^Q\X]MD! MDIF]R]1DMD@RF4H5&5(D<[OW="7L!E1C2YPD)V'_^I.,(218LFS`$E7[D@]H MR?UK2?VEEOSYMY@_7-W>MG_[\OD? M0?`-"#`D(&J-%ZW'64HB8-#AW`& M"0HPX0*14/'"\2>>?3B@(1*9T$HAM+04ZK]@11:HCX+>:7#6.WGA4?O+W__6 M:BU%QV@,(YBTU.\?H]OU,V>`8C&;,QJEH>`A9?.3E'>4[+OG9]V.(N](U@4D M0$004CEBA$.D_N(TQI$:S&",8@4NX#,`P8.4H#3"\@N)-GOXC,'DHHW)>!ZL M>E;\_;)SQV(QAXLVQ\D\AG9G`VZ(XC"-,_$.Y/\YN4+3+/(E@_`B0#;/!V3% M8TS#-_+9G)<3Q,?9(*<\F"(TS_CJ0"SXZI-,DD&WEX_U+_G'_^V'(4V)X/=H M@<8Q7*6,2?Y7_,1H#/%%VXYXR7RLIBEEN7B;87X$(>`GQ=)W$'803$V<`&$I M1`.,QCC&`@/ODV@H9L`V/M(CLF_K`%HD9[A<5RB^1SBZ)5=HC@6*=6#,U`[8 MYURN5!VW;[YTQ5S)A"^B:9[5*\1G%]<(<86TO;_&\4I M:"!4:NL`&DT22AX$#7\:46C(FF?X&N:48RG!;&I\IR0TSJ`RA%) M\XR66U8O[.=;NYZICQF-92#$E2X4BW+>C1WCYB5C:K2M'E@ M651AXW3J"9MG^I[1.3"QN)>AMY"Z4.F_N0K2]0;*IDGS0$;`!<.AG!*Y0ZSL M*!>*KY+AJ-#2!2R!I,J,OB)&I#//93R;)FDV]:]A@D.L1V7;L'E0UG;:)\O\ MR`#QE"U*0QD]H8GIC21;GX4MRB3FBW:WW7H&/)V)/!F\[`>Q\$WV;3N3F5-T M>)HD69^!=(>35?L)HTE9#$SK9(7D8ZU@]7R`I7>T;6&<^@"C1OQOB^_,!WR5 MU;,MN@\^H"OS!6S!-*7X MM%P,$3JM$A#[M&3L,-GLA/FT>*Q15=U*\FF!64['LCR'IRNL>&F94V2>+JRR M83D&[3VK*#537_ M4V.!!8XAEB5:?%I;UCM.Q?;+WT56!UA96N\5W^?.>WC27_[95"G>FH`'=!*$ MB,^"24R?]UF49_\(Y^5Y55EMN%"/@9+`UY>Y8EV3FM61^5+Q?]F?VKP671PD7AQEN!WI)W0:X&C'4[ MGR"])OHKH]INZ@.P0I?<&INQM0_P5CL954`5M/$!RC(?OI5IL895TMX;B'E" MPEA`6Z6I#\`>0(:XTIE;9<^M8>D:.BA.`:'LZ3VC3UBZ+I>+'UQEG6\P0224 M850_E&K`-".K=^`-R.6^V@X@#1UX`W(X5V>F=@!IZ,`)2+F::`(#R@TXMFD< M%!JA118[/-)^*+U5!MH]0PV.ZATXJ:8*`2)^(T/DP>;&C@Y3&;U;")E>5G:T M&A)3,Q<55/-\Y@PG-DA*Z1U#R'<"\C3E0%G0X3C&TRQ`TBF!&CVXA;FY0V"! MJ8C<05W;##&XE.*,KFBB$@RF,-=,O%.IV.$2LS6,(MW%H?4IT[D;=H,9KK&Y M<#PCK(TS?=K1VPVT.:OH4SG:;CBM$W.VD#]Z#[EJK&J+_-4!;^/\Z0OC&Q+4M\'/O@=OX9=9NR5$Z966Y_!K[ZHV#-^6BZ.Y)!9]* M"VJD'&GE%,01..(U`)=G*H[!-[<$7CL'X%5IT!YEL/NH?S@NQ/HLB4_ZK%9= M`]W)(GBGX@XD@])M*)_J'`\D@](-G,:KSXAN_%T&DZCCC-8OE MA695>FNNIJPZ5TV6CZV/@JJS1GP&T3=*(W6Z:#@9`0?V9*A`L&[YUVTSY8R. MT/.=G#(,H[B:^$L;.@3U.V4_;TGF=_)JJ,I;^GFDO'!6%1V]METU/MEF:W"V MH^>3T;4&9[G@W!C3,VE<5B=%`Y3M*P4$1*`:>3]]1; M%?.S%TCJ^0_[0/.N(Z\N`"Q@=P0)PNHJ[.'D!G.Y!!3_&CN[QYY]%XOB]4;2 M[D42[SL["O`TW<\T>-_9,8!_E(_?W]"_Z>THX#_3_8%_[\"]5=(&') MN]UM(?5TND^AQZ'%43C!?0I/&A'`MGKSJ5:I"1%LVS>?JI@:D<"6>^-349.] M!/8:OOA4W710$13&/&Y2&1^">5Z2(./J*(!5/4(6NV-/3&DY)[)7K MAH^MOU[*\5I<*?^.H:#*LNJ1F7UW[]'UQ-^8_L2372./P!SNKF5WGKL5YS97 M2!8,6@V7_'#E&56!'F91^GEE"EWNM4N"@UV98GJ$9U>FE+.Z4\I[?0QA2*XH M>9*31ODXV8UQ:G_F$14F@^U;N7AW$)M"?EM83-L]T9C&DWIQHSW@64#BY0"$_#J9*4>7B M$YBDF$R':S5Q"1/*8$DG%R+P.TRH.GPB0QA@P$5V&_9F+\O;M.Y`S.CF/=G: M.H/&.7`E9LE\'MM=`@']S"BA=G3-AA(ABO.;%]7Y!-X7@N%Q*E0IYR-=:F[U MTMCA1*GNTN6ZIUX]%P,U,..F^K:G,7+Y@B=%7CNV35O"Y*Z1V\2NHM/X9) M9:!T]`:LJN*W:^3@,@<4`Q_!$Y`45N6)&@@F4@>,0RS[G"Y?#Q^K=$*4J#)+ MP;)XPCP:U1HW#^[W+)\#45_J?S2%[VDR5INWN=)9VNQA*M0+XB.)0X.R9B_> MP-WB4/HD.*P&UMR'GTG%HKB-5EF'7F4.2]`8\QI>G<$U&2&ZFV[QJ?K"$J8V MN>#3(;MR@_O^)566)MJG`:L$LF(6SJ^#P56`&N-`G^:HB_04K1P7^#3A'4NL M-!CQ:785A^/4K3#]EO@?9[)`E\&G]-S5+*NP$693F MY%^H'V/9I_SD_U!+`P04````"``+>65'G*OYM8,X``!EM00`%0`<`&EN8G`M M,C`Q-3`Y,S!?9&5F+GAM;%54"0`#-K<[5C:W.U9U>`L``00E#@``!#D!``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`FGI\1Z9A]DO8CGKYB M7"CCO[X6ZOOB:/R;W/TT^_5US9MU=\M3=R==8LS9U,@VLYH,\56/V)2J@@)9 M)]^L]TX'@GWK'.PS:>4:J]L)7?Z2E;4XN\Z*EC6A\=")_,%Z##9L&07LE_*M M:P%W[$S/D]EE]?2!!-:%/.],,SX(Y\R!=O0$_.]O.G3K_=@1[Y*\?!3_8CRG MMH9#9UN_EH*&A6@:6,.X6([E'&X+0)H,6',^``A1^8_*?U3^H_(?E?^H_$?E M?\_*/UP=\JWM9RQMVA](F27B_WD]%[KSF/%I&U*$J_[`CKS9`5;\V!L%%4U_ MF+#'-QG-)0L_R1_DT/RTMB>]H>-O\\[Y9.FOER(GX*B?%A9`8W_Y)YQV\:>D\,UN*$N7T@G%9732U31V0ZC9IC0"-/["_DS@V=,5Z+KTN%HG,G0 M%Y2?B`TR$0>]DM-.*C\,WM!)+G64LOY(IEU;2D?FA\7?6=&4->&+85+/MX+. M#Y/_HD7QSY)]+6\IJ5A)LXNJ:IXTQ1?,&NCWS?0=)W+_WLZG]ZSH8++S[P/V M;!T`A.BP.B^0D1 M&IB["0CL9T3`C,8?$--?T&&"F-Y`<+^@`Z>U,X&H_HH.%<@@!:)[CPX=W(D% M/9G]Q97,&-5N3R@:3(H&P,$,A85)U0"Y]Z'`,&D;P!`+%!HFU4,3B0N2@ODV MF?&\3/-90:N$C1-AZ52LR+,V?-E&->])E;=_F@DA)]I91FQ=?,5O6J<39F&Q MWI<#)W_SQ\5QSB[*],.SE;;TTJ@);-Q)B@]_$*,Y;:;M@7;-\Y2.TI3.:FEM M'M,QXV+5?6ER3K,[=BM.=S6#.W6TJZM:9N56M9SDH^7/$NK1AC]L\=LV8:*J MY`7T@N=/+[=:Y'[4T_EF]XA-2YG^V(O-D4[*. MRNQZ0YQ>C<_SD@@Q3(KUJ6IQ371?GPEP99:4$ZH),;SX>R`6M8NO@P(YF^%E M4PQ5QE!E#%5^GZ%*A5!'EZ'<)=<92.=`&6E].>S;&2C?SSZQZ-_//K'$:O]T3^.V>@TS8Y:%QNYD0*O:OQ23N#AE&!-G+`X.E"#;@A.H:4 M1`X8.)M03HKLGV2N_KZ*QL'G@UVNOF2D'$TX;;>Y^O,:,@=,B"-HFE<5XW/] MBM31.6#CADYDIIKZ^YT$3C[\R(K'O)R,LD?YPK66!2VI`V96^NN9K-M_-5YN M.C5'$'H';-V)HT&N0C4CW12./JU?F-T4#C[]>UZ3:5[>R,-ZKCU!])2Q>D&L M7N#)E7/"&F&3\O:=:ED\4>.$TI$&8+Q5;\Z72JV.;25A:*:U[E8=Z>`8#[_. M3X69LE"1I>_H>/ZIS+\T])16*<]GK?&O7D%6;4-#DSM3.S\F\L$"P+'(X)$N M`W48]B_*JN:-0B,P$X9F&K1X=.2#!8!@]1]&#/NLX2QC14&X-H]=1>:?X4UW M#T`?,I'C`'`I78AC;#K]$;.FMX^D`JNG:!;ENN MVEUHW?Z`(6*8S:4'];E8U"]'2)L!)UP=`(3P"ROFC!U$SMB>F&WN*_JE$8RT M<1*MM-'2!F==5M_7+1(]-0KV]1+&1#]@".&%Y.]";LB=*(/XFE6D(@O+L';0 MU82#8MIFB0PDO5:_F-#E[VD6$H-ZBU"F"ROG03%7>%*$'2Y&DZ<;W7(T^K<9 M(/\"Y7K43(5RPDR6[&!K7IKDG4I*"$>)C2+$.Y6 M4D-$OS*A4Z.?10>KU=$;P2[U:F..*[JE:A^O9.8+$BC7JW9R6(\1P6`4NE2Y MC?=^@-`8QW2E93:+@4CE+< MV$V0]C)? MJ[9R8U.FPA@2PU#G=#UWP'*95GWZ+739@[6=2E0>E_0-@Z*D'T@_V'\I*EJ-J7\K9HE'9UK-MX!V7BW7S:.@&P<.6?C3OR5KKK7 MK!,=G0LVOC(($THJ_W=C1FDJ[:WJAJ8T?Y2GI/8RGHD\1($U(89*<8I(J7&?]56T@,T.!E#XRVXO.9RO>=26Q8,U0P'(%D7[`$,)O[(^-W(E7XS-AEK(YI=5OE$TXF3WDZ8A3HMW>5FT#E!P@!14Z M[R,M&_J1&NI5Z&@'7%+F`""$WR.W"S^HGOTNF@&PBF!T5XZKXZ;*2UI52_YT MYQFH32R?%,LG&<()/IG]5`KE-_^39NOCTDZ9MFY_`&5/[-P(Z((G8'\5L])$ M4":$@J=*.[T0]Y??&*##U6RRPM"M7[/IQ;=[_2=B`W MDR$N0-;3+X5RX4*F2C>SCNXJ^\NS@(LB4Z`.7;)]3RG;&18&@O-W1ZLGN,Y@ MLU]P^ZB+8S97T8G6;L<&ZY7"@5*4PB:'6?E/@$#]72>T$)_&9`MT9T,?,PN6 M$X'NK.@#M8>;'O\4ZQ6\GKX2O]OVH`NO#:(F6;P+Y1CCCO8T?H"[*0OX\>W# MBS=(U#VM:;7G%>7%>0:S\O)T*@ MV-_.`/;F]UZ&%5.P&QF;RVGU1'=&<\G'3_('.4@_;00DQ:_^.!/?5#Q9K/IS MWXCI'EARE;0`9>V23DBQ8*`C.*ZA<'`[8301RXC<:VXF=%,X^/19^9AS5LJE M2HJ+JFJVRU5OO@ZO M9@I"[X`M?=69388@]6G\)DZOQ>.HS$XVA:--BGN?3F(>M\TNH64N]J M=)E;.M+PC&OSYO3$@V0^?/;?#2V$?I1=R\(A6@!JPD$QC6O$[S@I*R$ZQ+*H MCN>;?]$]$FS=P8"SCP\`0O@E%_-B#R(O%GG2J-$.0^/%49K8S-)T0174T8T_ M@QKQ:#R)QCG2F=V#35'M>[:CV5H`=7$/E5D]%Z"WGR3%%!]D&JO9Q$2W6@VF M);-V'J%R)F9BQ$R,;GS6F1C](U-!)\M5GN3EF/%I*UI6?`$S,;1]^,V_`+#2 M/^NB32GG<\G!T>H?!I$A8M`P8QGJZK MD`(2@U'1Q[A7C'L=8MS+<@.@T:`!"@Z#'^.XO4G**6'VFM-@@TO1)XC?#?,] MN-)VW)71LQ0]2P@]2];*O&]WTN:#)&1Q_5ZPF"(,#?PK^^?$5X*AJIKRF\?"*9C?E-%7/+L MT[2/Q@LJXR5]H%E3T*OQ2`B/+"^:.G^DMS1M>"[?X#W[EA:-6!GG0MC(FU[- M8A5=C;1K-TVB>1O/4L7FJ$S;H M+#8%L\R?)A'$W'F7Y,+@+(7DG.2"KX14%:VK MI*1U/^4?UIE?,\"&IV@01(/@7"Y!>BF,^>QBO7!&[;JQM`VL>PH'F^F8/6_J MAM/15*9,_]EZ,3UOL\+HER:?M7_M96@">_-K:5HQY=/4O%ZR=5V0 MLAZ5V=F*,Y/.`F\X8./S`"`@L)^C?13MHV@?1?LHVD?1/HKVD6=;P59/"V(! M_)Q4M,P93U).L[Q.QB3-BUPHRU5S+\8T+V5Q8GF!Y%%`::,U;;,9F9/V'[1. MTBP1?)(RS4F1%$7:ZMFL?J`\*5@YJ2F?"IESW].H",>@7SLE-,X89?MNK82U M'^=4+`[+<)JZ25@@/'\D,O?W,B?WR_:>X=O[\&5(G3S90>NOS(4Q,3]15A-ZZ=+6ILHW7R\I)]9:M>I M7U.R#V_1_(OFWR)N_4$LR&DSO:2DHM=DWBZB<\9/R"RO2='^VCKG.HR45 M+:EH245+*EI2T9**EM3W9$FYT1R"F!V=[_7U,S8@7?DU,>`<^30L;J@0,3)L MMJSJL4S'%*MO^<3`'3M9E\*CF>D(W[6[`9LE!P`!DV6U_<+%Q=.F.9ZO%A/8 MG.K56[2AH@T5;:AH0T4;*MI0T8;ZGFRH'=0%=%-IQNU&:0]B,?8MVYW1FN1% ME4C!T)#UOMYS@7/%5X=1Z5S+/,QD53SP+A<73=NZDW><9/(Y.S*7WHK;6JRR M:YZG]$YT4#VP(MM2>WJWMU'?%&Q?'.?LHDS5[]%W$KCX\/HQA;;P9G6K&!<= MG0,VEBZFQ8L'KA8,3], MV..;O!TDN66.EC]+J$<;^O?BMQNCV6'?:&D"L-AI_QNHD+,9WCG1GHL7TQG) MN63K1*S7"559NGIB_\QWO\9R];6DO'K(9]?"3I.B?J*R@JW;^X?XG*UL(\%& M@#M&R(%H?\&$UASW!J+Z*Q)4.\0:@F3EJ)ZJV2WKQK)7'*_S.,B: M<12\WJBM+9]S>EY_6^%\A#7R[SE55Q+_5-%Q4USF8Y4_U:9I@.CO^FA].=P+ MS@O)N0*;9>L`,6'RS1P3[J*)X>L8X\7&)H*H8HSQ8HKQQO!I#)_&\&D,GV() MGSJ8';4N-KA(,-YP7`Q(Q?"-6I+$\`T.40GT(O3FI[MAY MRPO]0-('L47X_-DS@.R6I@VGFV5,M\YK9_TYJ)"QV>W5?9%/V@W]/PWA8E"+ M^69QUBX4/9J[8#K[D*4?Q2)1%^Q0D#CY^'HI7A::TBHZ.A=L#+,BS[9K.;Y M9-+-]HY=.0'3:H\W1#>Z2B('#)P)/*3(_DGFZN^K:&+]HYW9V-PMY\MC]X0] M"@5LA!K,&YK2_+$M&;Z/ M]:/O?L^@E['FE\R1!2NV**'][1G6-:>SA8YVS=EC+DW]:G,AGGU+:56=D.IA M7+"OMB#[]>X",B/E2(QL:XI\$!:#[&I^L^)F+;VQ>IY_HYEZDGMWX@"`V`C3O*K$HM+K MO3HZ!VSVXCX4AM653 MN>/5C'13./JT?F%V4SCX].]Y3:9Y>2.]3'.M>:VGC"4W8\E-3Z&Y;A>8*JYH MH`[`_I-;0N[HZGKA=E6QKZ<.P;XXFBF?$5[//Y*I[HZ)CC0`X\^491W;2L+0 M3&N3%W2D@V,\O)21OL3%YJO:"O^?ROQ+0T]IE?)\UH8*U2O(JFUH:')G:N?' M1#Y8`#@6V9/#VK"BN@E#,WTL'P:XG7%*LJOR=Z&GR^-)NK;?@J"8FX<&N'$" M/RVB-EP#0PAH'QJBD+VTTW"'DH<&<"'U#*&FRH5S4:9<*GNG=/%_$"1(!YA` MMBDCF;%`NWT'H4&"A+F.?+``L)U&8FWD+,O3[F0$JS:AH4CO"8C_3<(`SS%, M[VF6T>Q4C.(CD0[2=;FAJ_'+/UZ*L[)5F170=NTNP``TG&6L*`C7WK=7D85X MF&$A4:])KJR_T4'BG]'+C7B1@M$NDK",`FQU$SD.`)L'[V@I),]*U8KIT0,. MF)D)GXB_(DZ=-%`*"LG,@#7![I3XKM M,15&93EIXXJ;NT@%M5)3!A:PCC364-*Q>R7SGLV\S6E;*=Y8Z:?RS M&E\KBI6L#JV2U3K_I[H:`R)E)O(@`!J>/I"*KK.(MD-B6MW"NOT!0\2P')>) M,5MZD'8_0=H,^%[T`4`(O[!NV\M:K$W>TS7Y/3';W%?T M2R,8:5,)M9);2QN<]3O!@&Z1Z*E1L*^7UB;Z`4,(?^!LAMDUJTA%%I9A[:"K M"0?%M,T2&4A%$?UB0E>A5+.0-A^RT0:B4%9(4(X+! M*'2ITOW=R':ZV2U"N.+K%U\5V9\KT^F%G8QU, ME*O2.#V&J31G7?MU2[@\`LQUB?P:L2ZQ:0O'`F&]1R=L>I0`0"=YC!?_5U-H M*&B*4MS839!R9AVIG?X\O=;'":3N$SKEVAJEOB:N7S^-2^GJ!)>_U6D**/6I M3NW7;>$ZFKLC*B]/DO1UBN)%Y"[F@!_C7A^=](K$N2L)/^3=\B>&@<^IFH8? MM3F!Z=X](93F4I>W3>!`#D_J]7H3._`6C=O14'1.\H-NM,WBMOG/J- M_NWU_()5L/$;@7`'V%CT!:J)>$S/`KZ#VJ=^+!0M-L6K;YE2*%XLBET>YT*"A^5YM1+M88\008=#51*5:_1,#_H!QT+5"J7;BQV>=$, M.AA8-+"^#Z)!<6+3S%150Z!XL"A>P-=%H?X0;%I7CR)Q4*C#4;GT1=.A>'&K M7*KB_E!T6+2MIY@@X`$E*#@LNM1&(!-0\PZ*#HMNM*)2E\Z&(L*BX:RH--5" MH9"PZ"G=T@/\V`D4+C9UQ4U1?2AZ+,K-6IA"'M.#1BZPJ#@+_W8GLO]I"*_; M\(W\_2Y>B",L6LXR85>Q:==6YT(%6)J86;BS6^!YGQ_##C+&O2 MNDH9G_W05&]63^B^::%6*QQ)*=2OY"])E4_*?)RG1/R*Y]7G*A'6>])(/TTM M!J7.:95D5/Q85(G,56C(.M5`]4ZORV\LQJ;*IS.A)+[9&(3GH[.D?C;=OH=C MP:KXG4R-R5YK*[8I'C<^YD2V%;;KC.?B*WQ^O61?_Q_(?Q@_ M::J:32E_JV9)1^>:C7=`-M[MEXTC(!M'SMF046RZZEZS3G1T+MCXRB!,**G\ MUSL]``6_F'\TR1J31[74WHGVEYD>)J_(PC[8(RT@\80O@=L4I$/1/V')M3 M6OU&V823V4.>CC@EVGUAU39`O7524*$ MWCA]\//!SMX&!BD\%C>'.G:8E2;B&2>T""-PJK33"_$30?/Z MT*UFDQ6&;OV:32\&#C"@7+2:&6&]S3=H:@:Z]0GV"*);J!#?&>OIT$&Y<"%3 MI9M91X6:_:6DP$61*:+E=WON3\IVQD^A>1K8P75&9?V"V\>C(&9S%9UH[79L ML%ZY#BA%*6QRF)7_!`C47[:4A?@T9B6@.QOZF%FPY`%T9T4?J#W<]/BG6*_@ M]?25^-VV!_WJU"`>9(J%(!UCW-&>Q@]P-V4!/[Y]>/$&B;JG->U6YM['FG3[ MOMD)3!T+TT&?#>%@T^?E8\Y9Z5<[%.)(S6[DIB>M2>#=#12_G09 M>AN'@=P_@/;:KQC,FW9C+R_N*[C7T@9@71SFBTO,4IMJ=/E8.M+PC&NSX?3$ M@V0^?$[?):NDQVVIJ,W%9LRG8CM>C:_%']I75\3_59ALVOJ'MKS"+PO7WJ@% MJH+*/[LWM&@K#LE7*;1+24TX**;#K_U-GNXX*2N2MB4NCN>;?]$(4_L.!IS= M?0`0PB^YF'=\$'G'R)-RC88ZFMP%I0^&6=JVJ()FNO%G4"\/&D^M<8YT?IG! MI@#W/=O1;"V`NKB'9S\]OVYN/TF**3[(-&&SL8]NM1J,?&;M742Y;K43HYG` M09P7EE,)]*4I=V$Y[X\;E6:MS*FICILM],%UA@ M#%VZ,_!E`9VSW>\)[ZYPJ3D6Z#=;V=U2M(DU`S%BJSO?(X85),/L?;(4L4E> MCAF?MN?:CGEE5GWZS2;KP5K_'++V?@F?2XZ.5O^0`W>TX5!>_OJ/45&TS\?S MG'8'?,V$NR9Q>6)WEV")*L^JD8>9$"(GI"19=\DJ,V&XTELW=,9X+56-53*Y M(J)@;A`BVME6JE#',I__>0U-@8':X-:VP4`3CW."8?=ZH7%S63FV@KNR7E8E_DAK&`1=DV!EB"YS MG(D\!``N%G.=/]*-0P:``]3*/YQSJ?P)IAZI.'.$13"1EPZ6HTU5:&"-_(.Y M*!_%8#(^5[/>11*B=IM)MT&AP3S7K%KQ\<`*80!64J0KBRM"FP4%I-<=U(08 MF#9H$>8&(4"4M+H:GW`JU%S3V*M)0U0H+"=WE$]/Z;V);S5E6+:-IY.>.,"% M%U;3;L>Q$8I-4__`6N,48KNH"0,4LEQ>`;XN2'L%4PKQF=2#U:=IKD8% M;3C@%(X#@!"S4&(6BH[GP%DH8+L`DR7PDA>#4FUN$#C_1^?_41/&[)^8_1.S M?V+VC^OL'W,@`\U-5!C/F]D4]J$-=-,(!@L/&Z/+WP)C5#N%T>5J@3%9FZSH MTK;`4$W.$G1)6_#-MS,H?XE:8%`VT2,@RE_PH82[P(`8_XH/(RPZ"\3W'A^^ MKBP7=*<`CZ4]?L(-J'5=%I;G:`K1*VT&EPO;7AN!9LP,'2OM'I]#98;3-,T"X'6W@FH)MZ)0Y M.WBF*"XZ92:68)9)F;92'<\IJ9L71:6LVX6YE==RIW^'7D46XJ[=?YIE M<...W5"Q'M*\C51=E"F;MJ\HW#$9"+GF[#$7@WT\_U1)__/5C'(B]<)1*D9^ ML>T-=[3V^*D``S=EPHS[LWW@X&HLCF,JU.KLY('PB?K>):1-B-MJK>K4/HAR M=5\L'U^J+A8VF[*0&*Q5O'RW=VC70OXQL4]2J3_14[KXOQ5"?1=A@)Z+LT[C'![:8D46`% MM`AQT4R*^COR33K%*OD&QM0'6TP0%EK>$NEPB#&[3M``;+-MGD1HX-CU+='`W'E8-:5 MP;!IB@'8+15:K7Q/=IFX`8:E:A@"5$VY4'>TY^Y+D@"7&&G=905V*&@*&/8= M8`9ID(7].T(#^DD-[SFSF@XP@^PWLX".T(#N\-S8@=5T@!EDOYE%Z>=ZYI]3 MXWE)$^"^]?*5XCLV2K\T.:?*5%(%#OL.@EPJ3RG-JG/.II>;27LJ3";ZL!!: M_4CJLW9(=,U"7"2?+5?.U1B"Q$@?&,(R+4OAX86`@O40%N9F:A8`4Q?Y@._& M'P`$!-?[9<'<8[&XLQ,VE9$\G4-63QQK$\3:!$JB`,PVL]GB=B\I5E&3BZ\@FC'?IXUUZD_@^[+OTNYK9Z-)_=P#$0-8ZPGQ94-&$O6<6 MH5L*>X7\_*8J+(L`G8SP-4+Z7#YT.\K7L$"L'73YZKX&IU>V`;K1@@GGOL%Z M="*W!Q#M,)B29]!)5-<#H$Q&02]^[C4+?^#:ZK;"3Z0W.74!W^.\`:+.V4<\`,SI5P,UP]$WG M02I>203H M="1;%,\L9]5U#'2ZT$XH-9<]T6UBX+/Q3N\9HUO3SN"QWD4]T.T`EV.R#D?! MZT6@,PSV,1Y6)2>>1L1/A:%2:.[)NR1_"FJL?YXGF:SD5:SGS%Q,R*8W;W6# M[)F"E0AR=<%QR8JLDUX]T.PWQC)9&?UJ?$,KRA\U=VW!+4/FLH.E;GE@'/P#P`"@FL$,1/_$#+Q8ZIZ M3%6/J>HQ5;U7DIR="H3.W+.$"=6)T$5\+'%"#0ITP1U+G)JWF3Q:WT?"'%V] MBY60-J\N*6F=2,_#M"UQ2\JR(45"-APK"5WD;2=CQCO:][/AL$_*_,'?BGOE!!5_N$;1X+':3;[@`@1,]C]#Q&SV/T/$;/8_0\AG+A M.+>&!NJ:=*`3#M19Z<04&*@#TX41B"X1?6_07QC_`\LL=N4'&UA6JE-G)A"[ MOR=[=U[M.&(7/R6SY5W0A)190E<705LON^9/_>(3CK[F-P;AE&F?F8G/WFU] MJJ9'EY>3#L^V^A59+&X!UF8PL'SJ] MF(HE^+AX/U,/P-S"/XP/)'T0\I//-Q>$%@:@19#2XMUK^WA^)YC1.(HL6B*" M]1M75^6'-4($1NW,AC1!!$0N&*U'V*+E@<%"X/*.`8@8@(@!B"$4(;_C1*Q8 MH;DN3%.06@)J\_].T5X_Y.(;>+.8;]]QL/L7$.H3M8 M@:]"[,4MCN[0W7&^<42_?DXJ6N:,)VE;]B\9DU16!9XG57,O1C0OVRLF0AP\ M"A#M'9*VF8SNI%DR7A04(452%&D;`&*RQ'!2L'*2U)1/Q1ET7R_^PYI:?+N4 MID//V!D*7OU&WA!!WNE^T+*`3/XGS;:*R*QJ;7&!9,NST*.E@WL_Z@]^D.60 MQ.!GUJQVM73!:K:>X>OR_28E)_5W^XD M"T;T(?/)T:$F) MH/4M:VD#L-X>QN?+LU@3@U`3AF9:&[;2D0Z.\?"AMN<'WDIMN1$'WMEX3&4I M/GI->2K^1B:JR%"O/@(DY0A3:%5"'+`_3.0X`&R.]JA>E$`^*S,+3(8><,"\ ME.H]U^XO:+.#`11>>*Q*LTL!H`+101*6T>4+6P!^MRC#LBU+IH(Y?TDUZ_F2+4_4+*:$8O:%MD.&:<%G*VBB];9KZ!W9#RHE.#K[X>R`6M:NY M@P(YF^$%V@U]9,6C?,WPF1JJ!P!I,^#\V`.`$'YAQ13?@TCQ'4A>+,R7@RX9 M%NS28.;X",I$,N.\&.;0[`X9;&[@X!:KUC'/>JD'*-?21C#Z\M')"(,/?U,=,2>IH!0;VDG13)X# MA)U(2NL^#%"SW+\2/K;_(K1"-U]3V>VW)G"Z" MSL\`!-8W/0^=SP%0>Q)\U0*=Q02;3'5*`A`0MMJP.Z3Y`A%C*0F[/O@A]Q*` MV%#5?>US<0V($TN-U]ZWWH`XWR/!V97^V>^4]^>WL$?4F8H+!895?]%EZD*Q M85%A;*\I0O%A45GZY^D](3VTJ_,I*5)92D%::FPLOI'SY)$4#97_>IKXI,C) M_>+KB._6[PSF`"_?.QH3GU6U3]=<:7,4563^$[/.Q:#^+L=T5%7-=-8JF++> M?BHKE.2/>2:&[N;EI?Z^S7$!E*=@#V";S7`!^IW)[2*W0L\YZ^X`!\B;O/I\ MSBG=-/TL(.J:!P"X$H%/)JTFF]-`/>!4X`.`@"";^8%P>LWS5)E9^X(@IES' ME.M>*==[K*H\IKP:E=DMY8]YFI<3^9[;"[E7R2!1U?TG[?[=QR?B0!D^82,; M!Y+,#SJ+T>7J[&7U,ZA%@S(OQ#21V]6`][HE_,9"8U90S`JRPHH?8Z#=[':E MQ]2-/;^XV,LO,-!TCKY^GH%E<_3SV`TTJZ.?OW6@&1\JKT60D-;[9"F&D[P< M,SY=AB6$'K7(RDCNY\E]4PD\5;4FK5E-BH2T3[KVC#XY_Z[?0-&>V-^IXO*Q M./]%6UE^G.>B=SZ_7D)25SB%MG%1NE@<_YRD]0=2-F/Q_X:KGA^%DOMW4RQ> M,58X&)[_<<">WP.`@,!YO=CT>O:[:`;`*H+178GCXZ607?)701S9NC8Q@!`# M"+T""`-Q\UIL`G3.WFYQR6P5!MQ^.^V\,"N!C,^;H9U`.UTT>I:C9SEZEEU@ M["5QHH,8B4B%O<_689H.Q]WDT<,T/*>2H]S@BJ8_3-CCF_:F`9]+1H]6_Y## M?+2A22]__<>H*$[:'W/:G7IA)NRK_GMFUY7!VX?M3[<*-I_^X,`[%YV']DRU MH;6RW9ND.&FJFDTIUXP7A-X!6U?RTL''1@X`;>H\)<7JA%>S!FWCWUS??$]4 M8:QWD?AGM'W-56R`L?)!A@X*_VQ>D_DB!8"-TB]-+B-1[9[-'ZG6NPUN%\"C M0PI:W=!'6C9TXXW5;9=.-]6`G=P'``&!)SGZZ7TX6P_(3_\;91-.9@_RE(3` M4-''4$,,-<100PPUQ%`#AD6JE])H%BC`I<+4+@+-X/&40N;,$O_ M`!IT`2-['O.2M>#L7"=^P<6P90Q;'FK8LM]I,2"`,2Y[\'%9K4\2WSD(PJ3T M<@_T`HXZNC#0RS:6GGS?>0)"VF1"3"[J;%6LR+.VZ-::H))ELC:"XDU)FBP7 M)"NVS?D!.W_"6UZ`(TYWNENB"*\E7^_W`FK M!`N_,995MZS(MM@W4(4(@:Z*$/PF),"E$*]7Y=/OU!$O<+L`D/*BD4S$EWDYJ:XI;^_P'9,J3Q5\:VG#L]X.*U6M?`-UC*TKV+PH M4S:EHGSLI&7\-<"^IB.&:<+.B$":?4A+QG?*$@_*K/GO<@W`.4[ MCO4#$W]Y%"2MW%<,0P`.0@VS8%Y>$1:'XS$MJ7IE&*B#L,_;PYL(XW0Z966[ MQZI1+='LZ@TE`'8EL&-!2-"+UB.8C6ZK]KXMPH! MJ%$@,+9K"=8H;-)C:Z/",A^W20><.W@`$!`DZ-%"]#GY32C%G!1BNXZR:5[F M[5,UPNS6[PV[QC'?+>:[]&G08:0]\U)P!;"+V/X@N$BJU:I=$=`<2%[152&R<%FNQO2^8WX&I= MQ>B.`'M\EK%N=&>#/6(;QQ2Z8\,>KEND_@Z4/ELU4`P7W0G5=^P,P5YT)U:/ MW:"./`'1^7LYN_]A!0P+`A'[>T,;CKA7JAP0K[^WM'LG(1^2XLFHUDB!R41@S`3,[IZKYPNI5XB MS)&DDKAZ%FC/O]&4WG7G1A M3/"QSJS/&93Y6#YFVKBP3$H&NF!PGU6BD15^\<4LQ)B%:(45/T9D4LSM#HAI MFWM^B<:]&RB(\_0H$4-$RHF,U*Z>]"UIG;1?IH5`EW50]'.4.OF67Z>H0Y9] M.D#/6_8N)7L7:^X619%&:=I,FT*6WQ&+D-?YG[HG*?IWY-_VTO!Z//]`_L/X M22$F2&/Y]N@!%V[-FJ``]C;G1$]FSE^\$;GBWF89A]8U?6"/_8"[S M5"J8Y60TX701&M>Z?(ST`_;('@"$\+LC.I6C4UG)[!TG&96R7"]D5&3^&?Y4 MSL3("=,SNZ/I0\D*-IEK63&_M$IV_NZ^NQ:"+%:7_K\_\P:8?KK&A M\Y8X6`K0S8_NKI,#[$#%,/KZHZ\_^OIWP.A7=D=7/H[#"0;)SC.&[A3:&23( MD0N$C:U@@XT#*4C\Y9=$%ER8-M.$MY<09'KU-&]OM29CQI."E9.:\JF@+E-2 MIK20^RXI**EHWSB,TV_ZC:$Q5ITW M='U'+Q.P(T">+\E.QO7PNX$!QK7GXD@MSM"#/I.?-7-5+_L"3/LK\P-Z*U^<$*^ MH5*\9O("[7E>I:3HT+&<]3?@`.P!0`A_AL88\D'$D`<2S81I]>A"EP!-GO6P MU%$&,8Q39)A.1($,IQ-K:5K'X%L,OL7@VPX8W&UL550)``,VMSM6-K<[5G5X"P`! M!"4.```$.0$``.U]_6_DN)'H[P]X_P/?W@&7`/;.S,[F=_[ZQZ(^6MTM4E3Q2YMWP"8S8U-5Q6)5L5@L5OWA M?[^M,O)*BS)E^1^_^O#U^Z\(S6.6I/GS'[_Z\?'T[/'BYN:K__T??_A?IZ<_ MT)P64443LMB2IY=-GM#BDJTH^:_SAUMR2MY__/[]M_>?R(]/%^2;]Q]^=_KA MP^G[WYV>_LJFJ]??OWGWY\N7KMT61?^RHMC[#.CX#NCX\*]`QS\-0:NV:_K'K\ITM<[H5^^,*;VG M1HR&'7+_]8,!(`*HRKP-2:\!YB^593O1XW5[&"S>&@2 M`N(R*A<"[*8\?8ZB]3O8LM[1K"K;GYR*3>S]A\8@_U/SX[]<\3FP+:6/%8M_ MN5O#+O")KA:T:$D24_KC5]KCZREDL*.PHF'.'GLFPCW-^IS78NCQ4A6T9)LB MKC=@CAH<`IJ?_OCXU7^TB(G`3&K4Y.<:^?_]P[L=L<=3.2O:)8F*>(2T9L2[ MF/'-=UWM3VM9L-44'K/)C*OYP(DX7)(#J4KS12TK[[_[^%Y("OSD+YPX&D:(^?*"FC<%U+2HN;<.2DQDYZZ+V*BCZ3V63. M&8K*S7G*;O)XT(K(!V"$80^0Z]4'9'RY8TW38)_\7,- M6Y(H)_1O&[[TIRM:O;"$I/DK+2LAT_S7%1\:L]4ZRK=?^Q?F8:E@X[S3%5<[ M^^7%IJSX,;&X@.GD52%6XR$M?U'NFII?(??.$>BN-:-%3_;P$R`@[#ZJRW6& M9*6AH7R@F3@:\3/1]I;R0_,%6ZU2H8YRXZG]$<:@C@)W+4H-`4100`0)9$<# MWO0ZF!C.'/HRPJN*[UY/[S!>F0DP8[X>CQ*F)W.CCM>*!K_EO^62F< M$9@E[6:YK(D*H!%:$L0F\]%0#SZSBCZQ&D4:98^M:[3J*>@3MZ&FI:/_T+YU6 MUHQ97PB_@9$_1441238%Y1ADT&,/EFL);)"%#6<,R6Z#T[E6DOMC M51"PIJ=QC'84D8ZDYE>SG##.:3I;@24FR8:2OW6SY'Z4.+SN,X1U%`?PGC#J MQTS9[L"OROG9Y_3#Z;I(^=EGG?']CBU/^>1+OOTE]456E">GBZA,Q:^:8$+] MFRI:9/HNET54MKPQ"R1Y<]2`U@\[2MERCTY.IJ"2+?LTUB3.PWNSN?PJQ\[Z MFOKU^F/.J3,M=KV,9,=:O(S(`_CZ_I89Q9@\0QW MQ7-6%.P+H&YC@/13%+^D.2VVD-C1!IZ?F"""]G?OH:W/!CS,_F:"UXOK;D+@ M9-?6+S<0SOV.0%*Q[KJIHY%$D!#57=3P(36=^S[PS-EB*VX*OO]BQR_QL$#\ ML%S3.%VF-"$)780(HEI1=F9]<5P=%+XYA?2FG!LEB(PAW'\5`*M._1`BKZ[Z M-SW\LW/#E)(/^RSXYHD",!MH5)@LC03/9[,GV,N)X_4*[Y&_J9JF\EE&.1 MI\%!F*[532`E#=83PO&&O;!0,Y9-XI8K+^$CWQ\JSD2P.Z=16=*J/(470`A_ M00^45<]!C=*K#_%Q1TE-"*=C=KZ$YA*->A53^.XY),<-\X8F#YS4BTU1U`\^ M/G-^U?^0A=7TOL*&QM3078NI)AE3'`UG,T,K?^W+2FLE64'K[6G/J9U=N1'?A`5QS<28:W<3_71,SIJF.`\Z/W%3)VVHMP M7.P.Z9=T47%?_6[Y%+V-Q#=&OC*,;DB@>XQM+$F/!A'=):?DXG*7=WY";F\O M3`(9UN9H$,98WP8!&06/VG*=_I_"H5(2[UZ+B!^'.,>,L@!=.7]+J MA43Y=B_4$R@6/D$Z!T(>6LOARFWYW6E)\Y05IYR<)*U.EU&<9O"HM]PL6)%P MF8,R&ST>UY\UX31Q3(F3TV4KFZ=9%HM-C/%5XX=NEC_SA5Z=PL)@/*%PY%EU MKOQ/PZN_]KMZ=O7DVKGUI]:;&8QOYL6G%2?=I/B<^)3$C-H)P7QFY_8%%,E1 M3S*TG&&'P^?SY]ISF\G"V]C."G(6_]I(*WZ''JH MO?H)O^]1Q`G:HV=V^_S$I1O=FS'KX4K2O^-^PK/X9]JKVX20;QU`5J5:A="K M+'_7T-$C8W8BK+4ZHX*KSW)WKS2B7HB*D]/&J$YIDU1["NP`!6O3:B&_G3:) MM:=K[KR6D%K+/5?QL'V2C#O#;ODMAV4J_3[OZ!._H[TE'2CO$RY_"SF`MP^H9^;H'_%9[>,/,\]/ M"F_[]RUJ3]"$Y3"Q]PAGL!S?CI+Y&6'=99J8^#O">[\&\B:/"\B#OZ3UGS?Y M+G?R-HT6$``\+@^"_!II.#6Q^,K=T20'D\/C;*:85_0O_%\4KM"645J0URC; MB.3H7LITICM;1WO(5/%CAIP.[;NT02UE]H3N9]:\F'WP80.7(9,GM!FO=&M4 MW/2=>+Q,\[2B&5>)9&`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`D@)@*S]SIT8SQE$QCE^Z;HKZRXV)056]%"U6M4/A!]9W0(T'EB=8,L MY*E]OS9;?/SW]G_0;9S/SOX#,Y:GVEUD\=9Z;%$7^NYKVH;*_G;`Z,-78W M>S!].YPUZEFXG$.<'70ZI>SR;.>B%;U;[KDYRH=^H^.Q]D\&UY\O&C(`-:8APZ\43>4\0[+3KVF"'B9U2Y.2>XJCK:+&AB,-DPRL\ST.^O7L$,^A M)=0HA]E4MOD5J+OB. M1FV^#_C%L?EZ[RY)+3H#C?#HXS.-ON MP?-VKFT.M!PM`;S!SK3#W&3:+`I=P/8.?P_W_Z8IW_;'`MCE-7;2T>95:FUC=(*53"=BU] M^\A)ASWL&SH]=C,4#WT[M-S#H66EV^%\\G=H!W8$OFO!:PEHW3C"I<^\V;DS MOTYW-1B:Q2[]N"M15J)Q$1[::A,0#!B\:=89CO#G5&!=BUN-F[2N78>=U.B] MNW5:+&93^69:0Z=_'_E142)',0Y5`6<`GOO*%QPGZ:Z./QJ4KK%"/;XR3?62 M%@E9B?G$#1DARL.HA()I\\KW"65=4+ZW-''VLUZ-9^FY9/0+]&E$"ME7%$E! M`B9N9'5&B$A1'[^($D7:$W)VJAJ7'H9@H'OGX2>6;;AU*K;7:<970NHU2,:A MW84#>)[\A`XKJ=$&\@]DS&3:'/)<=3Y:IY`:"N'+NT66/M<9PA)3.C(:6VU^ M&*HO$RI!CS&?UF:"Z1=7XR9UG7/MB3@RFV.2PB8RS7.E?)8_/]%B!6<_B2H, M#<%6Q.^!\B7T?9P823>C&2'>3Y#!3GHU246\(4S9_J&E9SJ\\5S[KN=\W"TO MZ9+R\VAR\1(5S]+K6*UOL%7P5+"=E\+K(8<,)NZFK:,T(4WM`BY/,2L]YX9, M8SI#<=*]GRF*\%^E]IL6#_@-WM%<+"]#D8\LAWT_6Y/!.%>;3.?+*/K!SZ M#H'[TA8U%1C-L3TO3%KMP9%V1P31F9>7PZQ4FJ2G634K_:K3HRB**)YD2'1G M8`1247J0?&E%#R5&!8PH1LA[C8]HT.M(M(<6FVGPP_.5SBYW2=!R'VVAW+7L M2D<]&GNE,PS5VY7.,'K4E8ZMF6"N='K9=?6+-JV)N+K2&9$4-I%IOK6BK.Z6 M/S"6E(\L2Z3:,#@*K05[T)R_@N#HP`\HHRR0@92QCVGRQ'.F[VK-SQYP@#WV M.J[3/*UHQAU[F:A,_!J;]:N'Q=NC-3UR4$_67,T487AWM`SZU2>D)NA48[*N M\ILG2A\S9+3W0G`74?ER7[#7-*')^?;'DB8W^8UHII?FSV\*G!RRS-B7DH`(-1T)X<(SZFCY/E2)-^SB,'L<=W]!^B>:9?^9 MLR_Y(XU*EG/JRG)S=+VA/1Y]:2J!Z^GZ%+"?_@+H28N?U`0$NDH=8S.;S#O/ M1G+\<&?Q1!?B&&=Z=O-^8`M_2!L[F$M63UO)DY.3,J>1QW8D:9 M[OEVJ>G(VMB/!YI!6Z#[J`#"FM=NLCNF"9]B;YHT4#B_J]]0:/]=U+C)FB/? MGI"X1AZTXZX6XP>Z[^IS,T#=(?'\+KL0W=Q%?_+RK*J*=+$1WK%E.XET=#+;<>P]^*7D/3GZ3YJ04 ML'X;KN:/A44^K`1D:^5FJ$CB9^=1"19@"X//B@(2.(8*"MH'[%*=E`0XSQU- MDN]%LM]KE$&PL=:*O5<.OPIET5O%J?HR86E\IP6(EAG*RLB#8]"I`3U8SJU\ MC2Q0*K.:?4R+)V&'*K.DQEZ$X%DBT MGA0AY.%!IL+SY".,W&$C/PM\@>7E21:357'%\[MG+I]WRPO1`UHB#T-#L.^> M>Z"\O7ONX42]>S:B&7&E<-OVT":`6IRQ-8AW]?)Y:/&9#G=\5[4H7\[R!/[8 MG:[XZ>(B*HHM/U7]!,\-9"E@4[Y%5[S0P.$C,0!7Y,()\6M1T9S;PJ*:IB$B MP2&JR((^IWD.9V9XWBV@S6YZ5WF"FQR%BMEZTW)6T6.*7C`CAOJU%@^TK(HT MKFC2D%KGC@@?37V0F_`ETE)H8'!?][/%",^UTO.4G9";//9;L`[#<6;`QG"I M'/LW+9\Y2Y0B..53"ZD?,A3.??G-@A5)FHMKM;AWRP`-;T6487KI69^SM9#] M3]8U4D@X&94_22**'IN#O:*!NQIE10+E6/,7-#N8[E\0'%S?!2T_H&;K M\',3&:_\GS^N,_8%1)G_=9>+FB?7;;VA74K'KA782#:S+;`&IQ83].[WB/4Z M:VZ52-*A+\%QSEE^*M*(*J@[#[E"+`^4]FQM%9FKI?%\@2)>'C1>V(@&*,=B MKTR&8#JWM$U9\QIY&$%4,Y--XM`:1I@YC\)FE0_Q:.M/%H(,QK2&5$!D<]"W^TGPYX3V1E*]I=IH^<)$9&XU-.AZ"Z#]$#6M)+>&@QAXG28KB!)NB0] MT&=PC.3MD08'3!2!8T"N5[U!AN^#9$@MK@'23;YDQ:KI\+)@&VCM5<^C[6!P MP8HU*\2(`%V1AF6!C;/,4$B[MUZB$4)YO:DV!?V4YNEJLVKRG\O+#3U;YH]IFL"=3AH!WKE."F=#SE:0JPMQ MW8+R@V_!3Q*KFC12U.'?=4,BX<:F]T@T$Y,A+]&K>#*:$ZAWDD)CB8)_":GD M\/,Z6,S-1";>.8F/B,C!2G/ND,6T%#%EEE.RA5;3R882P67"O7Q2`C?(LFY% M+7Z_9%G&O@!D^#W<=7''KC?@:W+U%F>;!!Y7@3^5KNK>5WF^@:F(\WQ)OKS0 MO/M]^\.HH)QP:##(>0`6E7"V9F)RZW7!HOCEI"[[T6!=1!E,C)0OE%8DX3\, M8&+-+!2S)Z&S>/,^$*"7W?5/!F#WS?L`HL!OW@Q]^\CS(]4)+\#Y0]%]'Z)>566^?MA6R\:>K\(5S7&MC'-XMW M%U+&#J74J[GE^=9*Y$5?1S'$`+?*UX.JH=A;J`&0SF\Y!4[2(@W[I%#)4S:% M42'%1F%ZY`.MB(P/8W,D,.'LC8*;4F$);6$>Z"O+X&BS3Y8R>4WK&W3VL@*V M^_!8@YP<257(K#8]?C,4$PU#4)\W`/)N><'RDL:BK<4GEE)B/S$G::3-7DZ(R'>6/*WPFJFCHP+5VD(8ST*8,* MNIPV,M_IXP)3#]#^NQ2!)PCUY!U#XAY#5@U#TAZM?'A405R*DH@?\(`WD:`\ M0'@&K\',SOH8FK$>UJ/%;DTA:++.NITM[GU%IY(-101($B%C01015)&YSMFRB:H:'B3``V&.1#1; M,&(M&/$2E5#=;D'Y?QG[PBU53(N*'X_XR&86`,12$2`B;JVS0?*&QHFYLX,&Q<:"%_N#KL MWCT^$!W,/@3HZQ[I&#.J\YD%^A'W0D_P">DC_Q=R29=IG-(\]MN17$,TF#Z_ M_,I]3<$G6KVPWCOPNR\YI^XE7=]3SGUNW)YEF;&3OT=JB38>7\JC31!&IQS. M%K$KU]20FARRH^>$=!01W?DZ4KWI8LB,N>V[SJ9(9?F!*^+%Z3\@-)0WL$=`\L`A7QG+0$S(RO?F53U&I[HF_5 M.8?_BT0&AP&:\5ZY# M(J7R@4AY/0;H2W*/,6-DV`;]J*?P=WNOWB-!01#95H@$T^>3[RIMHGD(A!?K M#B)WN]8I$LG7^01=LTT.VGWI-L!=7]>>S+&1C!;?&8:9GHN9)$D*]UY1=A^E MR4W>O%J52-O(:&S!DF&HSAM\=&C)FN,]%;5S!.8P%3I&>,LF,LRO'+5/U)[8 M62S>,-X7\$ZQVMYSGE=G>0(AVO5*OH5/!X"4-GU$OK9\?8HPKH"3^9H4`[GG M/W^!-ZA0`;RA101[J=XT'>D?0@"9.9=]'_:`$6F6BER'NV7M^5QS/C1=7$1; MOY)E*;RE3<:B9J;@T(=)'%KW*?I]ND"\:\KJ)\L-;9!RUJ>NZ>82/`)GO);, M]@*%J-LI\WOV?FE4F=.U$-99%6<:!R^[5*(30'1(=5HR=-##&N!"Z'2FD1)0 MXQ]82V_R5@)9DAL4IL"L!H.524)S*#4[Y*8D&WB:3I4&4/L[BT[Y'GSG`8>F M6I/(,."G*ZBT/1LW=)C3(]ZG@GU^9:Y7)U*O+/;X!T@IDP/V52"[1T$8(Z;! M6S:=81B!*FG\]3-[?9?0%&3I6_@+B-"W/1'B/_K++3]C9E=Y-?Q:7#%BHI`, M0'(M%0(=J?&%>!RN8A[3X(C+9:]Q/M!GD2:55Y^CU6%NW-@PA``,@7.>GE&O M_PXI`:S>!4')2:;+'L_NC"S((D^\T/D$Z\0H0+L6HOO!0)I&PVH?4_E5)6YH M"0C#L,J]N;S@:(LHN\D3^O:?]/`!S.@XM,$\@.?)8C98B4!+.-Y`-E/&3:;- M(O>2,5B?2?9KM!SXJ:XXVKU`?1(U8N#=I M+A2D-49'/\#6%)4"]E9#5$H!JF:HQ?D8/1O?$4#TYN.J&NBXY+#I[/-\AQ"_ MT&23T;ME0TU-'M?N7MGZ\VU[*3>R&QA"P]X^X+`ZOYIHR`*1;6]V.\I(C[03 MJ'';CIC)7:_I2C++RS.3H,$/!2NE%R!:']D.'`C@H4('SX!\7D?P?6;K',(' M..@YKR".-ZN-Z`A]"25#XCHI@O\]H_`7>`VZ`HWYN_CYU+0YV^"QN0V6R/#E M/-FB%]FYSC>O3-+U;FE9?D]Z1).D1W7]2KM';JCN=G:U@+E>+L^.8)31LGG1 M(P^-2T9A';=]:,X=,D"G$>]VY5))>,(A-JS_N&3:1_BH<<`')FT(N7YG M\EB_,ZFI('&C`ZOV@(J/,LD@XKJ=&&;4PQPEDVC5W!4M6D`9MR&+;>- M*$;GAX?NG#W2'WLF7;`/=4G16$4UU)+A\Y(\=VSVPK574?)48?+P.7620LRW M+,K/G@LJVD7)6P0KAF%*+`^`<[[\'"7I<.*[!ELAW5;O8-%0$R86M10%J!"L MD@VFRS7/UH_ESU!4^9(NJB>.6>WZ*0=C+>`@4/=*P$]THIHTX#TA@#FP]Z=F M+IO&,=\%.O=OL/03929\B2[-.8K!?5W.PVO..:7!3%D"9L#7L(9-Y=8IAEHR M:E[9.=2]5\XA MWVEA-1T_YN6:QNDRI8G281X=CT[MDL#U)3XGI(HZS=.* MWJ:OT/:\XNQ.%UGS^EA^Y:SW$5*^U,#=E\IM439E$-&/L6S/P\US+$^T(W*+ M`Z4$:,HVPS%K-LJMRIK4_&4!V!B5Q$1;$%1URGOZU_ M99(FA4YC88AR4^JJQC8+&@>I96Q5J3%:9/882H: MHH$^?VS^#IK\L:?)]4__LNN<-A@.&!DU^=YX$)K[4UF++\QY?XR)3),SH1X2 MGN55FJ29:`#[2/D^*3)?KM[B;)/0!$I\7K#5>E,UE3\/F_3HOS&TC+5J7CL$GC6Z6W/<-8EGN4G2W5V65 MKOA><[>\Y[^`7>A6?GR?]"WZCE$#A[<$21UB4*F3;F:)<*YNQ8E^1\H):8D! MW6_)(>,3=7;?.D7FF!&+_6KB0&K!2"%,C2^06J>`[$O7%"1@-,SJC-!-.BM& MN*L?Y7$J6ILW%W]A-$E'>AB"@9[/(@/WV2Z0^U79=K(V'"L MZR(!ZUJK`"_9(3X157K#)HV,/>:"O+'L5*03)*S\=A7K*J9(,-H5?)F>@&)(HBFU]"&K^<7@*:G[\ M%\["_24]_L5$D=X!<"W`/WZ^>;JZ)(]/9T]7CU[7>X!)3#[S8$_,U=D?\H'F M#\X]YX$<8S9\?AXN(V1&K]$5N2%CK`KIYH%AU7+S^@.MN'D`T%MT\P@S*JAI M@7Y$+//HJ#-.OQ=7=4\BI*[J,9N\YT/5`6"MH\W(:'QFTQ!4U]*_BWW/XZ0S MQEPVD6,S*50[ED6A_Z'M@K7>LAQ:"DZ(H$$4TNJHF$N^PH1UT*EE.XM\@K/D MKYOZ4J!\8FVC7[H7OGQB%U'YPJ?QFB8T.=_^6$+6VQV?5`2WLV?0EU#X)B/7 MGRY18=.H'9#D6E5Z-,/]9-%2W0N7P\_A7S&GO,X)8BV]).H(#M.QT*D4,)]+ MZU=1.=D%C4IZ2>L_>X0VS4Y'U&\Z`*12Z2-R7IKQA?^+EEPK^@I0-W&''28+ MW;X3L2;,G-&>DTTWZW4F\B:B#/3M.F-?>J62QMI@3_L:FQ:JA\5YKF>/#))T M"1PEQ(UK6\[IXM+<$1:H<_;$-6&&C/8KKP]TS9?GA>M35Q'K`D*-M%A'W(T; MO2>=_#U29K7QN"^`N\,Z@UO4Z?QGQDSU77AYGR)%.$(U%%UJ^1AD`!$+%X50 M\I1-893G0%:4%C]%V08>*FU6:["WY=7;FL8531117-W/L*&M$?#>GNB-T(%Z MD&=];J^T6+"I\5]`17ZSI5'AN>K]9!%B6-Z%UZ2'M/SEFF\9-Z#SM*P>HNJP MP3GV[`H>RCF8-CV:?' MMH-I-E?4MM>BG-=FIY0Q38]3SDS?N3>[EG72K)OC(>A\FQTH]PG5.URXW!H3 M6E%9-;H$.TNF&5AHIL,1WS);I*\1/+K_(4ISN'B[RW<_DQ>3U/X.+=TC\/U< M3\'MU)*;'O(*M@="_4E'1/#\1/TU8&C&SB0+YWP[4I%]PI>V\W!V&((FXH0O MWSYE#71R<&2,]7WE5'%%H4E;<62O1RT<860F4O]#]"73&`+GZ2Y[G8H%RD#7 M2MJL9GC^!7J%Q:*\O(^VD&4G"Y$(^8KA^B76D'0,O<22LLNO`G3Y,K>0/U->;ZI-03^E>;K:K#AY(GOL MN`!(95G.D)?JC6=,HSB^9@_0BVYG'T71`,-!)#9X^I, M7'GPZ90Y.A.^M)Y2O_7534[+E0^9J3-E%;02ZB6LG>N>P@_#=O:40T#.]Y06 MX?SVE)8RMWL*?OZH/>6;]S/?4XX$$+6G#'/5\Y&(6TEN4\XW:08-P09;[FJ- MQ1Z*AF`ZKTT!6P/\KT6KV7_7U6E"R5HC'SQZG MT;^?K1H/"Q_F"#_,T[FJ+<=J)P!W#,FYZG88YZ>\'6ENU=>``S@%_K>9*_"Q M$*)46,)7WT4#%B7]VX93=?6JZJ92ETQE[7"P8.*TVEN7M6ICH5329\BI4Q M#13.!:ZE`3*:=X4$6S*XZ#6$!!*_*:O`3%CK63"[;G=[6[S8]=M]_IH537V@ MVAD0U?7T6SF:`L8*M3$!SD6^UZJQII$T1!)!#FG))$M6D(;0^E?E7&H<6ESF MP1Z,=M;.LTY!]\=S3E,"_2%I7JJ>7ZD'8V5_$*BOH]\P=LSISM8\$`14]TW-^8N2GR^OT3;3$'BN!@0-B MF&BNA\QW"KH>52;)Z:[FC4I;SY]/*ZA'`T2=D!U9I*&+",*ZNAE[0X(]*T:* MZT#F.V8M_.KWU6I!DP3>I[0O]KJ'T7?+XU^V!0MD=39,P2%U'HO6E_9CZ=F`(T62((WM@+-3,]NH$#:0I\VV48^T$T?SD MV!R%T()FUZC9*H^>A<^HZ850VA*P8Z7C=3XQCY4=@?8:(P/L1*"?46Q,SNWA MF-@("_T*VA-4Q=X46W'T$P95(E[R@4BA.@;HRZ\XQHSQ&(SH-^\OV*(G)>`_ M(5'%C^QP%OCX[A*>,<@ M_56_.\:-JWAG8PZHFEIMATVR@=PX4G2M-^.ZD>A2JY&HLPIW"G%A4_CGNR11 MO\-8_^1]M5Q2Z/M!=X=TB:J@8*!+%4W`Y4NY)A%EWB[/^JP1A]6NFFL1*A*% MDSII<[U)3/6KHY]I9:?O%!X04ENG(W1>::QM'E*2=4,566QGU!7*8(V8/<;/ M91,2!ZK$8`>2`;"^_1PB"K_W'%)D=^,QGZ^-_JU[1<5/2$T4T9VS]YU)*HU: MVY*:Y7-1V<->7)-55@;`NLH>(@JOLH<4V559\_DZ4-F6*/*;EJPPG3D0\JBE MM&JF>R\3%%.:E-=\YH\1)"'!92Q<0M_DK[3I$2G1UTG?XDL%C>/PI:5:Q&`4 MU-$L$;K94E)W1@5:(/R^RTS0GJB[LD@39(X9L=CW]KF&5-GR3+3@W-4LE&Z6 MZN'HK7$8K//;'LH1I=66)`T!HN0*JUYHT30E#55&7,UE-I5UX?+11H+;\I$6 M,LL\A;8;-&3-"I%'STU7QJD@PG0EG`[33+'I\S"Y\#&XQMGB_6 MNY$^`-);AO(`;E1^LI4Y8+*3`?$)-&T/<^.O M$@#P@,-+#L(QS?O7C`J:85X5X-`"-^RZ[IN)C[[VF?(K4&QT4SMVI/@U$]&W< M44%^#OT<:](J,!/6>A;,WDNONT66/@M"RYOZ0)'(9%+O*ZPXJJ&[EL3F.2GW M?;D@QC4MZ=]I0C(1*&0[BL)(HB;O&9*A?N7O,#YYD]_!.;QQXNOCK40(IWR* ME$0=%+Z<"QU:,(Z&Y3GNGT&?IOL>`CMIXADAXS&3Y(N9,-1S&'[WSO=!'J.1 MC,*&UO>A>0NB[Z-%AA3]$;+^RB5 M.2Z24?CMH0_-M537Z$@%^$)9Q$'N,4V6>'X_V;3ZNJ>%>+Q]F6:;2NK2CHS& MOGX@K8Y.U#N#4Z-"^=6FM!IDA(,&`.9QX%59CHL\2NP9WF5 M)J`WZ2MM[D)36EZ]Q=DFH0E<6D.)BTTE3HEWRT.54T9VK<)&JH@5&ESK%A!Y MVE)9OZ\BK.YU+DQS_;0JC#VVNXC,Z\W9Z^TB)[IYPV\X;U; M-KN0(+*\VU1E%>70"$6B)$@H2'68B,W7V6PB69@]R/G,*V@F,FV;:FDB44W4 MGE-6$K8CAYR2I/'C0AL$K,`R2VL1\C+S@N6,+D/8+:?P!)1-`T@SM3'3&47J)JH,2S?2;X>B6,(,Y?WT18JWZN?,JD'8R\P!H$ZOY%HL))UC1:.<2(P7Y)_ M_O:;C^*1W#]_\]U[DFRXG#%2T$R4.UA'1;4-=%&AYCZ;QM)9E-7ILD]-R^IH M`+);5D>!T&-9'?&6>-FE\,ZTGH[.XHS7T]'F^"PDN_81]JB=)M$*`'8E>0"1 MKU."/D48)]_E?!$^.B>'Q*"Z&V@&DN;\OX:0GM[.26U5$CBNKJ-LGL5=]M%5 MW'E4IO&TFVPU#+OWV,.X7.OKI&O315!Z=:O+Z["YV:H]1CG64EZVESU#(/FUYF1+=P4-5H:T_IRLE"5IW#Q5 MT3+YDF^LV/D#V&&,^P$1YA;=>%8VS'A+!-&:EA?++9,DJ;E6,M)WS0*P3*,] M.V3#T+4(]L&YKSNP2UPY(?_\_NOW[[^!D"9Y!>S_3G[W_N3]>_&_UK>/-M4+ M*^!%^+^3;SZ]./O!_-H/3LMS`*0$*C.T\Y!/"?[>N MBWQG83H&2)>-Z:Z%7VGL>G&=<8ZNZD1YN#.(^8'D)Y9%E6B^H.AT.1T`4H+U M$?DR_OH4878"E_-%Y:+MD`;1+(2@,7-N!FH==I%%97FW%#;B["V5171'QYLV M#3N$ZWS;`'Q0)*_.>/P9<`9N$B9E[5"',#6_PM4%ONTWJ)$(T^AX"_5_]^`Z MOWF=)^SU)%;17QG40&I(\"_52GE@VGPRE-Y/ MP(86P3=RZ56-PTCO$#S7TBMP=M)+OL&+KQWJ<>+[0-?\MZ)V$'!Z:+1YC+H/U5.HNNG%O!]@ M#IU<,L;HX:BRG'M!4KZY@-^S+(W'B"]1CJ,6!M>"-8&4Z?ZDHQDBDATN\'7(/4X,YS,WU!S- MBY\;JZ91E^\\/(P*,0/F>KZ]BU]HLH&^=)>T2%\C2$.X3:,%7#+`MEEUEY!/ MD"TXUJ'"%!SV[@^)UK5%:NF"<]^.,M(CC405`>*(H([\+.@CH5M<&"\CL[TV MGC-,TCRM.)6O\%:CXBL*Y8[J(OY;/M&#$'N`V*)" M7)@F*^=L[T$)K_E8*R;^$)@7J]XB]99UB*(.E8'HB0^(<]LW[[]Y_RO8RHX$ M$KU[#7/7KV8_T'73F.1N>:N14#8Z'JF?4KB^5%!*`$;+;,S&I$/Q#C^;C,8IPI1^/:;%3`=)HCL:% M(+OR0(7FM+P5A%2(E[(NY!@_;68O?=#,7OI@.7OI0Y#LI0^6LI?0U/__D[UT M*#"#V4N#?`QV#WH?%7>%>(F0B!!@^W)X_#YT[$OS>U$9!K_WH]W[PSF]")^R M#L-7I7K,=79EVE:R+"9?F0Y]:??*M(\A\)5IGQ2+-XMF,YSQE:G9Q"Q?F:9M M%S2@)D2&X30=&K\SE7/7T$Y`(W9P_ZY9<<4WQR2!_]J[JB'SH/4!QBHH`7LQ M!DH*)JN*K?F8!`M:&D0+7=I0068P*5L.*KB@23O):*6::P`SH**(0\,MA!'[8$-$$?OX38.(R+E8BB'6<4.^N:Q(S@EIJQZCZFK: M6R&$G[,?%Q7HB=8*>0A^#FJ!)/8I9YSI3K]78:=-PKH;V/0R6KM*.(I"4IFP2J!"JM+RA9 M;K)L"]?_49J<0*GF->P%YB7_;<`"4^R:L5O1DS\-I+LM$NN(J2GH0 MN"O#J3HR(X/&@:R;BOIAGDYK*@G#R8>AYO^45M$JS1]HE%7;VRR6J[MZ)$;' MAR&Z5NP&*ZG1DMO;"[PNVYJ!E;#>\<0"R/N(E+`)C`OUN*GM^[EMNCU-?,RD M][GQXR4U&I^/E3I*3DA#R_R>)FDNRN!3I"F<-CZ%+J--5D&93KDAE@["G1P/ M@+F6G`:AZ)&`-[P6R+9SE=+,)M"UJ5P4F!ZC?&>'-IH$-S<9*[F_.&97=3Y! M9X/*0;O6@@XWV2'G5C.PO=1B-L-PT-`N7O$#;Y0E_QEMY691-@9C%0]AN1:' MJZ_)#P(CX2CQ5M&<;"M&\:(^M?U+22Y>HK1815W0YIQ%!3_KW?/1_#P&89\\ M:1(E18;:"\O@=@U^&O,S4)2*+U_2DBRYNYAMR4K,JSSA1T1&H/5)E)6,T#<: M;\1K:;9]R[V\")9[*15.IK5TX=[Y+Z:ZO_)/++S7/P3M M]TW^8H:.K8+=DG?U:A[ZE;2K3<'J--5!NSXV#"E1A^"<6_<.GZ9I=R0U4C8R M7=X$$CF8 M(>+N#-"?IOGINB8@K&.L(4]#_K$N"P/I%SS5+?D.\0-CR33]&O_25+_D&+SK MEYP4(_VR.4.$?K7HR3/@#ZM>&N(TI%ZZ'#0\A=[Q,T3Q>0.U(2D_;L11=KXI MX>6MHAJ*[C>84^H8;-<*(O"3/0)(2P'^$&M_5M@R*G6"%.0<++9DT4ZL*<\< MHE:*MC`Q%"\-U4,\N<@%PZ),HU"0SGB,6JC@NH_K]7#;*"-D=S)6-.&9LNI:#/OA7!RT!8I,9Z=<)Z_=6OF10PDOB<\D'(EVL8X#.K][[#;+) MSS72,&=A!3>9/HM,P]K\L+VF9WER$>51$BEBVZJ!J`#W$$`?<9`U%:'9&JU! MI-L._2[M88@HLU),F#[OPIE`13-(V3`+YL]'Z\<#XQ>N\Z.4CQ+#A^_S*'44 M^`S/2PK\$&*$)VB#>D2`8(?XA-2H2<`)6+FA MS#=@\^!6IVDI4'):Q#O8"-["MW0&,.%*F6?:G#2-=*QI$4&]4/&JOKP6J;V? MTCQ=;59-B_GR;Z!>?`?L*2L M$_#;W[<_A'2+NI`P9P!W?2/">9J)F:W7!8OBEQ,"EJS%NH@RF!4WL916(K$_ M1,@,;828';$T/2+FKVG!AXI8BHC0Y&'15E0)T?%_N(28W9X,1H;QK& M+DC:.T!&"[9IGM/LS5XAQ5P^&E*-<`GJRR(]FAT=?(>7G6EQQ=",UW7L.&M>^!YR]EQ0*IZS2RVY MSGB,,5?!=9Y,![A)BYQTV/$VW>YL<&:]V#]9#IOVJ*4M@#W7$B4VF:,!K/I- M'K,5!"Y;%1WIMJGWD8G=EP+W<_6>"O3D-[3&_ML3DM/J^W"V=9S7A\96DX&^ MRW?!"2:YCXIJ^U1$>*/^J]6$!#01;ZT,;F6R884(F@A?6)F]<@%LS;, M`L/]RO"N?YHRLUHV#"F-A^#/P%+&!X1$8 M'W(?DNLE!FS\I&%P\C>EU_R2F"W!VV4$YA'``Y0L/=/@C^>'1U#C&UA]F^;T MAO]5=H"7#\0^,CH"Z/XTU&`D/P-.(I`&>DTDYR;39Y'_W/7Z"NSN2TZ3\SK6 M7%^'281&YQ.#;'49:)]IZC(:L/GI]N9D=.],!`4GI*&AO88.EJL^*D4,P\9Y M''+.M_W?*-)QI@.P?,0Y1N3WA!,PA0?!>XTCS!A#_0JHH&S)S<99GCS2XC6- MT_P9>MOF7('2*-O5S"N?.&'E\*^4*;4N4""%W"8IKM6@P]PK:5F&3>=ULI+, MQ_*$L_I*U9`/M&#%_8CI@;4.*9X*;DKLLH-L\T]1_A)5591?%IOGIA2&JKW< MV&A,[$`.U;4T=)@)H&Y+@9@TG+,W$UR$87A&(?K*C4H*F\@TWYX&CM\_@NA:$UJ4;=>X)@66;:J2KTP""5W0/J[^<9B><2H^LPG,"_2> M_B'Z\BF"Y+DHF_:']-+*3%Z2V]Q?IB6*M$7LFK1AWU)/RY) M0P_I-=GG5ZU$V0R:E-=\IH\TWA0TN=7HSJ[[&5*EQL#[4J@Q.C#J9']N"&5J MB:ASBF^/2[`'43!MJ6)8=AIZ^0]M1_NF7X#B2G!D*,:_EX!T?]1KT+;-,PRN M"ZU-P%2F[@BT+ZMF)^K:*3$J-\:A, M2@5<]V4):]Q$(*^+$]9UB/&IE%:G8T7TRW:6M)UEK1#P`@448E=FM*G"'"*Y M4D>ZV&0>&^K(;:]OQ'44IUE:;2\8QQKE5==5YE!9'VA,TU?1R[#YB:SAM0/P M&`VT2(:7QX`6Z9VLWD%YA7#^#MR]EF32TMSKFG6T]Y,>W;N?_>JXAF_JLXK> MQ./$->5C.(!GP4J:I<^BST\4BZZY)3>E+:5D4]8M`^,HBS<0A6[2UH_;ZQP[ M)'M-@D27'@ZHU[TG@%EV8:&8:Z$(8?2[D[\+DZ\"[LW@#Q$Q7W,_1*T?LV6' M3[Y-_:Z/@G]#;X=C>#.?=G-O++'H0O+?IGS,\A@9\O%%]QL<%8_2S_+D03S" M;5[12"*BRK'(,.@@3%^QST'DF("GI5E@GL5VQ2+J\@(G!&@@6G-Q%.)4BPF; MQ#6_RO!#PL1^+5I M031FY"=M?4AVY$GK4@9Z]G72F.\PX(NU#].'+[>TQV-]'AE]R<-"?T`0F.+H/R?D:0WE"0(>_<38EV,H=LRBSF'$J`D2V)&O/-/CC M\*K@4WUY=!P`:V*$4V\'=.'9OA`8PQO\#F",0*M!;/O<'X7LM<)U&]RZ)PK8O4U>Y?-9&<6L]>V!SIA^FD+Z-?9^S%?AY];Z7^`=`#E@%T;P1UFLD,=UBG4X#*;SCK?9]9%I5^,;&0T^HPZ M"-7]V711S:JT\S,2UF'_5H(4T)2?%G7-49!`OP M/&+VG*=_YS](-D5;5GYZV?FZMX9@P0G4M,\VXIWALJLD4/].U**'/J1?TBP[ MX7#B7V#8^F5;BNY*Y68!;Q1C2KZDG(((`'!6DRQ=AB@N;Z8CS)ZX>#4:9TON M^P,9I0W+,03-O?GH8_5R$L23Y]C\F'$"<0KDAYV"1H!UUC/S;%T%0_[;N**- MZZ`9P5E8N=SXS@^(X7T[O:3UGS>Y>#S(C[^7=,W*M)(_)]?]$)TO,(;`7][` M&"6X_`'[\T-8RA8I21JL0H.9*/U=JW2@5`)M\6)XGOJNB]2V<+I;WK+\&8+O M%]$ZA=PGH/9ND:7/PDC(R^%-AH"NI*2-R9<:3B`)HX]N9OQ=/>-<1`Z3::JY MHZ@)O,8U.6(OKSMX,=TY.ZLY-5T@F06>^]XD]_=S_;#8A"_1V^0H!M<*NB.! MU#3,*G8V90F8`5_]BN19S'>XGC\ID3_9,*2P'8+S9?H/\6+LNSGM".^J0PJG MM>:LQ(]#::^DY<[=ROFP."I?ZJ:(_/P51%^D(L-T>>E7$SZ+-KMWRZO5.F-; M2LL?NE;I9]P)5-Z&3?H6J3-:.%PKTN>N%W%'Q@G9$4*`DK!79M.6@AGQUS"2 M>9_'YU'^BSSA:G``)MZX!\BUC-Q_OB"`#9]M94BNG:[;T8JV93R`F`!!I>'E M9^-,\IWI?ISS<-/L//#`]:RZ%TUYK_)$8CX1$-#9\-J8O+T+U"<)]5K0Y8SM MY56=D)8H\2@:'J'4=)'1>3M[+3!=*)D%OOM5WJN_;3AAGVCUPI+=0YKRGF5I MO)6HJ]8W2`55PG:MDC5R4F,G/?0GI":`_-S\&?HPJK<$#,574Z^&$YJ6)2NV M4/=0X=PHQJ%\G`%XSEV=#JR^."43Y&>@0X*7SZ[#BT89]W-'!%> M>DW(J:"$',;E3TA-#1F?IB/W9Y*X,1/^&N\A76++;1:K-A+Y.-QN<@S/PY:R M:[9T>WMALJ_8H-[6YK+L3RK(#J*0#:;-LO!!H>8!S#DK"I$A=A&M^6\JV3$3 M`\)B6$B&*F1<2$:3K<"0O3G;C`RU+^TZLHC>O#T&AD;E>9 MX1'8%][^3C/BA;?96<:48//&V]&";:K=0^]`9V^)"#`--H6(7$)==99SOBL; M!"K'&D4J#V!ZBE!V6,-V"E2S]2CZJ.25Y\M^EK.VF.%-'K,55>>_C(['7NK+ MX/KR,J0$8%P*B[-!5/*[$\DOS>N%$Y+3,'DOXZ+")G/,KW(\\DU,5+PZ4-M2 MT6!;ZQNDDBAA^[:X91T@I4P-W+6:U\4H%RG"V M2Y/!#,[8')5;@RE*0$:HR^9B,L(GL\APKVH\MW+)2 M%H54C,1&A8XA^M*!`=08^;UP@2T%`+!)O!H+HF8LB)K3U^8 M1"6,8%E/U53@#)^[J2#.;C*G52X@MB4N=K^?6=ZFCC!J)7)J\W;V*LW13T^W MUH+F3ZT!ZXP5&\CSI-HX3N"4^]]^+K=906D)QT\1(5 MSU06U%$/QE8@&P3JK0[9('94-3)+\\#H!J`F.]Q$:QJNJHVIA81-X]AL7,?S M[:?HKZRXR*)2E7V)@&#?23S$Y%J91K*0%ELBZ"&"H)!9FYC5T?.8U"R?C13O MB(3FE@*NSK#^Q2Z8GV./\-7\/=*EJU'?=H:SKZ M[5(V[I9GZW41I25-/M/JKDAHD6UOT[]MTD0<8$0#\KOE59:*2:4YA\QE\_"Q MZQQ(P;SO"T2RE_8G@>9FM5ODK-;`1?M-1=O-7F(8@.AF2?@T23-/TILH$3,5 M14V;N8K:7__@BX+O_KG>8V_4L3?G[&4->[,>>U];]M*6O1W99%/6#6;B*(LW MT"U&/(#%]A7E@$134<;=^WQNS41]6'*=/J3>I-#A!GU?M!7_[POVFI90V;]/ M_M4;EX_R(BI?EAG[,G7/Q4&WO8U.HR+XSCB-7*MVU36G7.Q?.YK)CNB#G:NF MFP#AY%?'-(/]9<>:@G*;4X@7C"0J272P]]":07%#I.@M1J-XKR/9S'8!I&W1 M,>PF*^HYP[6`]X+5]CZ#_2A/X'7J&@C7[XB"`8'-A9V`RD/%44'+"1'4B*X/ M'3VSZI>"6B!F@^N>[S(*&MTM'VB4797PVKJE6W:;,3(<>Y\A`>OM1D."'W6G M86TNF%L-Z&#!MQ9`3VK\1&\RKFXVQ@2&3>5<^$IPMQ3ZD"D#P;J?6:SXU@?O M_+FJK-A93438R*XV[T>JFLD9&EX$%;=I8\,MBIR/>[)&HNH+@W"W8*-<'1$F M_/V6++[`HOSLN:#B=/&).U*PG-NNE6#='7DP=##E0U140`>!GP._#B73CZ5N MYH=Z>!_EI".%=+20CA@RKSE:*6J["Z]F,/^H)3/$47F2+C$\_+77X##&5$2`30X)`%">$DLJ4%V_P@T^@N-O__WMV7ZY@&SG-#LE[?O MO_O^[1N*7MU]NHMG-T=G9V__^Q]__7Q3]BC/,4(&3-W?K-[?W999@ M=DR7^,W_'EZ?OXG>?'_PM^\_7EV\^7)[].;#]^]_B-Z_C[[_(8K^\?>49'_\ M3?SG#N7X#7]EEE<__O+VOBA6?WOW[NO7K]]]NV/I=Y0MWGWX_ON#=UOJMS6Y M^&M2[`8TB7]XM_GCCO3%H[\>5+3O/WWZ]*[ZZXXT)VV$_*'OW_WOQ?E-?(^7 M*")97J`L%KSDY&]Y]?#KY_ M)\C?<=8+O,19$66TP-'/$<.I^(C1"K%B'14,93F*A2@YEZ]ZW3W#\U_>DNQN M%6V?)3CZKPZ/*M8K_,O;G"Q7*7[[KB'2BN&EZ`ZGF^<8 MC-JPF(HY1EF-FXS%YHJ8H_RNFEYE'BT06E5@O<-ID6]_4PD3??^^GF7_5?_Z M]V.2QRG-2X9O.3*'_"5_2$0Q&#%Q,:(/]@2YWDSC*S&+;QN3N(5=B6`=GC"^ MF#R7'\W8(^O$LP M$2Q\%/\0X'QL6"C\5[_/.`^)X.,T18MGQHGT[UV-*"A31R43D_R43TB4_ALC M=I(EQQRX%OYTI$.S>EQ_Q@T#5YAO1\DI_]USXQ1$.RZS`BT8JR\HQV)T@Y'\ MZROIQF+REK]'P5OSST.S=%+ID2/^5H;2,ZXQOOT3KUMX4]*-Q"1=+FEV4_!= MYN:>[VGY95F(ZA-1D2/G&#!H)/8W>N<:KR@K^-N%-=*ZDB#DX[!\2E+,CO@" M6?#-7LII*]4X#%[C!1%V2E9\1LNV):4B&X?%WVA:*NA9 MEFQP.'MI?C4#WA#Z$)$,$6L4D#*!HS%Y>Q24 MYX+C,7F3%)BBA",R>?M4D0"W5,?^/EHQDL5DE>(\HO,HIEE.4Y)4KZW*">Y0 M3JH_-1G:\@ZL>-_S+6/7QO?"[EY5]&>'A)YE\05>WKW(M<@)>LAC7)",+,ME MM2'FX4'];R'$02/"OOEM55*5%U5@^6520$EC@<76;)&&:N)'(3P1P^:)CEI7 MM"H3)7D:Z$(R?F0G%?P'9+SSKAGX;C0GME7B8KV!8"7XE&0V>%=HO7%!`!X M%U.?!&H1J=[;]B[#'"IU`)4Z?84XIJY#`,L'X/M/'850X+7'#BOUK;PK6W&P MO"TM1TV1&0I'740$?Z.;$'X2HE0GN,BCS*\DQ^8;M(\9>QT$HB= MT'0IA.@=#M&?[6;PK)K`)KV7P",M9![0-WWFH8TF)$E"S#_$_$/,/\3\G;2I M0\P_Q/Q#S+^K_'*#QQ?Y0[3;A;"EXRF1@<.6CDL?PI8A;#E(AT##<("E2.3' MB).OL+@.JVJJ]V=)5N*OAJ%(W6/&CD7"^`G!R!",=#@8>55/X:L4;=JM;&7O;R7HY<4/-'T@V6*6/'"XL9(%)6D/S&R-_Q-QO\WEO-8+ M'M/M MX7%$RXS;;BMQ8;!H@JN(T*E(+3!>F32GM2&K8EM*:)MI90Q:16HAY\$M^XU5 MF7//Y'#])2-_EO@8YS$CJ\K1EG\`H[&V11,36_E==.1V!(!G;#34=M@_R[C9 M5TH4NY[0-M.@2:,BGW@2TQ,Q;.9B3TI&$YJFB"FKZ65DXS/<#"P`=F$=N1L" MG(M@%5,N9>BP<+)%P6HXV=(;FWA5LO@>Y7@7Y'ENIRNGL_%X&R+648FGBT[] M;2!C0B%**$11\.UU(;.7594`3OE$E726F==]*-731(UM1/LJS6+ MCGY\$7[CBTU,7Y$E4D`O([/+L!)L.6&H%0NU8J!Y[0L.4BDIU,E]/85ANH"7 M+W-"(2<%I-]>STDQ7?C$EPFAD)-V\O%\T1F`E0+*X;_"GG"A`MNTH@*,RU3N M=PR->65*HX_&O%.YVE*N*B`^_=3G`U18.2Y[39*IW/4I-\&T13"^S!"EI%1? MM.B+60ZPN;0UMF`LIG+]:VAXU")['PV/IG+5K70"G(,2_;[,!ZVT6Q6A/R;B MBT\&T)?Z4GM??`\`&,HC3&`X"6[0D(QQ<+Q!`Q.QOJBV^'(.!Y!"4W60I.U`9JL@?79@)S2C9X[=PZP#SI**KF\V/@#9^#`L&P=` M-@YZ9V,"[;!N^5_Q%@'%5%;1]<'&5PIA0DHU_FF?61P++S^_QC$F#\+.4!YO MTY';:/7#-67&YY-0S-=B&&SEL!9B3]C35\!%6UH^=%%!+R0-K14TECLEG%8YB3#>5[SI5)#H#&A MT4IHM.)0HY4O&3>^R%\XV2EL,V/.>'QH5!$:573RGWW!!2PU-3)%O$E.:J>- MSMKW9:(HY*3@F+PO%1^=M(G?)V\A`M..81=?M`E@#>E2`[ZL(%-UTII;\Z5( MR!2,U@R?+V`8%+WH/5M?M"M,9-HI7P_&R/%#B1#MJLW^^K+5=+'K8;E=7W:@ M+@AUB"=[/*%4]EW'2(PONBAT\'+A7)+CYSO5&Y9A2LX7/0.V=``I&E],XBY; ME5E]D\>;NC(*`:UC\47EA!,%X43!`"<*S.O;+!TO^"F*Z7))JJ/@FSK[F&8% MR19<.9H?+``^;>PC!49LP0X3--.[V\M#$TP$'Q_%/P1,'QL)7?ZKWT_X.R6W M00W:.B0-DQ*Q='=+E"F>*:=FIQER5%329K4=G=YR,0+<3T1PV8]\3DIR*+:^H72*%6E M?"I2^XQK[I54$8_/_#5.N89.KD1+$\T-@C)"NTS?,I3E?.IR1//#=?,OJHLG MC1\0*HI#;:N";Z]K6Z?ELH?"SXX1+ZV[-W4(5`)20]]JZND%"!8J_WOJ\L,# MP%UMA:FOECWD?XV]>B$M\W5>BR]31BDI-8[&^*)K0+``PXV^I'+'+0QQ5(=H M-F-U=L`7I6&M*L;120'5&B:1)5\T:3>;!!K*>H5%=Y*X2RAN",4-+Q#:)\%C MJV%AP<;'\0T!PT0H[U MKW^?I6G5%9V)K]\6GM83]I'0+QE=83$;48:2]AXH>D+/LN8.YA<]$<-FFM2' MM-!&=5WC%65B[X#7%AB,M)A]>3P$@U)(\DA&'Q)V(6$7$G8A80?VXM2*Q#M` MI.)2N+7G2T0D'+!S(90XE4FB6CE0A\V7^&J(DH4HV0!1,F-79?S06/.B#;3I M=<`9C58T)2*8M_L'/%!F^L01PV;=6-OK:I'&RSNST0P3]?$\:Q09^*)?#`$R\0,ME4B]CU:,9#%9I=S&H'/1(B7G M;";5:ZNF*7V"I1PYU,:?>P0C^JJ$( M]S@I4WPYGW$5E)"T+,@#OL%QR8BX'?GD6YR6?&Z=KUL-[4238!86()R6K3K*]A1B*R&V$F(K(;:R=VQ% MK8]]63*2+9*.9U):\IX_1"1[X#]142W5S2=6/6)L3U?/RS#^J^J](*]4SWCP M-3OZFF-K9?9\+5,!X>C`.0KV^C8P98NW`T3(#'C!!34Z")<"$1T M]-\W%3X7)"/+_%5+3D?7Z*\LW%=1')YI0M]VCR#7G4V)XF MG*=A_$O(^T%>)5R0,2VU:\R-#I%+J)OVU<[1JPXT=ET^SXN M.--[.=//K[`\>YQIA^OM%P![T)V>%MSFX#8'MSFXS8.YS:!]-#C+P5D.SG)P MEH.SW+NSO(=5Z,M*TL/5CQ]D*:+0]2:.!!>(I'E4<&E*E!H&'WI^ZU2N&E.R MOU=(0TPP'%?=^F\92OA2/49K$=&Z*?A,NV(DQK?\`?D]?9SGS4B&R?AN]UE+ M&#\[)/0LBR_P\@ZS-LY:"?IX\>XJQ.K"@OQ&@DP;7:\(U*'(S=6#`NA9'.-5 M9>,>8JYN^4K_LR1<.=[2&YRFE`/@GSF2^.6GF[K3G=[[O%FUM\^G?1- MSLU&=O75^`3_;D$?WI'JBXH5?E#_6PAST/#1-K]M?/H6AUU)8X'%UD"6AFI\ MK[?:&\^6*T288.>(S]7%B]BJFKC;XNN'_?:[5"^_9MRDO2>K*\QBH>P7LD@) M>+Q-(9\REC3J\212R0"@P1`306)O?X1IE"ZP(WK[XNR46E1.EA2)D8KJ(L+.S9#SO M"&S.V9`Q\2)C,JU84Q>K/H3QG\>5VG<37P!X*1X%63.^!!;E$P#@6DY]$JA% MI/K8#QB`#VX"$+)Y*C!DV;R^XEQ3UR&`Y0,(_$P=A9`$WF.'E;J!8.D/W)8^ MI,`[I,#E/NMPB\)9,#I':X6"H##,Q';X"!YP[`X/PP M>7#V3LF#L?K1#ZP@27HP)C]-'I.]$BJ6"I%DMUCM5VAD^%17;OP17Y3S)]A'S# M>RIXER7I8:.MYNO1-WV^OHTFE!:$['O(OH>T=DAK.QE:#&GMD-8.:>U]Y)<; M/;[('Q*Z+F3F',_Z#YR9;JNL2'+$6%I7*-Z>S)8YKD\1JL7X(S(3`3`C,A,!,\$O] M]$O]"5X$SPQB/%@RF\>\0FP_2]P!3L2]_X9`R1K^2;)%O]UQ\@?A: MRC!;/[G#F=[@N&2XV5JYS8O8YWF]]F-I/OCR+B6+ZOO_3XD8AS5=-UM&M\EA M,+Q?MI.+)!8FD+Q!C(2DEY?OIN-YJFCFHZ+K@XVI=D$Z>ESL8JNYG!]5JD'S M.:&#>F!0W%YVEN5\HZW*EQ_?/%LL&.9S',^6M,R*6?(@5FY2,+)8M+/=\5&] MXGV,YZA,BVNDPE=*U`,#)UPBE";_1&OY^V4TH>M6#XPT5\QIO0$?T0=N[?.9 MMYV(U_B!I@]<#=1S47"5\5>NZY\9IVGCOK>'VQ?Y\9#+Y7RV6C%$N,7]&1>7 MPHKGVQGA^_*F[UU5M'\Y/^%;GEC-9"M.;P#MSXI].*]QC,E#U;]XB#G4_OC1 MQ*[3^R_90QMF3.74/6\TP:X87FULMBM&'TC.YUC>G(XGWV*M;[>\K/9B5OE@0PMT&[^VA\5D.58) MMV*P#?\3!;(5:L/Z.EZB2-BM0"XT^,9A7;4D+; M3"N+.%2D-JIE[NJ@7%[=\O`EXWXU/L9YS,BJRN')/X#16-NBB8FM_"XZ)(I\N$W5*@UI/TZ?*GD` MDU$QWATAN;K"K9Z8CMP=$<[$'L?-(S%]SK*8"6/C&&_^#Q)*]0`WQ:RB#HFV M33W\`>Z("5+G*G+;`G!0"4U(W)Y;!HUQYVL(7Q(D@2"T>J,#=S"3!"?'',D' M)$)&NP9$E_.7?SSG&TYEIDF$Z_HXJQ"4C"8T31%3GER7D=FXV6&CD*X0D3:) M:)#8Q/:\$?:7L-HD<855@+.E(W=#@.;>-:O5Y4DFFS4&3W#M2YV+2BZFW`"A MP]P0J,[][$T>8?7;T6PA]CRQ"SZ:48>8NS+9HDI--"><3%BC MA[@@K@AI:T)F;:16F_A,IS/.I:C\//FVPEDNO=OH"8U-7,,-0:%'$83-;2E! M?CD'!-QEY%8G`UZ5++Y'.=X5)#R/K"LW;./Q-D2L,[G/=E[E](*,"6T$^VI-K:,?7X1FZDH!O8S,+L-*L.6$X;@Y0(-Y=\):>I)8/;=]P4$J)85& MUE_/V7)=U8(O-G"Z[((O$T(A)^WD-_NB,P`K!51+/MR-0ZXM MF=#$Y=G\@%?V#W?[DBN3)%PLV^/%LL;73+DR"XS\^JG/!ZBPL05C87S7FFOK(]QFL%\W_Y_=EE\_`MM+O;*[6=GGSQR0#Z4G_DVQ??`P"&L@L9&(=/;N,`"W8:GI7S18F8 MB;Z=-YIV7+Z$O,`:%G)6WA>;%`R*NF>:+[X]0,OV!(3CBP5BB)AU2?3%LP?F MF/:&P=$)`@@#`AID3!T%<*3EU`:\]RY!]B0&I-6D[U=Z8 M.#YUC"WX]H%[P^2XV0K+Z^O[O_@R;2#%4+KZ05_"1A"71D4K/[GIRVSIGK*3 M5?C"D7$\@A+N:>EP3TO;*@*>[AYN23F'EDO]N8>S`]R$O5OCW>%VQ"FCI&CS M.URRQ4W`]KG69+B0J9M8]7D-T7"Q1.>P`YPO'2X>X"P:;=LHM"G):]KC$Y'"U?S7MY"WXX-M.W[!^+7T`7 M],"AF;[=WJCW`;52A&,S?3M\2Z7J*P['8_K6])9*V546#LCT;>)VG6MPE0L< M+'],X[YN2X!C-WU#>K>!P:[(@T,S?7-ZD^QLQ>5_2L2*J@I!_'[?".?!]"WJ M^DB51%GMHDH;@[$.(24%(XL%9MUQ\\>V;D:2NN/ACSVMO]4'CHH_IO1^%S4\ M(O;W=R\`X^_]8_.WZD^"[6L\?R/^_^7Z;"?CO3@>>+]B-"GC(H\I6WU7YN^V M=_1NX,NWLD09-_>C'Z.<+#(R)S'BOV(D_R./4)9$I8@B%XAD!>&V7K)I`M0*SXU_9.//C8@&V;Y[T2];O*VR_W)APR)L5>, MKACA;V'KJYI]^4W*T#$FG60E[%V@_U!V5.8%76+V7LZ2BJYO-CX`V?@P+!L' M0#8.>F?#K#MMDS'#OK;[LRIJS_`6"<645M'UP<97"F%"2C5^3^99'`OK+'], MFRJ;D.O(QQ>`6YQB2V25PK[F>O409_']$K$_U!Y(-!ZQYOROFW8,"<$ MTG2+!XQP0(Q'8TQV)Z]JB.5[Z)_RI6U_#QAA08Q:B;Y@3JG"@*,L7!;6W,US MQ?*0$X[/M#A^>3E_PI%R(FGI+8A0GP4XX;X`76.<_XKI@J'5/8EG#"/E9#(: M:^&6"Y1BOE<_X*S$G['F?A$5;;A*J=-52HN772&>L]U&8_'6G,,R)QG.\YHO ME1H"C0D7+H4+E^2'34=G]DO&-WOR%TYV"MO,>#`>'RZL`KG8;C$[:Q.\._!"!:4=7 MWQ=M`EA#N@"T+RO(5)VT9G+@.6>_P&C-)_D"AD'S&[UWZXMVA8E,.V6'P1@Y MWIP.X^\6].%= M@HG@ZZ/XAX#Q8R.YR7_U^PGGX7GC[SIW*?MSU^PKE*5SO$#IYL4MV6P%10^% MN+,%_W;H3E&$VT[1PZM/L@?":";F!TK/\KQ\?IUXDPLM<2_5Y-D]*@J4';-R M<427*Y2M537E.NK755F^Z6_Z_/(*.7X0^A[84M_^ENND9U0V&;[&:=6[2%RFI)Q& MD><3:M$59 M(ZDSC@H39:VR^7(FTJ"E(0 MNV2;.WVKZP"O,*NNC);(93#2JEB;:Z]G97%/F>A]HA='-L(!,:JJ&+`(3ZD= M8/^R++@NR!*2+:`RM`P)D;)7%V:ZG._"%%.4N&C-6^>#I(-%1=T/ M@SH3]S2*=%J/;;YLG?T9%S`15$.LM8`Z)^B.I$283+,LN2SN,6O\2BZ1?FST MWJ)P25+YG=P#120YRX[0BA0O2A>!U!;8SW,L+4W<_#$ZL,V>9M(W:9QA5A/? M4]):"'6C_+XJ>,GO3_XLN>I(15)V5APAQM;<]JA,>5G,VV2LG2A^W;]3<-GL MWJD(XFM&6$U&*#^&A&Q\AH_Q2H3D\LU,UW;\TY';$(#QR5R0!]S8:@!R@$:- M+\XIR;@Q=LX9X_L.=RD6XJQ*C3:620,;-+XP9]D#!Y.RM9SU-A(;3?]T%D[3 MCK&X>3VUL"H%$GH%ML:6T(_P(80&8+8_QG8YS.:5=MK6[E)K8PJDI6N#VZ+I6%).AXPM6 MN:H0+^8EHP[8'!28BAW.$["R.P/$?@*2/N'KR[0Q0P92@CR<%S"! MJ=.I'-@79\%PE>F*$X;S$"SL4J8:2%?PX\OQFNYS9F_CQG%?P0P9\RH37]P& M,YR,RE^'IQ*,,,$ M=,3,GT5D`HUI\=L`CL.G#4H97HBWCMV&T@0L0+V(5QZ$&3KZ2B:OT@QFX)@> M"GF$RO+A_1U!'M%Y%*/\/IJG]&N?Q_CAK[!_H-^45]C1?LF5,"*T@X5(E]G) M\@XGB5#*6V?B%*.B?-'+TWBO#(:JUOR+N_2^GK2_&SCQTL[ MN,)&>7B\/?KHLW`_N";<%5?PE*N!6-BH^!AO_F\D8_LC;):C"P9/^?8JHF7\ MGYL"'Z'BLJ2N8&ZJNV.2"Z./;VX:'=O78ZUT$&`X)AM[.4N:JE(BJV*$S1UU MLYO=HF\BA$QDVE-"987=)XOB+'N6EY0+H!YG^1M(F'LLO#26ZW%HE/WLDFRM M87BP>*VCW?IXV])0$[$:8QS[7#MSMK:@-"K=_`%."%E59KY(X,-E;!_OUKRL MF-RF.U2]M2!#'9NE-YC;\:18;XO@P)(]'VCWDQ68<0M(N1&_)+'0$@$7;9YO MB\TF$0/^`)M6+YQ+C5+L_B!GA'ZTS3M^VY8'./AM6[CL]FT!#W)&Z):(E9FP M+0]P\-N:QP"[/\B*T(^12;D\+VDL='!!ZSJN.HO_+`G#TJI^B1SP!P#/D0_6 MJ2;&.,E/&5V>-PN+96+IZ.V*4)E*PKXUDZ1MF-WKXU?U]+F<0V21TEN=6T^X MJDLC)3%NB%SJ)S@C:;/4$2!6D]RJ##ZT#Q*=[0_YO$B.Z%(D`E7!SG9BFZM^ MZMV/MJ%RG]V81[YX0D,> M&0JA(4]HR!,:\H`NF]\SL.`+6GO@0$%A#>\6F'):#5^S-MS$*S`;O7'+D'`] M[@PISX8<[O^XQM!VK6OPY&`79R[H6D@RP0ST] M&'4[_L3L@(4224"-V``;D7<#2;9G8O MEQDP'C'^$NX'S>[UC14_[!\Y2"W:X)[; M%$&$%\%YUIBF?_B416D#;!%^H6=:J>A5JYM^X.Q^^,8KAZX?,/_3%/3$5_DE@ M4'88U9NRFWW`4;3,&&XC=7%]]=OFQ9>%UQLJM'.W.5^6:9]0[HI!X-W/?"G, M&`)&H[YKCT".U6PSX\YX]"$BC4S^]M_K*!$]>=/=Q];WU31YVH@M-,W9VJM; MYN.+N['0[*"Y[[-L-/&H61'WN.7W./F5TD322C[1Z.-.# MX[&3/E\:CF5.TI7H9XL,!QIE*(0#C>%`HWL'&BUDXJ$E^Z;6DU?E"H8@P4VQ MX>(+[J,$]X4&+!6W<:F)$4HM_I:E6,H!-S2VEY9'J"[JY]R)2-*RNKD#95F) MT@@U3T'B^N#>G+*6\=WB,"-P,G8,9S21]HK_*"ZP;P95Z\.:LSE70O_&B.7D M6UL$J/O3NGFTO0@E.+CI0YYG#^I!$*F[,,+D`D7V1IOD8[JK9E_]&@O+FF]6 ME_-3DLV9Q7"[+5,0LFOV`^;]3W-(8V/1*K+X>;_6: MG'/^W3@SAR77?B1;7.#E'9:E.Y2T%E@7!USN:9J<+?DL?*AF;*X60#]B?#$N M$-]Z,LS6S3FA%`,PPLJU9>W3^W!]RYE1A(@-1CHDUJ],?ND?;)!#PLBS/ZHA M-G,_4K[$E%%F@0Q&AI162&F]UI36,,S>,L1G*C>*-HXD:+L#C7DMV;F^C/&0 M@7N&@K$5X@LT)H)3(V?`E\Q<5X2@WH8OS0PZX@1V9X9+ETP")X-]T)>5%PHG M7"B<<+PW`?B4('P`2M+7,TBFL3; M+.40?XCX2PAE4;QI1SU'L;B-9!WEY1W_'B2KBD1CFCUP0:HJT&J8\$+C))IO MVEJA-$K3N')4J;C:)$IIMH@*S);<5;TK-O^A9<'?G0G_HF,&T@E>Q\Y?.B3T M7MG/NI$9^8LOZJ?-S+9M,!F7I"V7"1O9ZVE%^2LO1!M`#G]BS&QS9+_,)KNO M?)[&K=$W+5T/;!SS.726\8]15HY,+>TQE_9]&S<*\E[1$6WVQ$55IY1MNSHF MNZZ.K8RI!G1,[TIX.UE@AM+DGV@M_VHRFAY>?Y7%ARC[0_[N5H)^7KS;"C>= M$;%RYD+H>V#K-[YRER2[%DIZK61(33GD*6,GM@-0I8D3G(Z?%)$T[)2D0V37 M,%@\5WCT^$6$CE9FGXC#_=P;>VV#5? MUB?S.19];O$59K&PB1>R5*;1,VRN"N'G;>_L`4PP';D;`C3QGA57VVL:#&22 M/,&U+W4N_!:F7%O0818$JJ_L$6M%QGR#Q"KV#3[JBXD!'->4=DLG&_R(_MU@ MYA^)70"^.8LUS+>13HYQZW.FJ*>!IBQ216J?<;5B5!+;*+']1I;E4E-4VT)C M@562Z5EMHQF?U>:M>A).GUR\9U'7-?FXQE6FX@HQ<:6"5G%#AMH4[1IE"Y4: M>?%W2RPJ9W0+A04V\0--'\3EXD\L.C7CD#&AC#B4$2OX]KJ,>%J%`5,(3X;* MW6A+'2`8>5@"^5 MV6!((-E<7^:)7LM*?$Q?E.M+\2@H&..+#E7++X^;^5)@#M8*ZL(;7Y0DP"+7 MAJY]40U*29MVJ+[JP9?5$L[LN'!FQW&;0KFE2*/!OFRH,&]-7[KC"QY0+0K) M*X(Q<;S#(<3HZ%:(X@M"X1P;0,YGJT==Q3&90@1<]@.#YY='0?5"`+-POA=O)TH%&5F\.1\HT3E_!V'1`TI++'YJS)V4H+O-VQWN M@K&W,%ZVR>@)E6%N$9@&`NX<'>_I8XY[XG;+E;*.748V/L.G'-3?!*:S/"^7 MJ\H+%A?.Q**[%'D@"5\'UR\[J9@.C]Z[*:*PK#J()H:Y*M)O5"P9L1PZ?K>G M#W!-S&N2_W'*,&[&N`R$;!MN5<2M*GR,WBD.,6BHP\F7+B+<@IC M1V!SHH0#.EX(5X23 M3$Y9R^&HTS,40-NM+W#HA*50]\67,JE06>E"9:7CD\1@U0RW@_I2INIRB1G? MFN^HFW'^KG[N<&MP8F#!(A_#K;*)PM46!1NN%&VB(*FBH,,5JCD,ECR<8BGW M^(E[9XOJ1Y+-*5O6+M0*L[HH[&X=W94YERG/=Z35C081JNX;[Y@F[/V]8V?T M!A)@K^3;(3>R^%AQKP,C_.EL?56+).\5#1W31R=XFA4,Q<4%RLHY_W_)9+=` M0\F';&7=^P<&Y18'FE9CQN-F%1^22-K3/X:8?1<1-E]=S78;C<4X\F$]96N^ MJRD%FU21'Z5&9%W2)F0(O"'T/;%V**JK/I0``EP6)4;K=AN6L0<H^<#*,#=XG(7`&DIQ?HT?<%;BSUB&OH0J!.Q#P'YJ`?M?,5TPM+H7&Q9$#!E] MR#F$G$/(.?1A%H4T0T@SA#1#7W-&O5]Y-U^DXE)YU,.[6:$"P3",X!TV-A-S M4\DO@#`RB_=XAU%(7H;D92^[D2Y%,-RQ`4>U2Y\9W:E@$C*ZL`,2JKBC=Z:* M$@II`-P[):J$09ZO\$Y'*'$P3"F,7P814VY19_FFF4-.4Y)4G1UV!+GHQ="( M%)49*A/"2>#E#WN_8L2RAYYXW>M`T"R.&1:/O\R>W0K%=>OE_!9]:\N)PD>- M'Z(]HCEGX5=*D_R&/BZH9S%:"97-EGB_HIS$$LZ5M/99KX#%LKFOH78\ MU1\=V&/T+(OI$HO%=LKW9Q%R)EDIVE3LE/0AGE.&-W1<#>+\@F24-:YQF67) MTZ>(>W[%K5_>>`DE>Z7`#$B!_:!WID]L[N\"NXK09%2VV*?HR^.N?,= M_A!G6#ZY-=16V&<5DB@]HLLES2HUD<^*@I&[LA!^ZBW=;/RY,`+F8N?7:ON> MGNHH'-MM0#01K\SP&6/BYD#-8N[IP39`V6B3>LY*)7Q"]:+OO`V.H9:N\;CQ M1>(,/)WC5Y4'K+9:H,.MBDBSVE_+%AMFUT`&V1)&-/Y!!MDMZ*T\KEA9:5;TN>W<(3J M4C,1<,J?N?B5FY4,I7R6SY(ER4AU6QGWOM53RFQPJ(`,%9"=*B"'8?9?F"SN MN4TPXV8;6N#/I2A*X([%QE+86-N799$7*$OX))=(8_@4FUN@A-47/*IB6YV> MX4]U*S2H$$I492B$HI?!BEZFDK9VL);!V7OH(!:O=Q-$B8@R.3=<;4/5^,C% M&:+(?KRN"H`78@FU?%`D6G3<-7 M';/W92\R1\:PYL*7*CQSH$SBD,/M8!;TLSE4X!2`5_M8%ZUDK?#!E[VR*^B: MR@0P/#]Z.3&5^54P-C_Y-W6,LN9@H'[V!:A.A;1@F#Y-XDJ,#B:8MF04;IZ: MAY`FIX\,ZB3@N'EGUP.J>>'H>&?,@\J%X?@X'H@RQV>/?!D<-6.CWG74^JY] MA$/IHY7>7V$M'$<_S?D]D_WC'ZJKFBZ]CQ!WB)/:.(KR1^L(?XO3,N';O0`F MXD"LR@)M;T'&M6J/N!,=Y4*VC@V'!WO_V%V(!Q9DK[-ZTI9;@S$-ZH,Z,&2C M7DS5$.1109[48FP"3SLA+N?/+:/94C1Q>`;>(,^>'#2'Z_8'*`K?1GBC*S!^ M1DNLK"J%#K-P])!K9KK&^*:@\1^7U>6>K?VAP?2AQ#=4P2KX#E6PYD6A2'A- MA7)9MM+X4]1IRX()1:+/4!AM4_<%TC$`H\;;LR\U(".CJ]"ROB`:ZL1=J!-W M/`DQ\K(S\YY\`=GE8GP7BT0'"-!8B@8?1(2_(UN(6H+M1;X9+J(YR4B!4RY? MTD+1+?+;R[O&CO+VR/0P$=U>&`1%;WN$8DR?]K1B[URP=[;C;M/E>\']2";7^^<<`,]Y]O];,'PIOQ`&4[3TH,I1@H?K4*U-&-C[#7[(51R[CUL4MCN\SFM+%6LFZ?L!K"=CW8[2&X/PS M%#K;AKY`U`4`"M4MOD1X]P0)JL5\"S`\ZVZC$-,`VGE:<($3">.MP*FR)HRF90HV:5?HI$KYUEN8Q8==9$ ME$,M275D/II3%J4T6W"$EYPZBU$6XU1HEBC%*,==LTN]OG/L+-,`S.^5;=JU M!3H7;SC:,=,:=#`881(Z`;&6GY9%R?#%!KWMM5;')9[-.5XWY%MQ_V^,`!P# M']0MLKR?*&<9?_V:O[PU76?\D%Y%N,:5DKY"K%B#YPIX4`\,2@-#O2XY4/YT M@$4^:F)#\-$X57G+.5`$J'7D;@B@S&OH!UALN:]>[A*)@*-MYL_`^NR4VT#_ M;M&*W1\T#;%IR?H1>_N@28A]R]_:S^=^?-(T!/]*^Q&[?H[K0E]CH6`3<9+Z ME.0Q2EOLM[V?%ZZ)"-GUD%V?5JA[3.,ZY'N?YY9`UKPO>&BEI1VB'K[DW<#@ M&+KYON`3\I(NY"4=SZE!%I%I&,(7;$*^<9]&_ONZ0J\P$;FW#_T*\Y`]A%N& MJS&9/FK2X!P8-//>[M,'31;(!8-FW/#1.=#ZR0F"`3/O[#AEP-2Y8#!HQAW< MG0-MSWP2I"RE_HOXSQU_-O_-_P=02P,$%`````@`"WEE1^:+;URU#P``+;8` M`!$`'`!I;F)P+3(P,34P.3,P+GAS9%54"0`#-K<[5C:W.U9U>`L``00E#@`` M!#D!``#M75M3XS@6?M^J_0_>//56C0B!IGN@FMX*MREJH6$A/37[-*782J)M M1\I(,I#Y]7LD7^(XCNTX@CA#7L"Q=*1S^71T="S+7_[U,O:=)R(DY>RTU=G; M;SF$N=RC;'C:^OZ(NH_GU]>M?WW]\@^$?B&,"*R(Y_2G3F\4,(^("SXFSF]G M#S<.MH:*34Y:;=?^L+?D\3=&_*G=E38AC8.T7X''79:,5D@!+"WC"XJU80?YPD] M0O-IH""G.GEQ1_GU=4D.`67]24(P(MA7HXG@7N`JZ7(QV0ND)CK:/S[PG+[^85L7][$D<76&J2OSNS!%NH?.?`^, M,Q:,\_OPE&BKZ82TH1*"6D10-Z$K)YHGD-3-YPP*2'()`HB'& M,ZL,L.P;AJ("8Y`%$L%](G-I3$D^D18OG\B4Y!!I`;R,\2,K'K7#PG156F!S MRJ3"S$UL_K*`D>=#4[MS?'S<-J5)5>GE581F.^W?;F\>S8AM.5@I0?N!(E=< MC"_(``<^L!ZP/P+LTP$E'O@,GXP)4W,54L4*BR%1W_"8R`EV2=61\O7O?W,< MXSSH>,*%Q,OXMK>Y1$)U4TD2*+KM**0DLJ^AD1A5>UM%* M?A15<9#$!'IT'&6[Q(QQ9>C-O?CN9$+9@$>WX*:.K4[B&/R!#!P3;9U@X6H/ M71R3M2$*FA"A*$0,J3#>-#`29'#:TFL,%,=&O_NXOP=17%QEH8-Y!V!F""`A M_LV,O9A6^^S3E@2]^B22^LW%<;&_JCA`X@:^L4I#A?+(8%6A@(0RVF"9)H*L M*A.02%@?4%*5961=" M:_5M"T5'.B"FTO6Y#`2!']^`*T>'0_<)7P8X:;XR? MA,,97Z5#WPKF*Y?G)N;DY M-P"_TP(Y-R`0ZH%$S@5(],ZQ_@E).F1T`,M$N"6H_"&-[0-86`J%81*R%:=4 MZ\D2OCK[N?C24S&D[Z-P@X3_?_SA'P,Q+$QU&&"R82)3"3V#69;"OF+^S` MENT/YI_J&,OK4.@A[!KF#!WY]%)=OW.S'T,@,30_+3[#*VC9EJ$/GY%[MF,Q8X/#3A/M4^+[E8U^*5^[%E_X]9^Z?G^&["@7,?=>Q\ MB*]VBVS+YJ4G2'@.($IDT(E/5A"P.KYDIW&'CS)*1-6&V`;5M(;4P* M=3<$*N6T;,*V8E>6H':0GTTMS:+M@%&0_;`)A\(.;($@/Y6Z),NR,_UZJUN/ M*$Q]&,CD1078W^A*.\N++4`=V%YR7X2,.KV0T1WV,#ACC_J!HD\$7(0;"*J? M;R'RXOJ!!X'-0/"QGDHF061KL#W!@H$+EPBB721'6)`8`990:)LK6WC,;KM- MX-A-,0S.+F;8N8P8=C3#>BJ,&=;0O(P8=NXA8'K4#"<`?>_`G,_=Q-=3JS`K MZ\,6:+*;;',S1;-?TQT(2G(ZKS'S5>W+%BCRD\E%B:3=U%7)8(9;XH,?]G)J MV/0?ZW%@"TB?\KQ+`8Z07K,#?\@PN%AKYWU*S$NDHF.3\\&,P4!$>,R%HG^& M<0AYF>@7*!`L1ES#R&5YM[IIKB'<,IP[P#W.^2NGFQ_ MC8FSV,+5Z^GTW!44VG=>Z/-@"TW&>@UJ.I=A+%97NO-#;/S=Y M#<>V2?XMP?LP/RN_D0=`.R=L`UT54(72L((_/%#Z-#%]3JQ5%[Y9"6R-D.RA M'>L-D.*!P9.!XKU;`NT^>\,5'Q!;!?PK+@?Y37PLVJ?MI"S\+9!U43L(/=9*L=3FSAZRAO.M7PN@V9=!X, MDRFTF8SI31P6``%#,S:=&\/F;L(KW"OU&@ZJ6D^V8)/_SL+2[5D[9U3!5JD3 M)?M3U`\D943*I*I-'[06`[8PE/M$9QF$4/IXR_[4.8NX2RKO/,X:IE5<3T2O M\&31'C>V4/>S5=0AIZ>9?4^/#;^TL\>@1W?FCTLWAZ5'7X@Q.-4G2O_>=5U! M=)T[EEJ*ZW4UK,/O!CW\TC)GO)^V*M6DOHDZ3EM*!/K3"$%?*JH"3?:+X,'D MM&4^I'-"P=PM)SQS.KPSY@Q,):;74**%:SGA_>CTS=-6F$6);P,**/=ZI@$O M"!&1/BN^2-#+<9]X'O%FF8$K@A5,FSFB%M5]16$]TE]=5@S]"^RJF*&9[$.` M#)3>$I!&)%)F[]:1)_Q0U8G'Q[`XSHJSLI'.N!#\6>^;[/$P_4-NL3N"(2ZF M7>8E3^-ZW.S#).=X0F&TFQ@W%FO--C:"X/"C(&HEHYX)6&023S^N%-1T?!]- M!/-FKE!O\X9/&^&N[].A(?E/@`6L:?RIN7^/I^&A:Z%U(U]2I)E:E=WXJZ@;HH M73H$S[U;S]7QROR(6[R]L0%6P'KR@.'&=[/\YY8UP$M`U`<^6\_"/8'U\[0+ M/)577#PJ[OZX%]0EO1$,@A'WO428U6C60%@D@7U3<68*;C$+!O`?!@0;9BQ6 M6*6!Z)L%D!#MDKM!^)`H9RA5J+AY7.H@^!J\HC"'3:5X[@Z'PGP0KCO6I]!T MO2<]97A*T.%P)F1]:Y\4OV1`5G8_-$XEK*@&36'D45&BA.H+=^`G+. M,<,>SHBRI'#S/B!\Y^-&O_(QVSZVID1MPP92R%^O49Y=#[W@GUSE_(K!,5$F4^D">N/\$ MLV04J"9OO4:_TXD,FPUN.-=12Y3[L&\\!-+N9"(PE<33B73AF>P5_2.(CCPP M&]GN!I<^-4XH>9=Y+4U:Z7X;]?Y`7`*1KSZ]F611)AQ* M4$4A%=K8_/JT2(![029A@OA>\"A_1`+$:8=$L$K5MZ:)RCS`LT%$?E%S0N(;O'_N(B#G,Z\ M#$O*&B[$08$0!]LBQ&&!$(>-%H*-L(*!="&"H3[1!K-I5I2"&@T4*-PT:8)I MD^OONBZ9F*/1SLB`"YBT(-(!KZ*?!OM^1M::Q,U3@\Z7QT_#*?:3[3;1[IA> MO.TQE+MR[<9ETS3G,H]UF99M:8TMDJ<;D93+E:JY*?EF\@1ZB$#T-'LH=\N9 M&OE3_8``^_Z\K:K6KB\798H,B5@WCJK&Z15](=Y\3%6'<%/2+D5IM"6/#1;E5:`W>D6S0+251%X$80+TD;ZHD4[\Y4FR-QO)=K*M+]KRM["II:1.`X42?$REA"7VXK:()67-$^(!YAN6W9&8O=E$ MMLTWPLPGP@HGM2H5FRC>?`9SP3[+BILGRJ-+&(8V+G5:^FX0[=*8EZ>D3@.% M,EO3`N&.`%%+,E0E=9HGE'YA7Z?5YL58N-M,QA==\,+=!C(^`E0L>4JZI*R! M0CSS92+DE31/@%^IPF/*'O2[6M.%L&1I:?,$27WB[]5/&@^5\Z8]-B[Y4R#] M>I_M*U7NFLUOCR9+CR(O454Y_;;JHB)6EA!MC]2O>A)PB?)>M^_MMT'%X[YK M:KEJZ]NOQXICN91\>S2Q]C&X):I:O_V_@"XKPJJ,9K$PQ=P-U?WHYK?;CT=8RW'DO;8[&JW]DLT7+E9K9),U:.U"M5G)U>MD>O MZYT.5J+.-1O_BVLQ_QRLUU#IDIZV7;\5O6$)\59H(7V>,';-&\\Z*IEPGQJ/ M'E\4*6.%-MY,)^%I7M(=D3&&G_\'4$L!`AX#%`````@`"WEE1WX^BOLGI@`` M#"4,`!$`&````````0```*2!`````&EN8G`M,C`Q-3`Y,S`N>&UL550%``,V MMSM6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`"WEE1_$GYJ-Y"@``"I(` M`!4`&````````0```*2!`Q0````(``MY94>`L``00E#@``!#D!``!02P$"'@,4````"``+>65'R(?#V"%,```] M$P0`%0`8```````!````I($,Z@``:6YB<"TR,#$U,#DS,%]L86(N>&UL550% M``,VMSM6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`"WEE1]RA6^PR.0`` MLO,$`!4`&````````0```*2!?#8!`&EN8G`M,C`Q-3`Y,S!?<')E+GAM;%54 M!0`#-K<[5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(``MY94?FBV] XML 20 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 4 - Property and Equipment (Details Textual) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Depreciation $ 59 $ 61
XML 21 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 3 - Intangible Assets, Net - Estimated Annual Amortization Expense for Intangible Assets (Details)
$ in Thousands
Sep. 30, 2015
USD ($)
2016, remaining $ 73
2017 97
2018 97
2019 97
2020 93
2021 76
Thereafter 179
Total $ 712
XML 22 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Jun. 30, 2014
Land and Building [Member]    
Property and equipment, gross $ 1,250 $ 1,250
Leasehold Improvements [Member]    
Property and equipment, gross 1,159 1,159
Machinery and Equipment [Member]    
Property and equipment, gross 5,416 5,362
Transportation Equipment [Member]    
Property and equipment, gross 16 16
Property and equipment, gross 7,841 7,787
Less: Accumulated depreciation and amortization (6,473) (6,414)
Total $ 1,368 $ 1,373
XML 23 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended
Sep. 17, 2015
Jul. 29, 2015
Jun. 27, 2012
Sep. 22, 2014
Jun. 27, 2012
Sep. 30, 2015
Sep. 30, 2014
Nov. 05, 2015
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2013
Feb. 21, 2008
Eurodollar [Member] | Term Loan [Member]                        
Line of Credit Facility, Interest Rate at Period End           3.75%     3.75%      
Debt Instrument, Basis Spread on Variable Rate           3.25%            
Eurodollar [Member] | Revolving Credit Facility [Member]                        
Line of Credit Facility, Interest Rate at Period End           3.25%     3.25%      
Debt Instrument, Basis Spread on Variable Rate           2.75%            
Term Loan [Member] | Scenario Event of Default [Member]                        
Number of Consecutive Monthly Installments           60            
Number of Consecutive Monthly Installments, Fixed Amount           59            
Debt Instrument, Interest Rate, Increase (Decrease)           2.00%            
Revolving Advances [Member]                        
Line of Credit Facility Covenant Aggregate Revolving Advance Percentage of Appraised Net Orderly Liquidation Value of Eligible Inventory           85.00%            
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance           $ 8,000,000            
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate           85.00%            
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate           65.00%            
Loan Agreement Mandatory Repayment Amount           $ 1,000,000            
Loan Agreement [Member]                        
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow                     50.00%  
Promissory Note [Member] | CD Financial LLC [Member]                        
Debt Instrument, Face Amount     $ 1,714,000   $ 1,714,000              
CD MDC Note [Member]                        
Repayments of Notes Payable     300,000                  
E. Gerald Kay [Member] | Vitamin Realty LLC [Member]                        
Debt Instrument, Interest Rate, Stated Percentage           4.00%            
Term Note [Member] | Convertible Line of Credit Note [Member] | Subsequent Event [Member]                        
Debt Instrument, Term   4 years                    
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate   4.57%                    
Revolving Credit Facility [Member]                        
Line of Credit Facility, Maximum Borrowing Capacity     $ 8,000,000   $ 8,000,000              
Convertible Line of Credit Note [Member]                        
Line of Credit Facility, Maximum Borrowing Capacity       $ 350,000                
Debt Instrument, Basis Spread on Variable Rate       3.25%                
Debt Instrument Convertible Aggregate Amount Advanced Trigger       $ 350,000                
Long-term Line of Credit           $ 350,000            
IBio Inc [Member] | Minimum [Member]                        
Share Price           $ 0.88     $ 0.88 $ 0.88 $ 0.88  
IBio Inc [Member]                        
Consecutive Trading Days for Stock Price Threshold           15 days            
Investment, Shares Sold           73,191            
Proceeds from Sale of Long-term Investments           $ 79,000            
Subsequent Event [Member] | Regents [Member]                        
Borrowings to Finance Machinery and Equipment to Secure Capital Lease               $ 14,000        
Regents [Member]                        
Borrowings to Finance Machinery and Equipment to Secure Capital Lease           14,000            
Debt Instrument, Interest Rate, Stated Percentage 5.70%                      
Capital Lease Obligations $ 90,000                      
Capital Lease Obligation Quarterly Lease Payment $ 2,000                      
CD Financial LLC [Member] | Default Rate [Member]                        
Debt Instrument, Interest Rate, Stated Percentage     10.00%   10.00%              
CD Financial LLC [Member]                        
Debt Instrument, Interest Rate, Stated Percentage     6.00%   6.00%             9.50%
Debt Instrument, Face Amount                       $ 4,500,000
Convertible Notes Payable     $ 5,350,000   $ 5,350,000              
Debt Instrument, Convertible, Conversion Price     $ 0.65   $ 0.65              
Embedded Derivative, Fair Value of Embedded Derivative Liability           15,000     $ 12,000      
Vitamin Realty LLC [Member]                        
Debt Instrument, Face Amount           686,000            
E. Gerald Kay [Member]                        
Debt Instrument, Face Amount           27,000            
Senior Notes     $ 11,727,000   $ 11,727,000              
Loans Payable, Noncurrent     $ 3,727,000   $ 3,727,000              
Debt Instrument, Periodic Payment           $ 44,000            
Share Price     $ 0.09   $ 0.09 $ 0.10     $ 0.09      
Repayments of Notes Payable           $ 147,000 $ 135,000          
Interest Paid         $ 333,000 173,000 $ 174,000          
Other Expenses         $ 217,000              
Capital Lease Obligations           $ 104,000     $ 125,000      
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 3 - Intangible Assets, Net
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]
Note 3. Intangible Assets, net
 
 
Intangible assets consist of trade names, license fees from the Branded Proprietary Products Segment, and unpatented technology from the Other Nutraceutical Businesses Segment. The carrying amount of intangible assets, net is as follows as of:
 
   
September 30, 2015
    
June 30, 2015
  
   
Gross Carrying
    
Accumulated
            
Gross Carrying
    
Accumulated
          
   
Amount
    
Amortization
    
Net
    
Amount
    
Amortization
    
Net
  
                                                 
Trade names
   $ 1,525     $ 909     $ 616     $ 1,525     $ 891     $ 634  
Unpatented technology
     547       547       -       547       540       7  
License agreement
     347       251       96       347       245       102  
Total
   $ 2,419     $ 1,707     $ 712     $ 2,419     $ 1,676     $ 743  
 
Amortization expense recorded on intangible assets for the three months ended September 30, 2015 and 2014 was $31 and $34, respectively. Amortization expense is recorded on the straight-line method over periods ranging from 13 years to 20 years based on contractual or estimated lives and is included in selling and administrative expenses. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test. Future unanticipated events affecting cash flows and changes in market conditions could affect such estimates and result in the need for an impairment charge. The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives. No impairment losses were identified or recorded in the three months ended September 30, 2015 and 2014 on the Company’s intangible assets.
 
The estimated annual amortization expense for intangible assets for the five succeeding fiscal years is as follows:
 
Year ending
  
Amortization
  
June 30,
  
Expense
  
         
2016, remaining
   $ 73  
2017
     97  
2018
     97  
2019
     97  
2020
     93  
2021
     76  
Thereafter
     179  
Total
   $ 712  
XML 25 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Debt Outstanding (Details) - USD ($)
 3 Months Ended
Sep. 30, 2015
Jun. 30, 2015
PNC Bank [Member] | Revolving Credit Facility [Member]    
Line of Credit Facility $ 4,219 $ 4,462
Line of Credit Facility, Interest Rate at Period End 3.25%  
Maturity date Jun. 27, 2017  
Less: Revolving Advances $ (4,219) (4,462)
PNC Bank [Member]    
Maturity date Jun. 27, 2017  
Notes Payable $ 1,669,000 1,802,000
Interest rate 3.75%  
PNC Equipment Finance Llc [Member]    
Line of Credit Facility $ 337 307
Line of Credit Facility, Interest Rate at Period End 4.57%  
Maturity date Jul. 29, 2019  
Less: Revolving Advances $ (337) (307)
CD Financial LLC [Member]    
Maturity date Jul. 07, 2017  
Notes Payable $ 1,714,000 1,714,000
Interest rate 6.00%  
Vitamin Realty LLC [Member]    
Maturity date Jul. 07, 2017  
Notes Payable $ 686,000 686,000
Interest rate 4.00%  
E. Gerald Kay [Member]    
Maturity date Jul. 07, 2017  
Notes Payable $ 27,000 27,000
Interest rate 4.00%  
Minimum [Member]    
Capitalized lease obligations 0.00%  
Capitalized lease obligations Feb. 26, 2016  
Maximum [Member]    
Capitalized lease obligations 7.10%  
Capitalized lease obligations Sep. 21, 2017  
Convertible Debt [Member]    
Maturity date Jul. 07, 2017  
Notes Payable $ 5,350,000 5,350,000
Interest rate 6.00%  
Line of Credit Facility $ 4,219,000 4,462,000
Capital Lease Obligations 104,000 125,000
Total outstanding debt 8,756,000 9,123,000
Less: Revolving Advances (4,219,000) (4,462,000)
Current portion of long term debt (707,000) (719,000)
Long term debt 3,830,000 3,942,000
Discount for embedded derivative (202,000) (230,000)
Convertible Note payable, net - CD Financial, LLC $ 5,148,000 $ 5,120,000
XML 26 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sales, net $ 9,445 $ 8,582
Cost of sales 8,130 7,281
Gross profit 1,315 1,301
Selling and administrative expenses 830 852
Operating income 485 449
Other income (expense), net:    
Interest expense (237) (240)
Change in fair value of derivative liabilities (3) 214
Other income, net 24 9
Other expense, net (216) (17)
Income before income taxes 269 432
Income tax expense, net 28 29
Net income $ 241 403
Interest expense on Convertible debt - CD Financial, LLC 82
Accretion of Convertible debt - CD Financial, LLC 28
Change in fair value of derivative liabilities (214)
Diluted net income $ 241 $ 299
Basic net income per common share (in dollars per share) $ 0.01 $ 0.02
Diluted net income per common share (in dollars per share) $ 0.01 $ 0.01
Weighted average common shares outstanding - basic (in shares) 21,105,174 21,105,174
Add: Equivalent shares outstanding (in shares) 50,039 199,775
Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in shares) 8,230,769
Weighted average common shares outstanding - diluted (in shares) 21,155,213 29,535,718
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 1 - Principles of Consolidation and Basis of Presentation
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Note 1. Principles of Consolidation and Basis of Presentation
 
Basis of Presentation of Interim Financial Statements
 
The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (“Form 10-K”), as filed with the SEC. The June 30, 2015 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results of operations for the three months ended September 30, 2015 are not necessarily indicative of the results for the full fiscal year ending June 30, 2016 or for any other period.
 
Nature of Operations
 
The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.
 
The Company’s business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers, under the following brands: Naturally Noni, Coconut Water, Aloe Pure, Peaceful Sleep, Green Envy, ACAI Extra, ACAI Cleanse, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement and (iii) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC.
 
Significant Accounting Policies
 
There have been no material changes during fiscal year 2016 in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015.
 
Investment in iBio, Inc
.
The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008.  The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be a permanent impairment of the investment. To date, there were cumulative impairment charges of approximately $2.2 million. The market value of the iBio Stock as of September 30, 2015 was approximately $0.8 million based on the trade price at the close of trading on September 30, 2015.
 
Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. During certain periods in the three months ended September 30, 2015 and the fiscal years ended June 30, 2015, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
 
As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock providing net trading proceeds of approximately $79 which were used to prepay principal outstanding under the Term Loan. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
 
Earnings Per Share.
Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible debt, subject to anti-dilution limitations using the treasury stock method and if converted method.
 
The following options and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three months ended September 30, 2015 and 2014:
 
 
   
Three Months Ended
  
   
September 30,
  
   
2015
    
2014
  
                 
Anti-dilutive stock options
     1,080,950       401,200  
Anti-dilutive shares for convertible notes payable
     8,230,769       -  
Total anti-dilutive shares
     9,311,719       401,200  
XML 28 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 7 - Commitments and Contingencies (Details Textual)
 3 Months Ended
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
May. 19, 2014
ft²
May. 15, 2012
USD ($)
Jan. 05, 2012
ft²
Jan. 04, 2012
ft²
Manhattan Drug Company [Member]              
Area of Real Estate Property | ft²           76,161 74,898
Payments for Rent $ 533,000            
AgroLabs [Member]              
Area of Real Estate Property | ft²       2,700      
Payments for Rent 27,000            
Vitamin Realty LLC [Member]              
Operating Leases, Rent Expense 184,000 $ 210,000          
Accrued Rent 1,200,000   $ 1,000,000        
Stock Purchase Agreement [Member]              
Loss Contingency, Estimate of Possible Loss         $ 600,000    
Environmental Issues [Member]              
Loss Contingency, Estimate of Possible Loss         $ 0.30    
Operating Leases, Rent Expense $ 225 $ 252          
XML 29 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 9 - Segment Information (Tables)
 3 Months Ended
Sep. 30, 2015
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
     
Sales, Net
    
Segment
                  
     
U.S.
    
International
            
Gross
            
Capital
  
     
Customers
    
Customers
    
Total
    
Profit
    
Depreciation
    
Expenditures
  
Contract Manufacturing
2015
 
$
6,930
 
 
$
1,815
 
 
$
8,745
 
 
$
1,041
 
 
$
59
 
 
$
54
 
 
 2014     5,743       2,065       7,808       1,151       60       351  
                                                   
Branded Proprietary Products
2015
 
 
147
 
 
 
172
 
 
 
319
 
 
 
128
 
 
 
-
 
 
 
-
 
 
 2014     129       210       339       6       -       1  
                                                   
Other Nutraceutical Businesses
2015
 
 
376
 
 
 
5
 
 
 
381
 
 
 
146
 
 
 
-
 
 
 
1
 
 
 2014     427       8       435       144       1       -  
                                                   
Total Company
2015
 
 
7,453
 
 
 
1,992
 
 
 
9,445
 
 
 
1,315
 
 
 
59
 
 
 
55
 
 
 2014     6,299       2,283       8,582       1,301       61       352  
Reconciliation of Assets from Segment to Consolidated [Table Text Block]
   
Total Assets as of
  
   
September 30,
    
June 30,
  
   
2015
    
2015
  
Contract Manufacturing
 
$
9,113
 
   $ 8,482  
                 
Branded Proprietary Products
 
 
1,296
 
     1,324  
                 
Other Nutraceutical Businesses
 
 
1,668
 
     1,817  
Total Company
 
$
12,077
 
   $ 11,623  
XML 30 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 7 - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details)
$ in Thousands
Sep. 30, 2015
USD ($)
Operating Lease Commitment [Member]  
2016, remaining $ 40
2017 24
2018 14
2019 2
2020 $ 1
2021
Thereafter
Total $ 81
Related Party Lease Commitment [Member]  
2016, remaining 422
2017 563
2018 563
2019 563
2020 563
2021 563
Thereafter 2,517
Total 5,754
2016, remaining 462
2017 587
2018 577
2019 565
2020 564
2021 563
Thereafter 2,517
Total $ 5,835
XML 31 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 1 - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Employee Stock Option [Member]    
Anti-dilutive stock options (in shares) 1,080,950 401,200
Warrant [Member]    
Anti-dilutive stock options (in shares) 8,230,769
Anti-dilutive stock options (in shares) 9,311,719 401,200
XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 2 - Inventories
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Inventory Disclosure [Text Block]
Note
2
. Inventories
 
Inventories are stated at the lower of cost or market using the first-in, first-out method and consist of the following:
 
   
September 30,
    
June 30,
  
   
2015
    
2015
  
                 
Raw materials
   $ 3,702     $ 2,371  
Work-in-process
     1,036       2,061  
Finished goods
     1,349       1,346  
Total
   $ 6,087     $ 5,778  
XML 34 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2015
Jun. 30, 2015
Current Assets:    
Cash $ 84 $ 71
Accounts receivable, net 2,803 2,638
Inventories 6,087 5,778
Investment in iBio, Inc. 501 501
Other current assets 358 334
Total current assets 9,833 9,322
Intangible assets, net 712 743
Property and equipment, net 1,368 1,373
Security deposits and other assets 164 185
Total Assets 12,077 11,623
Current Liabilities:    
Advances under revolving credit facility 4,219 4,462
Accounts payable (includes $423 and $290 due to related party) 6,034 5,148
Accrued expenses and other current liabilities 1,189 1,536
Current portion of long term debt 707 719
Total current liabilities 12,149 11,865
Long term debt 3,830 3,942
Subordinated convertible note, net - CD Financial, LLC 5,148 5,120
Derivative liabilities 15 12
Total liabilities $ 21,142 $ 20,939
Commitments and Contingencies
Stockholders' Deficiency:    
Common Stock, $0.002 par value; 50,000,000 shares authorized; 21,140,074 and 21,105,174 shares issued and outstanding, respectively $ 42 $ 42
Additional paid-in capital 44,684 44,676
Accumulated deficit (53,692) (53,935)
Less: Treasury stock, at cost, 34,900 shares (99) (99)
Total Stockholders' Deficiency (9,065) (9,316)
Total Liabilities and Stockholders' Deficiency $ 12,077 $ 11,623
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 2 - Inventories (Tables)
 3 Months Ended
Sep. 30, 2015
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   
September 30,
    
June 30,
  
   
2015
    
2015
  
                 
Raw materials
   $ 3,702     $ 2,371  
Work-in-process
     1,036       2,061  
Finished goods
     1,349       1,346  
Total
   $ 6,087     $ 5,778  
XML 36 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
Document And Entity Information - shares
 3 Months Ended
Sep. 30, 2015
Nov. 05, 2015
Entity Registrant Name INTEGRATED BIOPHARMA INC  
Entity Central Index Key 0001016504  
Trading Symbol inbp  
Current Fiscal Year End Date --06-30  
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Entity Common Stock, Shares Outstanding (in shares)   21,105,174
Document Type 10-Q  
Document Period End Date Sep. 30, 2015  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 3 - Intangible Assets, Net (Tables)
 3 Months Ended
Sep. 30, 2015
Notes Tables  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
   
September 30, 2015
    
June 30, 2015
  
   
Gross Carrying
    
Accumulated
            
Gross Carrying
    
Accumulated
          
   
Amount
    
Amortization
    
Net
    
Amount
    
Amortization
    
Net
  
                                                 
Trade names
   $ 1,525     $ 909     $ 616     $ 1,525     $ 891     $ 634  
Unpatented technology
     547       547       -       547       540       7  
License agreement
     347       251       96       347       245       102  
Total
   $ 2,419     $ 1,707     $ 712     $ 2,419     $ 1,676     $ 743  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
Year ending
  
Amortization
  
June 30,
  
Expense
  
         
2016, remaining
   $ 73  
2017
     97  
2018
     97  
2019
     97  
2020
     93  
2021
     76  
Thereafter
     179  
Total
   $ 712  
XML 38 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)
$ in Thousands
Sep. 30, 2015
Jun. 30, 2015
Due to related party, current $ 423 $ 290
Common stock, par value (in dollars per share) $ 0.002 $ 0.002
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 21,140,074 21,140,074
Common stock, shares outstanding (in shares) 21,105,174 21,105,174
Treasury stock, shares outstanding (in shares) 34,900 34,900
XML 39 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 7 - Commitments and Contingencies
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
Note 7. Commitments and Contingencies
 
(a) Leases
 
Related Party Leases.
Warehouse and office facilities are leased from Vitamin Realty, which is 100% owned by the Company’s chairman, Chief Executive Officer and major stockholder and certain of his family members, who are also executive officers and directors of the Company. On January 5, 2012, MDC, a wholly-owned subsidiary of the Company, entered into a second amendment of lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026. This Second Lease Amendment provides for minimum annual rental payments of $533, plus increases in real estate taxes and building operating expenses. On May 19, 2014, AgroLabs entered into an Amendment to the lease agreement entered into on January 5, 2012, with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which was to expire on January 31, 2019 to extend the expiration date to January 1, 2024. This additional lease provides for minimum lease payments of $27 with annual increases plus the proportionate share of operating expenses.
 
Rent expense for the three months ended September 30, 2015 and 2014 on these leases were $184 and $210 respectively, and are included in both cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. As of September 30, 2015 and June 30, 2015, the Company had an outstanding obligation to Vitamin Realty of $1.2 million and $1.0 million, respectively, included in accounts payable, accrued expenses and other liabilities and long term debt in the accompanying Condensed Consolidated Balance Sheet.
 
Other Lease Commitments.
The Company has entered into certain non-cancelable operating lease agreements expiring up through January 31, 2026, related to office and warehouse space, equipment and vehicles (inclusive of the related party lease with Vitamin Realty).
 
The minimum rental commitments for long-term non-cancelable leases are as follows:
 
 
   
Operating
    
Related Party
          
Year ending
  
Lease
    
Lease
          
June 30,
  
Commitment
    
Commitment
    
Total
  
                         
2016, remaining
   $ 40     $ 422     $ 462  
2017
     24       563       587  
2018
     14       563       577  
2019
     2       563       565  
2020
     1       563       564  
2021
     -       563       563  
Thereafter
     -       2,517       2,517  
Total
   $ 81     $ 5,754     $ 5,835  
 
Total rent expense, including real estate taxes and maintenance charges, was approximately $225 and $252 for the three months ended September 30, 2015 and 2014, respectively. Rent expense is included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.
 
(b) Legal Proceedings.
 
The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.
 
(c) Other Claims.
 
On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent the Company a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company. In the Demand Letter, Cedarburg demanded payment by the Company of $0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA. In addition, in the Demand Letter, Cedarburg informed the Company that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of $0.3 million.
 
On May 30, 2012, the Company sent a letter responding to the Demand Letter and setting forth the Company’s position that it has no obligation to indemnify Cedarburg as demanded. On June 18, 2012, Cedarburg responded to the Company’s letter and, on July 27, 2012, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. On December 18, 2012, Cedarburg responded to the Company’s letter and, on January 15, 2013, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. As of November 5, 2015, the Company has not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter. The Company intends to vigorously contest Cedarburg's demand as set forth in the Demand Letter.
XML 40 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 6 - Significant Risks and Uncertainties
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Concentration Risk Disclosure [Text Block]
Note 6. Significant Risks and Uncertainties
 
(a) Major Customers.
For the three months ended September 30, 2015 and 2014, approximately 87% and 81%, respectively of consolidated net sales, were derived from two customers. These two customers are in the Company’s Contract Manufacturing Segment and represent approximately 47% each and 63% and 26% of this Segment’s net sales in the three months ended September 30, 2015 and 2014, respectively. A third customer in the Branded Nutraceutical Segment, while not a significant customer of the Company’s consolidated net sales, represented approximately 77% and 78% of net sales in the three months ended September 30, 2015 and 2014, respectively, of the Branded Nutraceutical Segment. Accounts receivable from these two major customers represented approximately 86% and 83% of total net accounts receivable as of September 30 and June 30, 2015, respectively. The loss of any of these customers could have an adverse affect on the Company’s operations. Major customers are those customers who account for more than 10% of net sales.
 
(b) Other Business Risks.
Approximately 62% of the Company’s employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed on September 1, 2015 and will expire on August 31, 2018.
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 1 - Principles of Consolidation and Basis of Presentation (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 86 Months Ended
Sep. 30, 2015
Sep. 30, 2015
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2013
Jun. 27, 2012
Minimum [Member] | IBio Inc [Member]            
Share Price $ 0.88 $ 0.88 $ 0.88 $ 0.88 $ 0.88  
IBio Inc [Member] | Minimum Share Price Acceptable Before Required to Sell [Member]            
Share Price $ 0.88 $ 0.88        
IBio Inc [Member]            
Equity Method Investment, Ownership Percentage 6.00% 6.00%        
Investment Owned, Balance, Shares 1,266,706 1,266,706        
Asset Impairment Charges   $ 2,200        
Investment Owned, at Fair Value $ 800 $ 800        
Consecutive Trading Days for Stock Price Threshold 15 days          
Investment, Shares Sold 73,191          
Proceeds from Sale of Long-term Investments $ 79          
Share Price $ 0.10 $ 0.10 $ 0.09     $ 0.09
XML 42 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 4 - Property and Equipment (Tables)
 3 Months Ended
Sep. 30, 2015
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   
September 30,
    
June 30,
  
   
2015
    
2015
  
                 
Land and building
   $ 1,250     $ 1,250  
Leasehold improvements
     1,159       1,159  
Machinery and equipment
     5,416       5,362  
Transportation equipment
     16       16  
      7,841       7,787  
Less: Accumulated depreciation and amortization
     (6,473 )     (6,414 )
Total
   $ 1,368     $ 1,373  
XML 43 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
Significant Accounting Policies (Policies)
 3 Months Ended
Sep. 30, 2015
Accounting Policies [Abstract]  
Equity Method Investments, Policy [Policy Text Block]
Investment in iBio, Inc
.
The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008.  The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be a permanent impairment of the investment. To date, there were cumulative impairment charges of approximately $2.2 million. The market value of the iBio Stock as of September 30, 2015 was approximately $0.8 million based on the trade price at the close of trading on September 30, 2015.
 
 
Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. During certain periods in the three months ended September 30, 2015 and the fiscal years ended June 30, 2015, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
 
As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock providing net trading proceeds of approximately $79 which were used to prepay principal outstanding under the Term Loan. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
Earnings Per Share, Policy [Policy Text Block]
Earnings Per Share.
Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible debt, subject to anti-dilution limitations using the treasury stock method and if converted method.
 
The following options and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three months ended September 30, 2015 and 2014:
 
 
   
Three Months Ended
  
   
September 30,
  
   
2015
    
2014
  
                 
Anti-dilutive stock options
     1,080,950       401,200  
Anti-dilutive shares for convertible notes payable
     8,230,769       -  
Total anti-dilutive shares
     9,311,719       401,200  
XML 44 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 8 - Related Party Transactions
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]
Note 8. Related Party Transactions
 
See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt for related party securities transactions.
 
See Note 7(a). Leases for related party lease transactions.
XML 45 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 9 - Segment Information
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note 9. Segment Information
 
The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.
 
The Company has divided its operations into three reportable segments as follows: Contract Manufacturing, Branded Proprietary Products and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe and Canada, for the three months ended September 30, 2015 and 2014 were $1,992 and $2,283, respectively.
 
Financial information relating to the three months ended September 30, 2015 and 2014 operations by business segment are as follows:
 
 
     
Sales, Net
    
Segment
                  
     
U.S.
    
International
            
Gross
            
Capital
  
     
Customers
    
Customers
    
Total
    
Profit
    
Depreciation
    
Expenditures
  
Contract Manufacturing
2015
 
$
6,930
 
 
$
1,815
 
 
$
8,745
 
 
$
1,041
 
 
$
59
 
 
$
54
 
 
 2014     5,743       2,065       7,808       1,151       60       351  
                                                   
Branded Proprietary Products
2015
 
 
147
 
 
 
172
 
 
 
319
 
 
 
128
 
 
 
-
 
 
 
-
 
 
 2014     129       210       339       6       -       1  
                                                   
Other Nutraceutical Businesses
2015
 
 
376
 
 
 
5
 
 
 
381
 
 
 
146
 
 
 
-
 
 
 
1
 
 
 2014     427       8       435       144       1       -  
                                                   
Total Company
2015
 
 
7,453
 
 
 
1,992
 
 
 
9,445
 
 
 
1,315
 
 
 
59
 
 
 
55
 
 
 2014     6,299       2,283       8,582       1,301       61       352  
 
   
Total Assets as of
  
   
September 30,
    
June 30,
  
   
2015
    
2015
  
Contract Manufacturing
 
$
9,113
 
   $ 8,482  
                 
Branded Proprietary Products
 
 
1,296
 
     1,324  
                 
Other Nutraceutical Businesses
 
 
1,668
 
     1,817  
Total Company
 
$
12,077
 
   $ 11,623  
XML 46 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 1 - Principles of Consolidation and Basis of Presentation (Tables)
 3 Months Ended
Sep. 30, 2015
Notes Tables  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   
Three Months Ended
  
   
September 30,
  
   
2015
    
2014
  
                 
Anti-dilutive stock options
     1,080,950       401,200  
Anti-dilutive shares for convertible notes payable
     8,230,769       -  
Total anti-dilutive shares
     9,311,719       401,200  
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 6 - Significant Risks and Uncertainties (Details Textual)
 3 Months Ended 12 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Jun. 30, 2015
Sales Revenue, Net [Member] | Major Customer 1 [Member] | Customer Concentration Risk [Member]      
Concentration Risk, Percentage 47.00% 47.00%  
Sales Revenue, Net [Member] | Two Customers [Member] | Customer Concentration Risk [Member]      
Concentration Risk, Percentage 87.00% 81.00%  
Sales Revenue, Net [Member] | Major Customer 2 [Member] | Customer Concentration Risk [Member]      
Concentration Risk, Percentage 63.00% 26.00%  
Sales Revenue, Net [Member] | Major Customer 3 [Member] | Customer Concentration Risk [Member] | Branded Proprietary Products [Member]      
Concentration Risk, Percentage 77.00% 78.00%  
Accounts Receivable [Member] | Three Customers [Member] | Customer Concentration Risk [Member]      
Concentration Risk, Percentage 86.00%   83.00%
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member]      
Concentration Risk, Percentage 62.00%    
XML 48 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 7 - Commitments and Contingencies (Tables)
 3 Months Ended
Sep. 30, 2015
Notes Tables  
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]
   
Operating
    
Related Party
          
Year ending
  
Lease
    
Lease
          
June 30,
  
Commitment
    
Commitment
    
Total
  
                         
2016, remaining
   $ 40     $ 422     $ 462  
2017
     24       563       587  
2018
     14       563       577  
2019
     2       563       565  
2020
     1       563       564  
2021
     -       563       563  
Thereafter
     -       2,517       2,517  
Total
   $ 81     $ 5,754     $ 5,835  
XML 49 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 3 - Intangible Assets, Net (Details Textual) - USD ($)
 3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Minimum [Member]    
Finite-Lived Intangible Asset, Useful Life 13 years  
Maximum [Member]    
Finite-Lived Intangible Asset, Useful Life 20 years  
Impairment of Intangible Assets, Finite-lived $ 0 $ 0
Amortization of Intangible Assets $ 31,000 $ 34,000
XML 50 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash flows provided by operating activities:    
Net income $ 241 $ 403
Adjustments to reconcile net income to net cash from operating activities:    
Depreciation and amortization 91 95
Accretion of financing instruments and other non cash interest 60 $ 60
Stock based compensation 9
Change in fair value of derivative liabilities 3 $ (214)
Changes in operating assets and liabilities:    
Accounts receivable (165) (119)
Inventories (309) (1,276)
Other current assets (23) (83)
Security deposits and other assets (11) (15)
Accounts payable 887 763
Accrued expenses and other liabilities (347) (109)
Net cash provided by (used in) operating activities 436 (495)
Cash flows from investing activities:    
Purchase of property and equipment (41) (168)
Net cash used in investing activities (41) (168)
Cash flows from financing activities:    
Advances under revolving credit facility 8,553 8,792
Proceeds from Line of Credit Note 43 205
Repayments of advances under revolving credit facility (8,796) (8,332)
Repayments under term note payables (147) (135)
Repayments under capitalized lease obligations (35) (24)
Net cash (used in) provided by financing activities (382) 506
Net increase (decrease) in cash 13 (157)
Cash at beginning of period 71 451
Cash at end of period 84 294
Supplemental disclosures of cash flow information:    
Interest $ 173 $ 174
Income taxes
Supplemental disclosures of non-cash transactions:    
Accretion on embedded derivative feature of convertible note payable $ 28 $ 28
Amortization of prepaid financing costs 32 32
Financing on capitalized lease obligations $ 14 $ 185
XML 51 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt
 3 Months Ended
Sep. 30, 2015
Notes to Financial Statements  
Debt Disclosure [Text Block]
Note
5
.
Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt
 
As of September 30, 2015 and June 30, 2015, the Company had the following debt outstanding:
 
    Principal Amount     Interest Rate   Maturity Date
   
As of September 30, 2015
    
As of June 30, 2015
                  
Revolving advances under Senior Credit
                               
Facility with PNC Bank, National Association
   $ 4,219     $ 4,462       3.25%    
 
 6/27/2017  
Installment Note with PNC Bank
     1,669       1,802       3.75%    
 
 6/27/2017  
Line of Credit Note with
                                
PNC Equipment Finance
     337       307       4.57%    
 
 7/29/2019  
Promissory Note with CD Financial, LLC
     1,714       1,714       6.00%    
 
 7/7/2017  
Promissory Note with Vitamin Realty, LLC
     686       686       4.00%    
 
 7/7/2017  
Capitalized lease obligations
     104       125     0.00% - 7.10%  
2/26/2016
- 9/21/2017
                                 
Promissory Note with E. Gerald Kay
     27       27       4.00%    
 
 7/7/2017  
Total outstanding debt
     8,756       9,123                  
Less: Revolving Advances
     (4,219 )     (4,462 )                
Current portion of long term debt
     (707 )     (719 )                
Long term debt
   $ 3,830     $ 3,942                  
                                 
Convertible Note payable - CD Financial, LLC
   $ 5,350     $ 5,350       6.00%    
 
 7/7/2017  
Discount for embedded derivative
     (202 )     (230 )                
Convertible Note payable, net - CD Financial, LLC
   $ 5,148     $ 5,120                  
 
SENIOR CREDIT FACILITY
 
On June 27, 2012, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (“IHT Properties”) and Vitamin Factory (collectively, the “Borrowers”) entered into a Revolving Credit, Term Loan and Security Agreement (the “Loan Agreement”) with PNC Bank, National Association as agent and lender (“PNC”) and the other lenders party thereto.
 
The Loan Agreement provides for a total of $11,727 in senior secured financing (the “Senior Credit Facility”) as follows: (i) discretionary advances (“Revolving Advances”) based on eligible accounts receivable and eligible inventory in the maximum amount of $8,000 (the “Revolving Credit Facility”) and (ii) a term loan in the amount of $3,727 (the “Term Loan”). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and common stock of iBio owned by the Company. Revolving Advances bear interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 2.75% (3.25% as of September 30, 2015 and June 30, 2015). The Term Loan bears interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 3.25% (3.75% as of September 30, 2015 and June 30, 2015). Upon and after the occurrence of any event of default under the Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on June 27, 2017 (the “Senior Maturity Date”).
 
 
The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in sixty (60) consecutive monthly installments of principal, the first fifty nine (59) of which shall be in the amount of $44, commencing on the first business day of August, 2012, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the first business day of July, 2017. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof.
 
The Revolving Advances are subject to the terms and conditions set forth in the Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) $8.0 million or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Loan Agreement, of eligible accounts receivables (“Receivables Advance Rate”), plus (ii) up to the lesser of (A) 65%, subject to the provisions in the Loan Agreement, of the value of the eligible inventory (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), minus (iii) the aggregate Maximum Undrawn Amount of all outstanding Letters of Credit, minus (iv) such reserves as Agent may reasonably deem proper and necessary from time to time.
 
The Loan Agreement contains customary mandatory prepayment provisions, including, without limitation, (i) the requirement that if the trading price per share of the iBio Stock falls below a certain amount, the Company must sell the iBio Stock and use the proceeds to repay the Term Loan and (ii) the requirement to prepay the outstanding amount of all loans in an amount equal to fifty percent (50%) of Excess Cash Flow for each fiscal year commencing with the fiscal year ending June 30, 2013, payable upon delivery of the financial statements to PNC referred to in and required by the Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which prepayment amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof until the aggregate amount of payments made with regard to the Term Loan pursuant to the Loan Agreement equals $1.0 million. The Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Loan Agreement. As of September 30, 2015, the Company is in compliance with the fixed charge coverage ratio maintenance requirement.
 
During certain periods in the fiscal year ended June 30, 2013 and continuing through the quarter ended September 30, 2015, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. However, PNC temporarily waived the requirement to sell the iBio Stock due to certain trading rules and restrictions under Rule 144 under the Securities Act of 1933, as amended. As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock, providing net trading proceeds of approximately $79 which proceeds were used to prepay principal outstanding under the Term Loan.
 
 
In connection with the Senior Credit Facility, PNC and CD Financial entered into the Intercreditor and Subordination Agreement (the “Intercreditor Agreement”), which was acknowledged by the Borrowers, pursuant to which, among other things, (a) the lien of CD Financial on assets of the Borrowers is subordinated to the lien of PNC on such assets during the effectiveness of the Senior Credit Facility, and (b) priorities for payment of the debt for the Company and its subsidiaries (as described in this Note 5) are established.
 
In addition, in connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC.
 
CD FINANCIAL, LLC TROUBLED DEBT RESTRUCTURING
 
On June 27, 2012, the Company also entered into an Amended and Restated Securities Purchase Agreement (the “CD SPA”) with CD Financial, which amended and restated the Securities Purchase Agreement, dated as of February 21, 2008, between the Company and CD Financial, pursuant to which the Company issued to CD Financial a 9.5% Convertible Senior Secured Note in the original principal amount of $4,500 (the “Original CD Note”). Pursuant to the CD SPA, the Company issued to CD Financial (i) the Amended and Restated Convertible Promissory Note in the principal amount of $5,350 (the “CD Convertible Note”) and (ii) the Promissory Note in the principal amount of $1,714 (the “Liquidity Note”, and collectively with the CD Convertible Note, the “CD Notes”). The CD Notes mature on July 7, 2017.
 
The proceeds of the CD Notes were used to refinance (a) the Original CD Note, (b) a $300,000 note issued by MDC to CD Financial which was assigned by MDC to the Company, (c) past due interest in the aggregate amount of $333 and (d) other expenses owed to CD Financial by the Company in the aggregate amount of approximately $217.
 
The CD Notes are secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and iBio Stock owned by the Company. The CD Notes bear interest at an annual rate of 6% and have a default rate of 10%.
 
The CD Convertible Note is convertible at the option of CD Financial into common stock of the Company at a conversion price of $0.65 per share, subject to customary adjustments including conversion price protection provisions.
 
Pursuant to the terms of the Loan Agreement and the Intercreditor Agreement, during the effectiveness of the Senior Credit Facility, (i) the principal of the CD Convertible Note may not be repaid, (ii) the principal of the Liquidity Note may only be repaid if certain conditions under the Loan Agreement are satisfied, and (iii) interest in respect of the CD Notes may only be paid if certain conditions under the Intercreditor Agreement are satisfied.
 
The CD SPA contains customary representations and warranties, covenants and events of default, including, without limitation, an event of default tied to any change of control as defined in the CD SPA.
 
In connection with the CD SPA, the Borrowers entered into an Amended and Restated Security Agreement and Amended and Restated Subsidiary Guaranty.
 
As of September 30, 2015 and June 30, 2015, the related embedded derivative liability with respect to conversion price protection provisions on the CD Convertible Note has an estimated fair value of $15 and $12, respectively.
 
The Company used the following assumptions to calculate the fair value of the derivative liability using the Black-Scholes option pricing model:
 
   
September 30,
    
June 30,
    
June 27,
  
   
2015
    
2015
    
2012
  
                         
Risk Free Interest Rate
     0.64 %     0.64 %     0.72 %
Volatility
     70.80 %     71.60 %     144.10 %
Term (years)
  
1.75
   
2
   
5
 
Dividend Rate
     0.00 %     0.00 %     0.00 %
Closing Price of
                        
Common Stock
   $ 0.10     $ 0.09     $ 0.09  
 
OTHER LONG TERM DEBT
 
Related Party Debt
.
On June 27, 2012, MDC and the Company entered into separate promissory notes with (i) Vitamin Realty Associates, LLC (“Vitamin Realty”), which is 100% owned by E. Gerald Kay, the Company’s Chairman of the Board, Chief Executive Officer and major shareholder and certain of his family members, who are also executive officers and directors of the Company, and (ii) E. Gerald Kay, in the principal amounts of approximately $686 (the “Vitamin Note”) and $27 (the “Kay Note”), respectively (collectively the “Related Party Notes”). The principal amount of the Vitamin Note represents the aggregate amount of unpaid, past due rent owing by MDC under the Lease Agreement, dated as of January 10, 1997, between MDC, as lessor, and Vitamin Realty, as landlord, pertaining to the real property located at 225 Long Avenue, Hillside, New Jersey. (See Note 7. Commitments and Contingencies (a) Leases – Related Party Leases). The Kay Note represents amounts owed to Mr. Kay for unreimbursed business expenses incurred by Mr. Kay in the fiscal year ended June 30, 2008. The Related Party Notes mature on July 7, 2017 and accrue interest at an annual rate of 4% per annum. Interest in respect of the Related Party Notes is payable on the first business day of each calendar month. Pursuant to the terms of the Loan Agreement, during the effectiveness of the Senior Credit Facility, the Related Party Notes may only be repaid or prepaid if certain conditions set forth in the Loan Agreement are satisfied.
 
Capitalized Lease Obligations.
On September 17, 2015, the Company entered into a capitalized lease obligation with Regents Capital Corporation (“Regents”) in the amount of $90, which lease is secured by certain machinery and equipment to be financed with funds available from Regents and which lease matures on September 21, 2019. As of September 30, 2015 and November 5, 2015, the Company has borrowed $14 of the $90 available from Regents. The lease payment amount (based on the current amount outstanding under the lease) of approximately $2 is payable quarterly and has an imputed interest rate of 5.7%.
 
Equipment Financing Note.
On September 22, 2014, MDC entered into a Convertible Line of Credit Note (the “LC Note”) in the amount of $350 with PNC Equipment Finance, LLC (“PNCEF”). The LC Note is convertible into a term note upon completion of the advances under the LC Note. During the period from September 22, 2014 to and including the Conversion Date (defined below), the Company was able to borrow up to the full value of the LC Note ($350). The “Conversion Date” is the earliest to occur of (i) July 31, 2015 or (ii) the date when the Company notifies PNCEF that no more advances will be requested or (iii) the date when PNCEF has made advances in an aggregate amount of $350. As of September 30, 2015, the Company has requested and received advances under the LC Note in the amount of $350. Prior to the Conversion Date, amounts outstanding under the LC Note bore interest at a rate per annum (“Floating Rate”) which is at all times equal to the sum of LIBOR Rate plus 325 basis points (3.25%). The Company completed the advances on July 29, 2015 and converted the LC Note to a four year term note. On the Conversion Date, the Company elected a fixed rate interest of 4.57% as offered by PNCEF.
 
 
In addition, in connection with the LC Note, the following loan documents were executed: (i) a Security Agreement with PNCEF and MDC; (ii) a Guaranty and Security Agreement with PNCEF and the Company; and (iii) a Cross Collateralization Agreement with PNC, PNCEF and MDC.
XML 52 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 3 - Intangible Assets, Net - Finite-lived Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Jun. 30, 2015
Trade Names [Member]    
Gross Carrying Amount $ 1,525 $ 1,525
Accumulated Amortization 909 891
Net 616 634
Unpatented Technology [Member]    
Gross Carrying Amount 547 547
Accumulated Amortization $ 547 540
Net 7
Licensing Agreements [Member]    
Gross Carrying Amount $ 347 347
Accumulated Amortization 251 245
Net 96 102
Gross Carrying Amount 2,419 2,419
Accumulated Amortization 1,707 1,676
Net $ 712 $ 743
XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 141 199 1 false 57 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://healthproductscorp.us/20150930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://healthproductscorp.us/20150930/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://healthproductscorp.us/20150930/role/statement-condensed-consolidated-balance-sheets-unaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://healthproductscorp.us/20150930/role/statement-condensed-consolidated-balance-sheets-unaudited-parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://healthproductscorp.us/20150930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Note 1 - Principles of Consolidation and Basis of Presentation Sheet http://healthproductscorp.us/20150930/role/statement-note-1-principles-of-consolidation-and-basis-of-presentation Note 1 - Principles of Consolidation and Basis of Presentation Notes 6 false false R7.htm 006 - Disclosure - Note 2 - Inventories Sheet http://healthproductscorp.us/20150930/role/statement-note-2-inventories Note 2 - Inventories Notes 7 false false R8.htm 007 - Disclosure - Note 3 - Intangible Assets, Net Sheet http://healthproductscorp.us/20150930/role/statement-note-3-intangible-assets-net Note 3 - Intangible Assets, Net Notes 8 false false R9.htm 008 - Disclosure - Note 4 - Property and Equipment Sheet http://healthproductscorp.us/20150930/role/statement-note-4-property-and-equipment Note 4 - Property and Equipment Notes 9 false false R10.htm 009 - Disclosure - Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt Sheet http://healthproductscorp.us/20150930/role/statement-note-5-senior-credit-facility-subordinated-convertible-note-payable-net-cd-financial-llc-and-other-longterm-debt Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt Notes 10 false false R11.htm 010 - Disclosure - Note 6 - Significant Risks and Uncertainties Sheet http://healthproductscorp.us/20150930/role/statement-note-6-significant-risks-and-uncertainties Note 6 - Significant Risks and Uncertainties Notes 11 false false R12.htm 011 - Disclosure - Note 7 - Commitments and Contingencies Sheet http://healthproductscorp.us/20150930/role/statement-note-7-commitments-and-contingencies Note 7 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Document - Note 8 - Related Party Transactions Sheet http://healthproductscorp.us/20150930/role/statement-note-8-related-party-transactions Note 8 - Related Party Transactions Uncategorized 13 false false R14.htm 013 - Disclosure - Note 9 - Segment Information Sheet http://healthproductscorp.us/20150930/role/statement-note-9-segment-information Note 9 - Segment Information Uncategorized 14 false false R15.htm 014 - Disclosure - Significant Accounting Policies (Policies) Sheet http://healthproductscorp.us/20150930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 15 false false R16.htm 015 - Disclosure - Note 1 - Principles of Consolidation and Basis of Presentation (Tables) Sheet http://healthproductscorp.us/20150930/role/statement-note-1-principles-of-consolidation-and-basis-of-presentation-tables Note 1 - Principles of Consolidation and Basis of Presentation (Tables) Uncategorized 16 false false R17.htm 016 - Disclosure - Note 2 - Inventories (Tables) Sheet http://healthproductscorp.us/20150930/role/statement-note-2-inventories-tables Note 2 - Inventories (Tables) Uncategorized 17 false false R18.htm 017 - Disclosure - Note 3 - Intangible Assets, Net (Tables) Sheet http://healthproductscorp.us/20150930/role/statement-note-3-intangible-assets-net-tables Note 3 - Intangible Assets, Net (Tables) Uncategorized 18 false false R19.htm 018 - Disclosure - Note 4 - Property and Equipment (Tables) Sheet http://healthproductscorp.us/20150930/role/statement-note-4-property-and-equipment-tables Note 4 - Property and Equipment (Tables) Uncategorized 19 false false R20.htm 019 - Disclosure - Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Tables) Sheet http://healthproductscorp.us/20150930/role/statement-note-5-senior-credit-facility-subordinated-convertible-note-payable-net-cd-financial-llc-and-other-longterm-debt-tables Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Tables) Uncategorized 20 false false R21.htm 020 - Disclosure - Note 7 - Commitments and Contingencies (Tables) Sheet http://healthproductscorp.us/20150930/role/statement-note-7-commitments-and-contingencies-tables Note 7 - Commitments and Contingencies (Tables) Uncategorized 21 false false R22.htm 021 - Disclosure - Note 9 - Segment Information (Tables) Sheet http://healthproductscorp.us/20150930/role/statement-note-9-segment-information-tables Note 9 - Segment Information (Tables) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 1 - Principles of Consolidation and Basis of Presentation (Details Textual) Sheet http://healthproductscorp.us/20150930/role/statement-note-1-principles-of-consolidation-and-basis-of-presentation-details-textual Note 1 - Principles of Consolidation and Basis of Presentation (Details Textual) Uncategorized 23 false false R24.htm 023 - Statement - Note 1 - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-1-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details Note 1 - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Uncategorized 24 false false R25.htm 024 - Statement - Note 2 - Inventories - Inventory (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-2-inventories-inventory-details Note 2 - Inventories - Inventory (Details) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 3 - Intangible Assets, Net (Details Textual) Sheet http://healthproductscorp.us/20150930/role/statement-note-3-intangible-assets-net-details-textual Note 3 - Intangible Assets, Net (Details Textual) Uncategorized 26 false false R27.htm 026 - Statement - Note 3 - Intangible Assets, Net - Finite-lived Intangible Assets (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-3-intangible-assets-net-finitelived-intangible-assets-details Note 3 - Intangible Assets, Net - Finite-lived Intangible Assets (Details) Uncategorized 27 false false R28.htm 027 - Statement - Note 3 - Intangible Assets, Net - Estimated Annual Amortization Expense for Intangible Assets (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-3-intangible-assets-net-estimated-annual-amortization-expense-for-intangible-assets-details Note 3 - Intangible Assets, Net - Estimated Annual Amortization Expense for Intangible Assets (Details) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 4 - Property and Equipment (Details Textual) Sheet http://healthproductscorp.us/20150930/role/statement-note-4-property-and-equipment-details-textual Note 4 - Property and Equipment (Details Textual) Uncategorized 29 false false R30.htm 029 - Statement - Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-4-property-and-equipment-net-property-and-equipment-net-details Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Details Textual) Sheet http://healthproductscorp.us/20150930/role/statement-note-5-senior-credit-facility-subordinated-convertible-note-payable-net-cd-financial-llc-and-other-longterm-debt-details-textual Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Details Textual) Uncategorized 31 false false R32.htm 031 - Statement - Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Debt Outstanding (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-5-senior-credit-facility-subordinated-convertible-note-net-cd-financial-llc-and-other-long-term-debt-debt-outstanding-details Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Debt Outstanding (Details) Uncategorized 32 false false R33.htm 032 - Statement - Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Calculation of Fair Value of Derivative Liability (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-5-senior-credit-facility-subordinated-convertible-note-net-cd-financial-llc-and-other-long-term-debt-calculation-of-fair-value-of-derivative-liability-details Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Calculation of Fair Value of Derivative Liability (Details) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 6 - Significant Risks and Uncertainties (Details Textual) Sheet http://healthproductscorp.us/20150930/role/statement-note-6-significant-risks-and-uncertainties-details-textual Note 6 - Significant Risks and Uncertainties (Details Textual) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) Sheet http://healthproductscorp.us/20150930/role/statement-note-7-commitments-and-contingencies-details-textual Note 7 - Commitments and Contingencies (Details Textual) Uncategorized 35 false false R36.htm 035 - Statement - Note 7 - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-7-minimum-rental-commitment-for-longterm-noncancelable-leases-details Note 7 - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) Uncategorized 36 false false R37.htm 036 - Disclosure - Note 9 - Segment Information (Details Textual) Sheet http://healthproductscorp.us/20150930/role/statement-note-9-segment-information-details-textual Note 9 - Segment Information (Details Textual) Uncategorized 37 false false R38.htm 037 - Statement - Note 9 - Segment Information - Operations by Business Segment (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-9-segment-information-operations-by-business-segment-details Note 9 - Segment Information - Operations by Business Segment (Details) Uncategorized 38 false false R39.htm 038 - Statement - Note 9 - Segment Information - Operations by Business Segment - Total Assets (Details) Sheet http://healthproductscorp.us/20150930/role/statement-note-9-segment-information-operations-by-business-segment-total-assets-details Note 9 - Segment Information - Operations by Business Segment - Total Assets (Details) Uncategorized 39 false false All Reports Book All Reports In ''Condensed Consolidated Balance Sheets (Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Condensed Consolidated Statements of Cash Flows (Unaudited)'', column(s) 1 are contained in other reports, so were removed by flow through suppression. In ''Note 3 - Intangible Assets, Net - Estimated Annual Amortization Expense for Intangible Assets (Details)'', column(s) 2 are contained in other reports, so were removed by flow through suppression. In ''Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details)'', column(s) 2 are contained in other reports, so were removed by flow through suppression. inbp-20150930.xml inbp-20150930_cal.xml inbp-20150930_def.xml inbp-20150930_lab.xml inbp-20150930_pre.xml inbp-20150930.xsd true true XML 54 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 9 - Segment Information - Operations by Business Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Contract Manufacturing [Member] | UNITED STATES    
Sales, net $ 6,930 $ 5,743
Contract Manufacturing [Member] | International Customers [Member]    
Sales, net 1,815 2,065
Contract Manufacturing [Member]    
Sales, net 8,745 7,808
Gross profit 1,041 1,151
Depreciation 59 60
Capital expenditures 54 351
Branded Proprietary Products [Member] | UNITED STATES    
Sales, net 147 129
Branded Proprietary Products [Member] | International Customers [Member]    
Sales, net 172 210
Branded Proprietary Products [Member]    
Sales, net 319 339
Gross profit $ 128 $ 6
Depreciation
Capital expenditures $ 1
Other Nutraceutical Business [Member] | UNITED STATES    
Sales, net $ 376 427
Other Nutraceutical Business [Member] | International Customers [Member]    
Sales, net 5 8
Other Nutraceutical Business [Member]    
Sales, net 381 435
Gross profit $ 146 144
Depreciation $ 1
Capital expenditures $ 1
UNITED STATES    
Sales, net 7,453 $ 6,299
International Customers [Member]    
Sales, net 1,992 2,283
Sales, net 9,445 8,582
Gross profit 1,315 1,301
Depreciation 59 61
Capital expenditures $ 55 $ 352
XML 55 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Tables)
 3 Months Ended
Sep. 30, 2015
Notes Tables  
Schedule of Debt [Table Text Block]
    Principal Amount     Interest Rate   Maturity Date
   
As of September 30, 2015
    
As of June 30, 2015
                  
Revolving advances under Senior Credit
                               
Facility with PNC Bank, National Association
   $ 4,219     $ 4,462       3.25%    
 
 6/27/2017  
Installment Note with PNC Bank
     1,669       1,802       3.75%    
 
 6/27/2017  
Line of Credit Note with
                                
PNC Equipment Finance
     337       307       4.57%    
 
 7/29/2019  
Promissory Note with CD Financial, LLC
     1,714       1,714       6.00%    
 
 7/7/2017  
Promissory Note with Vitamin Realty, LLC
     686       686       4.00%    
 
 7/7/2017  
Capitalized lease obligations
     104       125     0.00% - 7.10%  
2/26/2016
- 9/21/2017
                                 
Promissory Note with E. Gerald Kay
     27       27       4.00%    
 
 7/7/2017  
Total outstanding debt
     8,756       9,123                  
Less: Revolving Advances
     (4,219 )     (4,462 )                
Current portion of long term debt
     (707 )     (719 )                
Long term debt
   $ 3,830     $ 3,942                  
                                 
Convertible Note payable - CD Financial, LLC
   $ 5,350     $ 5,350       6.00%    
 
 7/7/2017  
Discount for embedded derivative
     (202 )     (230 )                
Convertible Note payable, net - CD Financial, LLC
   $ 5,148     $ 5,120                  
Schedule of Derivative Liabilities at Fair Value [Table Text Block]
   
September 30,
    
June 30,
    
June 27,
  
   
2015
    
2015
    
2012
  
                         
Risk Free Interest Rate
     0.64 %     0.64 %     0.72 %
Volatility
     70.80 %     71.60 %     144.10 %
Term (years)
  
1.75
   
2
   
5
 
Dividend Rate
     0.00 %     0.00 %     0.00 %
Closing Price of
                        
Common Stock
   $ 0.10     $ 0.09     $ 0.09